<SEC-DOCUMENT>0001082554-26-000020.txt : 20260506
<SEC-HEADER>0001082554-26-000020.hdr.sgml : 20260506
<ACCEPTANCE-DATETIME>20260506063051
ACCESSION NUMBER:		0001082554-26-000020
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260506
DATE AS OF CHANGE:		20260506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UNITED THERAPEUTICS Corp
		CENTRAL INDEX KEY:			0001082554
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				521984749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26301
		FILM NUMBER:		26945681

	BUSINESS ADDRESS:	
		STREET 1:		1000 SPRING ST
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20910
		BUSINESS PHONE:		3016089292

	MAIL ADDRESS:	
		STREET 1:		1000 SPRING ST
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20910

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	UNITED THERAPEUTICS CORP
		DATE OF NAME CHANGE:	19990324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>uthr-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199,d:afadd3ba7ea644f5bcd5cbd7a3475b3c-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:uthr="http://www.unither.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>uthr-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-25">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-28">0001082554</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-102" name="uthr:DebtInstrumentAdditionalExtensionTerm" id="f-476">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="uthr-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="investment"><xbrli:measure>uthr:investment</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>uthr:plan</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>uthr:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>uthr:segment</xbrli:measure></xbrli:unit><xbrli:unit id="petition"><xbrli:measure>uthr:petition</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:BuildingsBuildingImprovementsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:BuildingsBuildingImprovementsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:FurnitureEquipmentAndVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:FurnitureEquipmentAndVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-01</xbrli:startDate><xbrli:endDate>2026-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-25</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:StockIncentivePlan2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:StockIncentivePlan2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:InducementStockIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:NewlyHiredEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:InducementStockIncentivePlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:NewlyHiredEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareTrackingAwardsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareTrackingAwardsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:ExecutivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:ExecutivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-11</xbrli:startDate><xbrli:endDate>2026-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-11</xbrli:startDate><xbrli:endDate>2026-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-11</xbrli:startDate><xbrli:endDate>2026-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-30</xbrli:startDate><xbrli:endDate>2026-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-04</xbrli:startDate><xbrli:endDate>2025-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-04</xbrli:startDate><xbrli:endDate>2025-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-04</xbrli:startDate><xbrli:endDate>2025-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-25</xbrli:startDate><xbrli:endDate>2025-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">uthr:SmithsMedicalASDIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001082554</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:LiquidiaTechnologiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.956%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2026</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-26301</ix:nonNumeric> </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">United Therapeutics Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">52-1984749</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1000 Spring Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Silver Spring</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MD</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">20910</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">301</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">608-9292</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former Name, Former Address and Former Fiscal Year,&#160;If Changed Since Last Report)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">UTHR</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.938%"><tr><td style="width:1.0%"/><td style="width:23.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.054%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s common stock, par value $.01 per share, as of April&#160;29, 2026, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">42,446,733</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:20pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_10">Part&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_10">FINANCIAL INFORMATION (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_13">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_19">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_22">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_25">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_28">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_31">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_70">Management's Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_94">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_94">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_97">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_97">36</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_100">Part&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_100">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_100">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_103">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_103">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_106">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_106">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_124">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_127">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:21.6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_133">53</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_136">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_136">54</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:20pt;font-weight:400;line-height:120%">PART&#160;I. FINANCIAL INFORMATION</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_13"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 1. Consolidated Financial Statements</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_16"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated Balance Sheets<br/>(In millions, except share and per share data)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-30">1,279.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-31">1,557.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable investments</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-32">874.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-33">1,363.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable, <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="f-34"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="f-35">no</ix:nonFraction></ix:nonFraction> allowance for 2026 and 2025</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-36">312.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-37">350.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-38">178.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-39">183.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-40">228.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-41">248.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-42">2,872.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-43">3,702.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable investments</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-44">1,317.4</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-45">1,776.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Goodwill and other intangible assets, net</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="f-46">115.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="f-47">116.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-48">1,840.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-49">1,729.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-50">335.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-51">357.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-52">233.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-53">196.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-54">6,714.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-55">7,880.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-56">498.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-57">488.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-58">100.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-59">72.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-60">599.1</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-61">560.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-62">214.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-63">223.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-64">813.1</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-65">783.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"></ix:nonFraction>&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"></ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">.01</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-71">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-73">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-77">.01</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79">245,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80">77,129,770</ix:nonFraction> and </span></div><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-81">76,452,253</ix:nonFraction> shares issued, and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-82">42,156,223</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-83">43,643,165</ix:nonFraction> shares outstanding </span></div><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">as of March 31, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-84">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-85">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-86">2,520.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-87">2,798.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-88">10.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-89">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-90">34,973,547</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-91">32,809,088</ix:nonFraction> shares as of March&#160;31, 2026 and December&#160;31, 2025, respectively</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-92">5,441.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-93">4,260.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-94">8,831.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-95">8,556.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-96">5,901.1</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-97">7,096.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 33.4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-98">6,714.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-99">7,880.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated Statements of Operations<br/>(In millions, except per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.276%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.328%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-100">781.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-101">794.4</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-102">133.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-103">92.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-104">138.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-105">149.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-106">184.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-107">170.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="f-108">455.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="f-109">411.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-110">325.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-111">382.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #9d9598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-112">41.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-113">51.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #9d9598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-114">3.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-115">6.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other expense, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-116">46.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-117">4.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-118">7.5</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-119">40.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-120">318.3</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-121">423.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-122">43.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-123">101.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-124">274.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-125">322.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-126">6.32</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-127">7.18</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-128">5.82</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-129">6.63</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-130">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-131">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-132">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-133">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income<br/>(In millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-134">274.9</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-135">322.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive income:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Defined benefit pension plan:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Actuarial gain (loss) arising during period, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-136">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="f-137">2.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Actuarial gain and prior service cost included in net periodic pension cost, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" scale="6" id="f-138">0.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" scale="6" id="f-139">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total defined benefit pension plan, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-140">0.1</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-141">3.2</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Unrealized (loss) gain arising during period, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="f-142">9.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="f-143">5.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Realized gain included in net income, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-144">1.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="f-145">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total (loss) gain on available-for-sale debt securities, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-146">11.0</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-147">5.4</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-148">11.1</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-149">2.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-150">263.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-151">324.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.017em;line-height:120%">During the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">three </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.017em;line-height:120%">months ended March&#160;31, 2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and 2025 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.017em;line-height:120%">the tax (benefit) expense in other comprehensive income was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" format="ixt-sec:numwordsen" scale="6" id="f-152"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" format="ixt-sec:numwordsen" scale="6" id="f-153">zero</ix:nonFraction></ix:nonFraction> for the defined benefit pension plan and $(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="6" id="f-154">3.5</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" scale="6" id="f-155">1.7</ix:nonFraction>&#160;million, respectively, for the available-for-sale debt securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">(In millions)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:32.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Loss) Income</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2026</span></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-156">76.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-157">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-158">2,798.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-159">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-160">4,260.4</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-161">8,556.9</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-162">7,096.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt 0 11.8pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-163">274.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-164">274.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-165">11.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-166">11.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under employee stock purchase plan (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-167">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-168">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">) withheld for taxes</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-169">58.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-170">58.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-171">327.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-172">1,172.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-173">1,500.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excise tax on net share repurchase</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTax" scale="6" id="f-174">8.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTax" scale="6" id="f-175">8.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued for RSUs vested</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-176">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-177">0.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-179">68.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-180">68.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-181">33.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-182">33.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2026</span></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-183">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-184">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-185">2,520.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-186">10.2</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-187">5,441.6</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-188">8,831.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-189">5,901.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.845%"><tr><td style="width:1.0%"/><td style="width:32.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Comprehensive</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Loss) Income</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2025</span></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-190">75.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-191">0.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-192">2,698.9</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-193">3.4</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-194">3,474.5</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-195">7,222.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-196">6,444.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt 0 11.8pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-197">322.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-198">322.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-199">2.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-200">2.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under ESPP</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-201">4.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-202">4.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs withheld for taxes</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-203">15.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-204">15.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued for RSUs vested</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-205">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-206">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-208">16.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-209">16.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-210">32.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-211">32.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2025</span></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-212">75.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-213">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-214">2,737.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-215">1.2</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-216">3,474.5</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-217">7,544.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-218">6,807.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">(In millions)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-219">274.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:0 1pt"/><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-220">322.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #929292;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-221">22.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-222">19.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></div></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-223">33.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-224">31.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized losses on equity securities</span></div></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-225">61.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-226">5.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-227">25.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-229">32.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-230">4.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-231">38.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-232">42.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-233">40.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-234">11.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-235">12.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-236">2.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other assets and liabilities</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-237">27.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-238">134.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-239">463.3</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-240">461.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant, and equipment</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-241">100.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-242">74.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment" scale="6" id="f-243">5.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment" scale="6" id="f-244">9.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of available-for-sale debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-245">701.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-246">692.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Maturities of available-for-sale debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-247">269.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-248">611.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Sales of available-for-sale debt securities</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-249">1,307.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchase of investment in privately held company</span></div></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" scale="6" id="f-251">25.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" format="ixt:fixed-zero" scale="6" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-253">743.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-254">164.7</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments to repurchase common stock</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-255">1,500.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Repayment of line of credit</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="f-258">100.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-259">68.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-260">16.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of stock under ESPP</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="6" id="f-261">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="6" id="f-262">4.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RSUs withheld for taxes</span></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-263">58.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-264">15.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-265">1,484.4</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-266">93.8</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt;text-indent:18pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-267">277.4</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-268">202.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-269">1,557.1</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-270">1,697.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-271">1,279.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-272">1,899.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-273">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-274">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-275">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-276">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash additions to property, plant, and equipment</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-277">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-278">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Excise tax on net share repurchase</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="uthr:NoncashExciseTaxOnNetShareRepurchases" scale="6" id="f-279">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="uthr:NoncashExciseTaxOnNetShareRepurchases" format="ixt:fixed-zero" scale="6" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements<br/>March&#160;31, 2026 (Unaudited)&#160;</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_34"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-281" continuedAt="f-281-1" escape="true">Organization and Business Description</ix:nonNumeric></span></div><ix:continuation id="f-281-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. In 2021, we converted to a Delaware public benefit corporation, with the express public benefit purpose </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to market the following therapies: Tyvaso DPI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Powder (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tyvaso DPI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Tyvaso</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nebulized Tyvaso</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Injection (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Unituxin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Unituxin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and Adcirca</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Adcirca</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We also derive revenues outside the United States from sales of Nebulized Tyvaso, Remodulin, and Unituxin, and within the United States from sales of commercial </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div></ix:continuation><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_37"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccounting" id="f-282" continuedAt="f-282-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-282-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, as filed with the SEC on February 25, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In our management&#8217;s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March&#160;31, 2026 and December&#160;31, 2025, and our statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for the three-month periods ended March&#160;31, 2026 and 2025. Interim results are not necessarily indicative of results for an entire year. Certain prior year amounts have been reclassified to conform to the current year presentation. In the consolidated statements of cash flows, we reclassified prior amounts within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">net unrealized losses on equity securities </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to conform with the current period presentation.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-283" escape="true"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Adopted During the Period</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items in the notes to the financial statements. Public business entities are required to apply the guidance prospectively and may elect to apply it retrospectively. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, although early adoption is permitted. We are evaluating the impact of adopting this guidance on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-284" continuedAt="f-284-1" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="f-284-1" continuedAt="f-284-2"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Marketable Investments</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Available-for-sale debt securities are recorded at fair value, with the portion of the unrealized gains and losses that are not credit-related included as a component of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive (loss) income</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in stockholders&#8217; equity, until realized. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-285" continuedAt="f-285-1" escape="true">Available-for-sale debt securities consisted of the following (in millions):</ix:nonNumeric></span><ix:continuation id="f-285-1" continuedAt="f-285-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-286">1,723.3</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-287">2.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-288">3.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-289">1,722.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-290">403.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-291">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-292">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-293">403.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-294">2,126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-295">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-296">4.1</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-297">2,126.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="6" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="6" id="f-299">808.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-300">1,317.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-301">2,126.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><ix:continuation id="f-285-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-302">2,433.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-303">10.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-304">0.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-305">2,443.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-306">603.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-307">3.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-309">606.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-310">3,036.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-311">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-312">0.3</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-313">3,050.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="6" id="f-314">37.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="6" id="f-315">1,236.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-316">1,776.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-317">3,050.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-indent:3.6pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-318" escape="true"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair value for those available-for-sale debt securities that were in an unrealized loss position as of March&#160;31, 2026 and December&#160;31, 2025, aggregated by investment category and length of time that the individual securities have been in a continuous loss position (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-319">822.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-320">3.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-323">822.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-324">3.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-325">119.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-326">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-329">119.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-330">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-331">942.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-332">4.1</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-335">942.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-336">4.1</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-337">215.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-338">0.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-339">3.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-341">218.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-342">0.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-343">19.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-347">19.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-349">234.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-350">0.3</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-351">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-353">238.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-354">0.3</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-284-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we held <ix:nonFraction unitRef="investment" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-355">98</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-356">87</ix:nonFraction> available-for-sale debt securities, respectively, that were in an unrealized loss position. In assessing whether the decline in fair value as of March&#160;31, 2026 of any of these securities resulted from a credit loss, we consulted with our investment managers and reviewed the credit ratings for each security. We believe that these unrealized losses are a direct result of the current interest rate environment and do not represent an indication of credit loss. We do not intend to sell the investments in unrealized loss positions prior to their maturity, and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="uthr:DebtSecuritiesAvailableForSaleImpairmentLoss" format="ixt-sec:numwordsen" id="f-357"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="uthr:DebtSecuritiesAvailableForSaleImpairmentLoss" format="ixt-sec:numwordsen" id="f-358">no</ix:nonFraction></ix:nonFraction> impairments due to credit loss on our available-for-sale debt securities during the three months ended March&#160;31, 2026 and 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-359" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of available-for-sale debt securities (in millions). Actual maturities may differ from contractual maturities because the issuers of certain of these debt securities have the right to call the securities or prepay their obligations under the securities with or without penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" scale="6" id="f-360">807.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" scale="6" id="f-361">808.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due in one to three years</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-362">1,319.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" format="ixt:num-dot-decimal" scale="6" id="f-363">1,317.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-364">2,126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="f-365">2,126.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in Equity Securities with Readily Determinable Fair Values</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values, in the aggregate, of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-366">65.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-367">126.9</ix:nonFraction> million as of March&#160;31, 2026 and December&#160;31, 2025, respectively, which are included in current </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. Changes in the fair value of publicly traded equity securities are recorded in our consolidated statements of operations within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. See Note 4&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Investments in Privately Held Companies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we maintained non-controlling equity investments in privately held companies of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-368">91.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-369">53.8</ix:nonFraction>&#160;million, respectively. We invested $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="f-370">25.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="c-50" decimals="INF" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt-sec:numwordsen" scale="0" id="f-371">zero</ix:nonFraction> in privately held companies during the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. We measure these investments using the measurement alternative because the fair values of these investments are not readily determinable. Under this alternative, the investments are measured at cost, less any impairment, and adjusted for any observable price changes. We include our investments in privately held companies within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other non-current assets</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When an observable price transaction occurs that is identified as similar or identical to our investment, we perform a valuation analysis to assess the fair value of our investment using various inputs, such as the discount rate, time to a liquidation event, and price volatility of peer company stocks. We adjust the fair value of our investment based on the valuation analysis and recognize the gain or loss in the period in which the observable price change occurred. During the three months ended March 31, 2026, one of the privately held companies in which we invested raised additional capital by issuing equity securities similar to ours at an increased valuation compared to prior financing rounds, which resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" scale="6" id="f-372">12.8</ix:nonFraction>&#160;million in the value of our investment. This gain was recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other expense, net </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These investments are subject to a periodic impairment review and, if impaired, the investment is measured and recorded at fair value in accordance with ASC 820, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For non-controlling equity investments in privately held companies in which we held an investment as of March 31, 2026, cumulative impairments and downward fair value adjustments were $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" scale="6" id="f-373">5.3</ix:nonFraction>&#160;million and cumulative upward fair value adjustments were $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" id="f-374">14.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-375" continuedAt="f-375-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-375-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We account for certain assets and liabilities at fair value and classify these assets and liabilities within the fair value hierarchy (Level 1, Level 2, or Level 3). Our other current assets and other current liabilities have fair values that approximate their carrying values.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-376" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets and liabilities subject to fair value measurements are as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-377">397.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-378">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-379">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-380">397.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-381">205.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-382">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-383">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-384">205.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-385">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-386">1,722.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-387">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-388">1,722.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-389">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-390">403.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-391">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-392">403.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-393">65.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-394">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-395">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-396">65.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-397">668.3</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-398">2,126.1</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-399">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-400">2,794.4</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" format="ixt:fixed-zero" scale="6" id="f-401">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" format="ixt:fixed-zero" scale="6" id="f-402">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" scale="6" id="f-403">34.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" scale="6" id="f-404">34.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-405">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-406">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-407">34.2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-408">34.2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-409">753.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-410">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-412">753.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-413">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-414">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-415">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-416">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-417">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-418">2,443.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-419">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-420">2,443.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-421">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-422">606.8</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-423">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-424">606.8</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-425">126.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-426">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-427">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-428">126.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-429">880.0</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-430">3,050.0</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-431">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-432">3,930.0</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" format="ixt:fixed-zero" scale="6" id="f-433">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" format="ixt:fixed-zero" scale="6" id="f-434">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" scale="6" id="f-435">32.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" scale="6" id="f-436">32.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-437">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-438">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-439">32.5</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-440">32.5</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Marketable Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Available-for-Sale Debt Securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> for further information. The fair value of these securities is principally measured or corroborated by trade data for identical securities for which related trading activity is not sufficiently frequent to be considered a Level 1 input or comparable securities that are more actively traded.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of these securities is based on quoted market prices for identical instruments in active markets. During the three months ended March&#160;31, 2026 and March&#160;31, 2025, we recognized $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-441">61.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-442">5.3</ix:nonFraction> million of net unrealized losses, respectively, on these securities. These net unrealized losses are recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other expense, net </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments&#8212;Marketable Investments&#8212;Investments in Equity Securities with Readily Determinable Fair Values</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> other current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of our contingent consideration obligations is estimated using probability-weighted discounted cash flow models (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DCFs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">). The DCFs incorporate Level 3 inputs, including estimated discount rates, that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. The fair value of our contingent consideration liabilities increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-443">1.7</ix:nonFraction>&#160;million during the period from December 31, 2025 to March&#160;31, 2026. The loss was recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">research and development </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">The carrying amounts of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">accounts receivable</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">, and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">accounts payable and accrued expenses</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"> approximate fair value because of their short maturities. The fair values of our marketable investments and contingent consideration are reported above within the fair value hierarchy. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-444" continuedAt="f-444-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-445" escape="true"><ix:continuation id="f-444-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following, net of reserves (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Raw materials</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-446">34.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-447">30.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Work-in-progress</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-448">35.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-449">35.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finished goods</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-450">108.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-451">117.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-452">178.3</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-453">183.1</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_49"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-454" continuedAt="f-454-1" escape="true">Property, Plant, and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-454-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-455" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following (in millions):</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-456">266.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-457">266.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings, building improvements, and leasehold improvements</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-458">949.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-459">944.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings under construction</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-460">704.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-461">592.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Furniture, equipment, and vehicles</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-462">509.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-463">493.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-464">2,430.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-465">2,297.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-466">589.3</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-467">567.8</ix:nonFraction>)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-468">1,840.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-469">1,729.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:4pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-470">21.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-471">19.6</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_52"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-472" continuedAt="f-472-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-472-1" continuedAt="f-472-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2025 Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2025, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Wells Fargo Bank, National Association (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Wells Fargo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) as administrative agent and a swingline lender, and various other lender parties, which provides for an unsecured revolving credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-473">2.5</ix:nonFraction>&#160;billion (which facility may, at our request, be increased by up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="uthr:LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" scale="6" id="f-474">750</ix:nonFraction>&#160;million in the aggregate subject to obtaining commitments from existing or new lenders for such increase and other conditions). In accordance with the terms of the 2025 Credit Agreement, in May 2026, we extended the maturity date of the 2025 Credit Agreement by <ix:nonNumeric contextRef="c-102" name="uthr:DebtInstrumentExtensionTerm" format="ixt-sec:durwordsen" id="f-475">one year</ix:nonNumeric>, to April 2031. The 2025 Credit Agreement provides the lenders with the ability to extend the maturity date by <span style="-sec-ix-hidden:f-476">one</span> additional year, to April 2032, if we request such an extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At our option, amounts borrowed under the 2025 Credit Agreement bear interest at either an adjusted Term Secured Overnight Finance Rate (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Term SOFR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) or a fluctuating base rate, in each case, plus an applicable margin determined on a quarterly basis based on our consolidated ratio of total indebtedness to EBITDA (as calculated in accordance with the 2025 Credit Agreement). To date, we have elected to calculate interest on the outstanding balance at an adjusted Term SOFR plus an applicable margin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 25, 2025, we borrowed $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-477">200.0</ix:nonFraction>&#160;million under the 2025 Credit Agreement, and used the funds to repay outstanding indebtedness under the 2022 Credit Agreement, as discussed below under the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the second quarter of 2025, we paid down the entire $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-478">200.0</ix:nonFraction> million balance under the 2025 Credit Agreement, which brought our aggregate outstanding balance to <ix:nonFraction unitRef="usd" contextRef="c-105" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-479">zero</ix:nonFraction> as of June 30, 2025. Our aggregate outstanding balance under the 2025 Credit Agreement remained <ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-480">zero</ix:nonFraction> as of March&#160;31, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The 2025 Credit Agreement contains customary events of default and customary affirmative and negative covenants. As of March 31, 2026, we were in compliance with these covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The interest expense reported in our consolidated statements of operations for the three months ended March&#160;31, 2026 and 2025 relates to the 2025 Credit Agreement and 2022 Credit Agreement, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-472-2"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2022, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2022 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Wells Fargo, as administrative agent and a swingline lender, and various other lender parties, which provided for: (1) an unsecured revolving credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="f-481">1.2</ix:nonFraction>&#160;billion; and (2) a second unsecured revolving credit facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-482">800.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2024, our outstanding aggregate principal balance under the 2022 Credit Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:LinesOfCreditCurrent" scale="6" id="f-483">300.0</ix:nonFraction>&#160;million. During the first quarter of 2025, we paid down $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-484">100.0</ix:nonFraction>&#160;million of our balance under the 2022 Credit Agreement, which brought our aggregate outstanding balance down to $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:LinesOfCreditCurrent" scale="6" id="f-485">200.0</ix:nonFraction>&#160;million as of March 31, 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 25, 2025, we terminated the 2022 Credit Agreement and entered into the 2025 Credit Agreement. We repaid in full all our obligations under the 2022 Credit Agreement in connection with the termination of the 2022 Credit Agreement and our entry into the 2025 Credit Agreement. There were no penalties associated with the early termination of the 2022 Credit Agreement.</span></div></ix:continuation><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_55"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-486" continuedAt="f-486-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-486-1" continuedAt="f-486-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we have <ix:nonFraction unitRef="plan" contextRef="c-3" decimals="INF" name="uthr:NumberOfEquityIncentivePlans" format="ixt-sec:numwordsen" scale="0" id="f-487">one</ix:nonFraction> shareholder-approved equity incentive plan: the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2015 Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). The 2015 Plan provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-488">14,770,000</ix:nonFraction> shares of our common stock pursuant to awards granted under the 2015 Plan, which includes <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-489">950,000</ix:nonFraction> shares that were added pursuant to an amendment and restatement of the 2015 Plan approved by our shareholders in June 2025. We also have <ix:nonFraction unitRef="plan" contextRef="c-114" decimals="INF" name="uthr:NumberOfEquityIncentivePlans" format="ixt-sec:numwordsen" scale="0" id="f-490">one</ix:nonFraction> equity incentive plan, the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2019 Inducement Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), that has not been approved by our shareholders, as permitted by the Nasdaq Stock Market rules. The 2019 Inducement Plan was approved by our Board of Directors in February 2019 and provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-491">99,000</ix:nonFraction> shares of our common stock under awards granted to newly hired employees. Currently, we grant equity-based awards to employees and members of our Board of Directors in the form of stock options and restricted stock units (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RSUs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) under the 2015 Plan, and we may grant RSUs to newly hired employees under the 2019 Inducement Plan. See the sections entitled </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> RSUs </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">below for additional information regarding these equity-based awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, we issued stock options and RSUs to certain executives with vesting conditions tied to the achievement of specified performance criteria through the end of 2028 and 2027, respectively. Additionally, during the three months ended March&#160;31, 2026 and 2025, we issued RSUs to certain other employees with vesting conditions tied to the achievement of specified performance criteria during specified performance periods, with the latest performance period ending in 2028. Throughout each performance period, we reassess the estimated performance and update the number of performance-based awards that we believe will ultimately vest. Estimating future performance requires the use of judgment. Upon the conclusion of the performance period, the performance level achieved and the ultimate number of stock options and RSUs that may vest are determined. Share-based compensation expense for these awards is recorded ratably over their vesting period, depending on the specific terms of the award and anticipated achievement of the specified performance criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We previously issued awards under the United Therapeutics Corporation 2011 Share Tracking Awards Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">STAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We discontinued the issuance of STAP awards in June 2015 and all remaining outstanding STAP awards were exercised during the first quarter of 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2012, our shareholders approved the United Therapeutics Corporation Employee Stock Purchase Plan (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which is structured to comply with Section&#160;423 of the Internal Revenue Code. See the section entitled </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ESPP </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">below for additional information regarding the ESPP.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-492" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table reflects the components of share-based compensation expense recognized in our consolidated statements of operations (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.603%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-493">11.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-494">8.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSUs</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-495">21.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-496">23.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">STAP awards</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-497">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-498">0.8</ix:nonFraction>)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ESPP</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-499">0.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-500">0.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense before tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-501">33.9</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-502">31.8</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-486-2" continuedAt="f-486-3"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We estimate the fair value of stock options using the Black-Scholes-Merton valuation model, which requires us to make certain assumptions that can materially impact the estimation of fair value and related compensation expense. The assumptions used to estimate fair value include the price of our common stock, the expected volatility of our common stock, the risk-free interest rate, the expected term of stock option awards, and the expected dividend yield. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, in addition to time-based stock options, we granted <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="f-503"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="f-504">0.3</ix:nonFraction></ix:nonFraction>&#160;million performance-based stock options in each period with grant date fair values of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" scale="6" id="f-505">53.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" scale="6" id="f-506">38.0</ix:nonFraction>&#160;million, respectively, calculated based on the assumed achievement of the relevant financial performance condition. During the three months ended March&#160;31, 2026 and 2025, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-507">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-508">7.7</ix:nonFraction> million of share-based compensation expense, respectively, related to performance-based stock options.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-509" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following weighted average assumptions were used in estimating the fair value of stock options granted to employees during the three months ended March&#160;31, 2026 and 2025:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected term of awards (in years)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-510">5.0</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-511">5.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-512">32.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-513">32.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-514">3.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-515">4.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-516">0.0</ix:nonFraction>&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-517">0.0</ix:nonFraction>&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-518" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity and status of stock options under the 2015 Plan during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Exercise</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Remaining</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Contractual</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Term (in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Value (in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-519">4,636,330</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-520">166.11</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-521">289,956</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-522">536.12</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-523">495,147</ix:nonFraction>)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-524">138.00</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="f-525">365</ix:nonFraction>)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-526">120.26</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-527">4,430,774</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-528">193.46</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-529">3.6</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-530">1,770.2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercisable as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-531">3,243,872</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-532">142.88</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-533">2.2</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-534">1,460.1</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-535">1,186,902</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-536">331.72</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-537">7.2</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="f-538">310.1</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The weighted average fair value of a stock option granted during each of the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-539">190.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-540">110.11</ix:nonFraction>, respectively. These stock options have an aggregate grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" scale="6" id="f-541">55.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" scale="6" id="f-542">39.0</ix:nonFraction> million, respectively. The total grant date fair value of stock options that vested during the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-543">36.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-544">1.2</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-545" continuedAt="f-545-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to stock options was recorded as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.832%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-546">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-547">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-548">0.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-549">0.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-550">11.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-551">8.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-552">11.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-553">8.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-554">0.2</ix:nonFraction>)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-555">0.2</ix:nonFraction>)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-556">11.3</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-557">8.3</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, unrecognized compensation cost related to stock options was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-558">97.0</ix:nonFraction>&#160;million. Unvested outstanding stock options as of March&#160;31, 2026 had a weighted average remaining vesting period of <ix:nonNumeric contextRef="c-116" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-559">2.3</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-486-3"><ix:nonNumeric contextRef="c-1" name="uthr:ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" id="f-560" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock option exercise data is summarized below (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.832%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of options exercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-561">495,147</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-562">131,474</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash received</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-563">68.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-564">16.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-565">182.9</ix:nonFraction>&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-566">29.1</ix:nonFraction>&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each RSU entitles the recipient to <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" format="ixt-sec:numwordsen" scale="0" id="f-567">one</ix:nonFraction> share of our common stock upon vesting. We measure the fair value of RSUs using the stock price on the date of grant. Share-based compensation expense for RSUs is recorded ratably over their vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, in addition to time-based RSUs, we granted <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-568"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-569">0.2</ix:nonFraction></ix:nonFraction>&#160;million performance-based RSUs in each period, with total grant date fair values of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="f-570">88.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="f-571">67.3</ix:nonFraction> million, respectively, calculated based on the assumed achievement of the relevant financial and non-financial performance conditions. During the three months ended March&#160;31, 2026 and 2025, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-572">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-573">8.3</ix:nonFraction> million of share-based compensation expense, respectively, related to performance-based RSUs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-574" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity with respect to, and status of, RSUs during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Grant Date</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-575">1,416,871</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-576">252.86</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-577">295,640</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-578">520.38</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-579">274,965</ix:nonFraction>)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-580">234.77</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-581">16,515</ix:nonFraction>)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-582">248.71</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-583">1,421,031</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-584">312.06</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div></ix:nonNumeric><ix:continuation id="f-545-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to RSUs was recorded as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.832%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-585">1.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-586">1.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-587">4.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-588">6.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-589">15.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-590">15.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-591">21.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-592">23.4</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-593">3.5</ix:nonFraction>)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-594">3.8</ix:nonFraction>)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-595">18.0</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-596">19.6</ix:nonFraction>&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, unrecognized compensation cost related to the grant of RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-597">273.4</ix:nonFraction> million. Unvested outstanding RSUs as of March&#160;31, 2026 had a weighted average remaining vesting period of <ix:nonNumeric contextRef="c-118" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-598">2.4</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ESPP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ESPP provides eligible employees with the right to purchase shares of our common stock at a discount through elective accumulated payroll deductions at the end of each offering period. Eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" format="ixt:num-dot-decimal" scale="-2" id="f-599">15</ix:nonFraction> percent of their base salary, subject to certain annual limitations as defined in the ESPP. The purchase price of the shares is equal to the lower of <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" format="ixt:num-dot-decimal" scale="-2" id="f-600">85</ix:nonFraction> percent of the closing price of our common stock on either the first or last trading day of a given offering period. In addition, the ESPP provides that no eligible employee may purchase more than <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-601">4,000</ix:nonFraction> shares during any offering period. The ESPP expires in June 2032 and limits the aggregate number of shares that can be issued under the ESPP to <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-602">3.0</ix:nonFraction> million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-603" continuedAt="f-603-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-603-1" continuedAt="f-603-2"><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Earnings Per Common Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of our outstanding stock options, outstanding RSUs, and shares issuable under the ESPP, as if the RSUs were vested, the stock options were exercised, and the shares expected to be issued under the ESPP at the end of the current offering period were issued.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-604" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The components of basic and diluted earnings per common share comprised the following (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.832%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-605">274.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-606">322.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average outstanding shares &#8212; basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-607">43.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-608">44.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of dilutive securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options, RSUs, and ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-609">3.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-610">3.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average shares &#8212; diluted</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-611">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-612">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-613">6.32</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-614">7.18</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-615">5.82</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-616">6.63</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options and RSUs excluded from calculation</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-617">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-618">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Calculated using the treasury stock method.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">The common shares underlying certain stock options and RSUs have been excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2026 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2026, our Board of Directors approved a share repurchase program authorizing up to $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-619">2.0</ix:nonFraction>&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract), </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">which program expires on March 9, 2027</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Pursuant to this authorization, we entered into <ix:nonFraction unitRef="agreement" contextRef="c-148" decimals="INF" name="uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-620">two</ix:nonFraction> accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citibank, N.A. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Citi</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) on March 9, 2026 to repurchase approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-621">1.5</ix:nonFraction>&#160;billion of our common stock in the aggregate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the 2026 ASR agreements, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-622">750</ix:nonFraction>&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-623">750</ix:nonFraction>&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we made an aggregate upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-8" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="f-624">1.5</ix:nonFraction>&#160;billion to Citi on March 11, 2026. Under the 2026 Uncollared ASR, we received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-625">992,120</ix:nonFraction> shares of our common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased" format="ixt:num-dot-decimal" scale="-2" id="f-626">70</ix:nonFraction> percent of the total shares expected to be repurchased under the 2026 Uncollared ASR, measured based on the closing price of our common stock on March 9, 2026. Under the 2026 Collared ASR, we received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-627">708,657</ix:nonFraction> shares of our common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-155" decimals="2" name="uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased" format="ixt:num-dot-decimal" scale="-2" id="f-628">50</ix:nonFraction> percent of the total shares expected to be repurchased under the 2026 Collared ASR, measured based on the closing price of our common stock on March 9, 2026. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2026 Collared ASR, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-629">463,682</ix:nonFraction> shares of our common stock on March 30, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final number of shares that we will ultimately repurchase pursuant to the 2026 ASR agreements will be determined based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2026 ASR agreements. As discussed above, under the 2026 Collared ASR, the final number of shares we will ultimately repurchase will also be subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the final settlement of the 2026 ASR agreements, we may be entitled to receive additional shares of our common stock, or, under certain limited circumstances, be required to make an additional cash payment to Citi or, if we so elect, deliver shares of our common stock to Citi. The scheduled termination date of the 2026 Uncollared ASR is in the second quarter of 2026. The scheduled termination date of the 2026 Collared ASR is in the third quarter of 2026.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-603-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The initial repurchase of our common stock under the 2026 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2026 ASR agreements was accounted for as a reduction to stockholders&#8217; equity in our consolidated balance sheets. The hedging period under the 2026 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on March 30, 2026. The final settlement of the transactions under the 2026 ASR agreements is accounted for as an unsettled forward contract indexed to our common stock until the final settlement occurs. The forward contract related to the 2026 ASR agreements was equity classified, in accordance with ASC 815, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, upon inception and we expect equity classification to remain appropriate through final settlement under the 2026 Uncollared ASR and the 2026 Collared ASR. During the three months ended March 31, 2026, we recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTaxPayable" scale="6" id="f-630">8.4</ix:nonFraction>&#160;million for an excise tax imposed under the Inflation Reduction Act of 2022 (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IRA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) as a result of our repurchase of shares under the 2026 ASR agreements.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2025 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2025, our Board of Directors approved a share repurchase program authorizing up to $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-631">1.0</ix:nonFraction>&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract). Pursuant to this authorization, we entered into <ix:nonFraction unitRef="agreement" contextRef="c-159" decimals="INF" name="uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-632">two</ix:nonFraction> accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citi on August 1, 2025 to repurchase approximately $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-8" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-633">1.0</ix:nonFraction>&#160;billion of our common stock in the aggregate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the 2025 ASR agreements, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-634">500</ix:nonFraction>&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-635">500</ix:nonFraction>&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we made an aggregate upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-8" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="f-636">1.0</ix:nonFraction>&#160;billion to Citi on August 4, 2025. Under the 2025 Uncollared ASR, we received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-637">1,274,296</ix:nonFraction> shares of our common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased" format="ixt:num-dot-decimal" scale="-2" id="f-638">75</ix:nonFraction> percent of the total shares expected to be repurchased under the 2025 Uncollared ASR, measured based on the closing price of our common stock on August 1, 2025. Under the 2025 Collared ASR, we received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-639">849,531</ix:nonFraction> shares of our common stock, representing approximately <ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased" format="ixt:num-dot-decimal" scale="-2" id="f-640">50</ix:nonFraction> percent of the total shares expected to be repurchased under the 2025 Collared ASR, measured based on the closing price of our common stock on August 1, 2025. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2025 Collared ASR, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-641">514,789</ix:nonFraction> shares of our common stock on August 25, 2025. The final settlement of the 2025 Uncollared ASR occurred in November 2025, and we received an additional <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-642">3,882</ix:nonFraction> shares of our common stock upon settlement. The final settlement of the 2025 Collared ASR occurred in January 2026, and we received <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt-sec:numwordsen" id="f-643">no</ix:nonFraction> additional shares of our common stock upon settlement as a result of a collar provision that established the minimum and maximum number of shares to be repurchased, as well as other adjustments. In total, we repurchased <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-644">2,642,498</ix:nonFraction> shares of our common stock under the 2025 ASR agreements that we currently hold as treasury stock in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final number of shares that we ultimately repurchased pursuant to the 2025 Uncollared ASR was based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2025 Uncollared ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The initial repurchase of our common stock and final settlements under the 2025 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2025 ASR agreements was accounted for as a reduction to stockholders&#8217; equity in our consolidated balance sheets. The hedging period under the 2025 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on August 25, 2025. The final settlements of the 2025 ASR agreements were accounted for as unsettled forward contracts indexed to our common stock until the final settlement occurred. The forward contracts related to the 2025 ASR agreements were equity classified, in accordance with ASC 815, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, through final settlement. Excise taxes imposed under the IRA as a result of our 2025 ASR agreements were $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ShareRepurchaseProgramExciseTax" scale="6" id="f-645">1.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_61"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-646" continuedAt="f-646-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-646-1" continuedAt="f-646-2"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">Our effective income tax rate (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%">ETR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">) for the three months ended March&#160;31, 2026 and 2025 was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="f-647">14</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="f-648">24</ix:nonFraction> percent, respectively. Our ETR for the three months ended March&#160;31, 2026 decreased compared to our ETR for the three months ended March&#160;31, 2025 primarily due to increased excess tax benefits from share-based compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OBBBA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) was enacted in the United States. The OBBBA includes provisions that allow both the immediate deduction of domestic research and experimental expenditures and the full expensing of the cost of certain qualifying assets in the year placed in service. The impacts of the OBBBA were reflected in our consolidated financial statements beginning in the period of enactment and continue to be reflected in the period ended March 31, 2026, resulting in decreases to both our deferred tax assets and cash tax liabilities. The OBBBA provisions did not have a material impact on our ETR for the period ended March 31, 2026.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-646-2">We record interest and penalties related to uncertain tax positions as a component of income tax expense. As of March&#160;31, 2026 and December 31, 2025, our unrecognized tax benefits, including related interest, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="uthr:UnrecognizedTaxBenefitsIncludingInterest" scale="6" id="f-649">30.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="uthr:UnrecognizedTaxBenefitsIncludingInterest" scale="6" id="f-650">28.7</ix:nonFraction>&#160;million, respectively.</ix:continuation> </span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_64"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-651" continuedAt="f-651-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-651-1" continuedAt="f-651-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Chief Executive Officer, as our Chief Operating Decision Maker (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CODM</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), manages our company as a single operating and reporting segment at the consolidated level. Our operating segment focuses on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. The accounting policies of our <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-652">one</ix:nonFraction> operating segment are the same as those described in Note 2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Summary of Significant Accounting Policies </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February&#160;25, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our CODM is regularly provided with revenue and expense forecasts, including product development plans, to manage the operations of our operating segment. Our CODM monitors forecasted to actual results for net income when assessing performance and allocating resources across the operating segment. Significant segment expenses are presented as </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">operating expenses </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The measure of the operating segment assets is reported in our consolidated balance sheets as </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">total assets</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="c-1" name="uthr:ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" id="f-653" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other sources of revenues were as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tyvaso DPI</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nebulized Tyvaso</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Orenitram</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unituxin</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adcirca</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-654">330.3</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-655">127.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-656">126.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-657">135.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-658">53.6</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-659">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-660">5.3</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-661">781.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-662">83.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-663">8.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-664">16.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-665">7.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-666">5.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-667">1.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-668">12.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-669">133.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-670">247.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-671">118.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-672">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-673">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-674">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-675">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="f-676">6.8</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-677">648.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-678">302.5</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-679">163.8</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-680">138.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-681">120.7</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-682">58.2</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-683">6.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-684">5.0</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-685">794.4</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-686">48.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-687">8.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-688">13.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-689">8.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-690">5.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-691">2.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-692">6.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-693">92.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-694">254.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-695">155.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-696">124.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-697">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-698">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-699">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="f-700">1.0</ix:nonFraction>)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="f-701">701.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">During the three months ended March 31, 2026 and 2025, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-702">44.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-703">9.0</ix:nonFraction>&#160;million of inventory reserve expense, respectively. Tyvaso DPI inventory reserve expense accounts for $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-704">39.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-705">5.8</ix:nonFraction>&#160;million of the total inventory reserve expense recorded during the three months ended March 31, 2026 and 2025, respectively. The Tyvaso DPI inventory reserve expense increased in 2026 mainly because we recorded an estimated $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" scale="6" id="f-706">26.8</ix:nonFraction>&#160;million loss related to a commercial supply agreement. This agreement is intended to provide us with sufficient inventory to meet the needs of our patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Total revenues and cost of sales include sales of infusion devices, including the Remunity</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and RemunityPRO</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pumps.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-651-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Geographic revenues are determined based on the country to which our products are shipped. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-707" continuedAt="f-707-1" escape="true">Total revenues from external customers in the United States and rest-of-world (</ix:nonNumeric></span><ix:continuation id="f-707-1" continuedAt="f-707-2"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ROW</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for each of our commercial products were as follows (in millions):</span></ix:continuation></div><ix:continuation id="f-707-2"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net product sales:</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tyvaso DPI</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-708">330.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-709">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-710">330.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-711">302.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-712">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-713">302.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nebulized Tyvaso</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-714">112.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-715">14.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-716">127.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-717">138.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-718">25.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-719">163.8</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total Tyvaso</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-720">442.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-721">14.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-722">457.5</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-723">441.1</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-724">25.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-725">466.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-726">108.8</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-727">17.8</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-728">126.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-729">120.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-730">18.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-731">138.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-732">135.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-733">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-734">135.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-735">120.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-736">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-737">120.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unituxin</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-738">49.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-739">4.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-740">53.6</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-741">56.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-742">1.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-743">58.2</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adcirca</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-744">2.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-745">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-746">2.9</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-747">6.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-748">&#8212;</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-749">6.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-750">5.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-751">0.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-752">5.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-753">4.7</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-754">0.3</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-755">5.0</ix:nonFraction>&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-756">744.2</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-757">37.3</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-758">781.5</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-759">749.6</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-760">44.8</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-761">794.4</ix:nonFraction>&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues. <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-762" continuedAt="f-762-1" escape="true">Revenue from these two distributors as a percentage of total revenues is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-762-1"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-763">52</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-764">52</ix:nonFraction>&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-225" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-765">35</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-226" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-766">34</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_67"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-767" continuedAt="f-767-1" escape="true">Litigation </ix:nonNumeric></span></div><ix:continuation id="f-767-1" continuedAt="f-767-2"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Sandoz Litigation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2019, Sandoz Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Sandoz</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and its marketing partner RareGen, LLC (now known as Liquidia PAH, LLC, a subsidiary of Liquidia Corporation) (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RareGen</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), filed a complaint in the U.S. District Court for the District of New Jersey against us and Smiths Medical ASD, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Smiths Medical</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), alleging that we and Smiths Medical engaged in anticompetitive conduct in connection with the plaintiffs&#8217; efforts to launch their generic version of Remodulin. In particular, the complaint alleged that we and Smiths Medical unlawfully impeded competition by entering into an agreement for Smiths Medical to produce cartridges used with the CADD-MS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3 (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MS-3</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) infusion system specifically for the delivery of subcutaneous Remodulin for our patients, without making these cartridges available for the delivery of Sandoz&#8217;s generic treprostinil injection. In March 2020, the plaintiffs filed an amended complaint to add a count alleging that we breached our earlier patent settlement agreement with Sandoz by refusing to grant Sandoz access to cartridges purchased for our patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Smiths Medical was dismissed from the case in November 2020, based on a settlement resolving the disputes between the plaintiffs and Smiths Medical. As part of this settlement, Smiths Medical paid the plaintiffs $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-4" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="f-768">4.25</ix:nonFraction>&#160;million, disclosed and made available to the plaintiffs certain specifications and other information related to the MS-3 cartridges, and granted to the plaintiffs a non-exclusive, royalty-free license in the United States to Smiths Medical&#8217;s patents and copyrights associated with the MS-3 cartridges and certain other information related to the MS-3 pumps and cartridges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2022, the court granted our motion for summary judgment with respect to all claims brought by the plaintiffs except the breach of contract claim. As a result, all antitrust claims, all claims under state competition laws, and the common law tortious interference claim were resolved in our favor. These were the only claims in the case that gave rise to any potential for trebling of damages, punitive damages, disgorgement, and/or the award of attorneys&#8217; fees. The court also denied the plaintiffs&#8217; request for injunctive relief.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The court granted Sandoz&#8217;s motion for summary judgment with respect to Sandoz&#8217;s breach of contract claim. The issue of what, if any, damages Sandoz is entitled to based on the court&#8217;s decision on the contract claim went to trial. On November 1, 2024, the court entered a final judgment in favor of Sandoz, ordering us to pay to Sandoz (a) approximately $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="f-769">61.6</ix:nonFraction> million in damages; (b) prejudgment interest in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:LitigationSettlementInterest" scale="6" id="f-770">9.0</ix:nonFraction> million; and (c) post-judgment interest. All parties appealed the final judgment, including the court&#8217;s March 30, 2022 summary judgment decision. The appeal is pending before the U.S. Court of Appeals for the Third Circuit, and oral argument was held in November 2025.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-767-2" continuedAt="f-767-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We accrued a liability of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="f-771">71.1</ix:nonFraction>&#160;million during 2024, an additional $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="f-772">3.0</ix:nonFraction>&#160;million during 2025, and an additional $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" scale="6" id="f-773">0.8</ix:nonFraction>&#160;million through the first quarter of 2026, reflecting, in the aggregate, the damages and pre-judgment interest amounts awarded in the final judgment, as well as post-judgment interest accrued through March 31, 2026. We currently do not expect that the amount of any loss in excess of these accruals would be material to our financial results; however, the amount ultimately payable, if any, could be higher or lower than this amount depending on the amount of post-judgment interest, and the outcome of appeals. We recorded this liability within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other non-current liabilities </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in this litigation. Among other things, we believe our settlement agreement with Sandoz did not provide Sandoz any rights with respect to delivery systems such as the MS-3. We also believe that the plaintiffs, who were on notice that Smiths Medical would discontinue the MS-3 system, failed to fulfill their duty to properly mitigate their exposure as a result of such discontinuation, and any damages they incurred are the result of market conditions and their own failure to properly plan their own product launch. However, due to the uncertainty inherent in any litigation, we cannot guarantee that appeals will not result in an outcome adverse to us. This litigation has involved, and will likely continue to involve, substantial costs to defend, and an adverse appellate outcome could result in substantial monetary damages in excess of the liability we have accrued to-date.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Litigation with Liquidia Technologies, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since March 2020, we have been engaged in litigation with Liquidia Technologies, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Liquidia</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) regarding its efforts to obtain FDA approval for Yutrepia</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a dry powder inhalation formulation of treprostinil. That litigation has included <ix:nonFraction unitRef="petition" contextRef="c-232" decimals="INF" name="uthr:NumberOfPetitions" format="ixt-sec:numwordsen" scale="0" id="f-774">two</ix:nonFraction> petitions for </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> review (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IPR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) filed by Liquidia with the Patent Trial and Appeal Board (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PTAB</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) of the U.S. Patent and Trademark Office (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">USPTO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), as well as multiple lawsuits we have brought alleging infringement by Liquidia of several of our patents. Most of these cases have now been finally resolved, and Liquidia received final approval from the FDA to market Yutrepia to treat pulmonary arterial hypertension (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PAH</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and pulmonary hypertension associated with interstitial lung disease (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PH-ILD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) in May 2025 and launched commercial sales in June 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have an ongoing patent infringement lawsuit against Liquidia, which was originally filed on September 5, 2023 in the U.S. District Court for the District of Delaware, alleging infringement of U.S. Patent No. 10,716,793 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8217;793 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), a patent related to Tyvaso with an expiration date in May 2027 that was later invalidated as a result of an IPR proceeding, and therefore is no longer at issue in this litigation. On November 30, 2023, we filed an amended complaint to assert a new patent: U.S. Patent No. 11,826,327 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8217;327 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which expires February 3, 2042, and is the only patent remaining at issue in the case. The claims of the &#8217;327 patent generally cover improving exercise capacity in patients suffering from PH-ILD by inhaling treprostinil at specific dosages. Trial took place in June 2025, and the parties are awaiting the court&#8217;s decision. If we prevail in this lawsuit, we believe that we will be entitled to a court order requiring Liquidia to remove the PH-ILD indication from Yutrepia&#8217;s product labeling, and that we may also be entitled to damages.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2021, we filed a motion in one of our earlier patent cases against Liquidia in the U.S. District Court for the District of Delaware to file an amended complaint adding trade secret misappropriation claims against Liquidia and a former Liquidia executive, Dr. Robert Roscigno. The court denied the motion based on a finding that adding the additional claims would impact the case schedule. Thus, we filed those claims as a separate case against Liquidia and Dr. Roscigno in North Carolina state court. Discovery is complete. On January 5, 2024, Dr. Roscigno filed a motion for summary judgment, which was denied on July 31, 2024. On July 3, 2024, Liquidia filed a motion for summary judgment, which was denied on July 23, 2025. The court has scheduled trial to commence in January 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We filed a new complaint on May 29, 2024, to commence a separate, related case against Liquidia and Dr. Roscigno in North Carolina state court. That case is in its early stages, and the parties are currently engaged in discovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 21, 2025, Liquidia filed a lawsuit against us in the U.S. District Court for the Middle District of North Carolina, alleging that Tyvaso DPI infringes U.S. Patent No. 10,898,494 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8216;494 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). This patent&#8217;s claims are directed to the treatment of pulmonary hypertension by administering specified amounts of treprostinil via a dry powder inhaler in a specified number of breaths. The patent expires May 5, 2037. Liquidia seeks damages and attorneys&#8217; fees. We filed a motion to dismiss or, alternatively, a motion to stay the case based on the argument that we co-own the asserted patent based on Liquidia&#8217;s and Dr. Roscigno&#8217;s alleged trade secret misappropriation subject to the pending North Carolina state court litigation. The court granted our motion to stay and denied the motion to dismiss. On May 9, 2025, we filed a lawsuit against Liquidia in the U.S. District Court for the Middle District of North Carolina, alleging that Yutrepia infringes U.S. Patent No. 11,357,782. This patent claims a method of treating pulmonary hypertension using inhaled treprostinil delivered using a specified dosage regimen. The patent expires May 14, 2027. We moved for a preliminary injunction, but the court denied that motion. Liquidia moved to dismiss or, alternatively, transfer the case to the U.S. District Court for the District of Delaware. The court denied Liquidia&#8217;s motion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We plan to continue to vigorously enforce our intellectual property rights related to Tyvaso DPI and Nebulized Tyvaso. In addition, we believe we have meritorious defenses and intend to vigorously defend ourselves against the claims made by Liquidia in its patent infringement lawsuit against us.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><ix:continuation id="f-767-3"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MSP Recovery Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2020, MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; and Series PMPI, a designated series of MAO-MSO Recovery II, LLC, filed a class action complaint against Caring Voices Coalition, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CVC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and us in the U.S. District Court for the District of Massachusetts. The complaint alleged that we violated the federal Racketeer Influenced and Corrupt Organizations (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RICO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) Act and various state laws by coordinating with CVC when making donations to a PAH fund so that those donations would go toward copayment obligations for Medicare patients taking drugs manufactured and marketed by us. The plaintiffs claim to have received assignments from various Medicare Advantage health plans and other insurance entities that allow them to bring this lawsuit on behalf of those entities to recover allegedly inflated amounts they paid for our drugs. In April 2021, the court granted our motion to transfer the case to the U.S. District Court for the Southern District of Florida.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October 2021, the plaintiffs filed an amended complaint that includes state antitrust claims based on alleged facts similar to those raised by Sandoz and RareGen in the matter described above. The amended complaint added MSP Recovery Claims Series 44, LLC as a plaintiff and Smiths Medical and CVC as defendants. In December 2021, we filed a motion to dismiss all of the plaintiffs&#8217; claims in the amended complaint, including the new antitrust claims. Smiths Medical also filed a motion to dismiss the plaintiffs&#8217; claims against Smiths Medical. In September 2022, the court dismissed all of the plaintiffs&#8217; claims against us and Smiths Medical without prejudice.</span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">In October 2022, the plaintiffs filed a second amended complaint, which added federal antitrust claims and consumer protection claims under other states&#8217; laws to the claims previously asserted. The second amended complaint also named Accredo Health Group, CVS Health Corporation, Express Scripts, Inc., and Express Scripts Holding Company (collectively, the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%">Specialty Pharmacies</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">), and the Adira Foundation as additional defendants. In March 2023, we filed our motion to dismiss the second amended complaint. The Specialty Pharmacies filed their own motion to dismiss, as did Smiths Medical. On March 22, 2024, the magistrate judge recommended dismissal of the plaintiffs&#8217; complaint against all defendants in its entirety with prejudice, and for administrative purposes, issued an order dismissing the complaint. On April 12, 2024, the plaintiffs filed an objection to the magistrate judge&#8217;s recommendation. On May 10, 2024, we filed a response to the plaintiffs&#8217; objection, as did the other defendants. If the district court judge adopts the magistrate judge&#8217;s recommendation and dismisses the case, the plaintiffs will have the right to appeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in this lawsuit.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Litigation with Humana and United Healthcare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Humana Inc. (</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Humana</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and United Healthcare Services, Inc. (</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">United</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) filed separate lawsuits against us in the U.S. District Court for the District of Maryland in December 2022 and November 2022, respectively. Each of these lawsuits includes allegations similar to those in the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> matter discussed above concer</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ning our charitable </span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">contributions</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to CVC. In particular, these lawsuits allege that our donations to CVC violated RICO and various state laws. We filed motions to dismiss both of these lawsuits in March 2023. On March 25, 2024, the court dismissed both the Humana and United complaints in their entirety. In both cases, the RICO claims were dismissed with prejudice. In the Humana case, the state law claims were dismissed without prejudice, and in the United case, some of the state law claims were dismissed with prejudice, while others were dismissed without prejudice. Neither Humana nor United filed an appeal to date, and their deadlines for filing appeals have passed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 24, 2024, Humana and United each filed lawsuits against us in the Circuit Court for Montgomery County, Maryland. These lawsuits include allegations similar to those in their lawsuits discussed above concerning charitable contributions. Humana and United allege that our donations to CVC give rise to common law causes of action, violations of state consumer protection statutes, and violations of insurance fraud statutes under the laws of various states. On July 22, 2024, we filed motions to dismiss both of these lawsuits. Oral argument on these motions to dismiss took place on October 24, 2024. On September 23, 2025, the court dismissed both lawsuits with prejudice. On October 20, 2025, Humana and United each appealed the court&#8217;s decision to the Appellate Court of Maryland, and those appeals are currently pending.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in these lawsuits.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Annual Report</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and our consolidated financial statements and accompanying notes included in</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Part&#160;I,&#160;Item 1 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">of this Quarterly Report on Form&#160;10-Q (this </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Report</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). All statements in this filing are made as of the date this Quarterly Report on Form&#160;10-Q is filed with the U.S. Securities and Exchange Commission (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and other sections of this report contain forward-looking statements made pursuant to the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and the Private Securities Litigation Reform Act of 1995. These statements, which are based on our beliefs and expectations about future outcomes and on information available to us through the date this Report is filed with the SEC, include, among others, statements related to the following:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Expectations of revenues, expenses, profitability, cash flows, and growth in the number of patients being treated with our products, including continued growth in sales of Tyvaso DPI, and anticipated growth in the number of patients with pulmonary hypertension associated with interstitial lung disease (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PH-ILD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) being treated with our Tyvaso products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The sufficiency of our cash on hand to support operations;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Our ability to obtain and maintain domestic and international regulatory approvals;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Our ability to maintain pricing and reimbursement levels for our products, in light of increasing competition, including from generic products, and pressure from government and other payers to decrease the costs associated with healthcare, including the potential impact of the Inflation Reduction Act of 2022 (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IRA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) on our business and the Trump administration&#8217;s most favored nation (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MFN</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) pricing initiatives, as well as the timing and outcome of our efforts to secure Medicare coverage for Nebulized Tyvaso to treat idiopathic pulmonary fibrosis (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), following the anticipated approval by the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The expected volume and timing of sales of our commercial products, as well as potential future commercial products, including the anticipated effect of various research and developm</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ent efforts on sales of these products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="background-color:#ffffff;color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The timing and outcome of clinical studies, other research and development efforts, and related regulatory filings and approvals, including our efforts to obtain FDA approval for Nebulized Tyvaso to treat IPF and ralinepag extended-release tablets to treat PAH;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The outcome of pending and potential future legal and regulatory actions by the FDA and other regulatory and government enforcement agencies related to our products and potential competitive products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The timing and outcome of ongoing litigation, including the lawsuit filed against us by Sandoz Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Sandoz</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and Liquidia PAH, LLC (formerly known as RareGen, LLC) (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RareGen</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">); our patent and trade secret litigation with Liquidia Technologies, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Liquidia</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) related to Yutrepia; Liquidia&#8217;s patent lawsuit against us related to Tyvaso DPI; and our litigation with Humana Inc., United Healthcare Services, Inc., MSP Recovery Claims, Series LLC, and related entities;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The impact of competing therapies on sales of our commercial products, including the impact of generic versions of Remodulin; established therapies such as Uptravi&#174;; and newer therapies such as Merck&#8217;s Winrevair&#174; and Liquidia&#8217;s Yutrepia;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The expectation that we will be able to manufacture sufficient quantities and maintain adequate inventories of our commercial products, through both our in-house manufacturing capabilities and third-party manufacturing sites;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Expectations regarding the amount and timing of capital expenditures to construct new facilities to support our product development and commercialization efforts, including our xenotransplantation-related facilities;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Expectations regarding the timing and impact of our business development efforts;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The adequacy of our intellectual property protection and the validity and expiration dates of the patents we own or license, as well as the regulatory exclusivity periods for our products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Any statements that include the words &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; or similar expressions; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Other statements contained or incorporated by reference in this Report that are not historical facts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We caution you that these statements are not guarantees of future performance and are subject to numerous evolving risks and uncertainties that we may not be able to accurately predict or assess, and that may cause our actual results to differ materially from anticipated results, including the risks and uncertainties we describe in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,&#160;Item&#160;1A&#8212;Risk Factors</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of this Report and risks and uncertainties described in other cautionary statements, cautionary language, and risk factors set forth in our other filings with the SEC.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Overview of Marketed Products</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We market and sell the following commercial products:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="background-color:#ffffff;color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Tyvaso DPI, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a dry powder inhaled formulation of the prostacyclin analogue treprostinil, approved by the FDA in May 2022 to improve exercise ability in patients with pulmonary arterial hypertension (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PAH</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and PH-ILD. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Nebulized Tyvaso,</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> a nebulized liquid inhaled formulation of treprostinil, approved by the FDA to improve exercise ability in patients with PAH. Nebulized Tyvaso was also approved by the FDA in March 2021 to improve exercise ability in patients with PH-ILD. Nebulized Tyvaso has also been approved with respect to PAH and/or PH-ILD in various countries outside of the United States.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a continuously infused formulation of treprostinil, approved by the FDA for subcutaneous and intravenous delivery to diminish symptoms associated with exercise in patients with PAH. Remodulin has also been approved in various countries outside of the United States. In February 2021, we launched U.S. sales of the Remunity Pump, a next-generation subcutaneous infusion system for Remodulin. In September 2025, we launched a new version of the Remunity Pump, called RemunityPRO, which is intended to improve the patient experience by making the pump easier to use.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an oral extended-release tablet form of treprostinil, approved by the FDA to delay disease progression and improve exercise capacity in PAH patients.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Unituxin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an infused monoclonal antibody approved in the United States and Canada for the treatment of high-risk neuroblastoma and approved in Japan for the treatment of neuroblastoma after high-dose chemotherapy.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#aa182c;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.55pt">Adcirca</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil, approved by the FDA to improve exercise ability in PAH patients. We sell Adcirca under an in-license from Eli Lilly and Company (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Lilly</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) that expires December 31, 2026.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our total revenues consist primarily of sales of the commercial products noted above, including the delivery devices (in the case of Tyvaso DPI, Nebulized Tyvaso, and Remodulin). We have entered into separate, non-exclusive distribution agreements with Accredo Health Group, Inc. and its affiliates (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Accredo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and Caremark, L.L.C. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CVS Specialty</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to distribute Tyvaso DPI, Nebulized Tyvaso, Remodulin, the Remunity and RemunityPRO Pumps, and Orenitram in the United States, and we have entered into an exclusive distribution agreement with Cencora Global Procurement Ltd. to distribute Unituxin in the United States. We also sell Nebulized Tyvaso, Remodulin, and Unituxin to distributors internationally. We sell Adcirca through Lilly&#8217;s pharmaceutical wholesale network. To the extent we have increased the price of any of these products, increases have typically been in the single-digit percentages per year, except for Adcirca, the price of which is set solely by Lilly. We also derive revenues from the sale of commercial </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion services, which are presented under </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> within Note 11&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We require our specialty pharmaceutical distributors to maintain reasonable levels of inventory reserves for our treprostinil-based therapies because the interruption of these therapies can be life threatening. Our specialty pharmaceutical distributors typically place monthly or semi-monthly orders based on current utilization trends and contractual minimum and maximum inventory requirements. As a result, sales of our treprostinil-based therapies can vary depending on the timing and magnitude of these orders and do not precisely reflect changes in patient demand. The information we have about patient demand, the number of patients using our products, and inventory held by our distributors, is based upon our review of patient utilization and inventory data provided to us by our specialty pharmaceutical distributors.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Generic Competition and Challenges to our Intellectual Property Rights </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We settled litigation with Sandoz related to its abbreviated new drug application (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ANDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) seeking FDA approval to market a generic version of Remodulin and in March 2019, Sandoz announced the availability of its generic product in the United States. We have also entered into similar settlement agreements with other generic companies, some of which have also launched sales of generic versions of Remodulin. Through March&#160;31, 2026, we have seen limited erosion of Remodulin sales as a result of generic treprostinil competition in the United States. We are currently engaged in litigation with Sandoz and its marketing partner, RareGen (now a subsidiary of Liquidia Corporation, the parent company of Liquidia), related to the infusion devices used to administer Remodulin subcutaneously. We understand that generic treprostinil was initially launched by Sandoz/RareGen for use only by intravenous infusion. In May 2021, Sandoz/Liquidia Corporation announced that Sandoz&#8217;s generic treprostinil was made available for subcutaneous use, following FDA clearance of a cartridge that can administer the product via the Smiths Medical CADD MS-3 pump. In addition, Liquidia has announced it is developing a new subcutaneous infusion system for its generic treprostinil product. See Note 12&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this Report.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Regulatory authorities in various European countries began approving generic versions of Remodulin in 2018, followed by pricing approvals and commercial launches in most of these countries in 2019 and 2020. As a result, our international Remodulin revenues have decreased compared to the period prior to generic launch, due to increased competition and a reduction in our contractual transfer price for Remodulin sold by certain international distributors for sales in countries in which the pricing of Remodulin is impacted by the generic competition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Nebulized Tyvaso and Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Potential Future Generic Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We settled litigation with Watson Laboratories, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Watson</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) related to its ANDA seeking FDA approval to market a generic version of Nebulized Tyvaso before the expiration of certain of our U.S. patents. Under the settlement, Watson was permitted to market its generic version of Nebulized Tyvaso in the United States as early as January 2026, although, to date, it has not received FDA approval to do so. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also settled litigation with Actavis Laboratories FL, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Actavis</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and ANI Pharmaceuticals, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ANI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) related to their ANDAs seeking FDA approval to market generic versions of Orenitram before the expiration of certain of our U.S. patents. Under the settlement agreements, Actavis and ANI can market their generic versions of Orenitram in the United States beginning in June 2027 and December 2027, respectively, although either or both of them may be permitted to enter the market earlier under certain circumstances. Competition from these generic companies could reduce our net product sales and profits. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Liquidia</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Yutrepia</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2025, Liquidia obtained final FDA approval to market Yutrepia, a dry powder formulation of treprostinil for inhalation, to treat PAH and PH-ILD. Liquidia announced that it launched sales of Yutrepia in June 2025. The Yutrepia new drug application (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">NDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was submitted under the 505(b)(2) regulatory pathway with Nebulized Tyvaso as the reference listed drug. Yutrepia competes directly with Tyvaso DPI, Nebulized Tyvaso, and our other treprostinil-based products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are engaged in patent litigation with Liquidia concerning Yutrepia. Specifically, we allege that Yutrepia infringes a patent we own covering the treatment of PH-ILD to improve exercise capacity in patients suffering from PH-ILD by inhaling treprostinil at specific dosages. If we are successful in this litigation, we believe Liquidia will be required to remove PH-ILD as a labeled indication for Yutrepia until the expiration of our patent in February 2042. We are also engaged in litigation with Liquidia alleging </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">trade</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> secret misappropriation. In this case, we allege that a former executive of ours misappropriated trade secrets related to Tyvaso when he utilized them as an executive of Liquidia to aid in the development of Yutrepia. Finally, we are engaged in separate litigation against Liquidia alleging that Yutrepia infringes a patent </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">that claims a method of treating pulmonary hypertension using inhaled treprostinil delivered in a specified dosage using a specified dosage regimen. This patent expires in May 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liquidia has also sued us, alleging infringement of a patent </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">with claims directed to the treatment of pulmonary hypertension by administering specified amounts of treprostinil via a dry powder inhaler in a specified number of breaths. That case is currently stayed pending developments in the trade secret misappropriation litigation described above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For further details regarding these and other litigation matters involving Liquidia and Yutrepia, please see Note 12&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to vigorously enforce our intellectual property rights related to our products. However, we may not prevail in defending our patent rights, and additional challenges from other ANDA filers or other challengers may surface with respect to our products. Our patents could be invalidated, found unenforceable, or found not to cover one or more generic forms of our products. If any ANDA filer or filer of a 505(b)(2) NDA for a branded treprostinil product were to receive approval to sell its treprostinil product and/or prevail in any patent litigation, our affected product(s) would become subject to increased competition. Patent expiration, patent litigation, and competition from generic or other branded treprostinil manufacturers could have a significant, adverse impact on our treprostinil-based product revenues, our profits, and our stock price. These potential effects are inherently difficult to predict. For additional discussion, see the risk factor entitled, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property rights may not effectively deter competitors from developing competing products that, if successful, could have a material adverse effect on our revenues and profit</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">s, contained in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,&#160;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;1A&#8212;Risk Factors&#160;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">included in this Report.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We devote substantial resources to our various clinical trials and other research and development efforts, which are conducted both internally and through third parties. From time to time, we also license or acquire additional technologies and compounds to be incorporated into our development pipeline. Our operating expenses include the costs described below.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Cost of Sales </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our cost of sales primarily includes costs to manufacture our products, royalty and sales-based milestone payments under license agreements granting us rights to sell related products, direct and indirect distribution costs incurred in the sale of our products, and the costs of inventory reserves for current and projected obsolescence. These costs also include share-based compensation and salary-related expenses for direct manufacturing and indirect support personnel, quality review and release for commercial distribution, direct materials and supplies, depreciation, facilities-related expenses, and other overhead costs.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our research and development expenses primarily include costs associated with the research and development of new products, new indications for existing products, and various post-marketing research activities. These costs also include share-based compensation and salary-related expenses for research and development functions, professional fees for preclinical and clinical studies, costs associated with clinical manufacturing, facilities-related expenses, regulatory costs, and costs associated with payments to third-party contract manufacturers before FDA approval of the relevant product. Expenses also include costs for third-party arrangements, including upfront fees and milestone payments required under license arrangements for therapies under development. We do not track fully burdened research and development expenses by individual product candidate.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Selling, General, and Administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our selling, general, and administrative expenses primarily include costs associated with the commercialization of approved products and general and administrative costs to support our operations, including share-based compensation and salary-related expenses. Selling expenses include product marketing and sales operations costs, as well as other costs incurred to support our sales efforts. General and administrative expenses include the core corporate support functions such as human resources, finance, and legal, and associated external costs to support those functions.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Currently, we grant stock options and restricted stock units under the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2015 Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and we may grant restricted stock units to newly hired employees under our 2019 Inducement Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2019 Inducement Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). The grant date fair values of stock options and restricted stock units are recognized as share-based compensation expense ratably over their vesting periods. The fair value of stock options is measured using inputs and assumptions under the Black-Scholes-Merton model. The fair value of restricted stock units is measured using our stock price on the date of grant. Historically, we granted awards under our Share Tracking Awards Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">STAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). Issuance of awards under this plan was discontinued in 2015 and all remaining outstanding STAP awards were exercised during the first quarter of 2025.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_76"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We focus our research and development efforts on the following pipeline programs. We also engage in a variety of additional research and development efforts, including efforts to develop new and improved devices to deliver our current commercial products and other small molecule therapies, some of which are intended for once-daily or as-needed administration, for a variety of pulmonary indications. In addition, we are developing technologies designed to increase the supply of transplantable organs and organ alternatives and improve outcomes for transplant recipients through xenotransplantation, regenerative medicine, and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Select Pipeline Programs</span><span style="color:#c12034;font-family:'DIN Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Mode of Administration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Current Status</span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">STUDY NAME</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Our Territory</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nebulized Tyvaso <br/>(treprostinil)</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">IPF</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Phase&#160;3 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">TETON-1</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> and</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%"> TETON-2 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">studies successful; preparing sNDA</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Nebulized Tyvaso <br/>(treprostinil)</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PPF</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Phase&#160;3 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">TETON-PPF </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">study </span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Ralinepag Tablets</span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(IP receptor agonist)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Oral</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PAH</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Phase 3 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">ADVANCE OUTCOMES</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> study successful; preparing NDA</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Ralinepag DPI</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PAH, PH-ILD, IPF, PPF</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Pre-IND non-clinical testing</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treprostinil SMI</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PAH, PH-ILD, IPF, PPF</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Pivotal pharmacokinetic studies for PAH and PH-ILD ongoing</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treprostinil SMI</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PH-COPD</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preparing IND for phase 2 study</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treprostinil-Iloprost SMI</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Inhaled PRN</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PAH</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preparing IND for phase 1 study</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Triple Combination Therapy</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Oral </span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PAH</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Formulation development and dosage design complete; planning pre-IND engagement with the FDA</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Worldwide</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Nebulized Tyvaso &#8212; </span><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">TETON </span><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Studies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September 2025, we announced that the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> phase 3 study of Nebulized Tyvaso in patients with IPF met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FVC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) relative to placebo. Nebulized Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann [</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">H-L</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">] estimate, p &lt;0.0001) from baseline to week 52 in patients with IPF. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Statistically significant improvements relative to placebo were also observed in most secondary endpoints, including time to first clinical worsening event, as well as changes from baseline to week 52 in percent predicted FVC, King&#8217;s Brief Interstitial Lung Disease quality of life questionnaire (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">K-BILD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) score, and diffusion capacity of lungs for carbon monoxide (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DLCO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). While not statistically significant, both time to first acute exacerbation of IPF and overall survival at week 52 trended in favor of Nebulized Tyvaso. Data from the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">study were published in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in March 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2026, we announced that the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study also met its primary endpoint, with an even stronger treatment effect than the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study. Specifically, the study demonstrated superiority of Nebulized Tyvaso over placebo for the change in absolute FVC by 130.1 mL (H-L estimate, p &lt;0.0001) from baseline to week 52. Nebulized Tyvaso achieved statistical significance for reducing the risk of clinical worsening and showed numerical improvement in other important secondary endpoints relative to placebo, including time to first acute exacerbation of IPF and changes in percent predicted FVC, K-BILD score, and DLCO.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Integrated analyses of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed statistically significant treatment effects compared to placebo from baseline to week 52 for the primary endpoint of change in absolute FVC by 111.8 mL (H-L estimate, p &lt;0.0001) and most secondary endpoints, including time to first clinical worsening and first acute exacerbation of IPF and changes in percent predicted FVC, K-BILD score, and DLCO. Overall survival at week 52 trended in favor of Nebulized Tyvaso but did not meet statistical significance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study enrolled 597 patients and was conducted outside the United States and Canada. </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">enrolled 598 patients in the United States and Canada. Treatment with Nebulized Tyvaso in these studies was well-tolerated, and the safety profile was consistent with previous Tyvaso studies and known prostacyclin-related adverse events. No new safety signal was seen in either study. Benefits of Nebulized Tyvaso were observed across all subgroups, such as use of background therapy (nintedanib, pirfenidone, or no background therapy), smoking status, and supplemental oxygen use. We intend to use the data from both the</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> studies to support a supplemental NDA (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">sNDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to the FDA to add IPF to the labeled indications for Nebulized Tyvaso, which we plan to submit by the end of summer 2026. We believe there are approximately 100,000 IPF patients in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are also conducting a phase 3 study of Nebulized Tyvaso called</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> TETON-PPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the treatment of progressive pulmonary fibrosis (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">); we enrolled the first patient in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-PPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in October 2023. The primary endpoint of the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-PPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study is the change in absolute FVC from baseline to week 52. The </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-PPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study was also prompted by a post-hoc analysis of data from the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">INCREASE</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study. PPF is a group of ILD conditions that exhibit progressive, self-sustaining fibrosis, and a similar disease course to IPF. PPF includes idiopathic interstitial pneumonias, autoimmune ILDs, chronic fibrosing hypersensitivity pneumonitis, and fibrotic ILDs related to environmental/occupational exposure. We are targeting enrollment of 698 patients in the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-PPF </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">study. While estimates vary, we believe the size of the U.S. PPF population is approximately 200,000 patients.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We and our distributors will also consider seeking amendments to the marketing authorizations for Nebulized Tyvaso in other countries where it is approved, to include IPF and/or PPF indications, and we will also consider seeking approval of Nebulized Tyvaso for these indications in countries where it is not yet approved. We also plan to seek FDA approval to expand the Tyvaso DPI label to include IPF and/or PPF, as applicable, following completion of any FDA-required bridging studies. Based on preliminary feedback from the FDA, these bridging studies may include pivotal clinical trials to establish safety and efficacy of Tyvaso DPI for treating patients with IPF and PPF. Both the FDA and the European Medicines Agency have granted orphan designation for treprostinil to treat IPF. </span></div><div><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%">Treprostinil SMI</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are developing a version of inhaled treprostinil that will be a drug-device combination consisting of treprostinil solution and a device known as a soft mist inhaler (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SMI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). SMI devices are propellant-free, hand-held mechanical devices that deliver an aerosol cloud of medication via a single breath. SMI devices would be more convenient for our patients than the current Tyvaso nebulizer, which requires several breaths using a much larger device that needs electricity. SMI devices are pocket-sized and disposable, and would be delivered with a pre-filled, multi-dose cartridge of drug product that is stored at room temperature and easily inserted into the device to begin use. Due to the multi-dose cartridge, which is intended to provide sufficient doses for up to 14 days of use, there is no need to fill the SMI device every day like a nebulizer. SMI devices may also provide a favorable adverse event profile compared to dry powder inhalers. We are targeting the same indications for which Nebulized Tyvaso is already approved (PAH and PH-ILD), as well as those for which we plan to seek FDA approval in the future (IPF and PPF), following completion of any FDA-required bridging studies. We are currently conducting pivotal pharmacokinetic studies to establish comparability between treprostinil SMI and Nebulized Tyvaso, to support a 505(b)(1) NDA for PAH and PH-ILD. Additionally, we are preparing an IND to enable us to conduct a phase 2 study of treprostinil SMI to treat patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PH-COPD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">).</span></div><div><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%">Treprostinil-Iloprost SMI</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are developing a fixed-dose, drug-device combination product consisting of treprostinil and iloprost solution and an SMI. We are targeting this product for </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">pro re nata</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PRN</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), or &#8220;as-needed&#8221;, use for PAH patients whose primary therapy is either an oral or inhaled prostacyclin-class therapy who may from time to time need a bridge between doses due to exercise activity. Iloprost is a prostacyclin-class therapy that is approved by the FDA to treat PAH via nebulized inhalation solution. Based on a preclinical research study, we believe there may be beneficial synergies when treprostinil and iloprost are dosed together on a PRN basis. We have completed pre-IND engagement with the FDA and are in the process of preparing an IND. Once the IND is cleared, we plan to proceed to a phase 1 pharmacokinetics and safety study in healthy volunteers, and eventually, a pivotal efficacy study in PAH patients. </span></div><div><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%">Ralinepag Extended-Release Tablets </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Ralinepag is a next-generation, once-daily, oral, extended-release, titratable, selective, and potent prostacyclin (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) receptor agonist that we are developing for the treatment of PAH. In March 2026, we announced the successful results of our pivotal </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ADVANCE OUTCOMES </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">study, which was a phase 3, event-driven clinical trial of an extended-release formulation of ralinepag tablets in PAH patients with a primary endpoint of time to first clinical worsening event. The study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55 percent compared with placebo in patients with PAH (hazard ratio 0.45, p&lt;0.0001).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Ralinepag demonstrated durable efficacy in delaying disease progression during the study, in which 80 percent of patients were on dual background therapy and 70 percent of patients were considered World Health Organization (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">WHO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)/New York Heart Association (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">NYHA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) Functional Class (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) II at baseline. Statistically significant improvements relative to placebo were also observed in important secondary endpoints, including six-minute walk distance (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">6MWD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and change in N-terminal pro-B-type natriuretic peptide (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">NT-proBNP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), with ralinepag increasing the odds of achieving clinical improvement by 47 percent from baseline to week 28 (p=0.015).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits were consistent across all patient subgroups, including time since diagnosis, disease etiology, baseline 6MWD, and use of background therapies, reinforcing the robustness of the treatment effect and the potential broad therapeutic relevance of ralinepag. Treatment with ralinepag was well-tolerated and the safety profile was consistent with known prostacyclin-related adverse events. No new safety signals were observed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We plan to submit an NDA for ralinepag extended-release tablets to the FDA by the end of summer 2026. If approved and launched, we expect ralinepag&#8217;s once-daily dosing profile to position it favorably compared with Uptravi (selexipag), which is a twice-daily IP-receptor agonist marketed by Johnson &amp; Johnson for the treatment of PAH. In 2025, Johnson &amp; Johnson reported global sales of Uptravi of over $1.9 billion, including over $1.5 billion in U.S. sales, reflecting a growth rate of approximately 5 percent over 2024.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Triple Combination Therapy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are developing an oral triple combination therapy consisting of ralinepag,</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> an endothelin receptor antagonist (</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ERA</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and a PDE-5 inhibitor. We have completed formulation development and dosage design work and plan to engage with the FDA on </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">our proposed clinical development strategy following submission of our NDA for ralinepag extended-release tablets. Our triple combination therapy is intended to provide a convenient means of dosing patients with existing first-line oral therapies for PAH (an ERA and a PDE-5 inhibitor), along with once-daily ralinepag.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Ralinepag DPI </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are developing a dry powder inhalation (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DPI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) version of ralinepag. In August 2025, we exercised the option under our license and collaboration agreement with MannKind Corp. to develop ralinepag DPI utilizing the dry powder formulation technology used to manufacture Tyvaso DPI. We believe the half-life of ralinepag may support once-daily dosing of ralinepag DPI. We are currently in the process of formulating ralinepag DPI for non-clinical studies and a subsequent phase 1 study in healthy volunteers to assess dosing and pharmacokinetic comparability with ralinepag extended-release tablets, which will inform a pivotal study in PAH patients to further assess safety and pharmacokinetic comparability. We initially intend to seek FDA approval of ralinepag DPI for PAH. We also plan to seek approval for PH-ILD, IPF, and PPF, which will require additional clinical studies assessing safety and efficacy in patients with these conditions. Under the terms of our expanded agreement with MannKind, we will pay MannKind up to $35 million in development milestones and a 10 percent royalty on net sales of ralinepag DPI. Under our license agreement with Arena Pharmaceuticals Inc. (now owned by Pfizer Inc.), we will be obligated to pay a $250.0 million milestone payment upon FDA approval of ralinepag DPI, and a low double-digit, tiered royalty on net sales. We are constructing a manufacturing facility in Research Triangle Park, North Carolina, which we plan to use to manufacture ralinepag DPI.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Manufactured Organs and Organ Alternatives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each year, end-stage organ failure kills millions of people. A significant number of these patients could have benefited from an organ transplant. Unfortunately, the number of usable, donated organs available for transplantation has not grown significantly over the past half century, while the need has soared. Our long-term goals are aimed at addressing this shortage. With advances in technology, we believe that creating an unlimited supply of tolerable manufactured organs and organ alternatives is now principally an engineering challenge, and we are dedicated to finding engineering solutions. We are engaged in research and development of a variety of technologies designed to increase the supply of transplantable organs and tissues and to improve outcomes for transplant recipients through xenotransplantation, regenerative medicine, and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">While we continue to develop and commercialize therapies for rare and life-threatening conditions, we view manufactured organs and organ alternatives as complementary solutions for a broad array of diseases, many of which (such as PAH and PH-ILD) have proven incurable to date despite the availability of pharmaceutical and biologic therapies. For this reason, we included the development of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;technologies that expand the availability of transplantable organs&#8221;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as part of our express public benefit purpose when we converted United Therapeutics to a public benefit corporation (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PBC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) in 2021.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xenotransplantation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our xenotransplantation program includes three development-stage organ products known as &#8220;xenografts&#8221;, which are intended to be transplanted from gene-edited pigs into humans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The UKidney&#8482; is an investigational-stage kidney from a pig with ten gene edits to support organ functioning in the human body. Six human genes were added to the pig genome to facilitate immune acceptance of the organ, while four genes were inactivated: three that contribute to porcine organ rejection in humans and one that can cause organ growth beyond what is normal for humans. The UHeart&#8482; is a heart from the same pig with ten gene edits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The UThymoKidney&#8482; is an investigational-stage kidney from a pig with a single gene edit, together with tissue from the pig&#8217;s thymus. The pig&#8217;s thymus tissue is intended to condition the recipient&#8217;s immune system to recognize the UThymoKidney as &#8220;self&#8221; and reduce the likelihood of rejection. The single gene that is disrupted in the pig is responsible for the synthesis of alpha-gal, a sugar on the surface of cells that can cause immediate rejection of a porcine organ when transplanted into the human body. Because tissues from pigs containing this gene edit do not contain detectable levels of the alpha-gal sugar, we refer to materials derived from this pig as GalSafe&#174;. In December 2020, the GalSafe pig was approved by the FDA for use as human food and as a potential source for biomedical purposes. Meat from GalSafe pigs is currently being provided to individuals with alpha-gal syndrome, an allergy to meat caused by a bite from the lone star tick. This approval marked only the second FDA approval of a gene-edited animal as a source of food, and the first such approval for a mammal.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January 2025, the FDA cleared our Investigational New Drug application (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IND</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) related to the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">EXPAND</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study of our UKidney product. This study is expected to enroll an initial cohort of six end-stage renal disease (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ESRD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) patients, expanding to up to 50 participants, and we intend to use the results of this study to support a Biologics License Application (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">BLA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with the FDA. This study is designed as a combination phase 1/2/3 trial (sometimes referred to as a &#8220;phaseless&#8221; study) to evaluate safety and efficacy seamlessly without moving through separate phase 1, phase 2, and phase 3 studies that are typically associated with conventional drug approvals. The first transplant in this study occurred in the fourth quarter of 2025, and the study is ongoing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2025, we submitted an IND to the FDA related to our anticipated </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">EXTEND</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> clinical study of our UThymoKidney product. In August 2025, the FDA cleared this IND, enabling us to commence this study, which we expect will be similar in size and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">scope to the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">EXPAND</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> study described above. We are engaging with the FDA on a potential IND for a study of our UHeart product.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2024, we completed a designated pathogen-free (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) facility in Virginia. We expect this DPF facility to supply xenografts compliant with FDA current Good Manufacturing Practices (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">cGMP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for human clinical trials, with a target capacity of up to 125 organs per year. We are constructing two additional DPF facilities in Minnesota and Texas. While we believe these DPF facilities will be capable of producing organs for commercial use, we are also planning to build additional and potentially larger cGMP DPF facilities for commercial use. While these projects will be capital-intensive, the timing and volume of these expenditures will be staggered and paced in a manner intended to balance our need to address market demand as soon as possible following FDA approval with the need to defer the most significant capital expenditures until we achieve certain clinical trial milestones.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regenerative Medicine</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:6.55pt">Miromatrix.</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> In December 2023, we acquired Miromatrix Medical Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Miromatrix</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), a company based in Minnesota focused on the development of new technologies for generating manufactured kidneys and liver alternatives composed of human primary cells. The development-stage Miromatrix external liver assist product, called miroliver</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ELAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#174;, uses a decellularized porcine liver matrix that has been seeded with human-derived cells and an extracorporeal blood circuit to maintain liver support in patients experiencing acute liver failure. Miromatrix first used its decellularization technology to successfully develop two acellular products, MiroMesh&#174; and MiroDerm&#174;, which received FDA 510(k) clearance for hernia repair and wound care applications, respectively, and which were later spun off by Miromatrix. In January 2026, we announced that Miromatrix completed a phase 1 study of miroliver</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ELAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in patients with acute liver failure. This study, which was the first human clinical trial of a manufactured organ alternative, met its primary endpoint. Miromatrix is planning to commence a phase 2 study, and the FDA has granted miroliver</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ELAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Regenerative Medicine Advanced Therapy designation. Miromatrix is also developing miroliver&#174;, a fully implantable manufactured liver alternative product, and mirokidney&#174;, a fully implantable manufactured kidney alternative product, both of which are based on decellularized porcine organ scaffolds that have been reseeded with human-derived cells. Initially the Miromatrix products are intended to be made with cells from a human donor other than the recipient (also called &#8220;allogeneic&#8221; cells), requiring the use of standard immunosuppression protocols. Future versions may be based on the patient&#8217;s own cells (known as &#8220;autologous&#8221; cells), reducing or eliminating the need for immunosuppression drugs. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:6.55pt">ULobe&#8482;.</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> The ULobe is a development-stage engineered lung lobe alternative made using a porcine lung scaffold that is decellularized and then re-cellularized with allogeneic human cells. In 2025, our Regenerative Medicine Laboratory in Research Triangle Park, North Carolina (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RTP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) produced 830 decellularized lung scaffolds, 345 recellularized lungs, and 1.65 trillion human cells for use in recellularization.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:6.55pt">ULung&#8482;.</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> The ULung is a development-stage engineered lung alternative composed of a 3D printed lung scaffold cellularized with human lung cells, with the goal of using autologous cells and reducing or eliminating the need for immunosuppression. The lung scaffold used in the ULung is printed using 3D printers being developed in collaboration with 3D Systems, Inc. Our Organ Manufacturing Group, located in Manchester, New Hampshire, has achieved recognition for developing the world&#8217;s most complex 3D printed object. Its lung scaffold designs consist of a record 44 trillion voxels that lay out 4,000 kilometers of pulmonary capillaries and 200 million alveoli, which demonstrate gas exchange in preclinical models. Under our agreement with 3D Systems, we also have the exclusive right to develop additional human solid organ alternatives using 3D Systems&#8217; printing technology.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:6.55pt">IVIVA.</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> In October 2023, we completed the acquisition of IVIVA Medical, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IVIVA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), a preclinical stage company based in Massachusetts, focused on bio-artificial manufactured kidney alternative products. IVIVA&#8217;s preclinical implantable kidney alternative product uses autologous cells to mimic important physiological functions of native kidneys in recipients to support their native kidney function without the need for immunosuppression. The product is designed to replace the need for external kidney dialysis.</span></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ex Vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lung Perfusion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EVLP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) program uses the first FDA-approved acellular EVLP technology on the market, the XVIVO Perfusion System (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">XPS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8482;) with Steen Solution&#8482; Perfusate, to offer the only commercially available centralized EVLP service in the United States. EVLP technology increases the number of transplantable lungs by giving surgeons the ability to assess the function of donor lungs to determine if the lungs are suitable for transplantation. This allows for the transplantation of lungs that would have otherwise not been transplanted. Centralized EVLP services make EVLP available to small and large transplant centers and remove barriers to the transplantation process to optimize organ utilization and increase the supply of transplantable lungs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our wholly owned subsidiary, Lung Bioengineering Inc., provides commercial EVLP services on a fee-for-service basis to transplant centers through dedicated facilities located in Silver Spring, Maryland and Jacksonville, Florida, using the XPS System. In 2024, Lung Bioengineering completed a registrational study of another centralized EVLP technology called the Centralized Lung Evaluation System (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CLES</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and submitted a premarket approval application to the FDA for commercial approval of CLES, which is under review by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Over 750 patients have received lung transplants following use of our centralized EVLP service.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sustainable Delivery of Organs and Organ Alternatives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Together with our work on therapeutic interventions, we are working with third parties to develop scalable technologies to efficiently deliver an unlimited supply of manufactured organs and organ alternatives to transplant centers and waiting patients, while minimizing environmental impact. Our organ delivery research efforts are focused on the development of piloted and autonomous electric vertical take-off and landing aircraft systems to quickly, reliably, and sustainably deliver organs and organ alternatives from manufacturing facilities to transplant centers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beginning in 2017, we entered into a series of agreements with BETA Technologies, Inc. to support the development of all-electric aircraft to help us meet our future distribution requirements for manufactured organs and organ alternatives. In October 2021, we successfully completed the first-ever drone delivery of a human lung for transplant at Toronto General Hospital, demonstrating the feasibility of our goal of delivering our manufactured organs and organ alternatives with zero carbon footprint aircraft. </span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October 2024, we entered into a collaboration agreement with Robinson Helicopter Company to support our efforts to develop and certify zero-emission, hydrogen-electric powered helicopters based on Robinson&#8217;s R44 and R66 helicopter models. In March 2025, we </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">completed</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> what we believe was the world&#8217;s first successful tes</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">t flight of a piloted hydrogen-electric powered helicopter at our test and development facility located in Quebec.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_79"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Future Prospects</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We anticipate that revenue growth over the near-term will be driven primarily by: (1) continued </span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">growth in sales of Tyvaso DPI; (2) continued </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">growth in the number of PH-ILD patients prescribed Tyvaso DPI and Nebulized Tyvaso</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; (3) the launch of ralinepag extended-release tablets for PAH, following FDA approval; (4) the launch of Nebulized Tyvaso for IPF, following FDA approval; (5) FDA approval and launch of treprostinil SMI; (6) continued growth in the number of patients prescribed Orenitram; </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and (7) modest price increases for some of our products. We believe that additional revenue growth in the medium- and longer-term will be driven by the additional products and indications described above under </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our ability to achieve our objectives, grow our business, and maintain profitability will depend on many factors, including among others: (1) the timing and outcome of preclinical research, clinical trials, and regulatory approval applications for new products and new indications for existing products; (2) the timing and degree of our success in commercially launching new products and new indications for existing products; (3) the demand for our products; (4) the net price of our products and the reimbursement of our products by public and private health insurance organizations, including the impact on such net prices and reimbursement amounts as a result of the IRA, MFN, and other government initiatives focused on drug pricing, and as a result of additional payer rebates, and the timing and degree of success in obtaining reimbursement for new products and new indications for existing products; (5) the competition we face within our industry, including competition from generic companies, the recent launch of Yutrepia, and the potential launch of new therapies for PAH, PH-ILD, IPF, and/or PPF; (6) our ability to effectively manage our business in an increasingly complex legal and regulatory environment; (7) our ability to defend against challenges to our patents; and (8) the risks identified in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Part II, Item&#160;1A&#8212;Risk Factors</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, included in this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have budgeted approximately $290 million for capital expenditures during 2026 and through the end of 2028 to construct additional facilities to support the development and commercialization of our products and technologies. This amount is primarily dedicated to (a) construction of a new manufacturing facility in RTP that we intend to use to manufacture ralinepag DPI; and (b) construction of clinical-scale DPF facilities in Stewartville, Minnesota and Houston, Texas. We plan to fund these capital expenditures using cash on hand.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We anticipate that our existing DPF facility in Virginia and the two planned DPF facilities in Minnesota and Texas will provide an initial commercial supply of our xeno-organ products if and when these products are approved by the FDA. However, if our xeno-organ products are approved by the FDA, we likely will need to continue building additional DPF facilities to address anticipated demand for these products. Additional DPF facilities will be very capital-intensive, but we expect they will be executed in stages, which will enable us to adjust the schedule (and anticipated cost) of construction depending on the progress of our clinical, regulatory, and commercial activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We operate in a highly competitive market in which several large pharmaceutical companies control many of the available PAH therapies, including Merck, which received FDA approval for Winrevair (sotatercept-csrk) to treat PAH in March 2024. These pharmaceutical companies are well established in the market and possess greater financial, technical, and marketing resources than we do. In addition, Yutrepia was approved by the FDA in May 2025 for treatment of PAH and PH-ILD, and the product was launched commercially in June 2025. Despite this increase in competition, we believe revenues from our existing product portfolio will continue to grow, particularly given the addressable U.S. market opportunity for Tyvaso DPI and Nebulized Tyvaso in patients with PH-ILD. In addition, with the successful results of our </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ADVANCE OUTCOMES</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> studies, we anticipate FDA approval of ralinepag extended-release tablets for PAH and Nebulized Tyvaso for IPF in the near-term, providing the opportunity for significant revenue through the end of the decade and beyond.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Results of Operations </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2026 and March&#160;31, 2025</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below presents the components of total revenues (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar <br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tyvaso DPI</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">302.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Nebulized Tyvaso</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">163.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(36.6)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total Tyvaso</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">457.5&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">466.3&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Orenitram</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Unituxin</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adcirca</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(52)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">781.5&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">794.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total Tyvaso net product sales decreased two percent to $457.5 million for the three months ended March 31, 2026, as compared to $466.3 million for the same period in 2025, driven by a decrease in Nebulized Tyvaso net product sales, partially offset by growth in Tyvaso DPI net product sales. Tyvaso DPI net product sales increased for the three months ended March 31, 2026, as compared to the same period in 2025, primarily due to an increase in quantities sold of $16.0 million and, to a lesser extent, a price increase. Nebulized Tyvaso net product sales decreased for the three months ended March 31, 2026, as compared to the same period in 2025, primarily due to a decrease in U.S. quantities sold of $33.3 million and, to a lesser extent, a decrease in international net product sales, partially offset by a price increase.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Remodulin net product sales decreased for the three months ended March 31, 2026, as compared to the same period in 2025, primarily due to a decrease in quantities sold of $11.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram net product sales increased for the three months ended March 31, 2026, as compared to the same period in 2025, primarily due to an increase in quantities sold of $10.2 million.</span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">The table below presents the breakdown of total revenues between the United States and rest-of-world (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%">ROW</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">) (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net product sales:</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tyvaso DPI</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nebulized Tyvaso</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">112.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">127.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">163.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total Tyvaso</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">442.9&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">457.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">441.1&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">466.3&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">108.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">17.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.0&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unituxin</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">49.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">53.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">56.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">58.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adcirca</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">744.2&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">37.3&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">781.5&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">749.6&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">44.8&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">794.4&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-Net Deductions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We recognize revenues net of: (1)&#160;rebates and chargebacks; (2)&#160;prompt pay discounts; (3) allowance for sales returns; and (4)&#160;distributor fees. These are referred to as gross-to-net deductions and are primarily based on estimates reflecting historical experiences as well as contractual and statutory requirements. We currently estimate our allowance for sales returns using reports from our distributors. The tables below present a reconciliation of the accounts associated with these deductions (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Rebates and Chargebacks</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Prompt Pay Discounts</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Allowance for Sales Returns</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Distributor Fees</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balance, January 1, 2026</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">238.9&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">258.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Provisions attributed to sales in:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">143.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments or credits attributed to sales in:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(122.7)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(137.9)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balance, March 31, 2026</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">229.4&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">247.9&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Rebates and Chargebacks</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Prompt Pay Discounts</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Allowance for Sales Returns</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Distributor Fees</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balance, January 1, 2025</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">140.8&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">159.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Provisions attributed to sales in:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">124.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments or credits attributed to sales in:</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(36.2)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(93.1)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(107.7)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balance, March 31, 2025</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">177.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes cost of sales by major category (dollars in millions):&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Category:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">132.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">See </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section below for discussion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, excluding share-based compensation. </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The increase in cost of sales for the three months ended March&#160;31, 2026, compared to the same period in 2025, was mainly due to an increase in inventory reserve expense. Of this increase amount, $26.8 million relates to an estimated loss from a commercial supply agreement that we maintain to provide sufficient Tyvaso DPI inventory to meet the needs of our patients.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'DIN Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes the nature of research and development expense by major expense category (dollars in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar <br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Category:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">External research and development</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Internal research and development</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 22.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">149.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.97pt">External research and development</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily includes fees paid to third parties (such as clinical trial sites, contract research organizations, and contract laboratories) for preclinical and clinical studies and payments to third-party contract manufacturers before regulatory approval of the relevant product.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.97pt">Internal research and development</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily includes salary-related expenses for research and development functions, internal costs to manufacture product candidates before regulatory approval, and internal facilities-related expenses, including depreciation, related to research and development activities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">See </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section below for discussion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.97pt">Other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily includes upfront fees and milestone payments to third parties under license agreements related to development-stage products and adjustments to the fair value of our contingent consideration obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development, excluding share-based compensation.</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> The decrease in research and development expense for the three months ended March&#160;31, 2026, as compared to the same period in 2025, was primarily due to a decrease in milestone payments for drug delivery device technologies, partially offset by an increase in personnel expenses. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, General, and Administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes selling, general, and administrative expense by major category (dollars in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.164%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Category:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total selling, general, and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">184.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">See </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> below for discussion.</span></div><div style="margin-bottom:6pt;margin-top:4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Share-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation expense by major category (dollars in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Category:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">STAP awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation expense by line item in our consolidated statements of operations (dollars in millions):</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.161%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The increase in share-based compensation expense for the three months ended March&#160;31, 2026, as compared to the same period in 2025, was primarily due to an increase in the number of unvested and outstanding performance-based stock options during the three months ended March 31, 2026, as compared to the same period in 2025. For more information, see Note 8</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Share-Based Compensation&#160;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Expense, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The change in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2026, as compared to the same period in 2025, was primarily due to net unrealized losses on equity securities. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Investments </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and Note 4&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Income tax expense for the three months ended March&#160;31, 2026 and 2025 was $43.4 million and $101.3 million, respectively. Our effective income tax rate (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ETR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for the three months ended March&#160;31, 2026 and 2025 was 14 percent and 24 percent, respectively. Our ETR for the three months ended March&#160;31, 2026 decreased compared to our ETR for the three months ended March&#160;31, 2025, primarily due to increased excess tax benefits from share-based compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract), </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">which program expires on March 9, 2027. </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the repurchase program, in March 2026, we entered into two accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citibank, N.A. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Citi</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) which comprise a $750&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $750&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). Under the 2026 ASR agreements, we made an aggregate upfront payment of $1.5&#160;billion to Citi and received initial deliveries of 992,120 and 708,657 shares of our common stock on March 11, 2026, representing approximately 70 percent and 50 percent of the total shares that would be repurchased under the 2026 Uncollared ASR and 2026 Collared ASR, respectively, measured based on the closing price of our common stock on March 9, 2026. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2026 Collared ASR, we received an additional 463,682 shares of our common stock on March 30, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final number of shares that we will ultimately repurchase pursuant to the 2026 ASR agreements will be determined based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2026 ASR agreements. As discussed above, under the 2026 Collared ASR, the final number of shares we will ultimately repurchase will also be subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments. At the final settlement of the 2026 ASR agreements, we may be entitled to receive additional shares of our common stock, or, under certain limited circumstances, be required to make an additional cash payment to Citi or, if we so elect, deliver shares of our common stock to Citi. The scheduled termination date of the 2026 Uncollared ASR is in the second quarter of 2026. The scheduled termination date of the 2026 Collared ASR is in the third quarter of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March 31, 2026, $500 million remained available under our Board&#8217;s share repurchase authorization through March 9, 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In August 2025, we entered into two accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citi, comprised of a $500&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $500&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). Under the 2025 ASR agreements, we made an aggregate upfront payment of $1.0&#160;billion to Citi and received initial deliveries of 1,274,296 and 849,531 shares of our common stock on August 4, 2025, representing approximately 75 percent and 50 percent of the total shares that would be repurchased under the 2025 Uncollared ASR and 2025 Collared ASR, respectively, measured based on the closing price of our common stock on August 1, 2025. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2025 Collared ASR, we received an additional 514,789 shares of our common stock on August 25, 2025. The final settlement of the 2025 Uncollared ASR occurred in November 2025, and we received an additional 3,882 shares of our common stock upon settlement. The final settlement of the 2025 Collared ASR occurred in January 2026, and we received no additional shares of our common stock upon settlement as a result of a collar </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">provision that established the minimum and maximum number of shares to be repurchased, as well as other adjustments. In total, we repurchased 2,642,498 shares of our common stock under the 2025 ASR agreements that we currently hold as treasury stock in our consolidated balance sheets.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_85"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Financial Condition, Liquidity, and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have funded our operations principally through sales of our commercial products and, from time-to-time, third-party financing arrangements. We believe that our current sources of liquidity are sufficient to fund ongoing operations and future business plans as we expect aggregate growth in revenues from our commercial products. Furthermore, our customer base remains stable, and we believe that it presents minimal credit risk. However, any projections of future cash flows are inherently subject to uncertainty, and we may seek other forms of financing. In April 2025, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which provides for an unsecured revolving credit facility of up to $2.5 billion. Our outstanding balance under the 2025 Credit Agreement, which matures in 2031, was zero as of March 31, 2026. See </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Unsecured Revolving Credit Facilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> below for further details.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Cash and Cash Equivalents and Marketable Investments</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents and marketable investments comprise the following (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:44.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,279.7&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,557.1&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(277.4)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable investments&#8212;current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">874.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,363.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(489.2)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable investments&#8212;non-current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,776.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(459.3)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total cash and cash equivalents and marketable investments</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,471.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,697.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,225.9)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash flows comprise the following (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.275%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Dollar Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">463.3&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">461.2&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">743.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(164.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">908.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></div></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,484.4)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(93.8)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1,390.6)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NM</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Calculation is not meaningful.</span></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our operating assets and liabilities consist primarily of accounts receivable, inventories, accounts payable, accrued expenses, and tax-related payables and receivables.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The increase of $908.4 million in net cash provided by investing activities for the three months ended March&#160;31, 2026, as compared to the same period in 2025, was primarily due to a $955.8 million increase in net proceeds from marketable investments; partially offset by: (1) a $25.9 million increase in cash paid to purchase property, plant, and equipment and (2) a $25.0 million increase in cash paid to purchase an investment in a privately held company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The increase of $1,390.6 million in net cash used in financing activities for the three months ended March&#160;31, 2026, as compared to the same period in 2025, was primarily due to a $1.5 billion payment to repurchase our common stock; partially offset by: (1) a $100.0 million decrease in cash used for a repayment on our line of credit and (2) a $51.7 million increase in proceeds from the exercise of stock options.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part I. Financial Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsecured Revolving Credit Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2022, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2022 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Wells Fargo, as administrative agent and a swingline lender, and various other lender parties, which provided for: (1) an unsecured revolving credit facility of up to $1.2 billion; and (2) a second unsecured revolving credit facility of up to $800.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 25, 2025, we terminated the 2022 Credit Agreement and entered into the 2025 Credit Agreement, which provides for an unsecured revolving credit facility of up to $2.5 billion in the aggregate. On April 25, 2025, we borrowed $200.0 million under the 2025 Credit Agreement and used the proceeds to repay all outstanding indebtedness under the 2022 Credit Agreement in connection with its termination. During the second quarter of 2025, we repaid the remaining $200.0 million balance under the 2025 Credit Agreement, which brought our aggregate outstanding balance to zero as of June 30, 2025. Our aggregate outstanding debt balance remained zero as of March 31, 2026. Refer to Note 7</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Debt&#8212;2025 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to our consolidated financial statements.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_88"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Summary of Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with U.S. generally accepted accounting principles requires our management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We continually evaluate our estimates and judgments to determine whether they are reasonable, relevant, and appropriate. These assumptions are frequently developed from historical data or experience, currently available information, and anticipated developments. By their nature, our estimates are subject to an inherent degree of uncertainty; consequently, actual results may differ. We discuss critical accounting policies and estimates that involve a higher degree of judgment and complexity in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,&#160;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in our 2025 Annual Report. There have been no material changes to our critical accounting policies and estimates as disclosed in our 2025 Annual Report.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_91"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See Note 2&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, to our consolidated financial statements for information on our anticipated adoption of recently issued accounting standards. </span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_94"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 3.&#160;Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our exposure to market risk has not materially changed since December&#160;31, 2025.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_97"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 4.&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on their evaluation, as of March&#160;31, 2026, our Chairperson and Chief Executive Officer and our Chief Financial Officer and Treasurer have concluded that our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended) are effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, summarized, processed, and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chairperson and Chief Executive Officer and our Chief Financial Officer and Treasurer, as appropriate to allow timely decisions regarding required disclosure. There have been no changes in our internal control over financial reporting that occurred during the period covered by this Report that have materially affected, or are reasonably likely to materially affect, such internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:20pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:20pt;font-weight:400;line-height:120%">Part&#160;II.&#160;OTHER INFORMATION</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_103"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 1.&#160;Legal Proceedings </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Please see Note 12</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Litigation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to our consolidated financial statements contained elsewhere in this Report, which is incorporated herein by reference.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_106"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 1A.&#160;Risk Factors</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investing in our securities involves uncertainty and risk due to a variety of factors. You should carefully consider each of the following risks and all of the other information contained in this Report and in other documents that we file with, or furnish to, the SEC before making any investment decision with respect to our securities. Statements in this section are based on our beliefs and opinions regarding matters that could materially adversely affect us in the future and are not representations as to whether such matters have or have not occurred previously. Further, the risks and uncertainties described below are not the only ones we face and should not be considered a complete statement of all potential risks or uncertainties that we face or may face in the future. Additional risks not presently known to us or that we currently deem immaterial may also materially affect our business.</span></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Risks Related to Our Products and Our Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We rely heavily on sales of our treprostinil-based therapies to generate revenues and support our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of our treprostinil-based therapies &#8212; Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram &#8212; comprise the vast majority of our revenues. Substantially decreased sales of any of these products could have a material adverse impact on our operations. A wide variety of events, such as withdrawal of regulatory approvals or substantial changes in prescribing practices or dosing patterns, many of which are described in other risk factors below, could cause sales of these products to materially decline, or to grow more slowly than expected. Our net revenues could also be negatively impacted by pricing pressure as a result of competitive challenges, the IRA, MFN policies, and other drug price reduction initiatives. The availability of generic versions of our products has negatively impacted our revenues, and these and additional generic products launched in the future may continue to do so. The approval and launch of new therapies may materially negatively impact sales of our current and potential new products. Sales may decrease if any third party that manufactures, markets, distributes, or sells our commercial products cannot do so satisfactorily, or we cannot manage our internal manufacturing processes. Finally, if demand for our Tyvaso products does not meet our expectations, the revenue opportunity for our treprostinil products could be significantly lower than we expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If our products fail in clinical trials, we will be unable to sell those products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To obtain approvals from the FDA and international regulatory agencies to sell new products, to expand the product labeling for our existing products, or to launch new delivery devices for our existing products, we must conduct clinical trials demonstrating that our products are safe and effective. Regulators have substantial discretion over the approval process. Regulators may require us to amend ongoing trials or perform additional trials, which have in the past and could in the future result in significant delays and additional costs and may be unsuccessful. Delays and costs associated with regulatory requirements to change or add trials have sometimes caused us to discontinue efforts to develop a particular product, and may do so again in the future. If our clinical trials are not successful, or we fail to address identified deficiencies adequately, we will not obtain required approvals to market the new product or new indication. We cannot predict with certainty how long it will take, or how much it will cost, to complete necessary clinical trials or obtain regulatory approvals of our current or future products. The time and cost needed to complete clinical trials and obtain regulatory approvals varies by product, indication, and country. In addition, failure to obtain, or delays in obtaining, regulatory approval has in the past and could in the future require us to recognize impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our clinical trials have been and in the future may be discontinued, delayed, canceled, or disqualified for various reasons, including: (1) pandemics; (2) manufacturing and supply chain disruptions; (3) the drug is unsafe or ineffective, or physicians and/or patients believe that the drug is unsafe or ineffective, or that other therapies are safer, more effective, better tolerated, or more convenient; (4) patients do not enroll in or complete clinical trials at the rate we expect, due to the availability of alternative therapies, the enrollment of competing clinical trials, or other reasons; (5) we, or clinical trial sites or other third parties, do not adhere to trial protocols and required quality controls under good clinical practices (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">GCP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) regulations; (6)&#160;patients experience severe side effects during treatment or die during our trials because of adverse events; and (7) the results of clinical trials conducted in a particular country are not acceptable to regulators in other countries.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We may not compete successfully with established or newly developed drugs or products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Competition could negatively impact our operating results. We compete with well-established drug companies for market share, as well as, among other things, funding, licenses, expertise, personnel, clinical trial patients and investigators, consultants, and third-party collaborators. Some of these competitors have substantially greater financial, marketing, manufacturing, sales, distribution, and technical resources, and a larger number of approved products, than we do. Some of these competitors also possess greater experience in areas critical to our success, such as research and development, clinical trials, sales and marketing, and regulatory matters.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Numerous treatments compete with our commercial therapies. For example, for the treatment of PAH, we compete with over fifteen branded and generic drugs. Sales of a generic version of Adcirca launched in August 2018 have had a material adverse impact on our sales of Adcirca. The availability of generic treprostinil injection in the United States could materially impact our revenues, and generic competition materially impacted our Remodulin revenues outside the United States. Our competitors are also developing numerous new products that may compete with ours, including products intended to treat PAH and/or PH-ILD. For example, Merck commercially launched Winrevair (sotatercept-csrk) in the United States in March 2024, which competes with our treprostinil-based products. In addition, in June 2025 Liquidia launched U.S. sales of Yutrepia for PAH and PH-ILD, which now competes with our treprostinil-based products. Additional treatments, such as Insmed Incorporated&#8217;s TPIP, are in late-stage clinical trials for treatment of PAH and/or PH-ILD. Each of these products could potentially materially adversely affect our revenues. There are also three therapies approved for the treatment of IPF, including Boehringer Ingelheim&#8217;s Jascayd</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (nerandomilast), which was approved by the FDA in October 2025 for IPF, and later for PPF. A wide variety of additional therapies are being developed by our competitors for the treatment of IPF. Existing and future approved IPF and PPF therapies would compete with Nebulized Tyvaso if it is approved for these indications, and any other products we may ultimately develop for IPF and PPF. The introduction of lower-priced competing products may reduce both the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Patients and doctors may discontinue use of our products if they perceive competing products as safer, more effective, less invasive, more convenient, and/or less expensive than ours. Doctors may reduce the prescribed doses of our products if they prescribe them in combination with competing products. In addition, many competing therapies are less invasive or more convenient than our products, and use of these competing therapies often delays or prevents initiation of our therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The successful commercialization of our products depends on the availability of coverage and adequacy of reimbursement from third-party payers, including governmental authorities and private health insurers. Pharmaceutical pricing and reimbursement pressures may negatively impact our sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The commercial success of our products depends, in significant part, on coverage by governmental payers such as Medicare and Medicaid, and private insurance companies. A reduction in the availability or extent of reimbursement from domestic or foreign government health care programs could have a material adverse effect on our business and results of our operations. Government and commercial payers are increasingly attempting to limit the price of medicinal products and frequently challenge the pricing of new or expensive drugs. In many markets outside the United States, governments control the prices of prescription pharmaceuticals through the implementation of reference pricing, price cuts, rebates, revenue-related taxes, and profit control. Financial pressures may cause United States government payers and/or private health insurers to implement policies that would reduce reimbursement rates for our products, limit future price increases, cap reimbursement rates for pharmaceuticals to rates paid internationally, require the automatic substitution of generic products, demand more rigorous requirements for initial coverage for new products, implement step therapy policies that require patients to try other medicines, including generic products, before using our products, or take other similar steps that could make it more difficult for patients to access our products. See, for example, the discussion of the IRA and the proposed GLOBE and GUARD regulations in the risk factor below entitled </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Government healthcare reform and other reforms could adversely affect our revenue, costs, and results of operations</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our prostacyclin analogue products (Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram) and our oncology product (Unituxin) are expensive therapies. Specialty pharmacy distributors may not be able to obtain adequate reimbursement for our products from commercial and government payers to motivate them to support our products. Third-party payers may reduce the amount of reimbursement for our products based on changes in pricing of other therapies for the same disease or the development of new payment methodologies to cover and reimburse treatment costs, such as the use of cost-effectiveness research or value-based payment contracts. Third-party payers often encourage the use of less-expensive generic alternative therapies, which has materially impacted our Adcirca revenues and which may materially impact our Remodulin revenues and revenues from our other products if and when generic competitors come to market. Similarly, pricing and rebating strategies for competitive therapies could put pressure on us to reduce the prices of our products and/ or offer increased rebates to third-party payers. If commercial or government payers do not cover our products or limit payment rates, patients and physicians could choose competing products or products with lower out-of-pocket costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We plan to submit an sNDA to the FDA by the end of summer 2026, seeking approval to add IPF to the labeled indications for Nebulized Tyvaso, based on the successful </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-1 </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TETON-2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> results. Following any FDA approval, we then plan to submit a request to the Durable Medical Equipment Medicare Administrative Contractors (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DME MACs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to revise the local coverage determination (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">LCD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) that governs Medicare Part B coverage for Nebulized Tyvaso, to allow coverage for the use of Nebulized Tyvaso for the new IPF indication. DME MACs have significant discretion with respect to the overall timing to update the LCD; once the process is initiated, it could take well over a year to complete. Until such time as the LCD is </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">updated, we expect revenues generated by sales of Nebulized Tyvaso for the new IPF indication could be limited, since we believe that most U.S. IPF patients are Medicare beneficiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our manufacturing strategy exposes us to significant risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We must be able to manufacture sufficient quantities of our commercial products to satisfy demand. We manufacture Nebulized Tyvaso drug product, Remodulin, Orenitram, and Unituxin, including the active ingredient in each of these products (and in Tyvaso DPI), at our own facilities and rely on third parties for additional manufacturing capacity for Nebulized Tyvaso and Remodulin. We also rely on third parties for our manufacturing, sometimes exclusively, as detailed under the risk factor below entitled, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We rely in part on third parties to perform activities that are critical to our business</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. If any of our internal or third-party manufacturing and supply arrangements are interrupted, we may not have sufficient inventory to meet future demand. Changes in suppliers and/or service providers could interrupt the manufacturing of our commercial products and impede the progress of our commercial launch plans and clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our internal manufacturing process subjects us to risks as we engage in increasingly complex manufacturing processes. We manufacture our entire supply of Orenitram and Unituxin without an FDA-approved back-up manufacturing site. We do not plan to engage a third party to manufacture Orenitram; however, we have initiated efforts to qualify a third party to manufacture Unituxin drug substance, which may not succeed or may take longer than we anticipate. Our manufactured organ and organ alternative programs will involve exceptionally complicated manufacturing processes, many of which have never been attempted on a clinical or commercial scale. It will take substantial time and resources to develop and implement such manufacturing processes, and we may never be able to do so successfully. Additional risks of our manufacturing strategy include the following:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We, our third-party manufacturers, and other third parties involved in the manufacturing process, such as third parties that operate testing and storage facilities, are subject to the current good manufacturing practices requirements of the FDA and its international counterparts, as applicable, current good tissue practices, and similar international regulatory standards, and other quality standards related to device manufacturing. Our ability to exercise control over regulatory compliance by our third-party manufacturers is limited.</span></div><div style="padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%;padding-left:6.55pt">We and our third-party manufacturers may need to increase our respective manufacturing capacity by constructing new facilities, and/or expanding existing facilities, in order to continue meeting anticipated demand for our products. These efforts are often costly and time-consuming, and must meet rigorous regulatory requirements. These efforts could be unsuccessful or take longer or cost more than we anticipate, due to a variety of factors including the lead time needed to procure, install, and qualify the highly specialized equipment necessary to manufacture the product.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We may experience difficulty designing and implementing processes and procedures to comply with applicable regulations as we develop manufacturing operations for new products.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Our primary manufacturing facilities are located in rapidly growing biopharmaceutical manufacturing hubs. Competition for experienced technical and entry level operations personnel is intense, and we may experience difficulty in staffing both our existing and future manufacturing facilities, which could limit the capacity of our facilities and/or delay startup of new facilities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Unituxin is a chimeric monoclonal antibody that has stringent quality control and stability requirements. The drug substance manufacturing process involves a complex, multi-step cell culture and purification process. Many biologic products, including Unituxin, are particularly sensitive to the conditions under which they are manufactured. Supplier-driven changes to any of the raw materials or components used in the manufacture of Unituxin, such as discontinuation or alteration, could have unintended impacts on the quality and shelf life of Unituxin and may inhibit or prevent our ability to supply acceptable finished product in sufficient quantities or at all. Batches of Unituxin that fail to meet certain release specifications cannot be sold into the market. We have a limited capacity to produce batches of Unituxin. If a sufficient number of batches fail to meet release specifications, we could face a shortage of drug product. During 2025 we encountered limitations on our ability to supply Unituxin to our distributor in Japan, which caused our distributor to delay starting new patients on this therapy in Japan. Our efforts to obtain FDA approval to adjust certain manufacturing specifications for Unituxin to reduce the risk of a shortage in the United States may prove unsuccessful. Furthermore, Unituxin has a limited shelf life, which impacts our ability to stockpile inventory at comparable levels to our other commercial products.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Natural and man-made disasters (such as fires, contamination, power loss, hurricanes, flooding, and other forms of severe weather (some of which could be exacerbated by climate change), earthquakes, terrorist attacks, and acts of war), disease outbreaks, and pandemics such as COVID-19 impacting our internal and third-party manufacturing and warehousing sites could cause a supply disruption.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The chemical, microbiological, and physical quality attributes of our products could be substandard and such products could not be sold or used or could be subject to recalls.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The FDA and its international counterparts could require new testing and compliance inspections of new manufacturers of our products, or new manufacturing facilities we operate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">If we produce products that do not meet FDA-approved specifications and we fail to detect these issues prior to distribution of these products, our products may be the subject of safety alerts, product recalls, or other corrective actions, and we may be charged in product liability claims and lawsuits which, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation and on our ability to attract and retain customers.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Regulatory agencies may not be able to timely inspect our facilities, or those of our third-party manufacturers, which could result in delays in obtaining necessary regulatory approvals for our products.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We may be unable to contract with needed manufacturers on satisfactory terms or at all.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The supply of materials and components necessary to manufacture and package our products may become scarce or unavailable, which in the past has delayed, and in the future could delay, the manufacturing and subsequent sale of such products. Products manufactured with substituted materials or components must be approved by the FDA and applicable international regulatory agencies before they can be sold.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Manufacturers of the devices used to administer our inhaled and infused therapies are subject to medical device requirements of the FDA and its international counterparts, as applicable. Any non-compliance, recall, or enforcement action issued against them could adversely impact our sales and operations.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The infrastructure of our internal manufacturing facilities, along with certain facilities of our third-party manufacturers, is aging. These facilities have highly sophisticated and complex utility systems and manufacturing equipment. If any of these systems or equipment require long-term repair or replacement, the impacted facility may not be able to manufacture product for a substantial period of time.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We and our third-party manufacturers rely upon local municipalities to supply our facilities with clean water, which is subsequently processed into high purity water and used as a key ingredient for several of our commercial drug products. If local municipalities are unable to supply water that meets relevant quality standards, we and our third-party manufacturers may be unable to manufacture these products until such a situation is remediated.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We and our third-party manufacturers rely upon utility companies to supply our facilities with electrical power. The U.S. power grid is aging and demand for electrical power is rapidly increasing, including as a result of the construction of data centers in certain regions. If utility companies cannot reliably supply electrical power, we and our third-party manufacturers may be unable to operate our facilities at full capacity.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Our supply chain for raw materials and consumables extends worldwide and is complex. Suppliers based in China, India, and Taiwan play a role in our supply chain to support our second- and third-tier suppliers. Political unrest or trade disputes involving China, India, Taiwan, or other countries in our supply chain could impact our ability and the ability of our third-party manufacturers to source raw materials and consumables. We also have limited visibility into the supply chains on which our primary suppliers rely; as such, we rely on our primary suppliers to have robust risk mitigation strategies to detect issues and prevent supply disruption. Our commercial active pharmaceutical ingredient and all of our finished commercial product is manufactured in the United States.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We are closely monitoring global military conflicts including those involving Iran, Israel, and Ukraine. Although we do not directly source any raw materials or consumables from the directly impacted countries, our international suppliers and service providers in these regions could be impacted by extended conflicts or an escalation of these conflicts into neighboring countries.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The cost of many key raw materials and consumables used in the manufacture of our products has increased due to significant inflationary pressure, and could increase further as a result of tariffs enacted by the Trump administration. Should the prices of raw materials and consumables further increase as a result of inflation or tariffs, we could see higher than average year-over-year increases in cost of goods sold. Tariffs and other trade barriers could also cause a substantial increase in the material costs associated with our construction activities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Any of our third-party manufacturers could undergo a change of control, causing a change in our business relationship with the relevant manufacturer. Such a change could impact our long-term supply outlook and cause us to seek alternatives that could require a lengthy regulatory approval process. Alternative suppliers may not be readily available, causing us to rely solely on internal capabilities to meet future demand.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">In 2024 we completed a designated pathogen-free facility (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DPF</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to produce our xenotransplantation products for human clinical studies. This facility houses gene-edited pigs in a highly controlled containment environment. This facility is a first of its kind, and unforeseen operational issues or disease outbreak amongst its herd could significantly impact the clinical development timelines for our xenotransplantation products. We are constructing two additional DPF facilities to mitigate operational risk and increase capacity. We will need to construct additional DPF facilities at significant expense to support the development and commercialization of our xenotransplantation products. If development of our xenotransplantation products fails or demand is significantly less than anticipated, we will not recoup our significant investment in these unique facilities as they would be difficult to repurpose. Conversely, prior to approval of our xenotransplantation products, we may not construct the number of facilities that we believe will ultimately be required to meet patient demand, which may delay our ability to meet demand when and if our xenotransplantation products are approved.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c41230;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Unituxin and Tyvaso DPI both require cold chain transportation since these products must be maintained at 2-8&#176;C while in transit. As a result, these products have an elevated risk of quality-control incidents compared to our other commercial products, which may be transported under room temperature conditions. We use third party logistics companies that specialize in cold chain transportation for high-value products; however, should a temperature excursion occur, it may cause loss of some or all product in the particular shipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any of these factors could disrupt sales of our commercial products, delay clinical trials or commercialization of new products, result in product liability claims and product recalls, and entail higher costs or lost revenues. Interruptions in our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">manufacturing process could be significant given the length of time and complexity involved in obtaining necessary regulatory approvals for alternative arrangements, through either third parties or internal manufacturing processes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We rely in part on third parties to perform activities that are critical to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Third parties assist us in activities critical to our operations, such as: (1) manufacturing our clinical and commercial products; (2) conducting clinical trials, preclinical studies, and other research and development activities; (3) obtaining regulatory approvals; (4) conducting pharmacovigilance and product complaint activities, including handling and reporting of adverse effects (including adverse events and product complaints); (5) manufacturing and obtaining regulatory approvals for the devices used to administer our drugs; and (6) marketing and distributing our products. Any disruption in the ability of third parties to continue to perform these critical activities could materially adversely impact our business and results of operations. Any change in service providers could interrupt the manufacture and distribution of our products and services, and impede the progress of our clinical trials, commercial launch plans, and related revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We rely on various distributors to market, distribute, and sell our commercial products. If they are unsuccessful in, or reduce or discontinue, their sales efforts, our revenues may decline materially. Outside the United States, we rely substantially on our international distributors to obtain and maintain regulatory approvals for our products and to market and sell our products in compliance with applicable laws and regulations. In the United States, we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty. If either of these two distributors places significantly larger or smaller orders in a given time period, our revenues can be impacted in a way that does not reflect patient demand.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We rely entirely on third parties to supply pumps and other supplies necessary to administer Remodulin. There are a limited number of pumps and other supplies available in the market, and the discontinuation of any particular pump could have a material, adverse impact on our Remodulin revenues if a viable supply of an alternate pump is not available. We rely entirely on ICU Medical to manufacture the CADD-Solis pump, which is the primary pump used to administer intravenous Remodulin in the United States. We rely entirely on DEKA Research &amp; Development Corp. and its affiliates to manufacture the Remunity and RemunityPRO Pumps, which are the primary pumps used to administer subcutaneous Remodulin in the United States. Additional ancillary supplies are used with these pumps, and a limited number of manufacturers that supply them.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lilly manufactures and supplies Adcirca for us. We use Lilly&#8217;s pharmaceutical wholesaler network to distribute Adcirca. If Lilly is unable to manufacture or supply Adcirca or its distribution network is disrupted, it could delay, disrupt, or prevent us from selling Adcirca.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We rely on two contract manufacturers &#8212; Forj Medical and Phillips-Medisize Corp. &#8212; to manufacture the Tyvaso Inhalation System for Nebulized Tyvaso. As Nebulized Tyvaso is a drug-device combination product, we cannot sell Nebulized Tyvaso without the Tyvaso Inhalation System. We also rely on various third parties to supply the monthly disposable device accessories that are used with the Tyvaso Inhalation System. We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement. If MannKind is unable to manufacture Tyvaso DPI in sufficient quantities for us for any reason, our commercial sales of Tyvaso DPI could be materially and adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also rely on various sole-source suppliers for manufacturing activities related to ralinepag. We are in the process of qualifying our Silver Spring facility to produce our primary commercial supply of ralinepag API, and our Research Triangle Park facility to produce our primary commercial supply of ralinepag tablets, if and when oral ralinepag is approved by the FDA. These efforts could be unsuccessful or take longer or cost more than we anticipate, in which case we may be more reliant on our existing third-party contract manufacturers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a further discussion of risks created by the use of third-party contract manufacturers, see the risk factor above entitled, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our manufacturing strategy exposes us to significant risks</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We rely heavily on third-party contract research organizations, contract laboratories, clinical investigative sites, and other third parties to conduct our clinical trials, preclinical studies, and other research and development activities. Third-party failure to conduct or assist us in conducting clinical trials in accordance with study protocols, quality controls, GCP, or other applicable requirements or to submit associated regulatory filings, could limit or prevent our ability to rely on results of those trials in seeking regulatory approvals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Reports of actual or perceived side effects and other adverse effects associated with our products could cause our sales to decrease or regulatory approvals to be revoked.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reports of adverse effects (including side effects and other adverse events, as well as product complaints) associated with our products could affect a physician&#8217;s decision to prescribe or a patient&#8217;s willingness to use our products, which may have a significant adverse impact on sales of our products. An example of a known risk associated with the pump system used for intravenous Remodulin is sepsis, which is a serious and potentially life-threatening infection of the bloodstream caused by a wide variety of bacteria. In addition, Unituxin is associated with severe side effects, and its label contains a boxed warning related to potential infusion reactions and neurotoxicity. We are required to report certain adverse effects to the FDA and its international counterparts. Development of new products, and new formulations, indications, and delivery devices for existing products, could result in new side effects and other adverse effects which may be serious in nature. If the use of our products harms patients or is perceived to harm patients, regulatory approvals could be revoked or otherwise negatively impacted.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Negative attention from special interest groups may impair our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our early-stage research and development involves animal testing required by regulatory authorities, which we conduct both directly and through contracts with third parties. Our organ manufacturing programs rely heavily on the use of animals to manufacture and test our products. Certain special interest groups categorically object to the use of animals for research purposes. Any negative attention, threats, or acts of vandalism directed against our animal research or manufacturing activities could impede the operation of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We may not maintain adequate insurance coverage to protect us against significant product liability claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The testing, manufacturing, marketing, and sale of drugs and diagnostics involve product liability risks. We may not be able to maintain our current product liability insurance at an acceptable cost, if at all. In addition, our insurance coverage may not be adequate for all potential claims. If losses significantly exceed our liability insurance coverage, we may experience financial hardship or potentially be forced out of business. Clinical testing and eventual marketing and sale of new products, reformulated versions of existing products, or use of existing products in new indications could expose us to new product liability risks that are not covered by our existing policies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If we fail to attract and retain key management and qualified scientific and technical personnel, we may not be able to achieve our business objectives.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Members of our management team, including our founder, Chairperson and Chief Executive Officer, Dr. Martine Rothblatt, play a critical role in defining our business strategy and maintaining our corporate culture. The loss of the services and leadership of Dr. Rothblatt or any other members of our senior management team could have an adverse effect on our business. We do not maintain key person life insurance on our senior management team members. Failure to identify, hire, and retain suitable successors for members of our senior management team and to transfer knowledge effectively could impede the achievement of our business objectives. Our future success also depends on our ability to attract and retain qualified scientific and technical personnel. Competition for such personnel in our industries is intense. If we fail to attract and retain such employees, we may not be successful in developing and commercializing new therapies.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_112"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Risks Related to Legal Compliance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We must comply with extensive laws and regulations in the United States and other countries. Failure to obtain approvals on a timely basis or to comply with these requirements could delay, disrupt, or prevent commercialization of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory agencies. Our research and development efforts must comply with extensive regulations, including those promulgated by the FDA, the U.S. Department of Agriculture, and their international counterparts, as applicable. The process of obtaining and maintaining regulatory approvals for new drugs, biologics, and medical devices is lengthy, expensive, and uncertain. The regulatory approval process is particularly uncertain for our organ manufacturing program. Once approved, the manufacture, distribution, advertising, and marketing of our products are subject to extensive regulation, including requirements related to product labeling, pharmacovigilance and adverse effect reporting and processing (including both adverse events and product complaints), storage, distribution, and record-keeping. Our product candidates have in the past and may in the future fail to receive regulatory approval. If granted, product approvals can be conditioned on the completion of post-marketing clinical studies, accompanied by significant restrictions on the use or marketing of a given product and withdrawn for failure to comply with regulatory requirements, such as post-marketing requirements and post-marketing commitments, or upon the occurrence of adverse effects subsequent to commercial introduction. Our ability to obtain regulatory approvals for our products has been, and in the future may be, materially impacted by the outcome and quality of our clinical trials and other data submitted to regulators, as well as the quality of our manufacturing operations and those of our third-party contract manufacturers and contract laboratories. In addition, third parties may submit citizen petitions to the FDA seeking to delay approval of, or impose additional approval conditions for, our products. Citizens petitions have in the past, and may in the future, significantly delay or prevent approval of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2025, the Trump administration announced a reduction in force at the U.S. Department of Health and Human Services, including layoffs at the FDA. These and other efforts to reduce the size of the FDA or its funding, combined with significant changes in FDA leadership, have begun to result in slower FDA response times and/or longer review periods, and may lead to less predictable outcomes. Future government shutdowns, funding disputes, reorganizations, furloughs, or reductions in resources or changes in priorities or focus may result in further delays. If response and review delays persist and/or worsen, they could potentially impact our ability to timely progress our pipeline efforts or obtain regulatory approval for new products and new indications for existing products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Regulatory approval for our currently marketed products is limited by the FDA and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any regulatory approval of our products is limited to specific diseases and indications for which our products have been deemed safe and effective. Regulatory approval is also required for new formulations and new indications for an approved product. While physicians may prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those approved by regulatory authorities (called &#8220;off-label&#8221; uses), our ability to promote our products is limited to those indications that are specifically approved by the FDA and its international counterparts. Failure to follow applicable </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rules and guidelines related to promotion and advertising can result in adverse regulatory actions by the FDA and its international counterparts &#8212; such as warning letters, enforcement actions, civil lawsuits, or criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We must comply with various laws in jurisdictions around the world that restrict certain marketing practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business activities may be subject to challenge under laws in jurisdictions around the world restricting marketing practices, such as:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Anti-kickback and false claim statutes, the Foreign Corrupt Practices Act, and the United Kingdom Bribery Act. In the United States, the Federal Anti-Kickback Statute prohibits, among other activities, knowingly and willfully offering, paying, soliciting, or receiving remuneration (i.e., anything of value) to induce, or in return for, the purchase, lease, order or arranging the purchase, lease or order of any health care product or service reimbursable under any federally financed healthcare program like Medicare or Medicaid. This statute is interpreted broadly to apply to arrangements between pharmaceutical manufacturers and prescribers, purchasers, specialty pharmacies, formulary managers, patients, and others. Our practices may not always qualify for safe harbor protection under this statute.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">The Federal False Claims Act, which prohibits any person from knowingly presenting or causing to be presented a false or fraudulent claim for payment of government funds, or making or causing a false statement material to a false or fraudulent claim. Pharmaceutical and health care companies have faced liability under this law for causing false claims to be submitted because they marketed a product for unapproved and non-reimbursable uses.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Analogous state laws and regulations, including anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid or, in several states, regardless of the payer, including private payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are also subject to numerous other laws and regulations that, while not specific to the healthcare industry, apply to the healthcare industry in important ways. For example, we are subject to antitrust regulations with respect to interactions with other participants in the markets we currently serve or may serve in the future. These antitrust laws are vigorously enforced in the U.S. and in other jurisdictions in which we operate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Compliance with these and similar laws on a state-by-state basis is difficult, time consuming, and requires substantial resources. Any investigation, inquiry, or other legal proceeding under these laws related to our operations, even if we successfully defend against it, or any penalties imposed upon us for failure to comply, could have a material adverse effect on our business and financial condition or reputation. Sanctions under these federal and state laws may include treble civil monetary penalties, payment of damages, fines, exclusion of our products from reimbursement under federal health care programs, imprisonment, and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Government healthcare reform and other reforms could adversely affect our revenue, costs, and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our industry is highly regulated and changes in law or government health care programs, like Medicaid or Medicare, may adversely impact our business, operations, or financial results. We cannot predict how future federal or state legislative or administrative changes related to healthcare reform will affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Political, economic, and regulatory developments may lead to fundamental changes in the U.S. healthcare industry, particularly given the persistent criticism of prescription drug costs in the U.S. We expect there will continue to be legislative and regulatory proposals to change the healthcare system in ways that could adversely impact our ability to commercialize and to sell our products profitably. Even proposals or executive actions that ultimately are deemed unlawful or otherwise repealed could negatively impact the U.S. pharmaceutical sector and our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Among other things, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things: bring more transparency to drug pricing; reduce the cost of prescription drugs under government payer programs; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IRA was enacted in 2022. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Medicare Part D coverage gap discount program with a new manufacturer discounting program (beginning in 2025). The U.S. Centers for Medicare &amp; Medicaid Services (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CMS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) has published the negotiated prices for the initial ten drugs, which went into effect in January 2026, and the subsequent 15 drugs, which will first be effective in 2027. The IRA permits the Secretary of the Department of Health and Human Services (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">HHS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has issued guidance, and is expected to continue to issue guidance, even while multiple lawsuits challenging the IRA negotiation requirement remain pending. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the Medicare Part D manufacturer discounting program that became effective January 1, 2025 pursuant to the IRA, manufacturers must give a 10 percent discount on Part D drugs in the initial coverage phase, and a 20 percent discount on Part D drugs in the so-called &#8220;catastrophic phase&#8221; (the phase after the patient incurs costs above the initial phase out-of-pocket threshold, which is $2,000 beginning in 2025). The IRA allows the 10 and 20 percent discounts to be phased in over time for certain drugs for &#8220;specified small manufacturers.&#8221; In April 2024, CMS informed us that we are deemed a specified small manufacturer.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram and Tyvaso DPI are both reimbursed under Medicare Part D, and the reimbursement amount is impacted by the 10 and 20 percent discounts under the IRA&#8217;s manufacturer discounting program. These increased discounts impact Tyvaso DPI and Orenitram revenues, while also having an industry-wide impact on the cost of Part D drugs. The impact on Tyvaso DPI and Orenitram revenues could be offset because of the IRA&#8217;s Part D redesign, which went into effect in 2025 and resulted in an increase in the number of patients able to afford these therapies. The amount of the offset, if any, is inherently uncertain and difficult to measure and predict.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The manner in which CMS has implemented the manufacturer discounting program will also increase financial obligations of Part D prescription drug plans with respect to beneficiaries in the catastrophic coverage phase. This may incentivize Part D prescription drug plans to seek greater price concessions from us in order to include our products on their formularies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">More recently, the One Big Beautiful Bill Act, which was enacted in July 2025, significantly reduced funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of our commercial products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Trump administration is pursuing a two-fold strategy to reduce drug costs in the U.S. On the one hand, the Trump administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as MFN pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as GLOBE and GUARD. If finalized and adopted, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the U.S. that is based on drug prices outside the U.S. would mark a drastic and unprecedented shift in the U.S. pharmaceutical market. While it is unclear whether and how the Trump administration proposals will be implemented, the Trump administration policies are likely to have a significant negative impact on the pharmaceutical industry and may negatively affect our ability to receive revenues from sales of our commercial products. Even regulatory proposals or executive actions that ultimately are deemed unlawful or otherwise repealed could negatively impact the U.S. pharmaceutical sector and our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Individual U.S. states have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, marketing cost disclosure, and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements of pharmaceutical manufacturers under such laws include advance notice of planned price increases; reporting price increase amounts and factors considered in taking such increases; wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies; and new product notice and reporting. Other legislation establishes so-called prescription drug affordability boards that could impose price caps on specific drugs, and at least one state board is imposing an upper payment limit. States are also seeking to implement general, across-the-board price caps for pharmaceuticals, or are seeking to regulate drug distribution. These state legislative measures could limit the price or payment for certain drugs or could complicate the distribution of drugs. A number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with state law requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information under transparency obligations. Additional legislation in these areas imposing additional requirements on manufacturers, as well as penalties for noncompliance, could be introduced in the future. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October 2020, HHS and the FDA issued a final rule and guidance concerning two new pathways for importing lower-cost drugs into the United States. The final rule allows certain prescription drugs to be imported from Canada, and the guidance describes procedures for drug manufacturers to facilitate the importation of FDA-approved drugs and biologics manufactured abroad and originally intended for sale in a foreign country into the United States. In January 2024, the FDA approved Florida&#8217;s drug importation plan. In November 2025, the FDA granted a six-month extension for Florida to begin implementing its plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IRA and other healthcare reform measures that may be adopted in the future may result in additional downward pressure on the payment that we receive for any approved product, and may adversely impact our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payment from commercial payers. Further state and federal healthcare reform measures adopted in the future could limit the amounts that state and federal governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is difficult to predict the impact, if any, that future federal or state legislation, or executive actions, might have on the use of and reimbursement for our products in the United States, such as the potential for the importation of generic versions of our products, for price caps under state laws, or for increased difficulties and costs related to the distribution of our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines, which could adversely impact our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We participate in, and have certain price reporting obligations to, the Medicaid Drug Rebate program and other governmental programs that require us to pay rebates or offer discounts on our products. Certain programs, such as the 340B program, impose limits on the price we are permitted to charge certain entities for our products or for any future products for which we receive regulatory approval. Changes to these programs could negatively affect the coverage and reimbursement by these programs of our products or any future products for which we receive regulatory approval and could negatively impact our results of operations. Our failure to comply with these price reporting, rebate payment, or pricing requirements could adversely impact our financial results. Applicable laws and regulations, including the IRA, could affect our obligations in ways we cannot anticipate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. If we must restate or recalculate information provided under these programs, our costs of compliance could increase. We could be held liable for errors in the submissions we are required to make with respect to governmental drug pricing programs, including retroactive rebates and program refunds. We may incur significant civil monetary penalties if we are found to have knowingly provided false information to the government or to have charged 340B covered entities more than the statutorily mandated ceiling price, and resolution of any claims that we violated these provisions could be costly. Certain failures to timely submit required data also could result in a civil monetary penalty for each day the information is late. We could also become subject to allegations under the False Claims Act and other laws and regulations. In addition, misreporting and failure to timely report data to CMS also can be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid Drug Rebate program. If CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CMS, the U.S. Department of Veterans Affairs, the Office of Inspector General of the Department of Health and Human Services (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OIG</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and other governmental agencies have pursued manufacturers that were alleged to have failed to report data to the government in a timely manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that any submissions we are required to make under governmental drug pricing programs will not be found to be incomplete or incorrect.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Similar political, economic, and regulatory developments are occurring in other countries and may affect our profitability. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EU</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) or member state level may result in significant additional requirements or obstacles that may increase operating costs. Healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines and medical devices by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval or certification of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize our product candidates, if approved or certified. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We participate in the Public Health Service&#8217;s 340B drug pricing program (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">340B program</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and have implemented a policy regarding the distribution of our drugs at 340B ceiling prices through third-party pharmacies that contract with 340B covered entities, known as &#8220;340B contract pharmacies&#8221;. Under our 340B contract pharmacy policy, which we adopted to address program integrity risks, our drugs are only shipped at the 340B ceiling price to those 340B contract pharmacies that meet certain criteria. Our policy has no impact on 340B purchases by 340B covered entities themselves. Our contract pharmacy policy preserves patient access, while addressing compliance and integrity concerns resulting from the proliferation of contract pharmacies. Nonetheless, the U.S. Department of Health and Human Services (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">HHS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), in a non-binding (and now-retracted) Advisory Opinion, stated that manufacturers in the 340B program are obligated to sell their covered outpatient drugs at the 340B ceiling price to all contract pharmacies acting as agents of a covered entity. Certain covered entities have expressed the view that participating manufacturers are obligated to sell their covered outpatient drugs to all contract pharmacies of a covered entity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We and certain other manufacturers initiated litigation challenging the Advisory Opinion and the U.S. Health Resource Services Administration (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">HRSA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)&#8217;s position on contract pharmacies generally. HHS subsequently withdrew the Advisory Opinion, but HRSA issued letters to manufacturers, including us, threatening enforcement action if the manufacturers do not abandon their 340B contract pharmacy policies. We filed suit against HHS and HRSA in June 2021 in the U.S. District Court for the District of Columbia. In September 2021, HRSA sent to us, along with the other manufacturers challenging HRSA&#8217;s 340B interpretation, letters stating that HRSA was referring this issue to the OIG for potential enforcement action. We have not had any communication from the OIG regarding our 340B contract pharmacy policy. In November 2021, the court granted our motion for summary judgment, ruling that the letters threatening enforcement action &#8220;contain legal reasoning that rests upon an erroneous reading of Section 340B.&#8221; HRSA appealed, and the appellate court affirmed the lower court&#8217;s decision in our favor.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If HRSA develops a new theory of liability, we may face enforcement action or penalties as well as adverse publicity. Such an outcome may also prompt other parties to challenge our policies. It is also possible that covered entities could bring an action against us under the administrative dispute resolution pathway. We expect the compliance of policies like ours will continue to be litigated. We may also face enforcement action under the laws of certain states that are seeking to impose their own 340B contract pharmacy requirements. Such actions could, if determined adversely to us, result in penalties and other sanctions that could have a negative impact on our business. If we are unable to curb the proliferation of abuses caused by 340B contract pharmacies, we could see increased sales at 340B ceiling prices, which could have a material adverse impact on our revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Patient assistance programs for pharmaceutical products have come under increasing scrutiny by governments, legislative bodies, enforcement agencies, and other third parties. These activities may result in actions that effectively reduce prices or demand for our products, harm our business or reputation, or subject us to fines or penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and manufacturers&#8217; donations to third-party charities that provide such assistance, are subject to heightened scrutiny. The Department of Justice (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DOJ</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) has taken enforcement action against pharmaceutical companies alleging violations of the Federal False Claims Act and other laws in connection with patient assistance programs. We have been, and may in the future, be subject to DOJ investigations with respect to our support of non-profit patient assistance programs, which can result in sanctions, fines, or other payments and agreements with respect to our compliance programs. As discussed in Note 12&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, to our consolidated financial statements, we have been sued by Humana Inc., United Healthcare Services, Inc., and various parties in the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> litigation for allegedly violating RICO and various state laws in connection with our donations to a charity. These lawsuits, or other lawsuits in the future, could result in significant monetary judgments and the imposition of other penalties against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Members of Congress have called upon the OIG to issue revised guidance about patient assistance programs. Actions taken by the OIG, the DOJ, or other agencies as a result of this industry-wide inquiry could reduce demand for our products and/or coverage of our products by federal and state health care programs. If any or all of these events occur, our business, prospects, and stock price could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payers and pharmacy benefit managers have developed mechanisms to limit the benefits patients receive under co-pay assistance programs through imposing so-called co-pay accumulator or maximizer programs. These programs do not allow a patient using co-pay assistance to count the manufacturer&#8217;s co-payment contribution toward their annual out-of-pocket payment maximum/deductible. Once the co-pay benefit has been exhausted, patients are faced with paying the full out-of-pocket maximum/deductible. Some states have passed legislation to limit the use of co-pay accumulator programs, while some other states have indicated that these programs should be allowed to limit cost of care and encourage patients to use lower cost generics. In addition, some states have imposed restrictions on manufacturer co-pay programs when therapeutic equivalents are available. Growing use of such programs, or new laws limiting manufacturer ability to provide co-pay assistance, could affect patient access to our products and limit product utilization, which may, in turn, adversely affect our business, prospects, and stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Improper handling of hazardous materials used in our activities could expose us to significant remediation liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities involve the controlled use of chemicals and hazardous substances. We are expanding these activities in both scale and location. Patients may dispose of our products using means we do not control. Such activities subject us to numerous federal, state, and local environmental and safety laws and regulations that govern the management, storage, and disposal of hazardous materials. Compliance with current and future environmental laws and regulations can require significant costs. The risk of accidental contamination or injury from these materials cannot be eliminated. Once chemical and hazardous materials leave our facilities, we cannot control the manner in which such hazardous waste is disposed of by our contractors. We could be liable for substantial civil damages or costs associated with the cleanup of the release of hazardous materials and such liability could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The increasing use of social media platforms and artificial intelligence-based software presents new risks and challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate information about our products and the diseases that our therapies are designed to treat. Social media practices in our industry continue to evolve and regulations related to such use are not always clear. This evolution creates uncertainty and risk of noncompliance. For example, patients and others may use social media channels to comment on the effectiveness of a product or to report alleged adverse effects, such as adverse events and product complaints. When such disclosures occur, we may fail to monitor and comply with applicable adverse effect reporting obligations or we may not be able to defend against political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate comments about us on any social networking website. If any of these events occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions, or incur other harm to our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Additionally, artificial intelligence-based software is increasingly being used in our business and in the biopharmaceutical industry generally. As with many developing technologies, artificial intelligence-based software presents risks and challenges that could affect its further development, adoption, and use, and therefore our business. For example, algorithms employed by such software may be flawed; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices could impair the accuracy and usefulness of the results. If our analyses assisted by artificial intelligence applications are deficient or inaccurate, we could be subject to competitive harm, potential legal liability, and brand or reputational harm. Furthermore, use of artificial intelligence-based software may lead to the inadvertent release of confidential information which may impact our ability to realize the benefit of our intellectual property and expose us to liability and brand or reputational harm.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_115"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property and Data Privacy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If any of the agreements under which we license or acquired intellectual property rights are breached or terminated, we could lose our rights to continue to develop, manufacture, and sell the products covered by such agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business depends upon our continuing ability to exploit our intellectual property rights acquired from third parties under product license and purchase agreements covering drugs or other products or technology. We may be required to license additional intellectual property owned by third parties to continue to develop and commercialize our products. This dependence on intellectual property developed by others involves the following risks:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">We may be unable to obtain rights to intellectual property that we need for our business at a reasonable cost or at all;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">If any of our product licenses or purchase agreements are terminated, we may lose our rights to develop, make, and sell the products to which such licenses or agreements relate;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">Our rights to develop and market products to which the intellectual property relates are frequently limited to specific territories and fields of use (such as the treatment of particular diseases); and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">If a licensor of intellectual property fails to maintain the intellectual property licensed, we may lose any ability to prevent others from developing or marketing similar products covered by such intellectual property. In addition, we may be forced to incur substantial costs to maintain the intellectual property ourselves or take legal action seeking to force the licensor to do so.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our intellectual property rights may not effectively deter competitors from developing competing products that, if successful, could have a material adverse effect on our revenues and profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The period under which our commercial and developmental therapies are protected by our patent rights is limited. Our patents related to our individual treprostinil-based products expire at various times through 2042. We entered into settlement agreements with certain generic drug companies permitting them to launch generic versions of Remodulin in the United States and other companies to launch generic versions of Nebulized Tyvaso and Orenitram in the United States. In some instances, the FTC has brought actions against brand and generic companies that have entered into such agreements, alleging that they violate antitrust laws. Even in the absence of an FTC challenge, other governmental or private litigants may assert antitrust or other claims against us relating to such agreements. We have been sued by Sandoz for violating our settlement agreement with them, and we have accrued a liability of $74.9 million in connection with such suit, reflecting the final judgment and post-judgment interest accrued through the end of March 2026, although our ultimate liability may be greater. Other actions against us in the future could result in significant monetary judgments and the imposition of other penalties against us. We have no issued patents or pending patent applications covering the Unituxin drug product. For further details, see </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;I,&#160;Item 2&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Generic Competition and Challenges to our Intellectual Property Rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We cannot be sure that our existing or any new patents will effectively deter or delay competitors&#8217; efforts to bring new products to market, or that additional patent applications will result in new patents. When our patents expire, competitors may develop generic versions of our products and market them at a lower price. Competitors may also seek to design around our patents or exclude patented methods of treatment, such as patent-protected indications, from the label for generic versions of our products in an effort to develop competing products that do not infringe our patents. In addition, patent laws of foreign jurisdictions may not protect our patent rights to the same extent as the United States&#8217; laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Third parties have challenged, and may in the future challenge, the validity of our patents, through patent litigation and/or initiating proceedings, including re-examinations, IPRs, post-grant reviews, and interference proceedings, before the USPTO or other applicable patent filing offices, or other means. For example, Liquidia is challenging various patents related to Nebulized Tyvaso and our other treprostinil-related products, and has successfully challenged some of them.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Patent litigation can be time consuming, distracting, and costly, and the outcome may be difficult to predict and unfavorable to us. If we are unsuccessful in the defense of our patents, our business could be negatively impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect our proprietary know-how and other confidential technological advances. Our confidentiality agreements with our employees and others to whom we disclose trade secrets and confidential information may not necessarily prevent our trade secrets from being used or disclosed without our authorization, as we allege happened in our lawsuit against Liquidia and Dr. Roscigno. These agreements may be difficult, time-consuming, and expensive to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">enforce or may not provide an adequate remedy in the event of unauthorized disclosure. If our trade secrets were lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us, and our business and competitive position could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Third parties have alleged, and may in the future allege, that our products or services infringe their patents and other intellectual property rights, which could result in the payment of royalties that negatively affect our profits, subject us to costly and time-consuming litigation, or cause us to lose the ability to sell the related products</span><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the extent third-party patents to which we currently do not hold licenses are necessary for us to manufacture, use, or sell our products, we would need to obtain necessary licenses to prevent infringement. For products or services that utilize intellectual property of strategic collaborators or other suppliers, such suppliers may have an obligation to secure the needed license to these patents at their cost; if not, we would be responsible for the cost of these licenses. Royalty payments and other fees under these licenses would erode our profits from the sale of related products and services. Moreover, we may be unable to obtain these licenses on acceptable terms or at all. If we fail to obtain a required license or are unable to alter the design of the product to avoid infringing a third-party patent, we would be unable to continue to manufacture or sell related products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If a third party commences legal action against us for infringement, we may incur significant costs to defend ourselves against the claims made in the action and our management&#8217;s attention could be diverted from our day-to-day business operations, whether or not the action has merit. An adverse judgment or settlement resulting from the action could require us to pay substantial amounts in damages for infringement or to obtain a license to continue to use the intellectual property that is the subject of the infringement claim, or could result in injunctive relief limiting our ability to develop, manufacture, or sell our products. In April 2025, Liquidia initiated litigation against us alleging that Tyvaso DPI infringes a patent assigned to Liquidia. While we believe we have meritorious defenses and will vigorously defend against these claims, this litigation could be time consuming and ultimately may not be resolved in our favor, in which case, we could be required to pay substantial damages.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity incidents and other disruptions impacting our networks, systems, or data may have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, much of which is outsourced to third parties including in cloud-based platforms. We collect, store, and use sensitive or confidential data, including intellectual property, our proprietary business information and that of our suppliers, patients, healthcare providers, and business partners, and personally identifiable information. We recently launched a new patient relations program, United Therapeutics Cares, which has increased our access to sensitive information about our patients. Actual or alleged cybersecurity incidents, including those caused by employee error, malfeasance, system failures, malware, ransomware, viruses, distributed denial of services attacks, credential harvesting, social engineering, and other forms of unauthorized access or disclosure to, or disrupting the operation of, our networks and systems or those of our customers, suppliers, vendors, and other service providers, can cause the loss, destruction, or unauthorized access or disclosure of data, including personal information of employees or confidential or proprietary information, disruption of our manufacturing and other operations, and damage to our reputation and competitive position, any of which could be costly to address and remediate and adversely affect our business, financial condition, or results of operations. We are also subject to laws and regulations in the United States and abroad, such as the Health Insurance Portability and Accountability Act of 1996 and European Union regulations related to data privacy, which require us to protect the privacy and security of certain types of information. Therefore, cybersecurity incidents could expose us to significant civil and/or criminal penalties, as well as private litigation, all of which could adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the past we have experienced, and in the future we may again experience, data security incidents. The preventive actions we take to reduce exposure to, and the risks associated with, cybersecurity incidents may be insufficient to prevent or mitigate the effects of material cybersecurity incidents in the future. Because the tools and methods &#8212; including those deploying artificial intelligence technology &#8212; used by threat actors to damage or obtain unauthorized access to networks, systems, and data change frequently, and are often not known until used against a target, we may be unable to anticipate these tools or methods or implement adequate preventative measures. It is impossible to eliminate all cybersecurity threats and exposure to cybersecurity incidents, and thus our networks and systems, as well as those of our service providers, suppliers, customers and other third parties, remain potentially vulnerable to known or unknown threats.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_118"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Risks Related to Our Financing Capacity, Indebtedness, and Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If we need additional financing and cannot obtain it, our product development and sales efforts may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may be required to seek additional sources of financing to meet unplanned or planned expenditures. Unplanned expenditures could be significant and may result from necessary modifications to product development plans or product offerings in response to difficulties encountered with clinical trials. We may also face unexpected costs in preparing products for commercial sale, or in maintaining sales levels of our currently marketed therapeutic products. Our 2025 Credit Agreement contains affirmative and negative covenants that, among other things, limit our ability to incur additional </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">indebtedness. If we are unable to obtain additional funding on commercially reasonable terms or at all, we may be compelled to delay clinical studies, curtail operations, or obtain funds through collaborative arrangements that may require us to relinquish rights to certain products or potential markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our portfolio of investments is subject to market, interest, operational, and credit risk that may reduce its value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We maintain a portfolio of investments that includes: (1) corporate debt securities; (2) strategic investments in publicly traded equity securities; and (3) strategic equity investments in privately held companies. These investments are subject to general economic conditions, volatility in the financial marketplace, market- and industry-wide dynamics, the current elevated interest rate environment and changes in interest rates, industry- and company-specific developments impacting the business, prospects, and credit ratings of the issuer of the securities, and other factors, each of which has affected, and may in the future affect, the income that we receive from our investments, the net realizable value of our investments, and our ability to sell them. These factors have caused, and could in the future cause, us to: (a) experience a decline in our investment income; (b) record impairment charges to reduce the carrying value of our investment portfolio; or (c) sell investments for less than our acquisition cost; each of which in turn could negatively impact our liquidity and our earnings. Our efforts to mitigate these risks through diversification of our investments and monitoring of our portfolio&#8217;s overall risk profile may not be successful and the value of our investments may decline. The privately held companies we have invested in may be particularly susceptible to the factors described above as these companies are typically in the early stages of developing technologies or products that may never materialize, which could result in a loss of all or a substantial part of our investment in these companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully identify, finance, consummate, and/or integrate acquisitions, our business operations and financial position could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We seek to expand our business in part through acquisitions of complementary businesses, products, and technologies. The success of this strategy will depend on our ability to identify, and the availability of, suitable acquisition candidates. We may incur costs related to an acquisition but may be unable or unwilling to consummate the proposed transaction. Acquisitions involve numerous risks, including: the ability to realize anticipated synergies and manage the integration of personnel, products, and acquired infrastructure and controls; potential increases in operating costs; managing geographically remote operations; the diversion of management's attention from other business concerns; potential disruptions in ongoing operations during integration; risks inherent in entering markets and sectors in which we have limited or no direct experience; and the potential loss of key employees, customers, or vendors and other business partners of the acquired companies. External factors, such as compliance with law, may also impact the successful integration of an acquired business. Acquisitions could involve dilutive issuances of equity securities, the incurrence of debt, one-time write-offs of goodwill (or in-process research and development assets), and substantial amortization expenses of other intangible assets. We may be unable to obtain financing on favorable terms, or at all, if necessary to finance future acquisitions, which may make acquisitions impossible or more costly. The terms of financing we obtain may be onerous and restrict our operations. Further, certain acquisitions may be subject to regulatory approval, which can be time consuming and costly to obtain or may be denied, and if obtained, the terms of such regulatory approvals may limit our ongoing operations or require us to divest assets.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_121"></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The price of our common stock can be highly volatile and may decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The price of common stock can be highly volatile within the pharmaceutical and biotechnology sector. Consequently, significant price and volume fluctuations in the market may not relate to operating performance. The price of our common stock could decline sharply due to general market conditions as well as the following factors, among others:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">quarterly and annual financial results and any failure to meet our expectations or those of securities analysts, including expectations regarding revenues for our existing products, new products, or new indications for existing products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">timing of enrollment and results of our clinical trials;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">announcements regarding generic or other challenges to the intellectual property related to our products, the launch and successful commercialization of generic versions of our products or other competitive products, and the impact of competition from generic and other products on our revenues;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">announcements regarding litigation matters, including our ongoing litigation with Liquidia, among others;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">announcements regarding our efforts to obtain regulatory approval of, and to launch commercial sales of, new products and new indications for existing products;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">physician, patient, investor, or public concerns regarding the efficacy and/or safety of products marketed or being developed by us or by others;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">changes in laws and regulations affecting reimbursement of our therapeutic products by government payers, changes in reimbursement policies of private insurance companies, including the implementation and impacts of the IRA and other governmental efforts to reduce drug prices, and negative publicity surrounding the cost of high-priced therapies;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">announcements of technological innovations or new products or announcements regarding our existing products, including in particular the development of new, competing therapies;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">substantial sales of our common stock by us or our existing shareholders, or concerns that such sales may occur;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">future issuances of common stock by us or other activity which could be viewed as being dilutive to our shareholders;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">rumors or incorrect statements by investors and/or analysts concerning our company, our products, or our operations;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">failures or delays in our efforts to obtain or maintain domestic or international regulatory approvals;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">discovery of previously unknown problems with our marketed products, or problems with our manufacturing, regulatory, compliance, promotional, marketing, or sales activities that result in regulatory penalties or restrictions on our products, up to the withdrawal of our products from the market; and</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.55pt">accumulation of significant short positions in our common stock by hedge funds or other investors or the significant accumulation of our common stock by hedge funds or other institutional investors with investment strategies that may lead to short-term holdings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Provisions of Delaware law, our charter, bylaws and employment and license agreements, among other things, could prevent or delay a change of control or change in management that may be beneficial to our public shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain provisions of Delaware law, our restated certificate of incorporation, and bylaws may prevent, delay, or discourage a merger, tender offer, or proxy contest; the assumption of control by a holder of a large block of our securities; and/or the replacement or removal of current management by our shareholders. For example, as a result of our conversion to a PBC, our Board is required to consider and balance the financial interests of shareholders, the interests of stakeholders materially affected by our conduct, and the pursuit of our specific public benefit purpose when evaluating takeover offers. This requirement of Delaware law may make our company a less attractive takeover target than a traditional for-profit corporation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-competition and all other restrictive covenants in most of our employment agreements will terminate upon a change of control that is not approved by our Board. Similarly, a change of control, under certain circumstances, could accelerate the vesting of outstanding stock options, and restricted stock units. Any increase in our stock price resulting from the announcement of a change of control, and our broad-based change of control severance program, under which our employees may be entitled to severance benefits if they are terminated without cause (or they terminate their employment for good reason) following a change of control, could make an acquisition of our company significantly more expensive to the purchaser.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We enter into certain license agreements that generally prohibit our counterparties or their affiliates from taking necessary steps to acquire or merge with us, directly or indirectly throughout the term of the agreements, plus a specified period thereafter. We are also party to certain license agreements that restrict our ability to assign or transfer the rights licensed to us to third parties, including parties with whom we wish to merge, or those attempting to acquire us. These agreements often require that we obtain prior consent of the counterparties if we contemplate a change of control. If these counterparties withhold consent, related agreements could be terminated and we would lose related license rights. For example, Lilly and MannKind have the right to terminate our license agreements related to Adcirca and Tyvaso DPI, respectively, in the event of certain change of control transactions. These restrictive change of control provisions could impede or prevent mergers or other transactions that could benefit our shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our shareholders must rely on stock appreciation for any return on their investment in us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have never paid, and do not intend to pay, cash dividends. The terms of our current or future debt arrangements we may enter into may restrict us from doing so. As a result, the return on an investment in our common stock depends entirely upon the future appreciation, if any, in the price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Our exclusive forum bylaw may limit our shareholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers, or other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our bylaws provide that, to the fullest extent permitted by law, unless we agree in writing to an alternative forum, (1) the Delaware Court of Chancery (or, if such court does not have, or declines to accept, jurisdiction, another state court or a federal court located in Delaware) will be the exclusive forum for any complaint asserting any internal corporate claims, including claims in the right of the corporation based upon a violation of a duty by a current or former director, officer, employee, or shareholder in such capacity, or as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery; and (2) the federal district courts will be the exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. The choice of forum provision may limit our shareholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers, or other employees, and may discourage such lawsuits. There is uncertainty as to whether a court would enforce this provision. If a court ruled the choice of forum provision was inapplicable or unenforceable in an action, we may incur additional costs to resolve such action in other jurisdictions. Our choice of forum provision is intended to apply to the fullest extent permitted by law to the above-specified types of actions and proceedings, including any derivative actions asserting claims under state law or the federal securities laws. Our shareholders will not be deemed, by operation of the choice of forum provision, to have waived our obligation to comply with all applicable federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">In 2021, we converted to a Delaware PBC. Conversion may not result in the benefits that we anticipate, requires our directors to balance the interest of shareholders with other interests, and may subject us to additional litigation and other risks.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may not be able to achieve our public benefit purpose or realize the expected positive impacts from being a PBC.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">One of the primary distinctions between a PBC and a traditional Delaware for-profit corporation is that, in making decisions, the directors of a PBC have an obligation to balance the financial interests of shareholders, the interests of stakeholders materially affected by the PBC&#8217;s conduct, and the pursuit of the corporation&#8217;s specific public benefit purpose. The application of this balancing obligation may allow our directors to make decisions that they could not have made pursuant to the fiduciary duties applicable prior to PBC conversion. There is no guarantee that our Board will resolve conflicts among the financial interests of our shareholders, our public benefit purpose, or stakeholders materially affected by our conduct, in favor of our shareholders&#8217; financial interests. For instance, in a sale of control transaction, our Board would be required to consider and balance the factors listed above and might choose to accept an offer that does not maximize short-term shareholder value due to its consideration of other factors. This requirement of Delaware law may make our company a less attractive takeover target than a traditional for-profit corporation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A Delaware PBC must also provide its shareholders with a statement, at least every other year, as to the PBC&#8217;s assessment of the success of its efforts to promote its public benefit purpose and the best interests of those materially affected by the PBC's conduct. If the public perceives that we are not successful in promoting our public benefit purpose, or that our pursuit of our public benefit purpose is having a negative effect on the financial interests of our shareholders, that perception could negatively affect our reputation, which could adversely affect our business, results of operations, and stock price. In addition, Delaware's PBC statute may be amended to require more explicit or burdensome reporting requirements that could increase the time and expense required to comply.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">As a Delaware PBC, we may be subject to increased litigation risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Shareholders of a Delaware PBC (if they, individually or collectively, own the lesser of (1) two percent of the PBC&#8217;s outstanding shares; or (2) shares with a market value of $2 million or more on the date the lawsuit is instituted) can file a derivative lawsuit claiming the directors failed to balance shareholder and public benefit interests. Traditional Delaware for-profit corporations are not subject to this potential liability. As a PBC, we may be subject to increased derivative litigation, which may be costly and require management&#8217;s attention, which may adversely affect our financial condition and results of operations. In addition, there is currently limited case law involving PBCs (including case law interpreting and applying the balancing obligation of PBC directors), which may expose us to additional litigation risk generally until additional case law develops or additional legislative action is taken.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_124"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Average Price Paid Per Share (or Unit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1, 2026 - January 31, 2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/><td style="border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/><td style="border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">February 1, 2026 - February 28, 2026</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 1, 2026 - March 31, 2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,164,459</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,164,459</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,164,459</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,164,459</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">As announced on March 9, 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0 billion (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract) in aggregate repurchases of our common stock, which program expires on March 9, 2027. Pursuant to this authorization, we entered into the 2026 ASR agreements, comprised of a $750.0&#160;million 2026 Uncollared ASR and a $750.0&#160;million 2026 Collared ASR, with Citi on March 9, 2026 to repurchase $1.5 billion of our common stock. We made an aggregate upfront payment of $1.5&#160;billion to Citi and received initial deliveries of 992,120 and 708,657 shares of our common stock on March 11, 2026, representing approximately 70 percent and 50 percent of the total shares that would be repurchased under the 2026 Uncollared ASR and 2026 Collared ASR, respectively, measured based on the closing price of our common stock on March 9, 2026. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2026 Collared ASR, we received an additional 463,682 shares of our common stock on March 30, 2026. The total number of shares ultimately repurchased pursuant to the 2026 ASR agreements, and the average price paid per share, will be determined upon final settlement and will be based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period under the 2026 ASR agreements, less a discount and subject to adjustments in accordance with the terms and conditions of the 2026 ASR agreements. As discussed above, under the 2026 Collared ASR, the final number of shares we will ultimately repurchase will also be subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments. At the final settlement of the 2026 ASR agreements, we may be entitled to receive additional shares of our common stock, or, under certain limited circumstances, be required to make an additional cash payment to Citi or, if we so elect, deliver </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares of our common stock to Citi. The scheduled termination date of the 2026 Uncollared ASR is in the second quarter of 2026. The scheduled termination date of the 2026 Collared ASR is in the third quarter of 2026.</span></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_127"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Trading Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">March&#160;31, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, no director or Section 16 officer <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-775"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-776">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-777"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-778">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:18pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Item 6.&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #9d9598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1.5pt solid #9d9598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #9d9598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465921121499/tm2128821d1_ex3-1.htm">Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 1, 2021</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm">Eleventh</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm"> Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit&#160;3.1 of the Registrant&#8217;s Current Report on Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm">January 22</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm">6</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reference is made to Exhibits&#160;</span><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465921121499/tm2128821d1_ex3-1.htm">3.1</a></span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_ex3-1.htm">3.2</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="uthrex31103312026.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="uthrex31203312026.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32.1**</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="uthrex32103312026.htm">Certification of Principal Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">32.2**</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="uthrex32203312026.htm">Certification of Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">101*</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following financial information from our Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2026, filed with the SEC on May&#160;6, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (1)&#160;our Consolidated Balance Sheets as of March&#160;31, 2026 and December&#160;31, 2025; (2)&#160;our Consolidated Statements of Operations for the three-month periods ended March&#160;31, 2026 and 2025; (3)&#160;our Consolidated Statements of Comprehensive Income for the three-month periods ended March&#160;31, 2026 and 2025; (4) our Consolidated Statements of Stockholders&#8217; Equity for the three-month periods ended March&#160;31, 2026 and 2025; (5) our Consolidated Statements of Cash Flows for the three-month periods ended March&#160;31, 2026 and 2025; and (6)&#160;the Notes to our Consolidated Financial Statements.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #939598;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="border-bottom:1pt solid #939598;border-top:1pt solid #939598;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #939598;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the iXBRL document)</span></td></tr></table></div><div style="margin-bottom:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: Except as otherwise noted above, all exhibits incorporated by reference to the Registrant&#8217;s previously filed reports with the Securities and Exchange Commission are filed under File No. 000-26301.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly Report</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span></div></td></tr></table></div></div></div><div id="iafadd3ba7ea644f5bcd5cbd7a3475b3c_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iafadd3ba7ea644f5bcd5cbd7a3475b3c_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Part II. Other Information</span></div></div><div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#6d6e70;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:16pt;font-weight:400;line-height:120%">Signatures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">UNITED THERAPEUTICS CORPORATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 6, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">/s/ MARTINE&#160;ROTHBLATT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Martine Rothblatt, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chairperson and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">/s/ JAMES C. EDGEMOND</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">James C. Edgemond</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Therapeutics, a public benefit corporation</span></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>uthrex31103312026.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ifaacff80a3254108a33214335f0bf32b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">I, Martine Rothblatt, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">I have reviewed this quarterly report on Form 10-Q of United Therapeutics Corporation&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.26pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.54pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.26pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 6, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#47;s&#47; MARTINE ROTHBLATT</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Martine Rothblatt, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chairperson and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>uthrex31203312026.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i70b744a38d1743b7bfc69eb209764f2d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">I, James C. Edgemond, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">I have reviewed this quarterly report on Form 10-Q of United Therapeutics Corporation&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.26pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.54pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.26pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.38pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 6, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#47;s&#47; JAMES C. EDGEMOND</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">James C. Edgemond</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>uthrex32103312026.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id1356b3e181b4412b699fe209aecf961_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of United Therapeutics Corporation (the &#34;Company&#34;) on Form 10-Q for the period ended March&#160;31, 2026 as filed with the Securities and Exchange Commission (the &#34;Report&#34;), I, Martine Rothblatt, Chairperson and Chief Executive Officer of the Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 6, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#47;s&#47; MARTINE ROTHBLATT</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Martine Rothblatt, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chairperson and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">United Therapeutics Corporation</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">THE FOREGOING CERTIFICATION IS BEING FURNISHED SOLELY PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 AND IS NOT BEING FILED AS PART OF THE FORM 10-Q OR AS A SEPARATE DISCLOSURE DOCUMENT.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>uthrex32203312026.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic2af0ae124834e3ab06bcabf97177502_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of United Therapeutics Corporation (the &#34;Company&#34;) on Form 10-Q for the period ended March&#160;31, 2026 as filed with the Securities and Exchange Commission (the &#34;Report&#34;), I, James C. Edgemond, Chief Financial Officer and Treasurer of the Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.87pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">May 6, 2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#47;s&#47; JAMES C. EDGEMOND</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">James C. Edgemond</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">United Therapeutics Corporation</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">THE FOREGOING CERTIFICATION IS BEING FURNISHED SOLELY PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 AND IS NOT BEING FILED AS PART OF THE FORM 10-Q OR AS A SEPARATE DISCLOSURE DOCUMENT.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>uthr-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:uthr="http://www.unither.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.unither.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uthr-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uthr-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uthr-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="uthr-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.unither.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.unither.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.unither.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952154 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952156 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.unither.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDescription" roleURI="http://www.unither.com/role/OrganizationandBusinessDescription">
        <link:definition>9952158 - Disclosure - Organization and Business Description</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.unither.com/role/BasisofPresentation">
        <link:definition>9952159 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.unither.com/role/Investments">
        <link:definition>9952160 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.unither.com/role/FairValueMeasurements">
        <link:definition>9952161 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.unither.com/role/Inventories">
        <link:definition>9952162 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.unither.com/role/PropertyPlantandEquipment">
        <link:definition>9952163 - Disclosure - Property, Plant, and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.unither.com/role/Debt">
        <link:definition>9952164 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.unither.com/role/ShareBasedCompensation">
        <link:definition>9952165 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.unither.com/role/StockholdersEquity">
        <link:definition>9952166 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.unither.com/role/IncomeTaxes">
        <link:definition>9952167 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.unither.com/role/SegmentInformation">
        <link:definition>9952168 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.unither.com/role/Litigation">
        <link:definition>9952169 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.unither.com/role/BasisofPresentationPolicies">
        <link:definition>9955511 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.unither.com/role/InvestmentsTables">
        <link:definition>9955512 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.unither.com/role/FairValueMeasurementsTables">
        <link:definition>9955513 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.unither.com/role/InventoriesTables">
        <link:definition>9955514 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.unither.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9955515 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.unither.com/role/ShareBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.unither.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.unither.com/role/SegmentInformationTables">
        <link:definition>9955518 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails">
        <link:definition>9955519 - Disclosure - Investments - Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>9955520 - Disclosure - Investments - Current and Non-current of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails">
        <link:definition>9955521 - Disclosure - Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.unither.com/role/InvestmentsNarrativeDetails">
        <link:definition>9955522 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails" roleURI="http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails">
        <link:definition>9955523 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails" roleURI="http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails">
        <link:definition>9955524 - Disclosure - Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails" roleURI="http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails">
        <link:definition>9955525 - Disclosure - Investments - Investments in Privately-Held Companies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.unither.com/role/FairValueMeasurementsDetails">
        <link:definition>9955526 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.unither.com/role/InventoriesDetails">
        <link:definition>9955527 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>9955528 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>9955529 - Disclosure - Property, Plant, and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.unither.com/role/DebtDetails">
        <link:definition>9955530 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationGeneralNarrativeDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails">
        <link:definition>9955531 - Disclosure - Share-Based Compensation - General Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails">
        <link:definition>9955532 - Disclosure - Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionsNarrativeDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails">
        <link:definition>9955533 - Disclosure - Share-Based Compensation - Stock Options Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAssumptionsForStockOptionsDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails">
        <link:definition>9955534 - Disclosure - Share-Based Compensation - Assumptions For Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStatusofStockOptionsDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails">
        <link:definition>9955535 - Disclosure - Share-Based Compensation - Status of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>9955536 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionsExerciseDataDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails">
        <link:definition>9955537 - Disclosure - Share-Based Compensation - Stock Options Exercise Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockUnitsNarrativeDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails">
        <link:definition>9955538 - Disclosure - Share-Based Compensation - Restricted Stock Units Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockUnitsStatusDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails">
        <link:definition>9955539 - Disclosure - Share-Based Compensation - Restricted Stock Units Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>9955540 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails" roleURI="http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails">
        <link:definition>9955541 - Disclosure - Stockholders&#8217; Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.unither.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955542 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.unither.com/role/IncomeTaxesDetails">
        <link:definition>9955543 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationGeneralDetails" roleURI="http://www.unither.com/role/SegmentInformationGeneralDetails">
        <link:definition>9955544 - Disclosure - Segment Information - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationGeographicInformationDetails" roleURI="http://www.unither.com/role/SegmentInformationGeographicInformationDetails">
        <link:definition>9955545 - Disclosure - Segment Information - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationConcentrationRiskDetails" roleURI="http://www.unither.com/role/SegmentInformationConcentrationRiskDetails">
        <link:definition>9955546 - Disclosure - Segment Information - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.unither.com/role/LitigationDetails">
        <link:definition>9955547 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" abstract="false" name="AdvancePaymentRelatedToPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_NoncashExciseTaxOnNetShareRepurchases" abstract="false" name="NoncashExciseTaxOnNetShareRepurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" abstract="false" name="ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" abstract="false" name="ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="uthr_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" abstract="false" name="DebtSecuritiesAvailableForSaleImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_PrivatelyHeldCompaniesMember" abstract="true" name="PrivatelyHeldCompaniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" abstract="true" name="BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_FurnitureEquipmentAndVehiclesMember" abstract="true" name="FurnitureEquipmentAndVehiclesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2025CreditAgreementMember" abstract="true" name="A2025CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_CreditAgreement2022Member" abstract="true" name="CreditAgreement2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" abstract="true" name="CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" abstract="true" name="CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_DebtInstrumentExtensionTerm" abstract="false" name="DebtInstrumentExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="uthr_DebtInstrumentAdditionalExtensionTerm" abstract="false" name="DebtInstrumentAdditionalExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="uthr_StockIncentivePlan2015PlanMember" abstract="true" name="StockIncentivePlan2015PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_InducementStockIncentivePlan2019Member" abstract="true" name="InducementStockIncentivePlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_NewlyHiredEmployeesMember" abstract="true" name="NewlyHiredEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_NumberOfEquityIncentivePlans" abstract="false" name="NumberOfEquityIncentivePlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="uthr_ShareTrackingAwardsPlanMember" abstract="true" name="ShareTrackingAwardsPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" abstract="true" name="ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" abstract="true" name="RestrictedStockUnitsRSUsWithPerformanceConditionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_ExecutivesMember" abstract="true" name="ExecutivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_NetIncomePerCommonShareAbstract" abstract="true" name="NetIncomePerCommonShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="uthr_A2026ShareRepurchaseProgramMember" abstract="true" name="A2026ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2026AcceleratedShareRepurchaseAgreementsMember" abstract="true" name="A2026AcceleratedShareRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" abstract="true" name="A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" abstract="true" name="A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2025ShareRepurchaseProgramMember" abstract="true" name="A2025ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2025AcceleratedShareRepurchaseAgreementsMember" abstract="true" name="A2025AcceleratedShareRepurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" abstract="true" name="A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" abstract="true" name="A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" abstract="false" name="ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" abstract="false" name="StockRepurchaseProgramPercentageOfSharesToBeRepurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="uthr_UnrecognizedTaxBenefitsIncludingInterest" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" abstract="true" name="ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="uthr_TyvasoDPIMember" abstract="true" name="TyvasoDPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_NebulizedTyvasoMember" abstract="true" name="NebulizedTyvasoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_RemodulinMember" abstract="true" name="RemodulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_OrenitramMember" abstract="true" name="OrenitramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_UnituxinMember" abstract="true" name="UnituxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_AdcircaMember" abstract="true" name="AdcircaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" abstract="true" name="NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="uthr_TyvasoMember" abstract="true" name="TyvasoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_SandozIncMember" abstract="true" name="SandozIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_LiquidiaTechnologiesInc.Member" abstract="true" name="LiquidiaTechnologiesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_SmithsMedicalASDIncMember" abstract="true" name="SmithsMedicalASDIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="uthr_NumberOfPetitions" abstract="false" name="NumberOfPetitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>uthr-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d1dc9-bd6a-7982-9af2-10e16056933e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d1dc9-bd6a-7982-9af2-10e16056933e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019d1dc9-bd6a-791c-8f36-f19a9d9c9f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019d1dc9-bd6a-791c-8f36-f19a9d9c9f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019d1dc9-bd6a-7b80-b9cd-debf847999be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019d1dc9-bd6a-7b80-b9cd-debf847999be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019d1dc9-bd6a-7380-939a-04ac42c07a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:to="loc_us-gaap_InventoryNet_019d1dc9-bd6a-7380-939a-04ac42c07a1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019d1dc9-bd6a-7cc6-a1b7-f31a169a920a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-70ad-aec0-284bc58fa642" xlink:to="loc_us-gaap_OtherAssetsCurrent_019d1dc9-bd6a-7cc6-a1b7-f31a169a920a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019d1dc9-bd6a-7b26-a7c6-990d90308656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-7260-bad1-8ddd844a4f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019d1dc9-bd6a-7b26-a7c6-990d90308656" xlink:to="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-7260-bad1-8ddd844a4f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019d1dc9-bd6a-7593-b475-870549a7ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019d1dc9-bd6a-7b26-a7c6-990d90308656" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019d1dc9-bd6a-7593-b475-870549a7ba34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-7c4e-aa75-1926c9bac3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-7c4e-aa75-1926c9bac3f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_019d1dc9-bd6a-7641-8d9a-2adfc6c1dacb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_019d1dc9-bd6a-7641-8d9a-2adfc6c1dacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_019d1dc9-bd6a-7bd3-82eb-36f901b4c929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_019d1dc9-bd6a-7bd3-82eb-36f901b4c929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6a-7b2a-92ef-a90060036889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6a-7b2a-92ef-a90060036889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_019d1dc9-bd6a-7906-b54a-62d7e93b2449" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_019d1dc9-bd6a-7906-b54a-62d7e93b2449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019d1dc9-bd6a-7ccf-892c-26107e23f4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019d1dc9-bd6a-73e6-9502-ab4eb8b691b9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019d1dc9-bd6a-7ccf-892c-26107e23f4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019d1dc9-bd6a-7bfb-98a8-72d9424fbc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_PreferredStockValue_019d1dc9-bd6a-7bfb-98a8-72d9424fbc5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019d1dc9-bd6a-7a76-8aea-8d669f761272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_CommonStockValue_019d1dc9-bd6a-7a76-8aea-8d669f761272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019d1dc9-bd6a-76a8-8bd9-8af08bc67d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019d1dc9-bd6a-76a8-8bd9-8af08bc67d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019d1dc9-bd6a-7ab2-aa24-0ed135c4de95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019d1dc9-bd6a-7ab2-aa24-0ed135c4de95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019d1dc9-bd6a-76f1-b559-8668c5033491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019d1dc9-bd6a-76f1-b559-8668c5033491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019d1dc9-bd6a-786d-9bc4-a8099414502a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7cd1-a73d-77f44aead81b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019d1dc9-bd6a-786d-9bc4-a8099414502a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-7ddd-8c7e-e34948e577ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019d1dc9-bd6a-7adb-a3b0-8564e5150b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-7ddd-8c7e-e34948e577ce" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019d1dc9-bd6a-7adb-a3b0-8564e5150b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019d1dc9-bd6a-74b0-b2b7-54436b9d2c10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-7ddd-8c7e-e34948e577ce" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019d1dc9-bd6a-74b0-b2b7-54436b9d2c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7c35-ba40-4d442ff91266" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019d1dc9-bd6a-765b-81aa-13079605f245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7c35-ba40-4d442ff91266" xlink:to="loc_us-gaap_Liabilities_019d1dc9-bd6a-765b-81aa-13079605f245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-73d0-977c-fa6ffccc0b22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7c35-ba40-4d442ff91266" xlink:to="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-73d0-977c-fa6ffccc0b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019d1dc9-bd6a-7668-a7dd-1369f882ab94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7c35-ba40-4d442ff91266" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019d1dc9-bd6a-7668-a7dd-1369f882ab94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-74c0-8589-288b9f677681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-710a-9396-fc587c3c2823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-74c0-8589-288b9f677681" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-710a-9396-fc587c3c2823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019d1dc9-bd6a-7f0e-a4b7-24fa1db8e031" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-74c0-8589-288b9f677681" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019d1dc9-bd6a-7f0e-a4b7-24fa1db8e031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7a12-96ce-5c49d64787ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019d1dc9-bd6a-7fbd-b40d-833a258484b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7a12-96ce-5c49d64787ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019d1dc9-bd6a-7fbd-b40d-833a258484b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019d1dc9-bd6a-73ec-9342-453dbb4a6f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7a12-96ce-5c49d64787ad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019d1dc9-bd6a-73ec-9342-453dbb4a6f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-bd6a-711c-9c15-0df2190b9604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7a12-96ce-5c49d64787ad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-bd6a-711c-9c15-0df2190b9604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-75be-bc64-4951eb8bd55d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7cfc-92dc-d668712c2285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-75be-bc64-4951eb8bd55d" xlink:to="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7cfc-92dc-d668712c2285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-76a8-908e-0ba411f3e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-75be-bc64-4951eb8bd55d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-76a8-908e-0ba411f3e30b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7c5e-8f3e-c6f5146c8bec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-bd6a-7df4-a56c-1462e903e08c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7c5e-8f3e-c6f5146c8bec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-bd6a-7df4-a56c-1462e903e08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-72f5-be72-4e806e1f43e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7c5e-8f3e-c6f5146c8bec" xlink:to="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-72f5-be72-4e806e1f43e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7eb2-9779-d9ef07dad9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019d1dc9-bd6a-71ac-b083-70356461d697" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7eb2-9779-d9ef07dad9d6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019d1dc9-bd6a-71ac-b083-70356461d697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019d1dc9-bd6a-7428-8a96-5098b6b43ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7eb2-9779-d9ef07dad9d6" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019d1dc9-bd6a-7428-8a96-5098b6b43ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019d1dc9-bd6a-7538-86a9-f0700308999b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7eb2-9779-d9ef07dad9d6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019d1dc9-bd6a-7538-86a9-f0700308999b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ad1-9995-99a31b821c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-772d-9a5f-d1c6d7888e46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ad1-9995-99a31b821c7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-772d-9a5f-d1c6d7888e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7863-b98a-05c950312b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ad1-9995-99a31b821c7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7863-b98a-05c950312b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-73a5-a8ab-aac2bb478238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_019d1dc9-bd6a-781b-acf2-c2f8e13e5432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-73a5-a8ab-aac2bb478238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_019d1dc9-bd6a-781b-acf2-c2f8e13e5432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_019d1dc9-bd6a-748e-ad5c-5641c8b6d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-73a5-a8ab-aac2bb478238" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_019d1dc9-bd6a-748e-ad5c-5641c8b6d8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7588-92b7-10d0a5163539" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_019d1dc9-bd6a-7f11-bcee-e57f1528e51f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7588-92b7-10d0a5163539" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_019d1dc9-bd6a-7f11-bcee-e57f1528e51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019d1dc9-bd6a-761a-bc44-2b9f014d64e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7588-92b7-10d0a5163539" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019d1dc9-bd6a-761a-bc44-2b9f014d64e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-bd6a-7082-a6bb-d567ab6f4fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7831-a2a5-573a120e96f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-bd6a-7082-a6bb-d567ab6f4fbc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7831-a2a5-573a120e96f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-74c0-952b-37fa3c133c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-bd6a-7082-a6bb-d567ab6f4fbc" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-74c0-952b-37fa3c133c4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-797e-b9c5-8ea2d20fb3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-797e-b9c5-8ea2d20fb3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019d1dc9-bd6a-7951-bf90-bbfc5d01578f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019d1dc9-bd6a-7951-bf90-bbfc5d01578f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019d1dc9-bd6a-77bb-afc9-903eb02773ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_ShareBasedCompensation_019d1dc9-bd6a-77bb-afc9-903eb02773ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d1dc9-bd6a-7479-80eb-7ae0262c052a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d1dc9-bd6a-7479-80eb-7ae0262c052a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019d1dc9-bd6a-7a0f-8c17-e7469e255cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019d1dc9-bd6a-7a0f-8c17-e7469e255cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_019d1dc9-bd6a-7a90-b71f-bcf105887e49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_019d1dc9-bd6a-7a90-b71f-bcf105887e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019d1dc9-bd6a-7e40-80fa-485be1509778" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019d1dc9-bd6a-7e40-80fa-485be1509778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019d1dc9-bd6a-7008-b903-0404e74a54c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019d1dc9-bd6a-7008-b903-0404e74a54c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019dd9ec-3e3b-7f9e-ad7b-0403bdf733c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019dd9ec-3e3b-7f9e-ad7b-0403bdf733c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019dd9ec-3e3b-7e95-ad47-27f983a8c9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7572-b8cb-bfa051acca27" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019dd9ec-3e3b-7e95-ad47-27f983a8c9b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-7357-9e18-364081b3754c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7cab-80f5-4ea774904c38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-7357-9e18-364081b3754c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7cab-80f5-4ea774904c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7cf9-bc74-1308ed2c32bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-7357-9e18-364081b3754c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7cf9-bc74-1308ed2c32bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7aad-9b15-ea06a3334df0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-7357-9e18-364081b3754c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7aad-9b15-ea06a3334df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019d1dc9-bd6a-7c55-97f5-3d46f4cd47f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019d1dc9-bd6a-7c55-97f5-3d46f4cd47f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_019d1dc9-bd6a-7833-9cec-02b1fef3c98d" xlink:href="uthr-20260331.xsd#uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_019d1dc9-bd6a-7833-9cec-02b1fef3c98d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019d1dc9-bd6a-7ecf-bd35-1825e31aeff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019d1dc9-bd6a-7ecf-bd35-1825e31aeff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019d1dc9-bd6a-7145-bf20-f276f037d41d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019d1dc9-bd6a-7145-bf20-f276f037d41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019d89ef-899b-76da-8204-ed9ab2612d51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019d89ef-899b-76da-8204-ed9ab2612d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_019d89ef-899b-7615-9f7d-edd591ce14c8" xlink:href="uthr-20260331.xsd#uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7e78-bcb7-bfc4fe3879ad" xlink:to="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_019d89ef-899b-7615-9f7d-edd591ce14c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-bd6a-7883-a760-e7ee77627f72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-bd6a-7883-a760-e7ee77627f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_019d1dc9-bd6a-7d63-aefd-7c2e0f260c22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_019d1dc9-bd6a-7d63-aefd-7c2e0f260c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6a-7254-a823-6e7a33c5ab92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6a-7254-a823-6e7a33c5ab92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019d1dc9-bd6a-79b2-9c0e-63b8959ab333" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019d1dc9-bd6a-79b2-9c0e-63b8959ab333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-7c22-b182-b4aa9c54160d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7dd2-8500-5b67791357fd" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-7c22-b182-b4aa9c54160d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7bbd-9310-9f3d9f995005" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7512-9a71-8727b1e1276e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7bbd-9310-9f3d9f995005" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7512-9a71-8727b1e1276e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-7f42-ac5f-a158c1bc4627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7bbd-9310-9f3d9f995005" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-7f42-ac5f-a158c1bc4627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7c75-a761-cc1da9a5ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7bbd-9310-9f3d9f995005" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7c75-a761-cc1da9a5ce98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-72c9-9613-b72c6ad3727f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7240-a769-619b4d523410" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-72c9-9613-b72c6ad3727f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7240-a769-619b4d523410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-7ab5-ab18-d1e833d25505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-72c9-9613-b72c6ad3727f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-7ab5-ab18-d1e833d25505" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7c9a-acba-4c818e782411" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-7bdc-a6df-ce100c1bd15e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7c9a-acba-4c818e782411" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-7bdc-a6df-ce100c1bd15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-7acd-b9b5-393e7c7d7c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7c9a-acba-4c818e782411" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-7acd-b9b5-393e7c7d7c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-7f9b-a49e-c96b40ed0226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-7f57-986b-35637bf77ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-7f9b-a49e-c96b40ed0226" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-7f57-986b-35637bf77ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-7af8-8eed-ac9e80750413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-7f9b-a49e-c96b40ed0226" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-7af8-8eed-ac9e80750413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-bd6a-7f7d-aedf-5c778f5688bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_019d1dc9-bd6a-7ca9-aabb-7f29a8a5c633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-bd6a-7f7d-aedf-5c778f5688bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_019d1dc9-bd6a-7ca9-aabb-7f29a8a5c633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_019d1dc9-bd6a-7d7e-a0db-77aac82e8db8" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-bd6a-7f7d-aedf-5c778f5688bc" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_019d1dc9-bd6a-7d7e-a0db-77aac82e8db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-bd6a-78e2-a310-63d50b0f2862" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_019d1dc9-bd6a-76b7-a269-50fda2cd4b08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-bd6a-78e2-a310-63d50b0f2862" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_019d1dc9-bd6a-76b7-a269-50fda2cd4b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_019d1dc9-bd6a-75e3-9084-bd2474faafc2" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-bd6a-78e2-a310-63d50b0f2862" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_019d1dc9-bd6a-75e3-9084-bd2474faafc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7413-9bdc-022ed74ffcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7464-aaf1-ec69e7cb22eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7413-9bdc-022ed74ffcb8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7464-aaf1-ec69e7cb22eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7e5c-b17d-7ac0426db166" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7413-9bdc-022ed74ffcb8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7e5c-b17d-7ac0426db166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-7047-9dd1-8397a8f9ffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7413-9bdc-022ed74ffcb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-7047-9dd1-8397a8f9ffb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-7c00-bb6c-f6bf657132ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-7f53-b3a0-5d217b9bda21" xlink:href="uthr-20260331.xsd#uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-7c00-bb6c-f6bf657132ed" xlink:to="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-7f53-b3a0-5d217b9bda21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InventoriesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74b6-8062-45282526d8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019d1dc9-bd6b-7547-9468-f47d3f91e445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74b6-8062-45282526d8d4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019d1dc9-bd6b-7547-9468-f47d3f91e445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019d1dc9-bd6b-7bd9-b187-d8ed23b539cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74b6-8062-45282526d8d4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019d1dc9-bd6b-7bd9-b187-d8ed23b539cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019d1dc9-bd6b-74b7-a53f-4bcc89e7057c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74b6-8062-45282526d8d4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019d1dc9-bd6b-74b7-a53f-4bcc89e7057c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-73c1-bbf4-71e80bf3e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-7ee6-aa07-9db36bde8beb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-73c1-bbf4-71e80bf3e33f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-7ee6-aa07-9db36bde8beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7172-9e06-d9e5dd16fa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-73c1-bbf4-71e80bf3e33f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7172-9e06-d9e5dd16fa9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-7629-9a2d-48fad5140413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7909-8298-196dbe47bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-7629-9a2d-48fad5140413" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7909-8298-196dbe47bc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-753d-b696-9af205bba86d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-7629-9a2d-48fad5140413" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-753d-b696-9af205bba86d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be07-718a-be07-6a3442ee6dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be07-7c5e-8069-81282b936f46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be07-718a-be07-6a3442ee6dd3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be07-7c5e-8069-81282b936f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019d1dc9-be07-7154-a658-de00e1690b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be07-718a-be07-6a3442ee6dd3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019d1dc9-be07-7154-a658-de00e1690b75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationGeneralDetails"/>
  <link:calculationLink xlink:role="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_019d1dc9-be07-760b-8996-042d8615fc87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7294-bf76-3a0be73619ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_019d1dc9-be07-760b-8996-042d8615fc87" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7294-bf76-3a0be73619ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7cab-aff4-75d9402c5f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_019d1dc9-be07-760b-8996-042d8615fc87" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7cab-aff4-75d9402c5f13" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>uthr-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:to="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-7ec2-8604-c199adeaf558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:to="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-7ec2-8604-c199adeaf558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:to="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019d1dc9-bd6a-71c1-ae34-9be37923b785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_CommonStockMember_019d1dc9-bd6a-71c1-ae34-9be37923b785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019d1dc9-bd6a-75f7-9d76-670a388b38a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019d1dc9-bd6a-75f7-9d76-670a388b38a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019d1dc9-bd6a-7f5d-93a5-87a4fd150981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019d1dc9-bd6a-7f5d-93a5-87a4fd150981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019d1dc9-bd6a-7861-970b-bf26bb5b0439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019d1dc9-bd6a-7861-970b-bf26bb5b0439" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019d1dc9-bd6a-7373-b1ef-2a55b833704d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_RetainedEarningsMember_019d1dc9-bd6a-7373-b1ef-2a55b833704d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-785e-bce1-6d7b0fa54111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-785e-bce1-6d7b0fa54111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7fff-8b97-022fbb0fdd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7fff-8b97-022fbb0fdd9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7dd2-a360-e0d19a6c724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7dd2-a360-e0d19a6c724c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ee9-9611-778590da13dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ee9-9611-778590da13dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019d1dc9-bd6a-7dda-b52e-fc97bd6d3b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019d1dc9-bd6a-7dda-b52e-fc97bd6d3b8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-79d1-907c-c5c10731297b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-79d1-907c-c5c10731297b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019d1dc9-bd6a-7aae-8ddc-8bec278320f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019d1dc9-bd6a-7aae-8ddc-8bec278320f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax_019d3275-d58f-7dfc-9625-5af7904dccb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTax_019d3275-d58f-7dfc-9625-5af7904dccb4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019d1dc9-bd6a-74b5-ad94-9bc0bfeeee86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019d1dc9-bd6a-74b5-ad94-9bc0bfeeee86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6a-7fad-b3b2-ad47de2f6737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6a-7fad-b3b2-ad47de2f6737" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019d1dc9-bd6a-7aed-9fe4-3a055d6002c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019d1dc9-bd6a-7aed-9fe4-3a055d6002c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019d1dc9-bd6a-7956-bfdb-759562872006" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019d1dc9-bd6a-7956-bfdb-759562872006" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-7687-98c5-2f101776dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-787f-9d2d-2fac8cef9baa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-72cb-a6eb-763db369e7a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-72cb-a6eb-763db369e7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-79be-a372-43b7c167b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-79be-a372-43b7c167b6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-7068-8432-0c1f75e54889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-7068-8432-0c1f75e54889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7b5d-b737-5a63da8a34a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7b5d-b737-5a63da8a34a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7345-92d1-56810f7bec15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7345-92d1-56810f7bec15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-70c1-8b31-3f009403c505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-70c1-8b31-3f009403c505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c2d-a9bb-91588137976f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c2d-a9bb-91588137976f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-766d-9c18-82f8aed7fc37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-766d-9c18-82f8aed7fc37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_019d1dc9-bd6a-7f0d-b867-d188aa44ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_019d1dc9-bd6a-7f0d-b867-d188aa44ca8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesCurrentMember_019d1dc9-bd6a-7b8e-8151-4bdf4ed6cd3c" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_uthr_MarketableSecuritiesCurrentMember_019d1dc9-bd6a-7b8e-8151-4bdf4ed6cd3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesNoncurrentMember_019d1dc9-bd6a-7917-8de4-cf320abee059" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_uthr_MarketableSecuritiesNoncurrentMember_019d1dc9-bd6a-7917-8de4-cf320abee059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-747d-ae29-bb488d56b9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-747d-ae29-bb488d56b9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7225-b30e-410420d5e296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7225-b30e-410420d5e296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c95-bd78-2d2d4db55e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c95-bd78-2d2d4db55e58" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-72b5-a0bd-5575e4517828" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-72b5-a0bd-5575e4517828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-759c-b404-64d3bdb5ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-759c-b404-64d3bdb5ca70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-785c-baba-ec1cf6deee59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-785c-baba-ec1cf6deee59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-73f8-a756-69ba58cfe68a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-73f8-a756-69ba58cfe68a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7aeb-a0d5-311a27713a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7aeb-a0d5-311a27713a49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-727e-a2c6-19632afd7ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-727e-a2c6-19632afd7ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-752f-a002-67a4e697bd62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-752f-a002-67a4e697bd62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-742a-9f2d-9c4b15965fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-742a-9f2d-9c4b15965fd6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7916-9f5f-15295843ee9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7916-9f5f-15295843ee9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PrivatelyHeldCompaniesMember_019d1dc9-bd6a-7bf7-9607-2fbaa98d164b" xlink:href="uthr-20260331.xsd#uthr_PrivatelyHeldCompaniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:to="loc_uthr_PrivatelyHeldCompaniesMember_019d1dc9-bd6a-7bf7-9607-2fbaa98d164b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019d1dc9-bd6a-795a-8386-673dd0354a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019d1dc9-bd6a-795a-8386-673dd0354a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019d3292-a668-7f46-8f49-4e8606b77b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019d3292-a668-7f46-8f49-4e8606b77b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019d8a0f-02b5-72ea-acd4-29eab643ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019d8a0f-02b5-72ea-acd4-29eab643ba40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-79ed-933b-4d4a91d12a86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-79ed-933b-4d4a91d12a86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-756b-b0b0-25f28f9053b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-756b-b0b0-25f28f9053b4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-7ccf-9f84-deb5e78cc00e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-7ccf-9f84-deb5e78cc00e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019d3298-7bb7-796d-bbab-6afc1c049973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019d3298-7bb7-796d-bbab-6afc1c049973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cb4-98a0-b46adf34ada8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cb4-98a0-b46adf34ada8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019d3298-7bb7-76f3-898d-2560b514e051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019d3298-7bb7-76f3-898d-2560b514e051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019d3298-7bb7-7aa1-9a61-cfd4499f43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019d3298-7bb7-7aa1-9a61-cfd4499f43cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019d3298-7bb7-7b85-829c-ed75f56c300e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019d3298-7bb7-7b85-829c-ed75f56c300e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-72eb-ba51-d10d9263a543_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-72eb-ba51-d10d9263a543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_019d3298-7bb7-74f7-9d43-b91bcf69ebd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_019d3298-7bb7-74f7-9d43-b91bcf69ebd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-7678-81b3-847ab5993d57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-7678-81b3-847ab5993d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019d3298-7bb7-73b1-9b9c-00e7cfb5e321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019d3298-7bb7-73b1-9b9c-00e7cfb5e321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_019d3298-7bb7-78ee-8ff9-8166660adaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:to="loc_us-gaap_BankTimeDepositsMember_019d3298-7bb7-78ee-8ff9-8166660adaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-706c-af3b-01be18126800_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-706c-af3b-01be18126800_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d3298-7bb7-7b8d-9603-7dd2efa8b472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d3298-7bb7-7b8d-9603-7dd2efa8b472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d3298-7bb7-76d9-a197-cd9d73192eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d3298-7bb7-76d9-a197-cd9d73192eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-764f-ac48-b78477350eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-764f-ac48-b78477350eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7890-98d8-f4fdc26a1e70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7890-98d8-f4fdc26a1e70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7f81-ab26-dc4c1b074234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7f81-ab26-dc4c1b074234" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7ca3-be0c-18484db82bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7ca3-be0c-18484db82bb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-71a5-9839-3423a8b91ec0" xlink:href="uthr-20260331.xsd#uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:to="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-71a5-9839-3423a8b91ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-75f5-ba0c-e5136bc9e783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-75f5-ba0c-e5136bc9e783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d3298-7bb7-7065-ae6f-8c903aa389b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d3298-7bb7-7065-ae6f-8c903aa389b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019d3298-7bb7-7bc8-ad94-e8287bcbd851" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019d3298-7bb7-7bc8-ad94-e8287bcbd851" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-730f-9412-cb0e002e7700_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-730f-9412-cb0e002e7700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_019d1dc9-bd6b-7045-91db-42505511845f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_019d1dc9-bd6b-7045-91db-42505511845f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_019d1dc9-bd6b-7369-a323-a02aaa23582e" xlink:href="uthr-20260331.xsd#uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_019d1dc9-bd6b-7369-a323-a02aaa23582e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_019d1dc9-bd6b-73f6-b422-6922cbbcd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_us-gaap_ConstructionInProgressMember_019d1dc9-bd6b-73f6-b422-6922cbbcd5b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_FurnitureEquipmentAndVehiclesMember_019d1dc9-bd6b-71c8-8364-b2086eb44a04" xlink:href="uthr-20260331.xsd#uthr_FurnitureEquipmentAndVehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_uthr_FurnitureEquipmentAndVehiclesMember_019d1dc9-bd6b-71c8-8364-b2086eb44a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-77de-8cef-1e67b0311e90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-77de-8cef-1e67b0311e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7075-a45a-06e52d600a97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7075-a45a-06e52d600a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-7e57-a02d-4a89fbafd430" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-7e57-a02d-4a89fbafd430" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/DebtDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:to="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-7998-ba23-030ad64e7858_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-7998-ba23-030ad64e7858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025CreditAgreementMember_019d1dc9-bd6b-78da-bfe2-438401a722b8" xlink:href="uthr-20260331.xsd#uthr_A2025CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:to="loc_uthr_A2025CreditAgreementMember_019d1dc9-bd6b-78da-bfe2-438401a722b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:to="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-72c0-b00e-a84a257d2f69" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:to="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-72c0-b00e-a84a257d2f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-73c2-821a-c41f88377b63" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:to="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-73c2-821a-c41f88377b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7ba1-ad43-c943b7931dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7ba1-ad43-c943b7931dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019d7539-f01d-74bf-82c5-f6a1e33cae78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:to="loc_us-gaap_SubsequentEventMember_019d7539-f01d-74bf-82c5-f6a1e33cae78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019d1dc9-bd6b-72aa-925b-baaa4d30044c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019d1dc9-bd6b-72aa-925b-baaa4d30044c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_019d1dc9-bd6b-7cc0-8a71-7d53381cf80f" xlink:href="uthr-20260331.xsd#uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_019d1dc9-bd6b-7cc0-8a71-7d53381cf80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentExtensionTerm_019d1dc9-bd6b-72cc-abde-254e67c94887" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_DebtInstrumentExtensionTerm_019d1dc9-bd6b-72cc-abde-254e67c94887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentAdditionalExtensionTerm_019d753a-eafc-7466-a1cd-097c5d761ed4" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentAdditionalExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_DebtInstrumentAdditionalExtensionTerm_019d753a-eafc-7466-a1cd-097c5d761ed4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019d1dc9-bd6b-7e82-97da-0ad3a1d86b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019d1dc9-bd6b-7e82-97da-0ad3a1d86b85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019d1dc9-bd6b-7cce-b0ff-142760b84984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019d1dc9-bd6b-7cce-b0ff-142760b84984" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019d1dc9-bd6b-7210-9736-b1fb4788c660" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LongTermDebt_019d1dc9-bd6b-7210-9736-b1fb4788c660" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_019d1dc9-bd6b-731c-b461-f312df9bc977" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LinesOfCreditCurrent_019d1dc9-bd6b-731c-b461-f312df9bc977" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationGeneralNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:to="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7eb7-b0fe-010301df1fda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:to="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7eb7-b0fe-010301df1fda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:to="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockIncentivePlan2015PlanMember_019d1dc9-bd6b-7325-94c0-b00a05d20341" xlink:href="uthr-20260331.xsd#uthr_StockIncentivePlan2015PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:to="loc_uthr_StockIncentivePlan2015PlanMember_019d1dc9-bd6b-7325-94c0-b00a05d20341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_InducementStockIncentivePlan2019Member_019d1dc9-bd6b-7cea-984f-47e53908e95e" xlink:href="uthr-20260331.xsd#uthr_InducementStockIncentivePlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:to="loc_uthr_InducementStockIncentivePlan2019Member_019d1dc9-bd6b-7cea-984f-47e53908e95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:to="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NewlyHiredEmployeesMember_019d1dc9-bd6b-7c2b-b4cf-446f4eaaad89" xlink:href="uthr-20260331.xsd#uthr_NewlyHiredEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:to="loc_uthr_NewlyHiredEmployeesMember_019d1dc9-bd6b-7c2b-b4cf-446f4eaaad89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfEquityIncentivePlans_019d1dc9-bd6b-7427-b7bb-ba008c4e9627" xlink:href="uthr-20260331.xsd#uthr_NumberOfEquityIncentivePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_uthr_NumberOfEquityIncentivePlans_019d1dc9-bd6b-7427-b7bb-ba008c4e9627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019d1dc9-bd6b-7b2c-b694-7c38118c747d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019d1dc9-bd6b-7b2c-b694-7c38118c747d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019d1dc9-bd6b-71a7-8e34-084ed1236f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019d1dc9-bd6b-71a7-8e34-084ed1236f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-789f-8157-cfa3a8e09d69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-789f-8157-cfa3a8e09d69" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-765f-b872-7030cba8b31f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-765f-b872-7030cba8b31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-745b-b6ae-5e68e18d4245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-745b-b6ae-5e68e18d4245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7e9a-83ce-6921251db517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7e9a-83ce-6921251db517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareTrackingAwardsPlanMember_019d1dc9-bd6b-74e7-b0a2-4a939924d005" xlink:href="uthr-20260331.xsd#uthr_ShareTrackingAwardsPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_uthr_ShareTrackingAwardsPlanMember_019d1dc9-bd6b-74e7-b0a2-4a939924d005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d1dc9-bd6b-7e6c-b835-b8cb0b0c4d03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_EmployeeStockMember_019d1dc9-bd6b-7e6c-b835-b8cb0b0c4d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-75ac-aa60-becfc8a07175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-75ac-aa60-becfc8a07175" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:to="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-7329-86fb-f68dcf9717ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-7329-86fb-f68dcf9717ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_019d4758-5978-7efe-a22e-4bdabfd796c0" xlink:href="uthr-20260331.xsd#uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:to="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_019d4758-5978-7efe-a22e-4bdabfd796c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d4758-9381-750c-912a-d34352280d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d4758-9381-750c-912a-d34352280d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d4758-5978-76f0-b58b-21f9993a56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d4758-5978-76f0-b58b-21f9993a56ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_019d4758-5978-78b0-9ed0-36351f1f907a" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_019d4758-5978-78b0-9ed0-36351f1f907a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d4758-5978-784f-a9eb-3ade91cd2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d4758-5978-784f-a9eb-3ade91cd2a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d4758-9381-7301-9ae1-9a1fa6e1ecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d4758-9381-7301-9ae1-9a1fa6e1ecc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019d4758-9381-70d6-84c1-dd84b36951af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019d4758-9381-70d6-84c1-dd84b36951af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d4759-046f-7470-b49b-9a9c75bd4012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d4759-046f-7470-b49b-9a9c75bd4012" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d4759-046f-7cbd-b456-83e431d9605b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d4759-046f-7cbd-b456-83e431d9605b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationAssumptionsForStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-736e-b69a-1d159639432a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-736e-b69a-1d159639432a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d1dc9-bd6b-7cdc-9c5a-c711e58311e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d1dc9-bd6b-7cdc-9c5a-c711e58311e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019d1dc9-bd6b-72d8-ae47-2a68625c93b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019d1dc9-bd6b-72d8-ae47-2a68625c93b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d1dc9-bd6b-7631-ba78-0e80efbfb81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d1dc9-bd6b-7631-ba78-0e80efbfb81b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d1dc9-bd6b-7374-ab17-5f3ea78a86d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d1dc9-bd6b-7374-ab17-5f3ea78a86d7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStatusofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-79cc-a4cb-e801454bc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-79cc-a4cb-e801454bc8ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7d38-83f6-ba00e05f71a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7d38-83f6-ba00e05f71a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-7b33-82b7-4d60430f6a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-7b33-82b7-4d60430f6a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-7115-8cbe-77232bd93470" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-7115-8cbe-77232bd93470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019d1dc9-bd6b-7b1e-a68d-02b5b73827fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019d1dc9-bd6b-7b1e-a68d-02b5b73827fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7058-8bd3-3ad6571c087c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d1dc9-bd6b-7f00-91c9-8f1d9a36e916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d1dc9-bd6b-7f00-91c9-8f1d9a36e916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d1dc9-bd6b-7c1b-9467-f0009836812e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d1dc9-bd6b-7c1b-9467-f0009836812e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7ca9-ad5f-fc6cb5b89efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7ca9-ad5f-fc6cb5b89efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-72e9-b055-77c9d62b124e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-72e9-b055-77c9d62b124e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-7e38-8b37-960fa7f808d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-7e38-8b37-960fa7f808d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-711b-a317-07761523d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-711b-a317-07761523d5c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7322-ac18-7466f8cccca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d1dc9-bd6b-75f6-8d8b-32f6c8f190e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d1dc9-bd6b-75f6-8d8b-32f6c8f190e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7e40-b381-dd073230a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7e40-b381-dd073230a97d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d1dc9-bd6b-7b33-ba71-cbe7de78172a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d1dc9-bd6b-7b33-ba71-cbe7de78172a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-77e8-a3c8-83eec38b0e28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-77e8-a3c8-83eec38b0e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-7694-999a-36cc78979b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-7694-999a-36cc78979b53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019d1dc9-bd6b-7993-afd4-9eea55727a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019d1dc9-bd6b-7993-afd4-9eea55727a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d1dc9-bd6b-7e3a-ba03-5441e2bfc267" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d1dc9-bd6b-7e3a-ba03-5441e2bfc267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019d1dc9-bd6b-700b-a3f5-13ec325e1781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019d1dc9-bd6b-700b-a3f5-13ec325e1781" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-7e51-9722-48f961af1d04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-7e51-9722-48f961af1d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_019d1dc9-bd6b-7919-9d7f-9f921a1ac180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_CostOfSalesMember_019d1dc9-bd6b-7919-9d7f-9f921a1ac180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d1dc9-bd6b-7e46-a52f-4ab761a7152a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d1dc9-bd6b-7e46-a52f-4ab761a7152a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019d1dc9-bd6b-7185-9043-74321a0b12aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019d1dc9-bd6b-7185-9043-74321a0b12aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7f4c-81be-778da2e8b4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7f4c-81be-778da2e8b4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7a8c-8dfb-68f23c511ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7a8c-8dfb-68f23c511ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7301-b24f-c743c60ab56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7301-b24f-c743c60ab56d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-737f-8390-1b633fc17cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-737f-8390-1b633fc17cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-768e-a586-ea4dc9554cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-768e-a586-ea4dc9554cd8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStockOptionsExerciseDataDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7be8-aec7-9056ac93c36e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7be8-aec7-9056ac93c36e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7905-a353-453edc1df37d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7905-a353-453edc1df37d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:to="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-79a9-9bca-3150ff69658a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-79a9-9bca-3150ff69658a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6b-7545-bf4e-416b35925b15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6b-7545-bf4e-416b35925b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d1dc9-bd6b-7efe-be08-9a4771e20b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d1dc9-bd6b-7efe-be08-9a4771e20b50" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:to="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-76d5-ba9b-73bbd889af3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-76d5-ba9b-73bbd889af3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d475c-c882-7512-91ae-6704baf971aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d475c-c882-7512-91ae-6704baf971aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_019d475c-c882-7596-8633-1c92d9ab763b" xlink:href="uthr-20260331.xsd#uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:to="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_019d475c-c882-7596-8633-1c92d9ab763b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:to="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-70ab-9bd4-bf90cc637af7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-70ab-9bd4-bf90cc637af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ExecutivesMember_019d475c-c882-73e3-94dc-5b9ea04fc82f" xlink:href="uthr-20260331.xsd#uthr_ExecutivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:to="loc_uthr_ExecutivesMember_019d475c-c882-73e3-94dc-5b9ea04fc82f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_019d475c-c882-72a2-b396-347cad77ddf4" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_019d475c-c882-72a2-b396-347cad77ddf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d475c-c882-7c72-bb7f-6fccb1715bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d475c-c882-7c72-bb7f-6fccb1715bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_019d475c-c882-7bbb-9171-5958eb5e22f8" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_019d475c-c882-7bbb-9171-5958eb5e22f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d475c-c882-7539-a9b6-e9c9bd9e7983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d475c-c882-7539-a9b6-e9c9bd9e7983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019d475c-fbe7-7e07-8c26-15ed3a3ef112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019d475c-fbe7-7e07-8c26-15ed3a3ef112" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d475c-fbe7-704f-8cc2-78eb7d949c51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d475c-fbe7-704f-8cc2-78eb7d949c51" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationRestrictedStockUnitsStatusDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7907-90c1-d470d29a0eae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7907-90c1-d470d29a0eae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7141-89df-e41f1951dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7141-89df-e41f1951dfa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-7e3b-9922-4cd46d9873fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-7e3b-9922-4cd46d9873fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d1dc9-bd6b-7976-869d-6d327aa835a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d1dc9-bd6b-7976-869d-6d327aa835a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d1dc9-bd6b-75e4-876b-33d5d0916f64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d1dc9-bd6b-75e4-876b-33d5d0916f64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d1dc9-bd6b-729b-906c-f5d0a4c0d157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d1dc9-bd6b-729b-906c-f5d0a4c0d157" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-78d9-bf86-915bf2d51ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-77a2-9eec-7476e8f22e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-77a2-9eec-7476e8f22e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-7762-b551-201e544708de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-7762-b551-201e544708de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-743d-a7f2-fcf79f5fdc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-743d-a7f2-fcf79f5fdc1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d1dc9-bd6b-765e-8ea2-63ca0e18c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d1dc9-bd6b-765e-8ea2-63ca0e18c18c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-72a7-997f-0410b96b13f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-70ca-ab97-819b6e4f85c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-70ca-ab97-819b6e4f85c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d1dc9-be07-7697-a977-2cc719777c79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:to="loc_us-gaap_EmployeeStockMember_019d1dc9-be07-7697-a977-2cc719777c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d1dc9-be07-7de1-8854-90b16b20a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d1dc9-be07-7de1-8854-90b16b20a50f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d1dc9-be07-73ec-b4c1-074f5f632464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d1dc9-be07-73ec-b4c1-074f5f632464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d1dc9-be07-7531-82f0-2ad46fff92eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d1dc9-be07-7531-82f0-2ad46fff92eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019d1dc9-be07-7e43-ad5b-bff0b9577aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019d1dc9-be07-7e43-ad5b-bff0b9577aa6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7b11-bfc5-53262a8296f5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7b11-bfc5-53262a8296f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:href="uthr-20260331.xsd#uthr_A2026ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:to="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4ef7-49e4-763b-94b1-f42f33af0fe2" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4ef7-49e4-763b-94b1-f42f33af0fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4ef7-b0d2-75eb-908b-c7033b26d87a" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4ef7-b0d2-75eb-908b-c7033b26d87a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:href="uthr-20260331.xsd#uthr_A2025ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:to="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4778-91ea-7508-b94d-df16b77c5d0e" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4778-91ea-7508-b94d-df16b77c5d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4778-91ea-79d0-b1f8-92e710a5a86a" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4778-91ea-79d0-b1f8-92e710a5a86a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019d4778-91ea-70ce-950f-a10929cdf273" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019d4778-91ea-70ce-950f-a10929cdf273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_019d4778-91ea-7e9c-8b5f-a04b7fd91695" xlink:href="uthr-20260331.xsd#uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_019d4778-91ea-7e9c-8b5f-a04b7fd91695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d4778-91ea-763c-b5c5-f1417025f594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d4778-91ea-763c-b5c5-f1417025f594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019d4778-91ea-745b-b382-99e72e8f2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019d4778-91ea-745b-b382-99e72e8f2e05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_019d4778-91ea-7b9b-abca-c68519663d31" xlink:href="uthr-20260331.xsd#uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_019d4778-91ea-7b9b-abca-c68519663d31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019dd244-6347-7dee-b366-bdda2931e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019dd244-6347-7dee-b366-bdda2931e21a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax_019dd241-a02a-7c8c-94e3-97823b26db3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTax_019dd241-a02a-7c8c-94e3-97823b26db3f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationGeneralDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:href="uthr-20260331.xsd#uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:to="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7c74-a0d2-75ab28e9f944_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7c74-a0d2-75ab28e9f944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7a14-9e86-371e895d0389" xlink:href="uthr-20260331.xsd#uthr_TyvasoDPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7a14-9e86-371e895d0389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-7c57-999d-d5723d1cf109" xlink:href="uthr-20260331.xsd#uthr_NebulizedTyvasoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-7c57-999d-d5723d1cf109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RemodulinMember_019d1dc9-be07-7ac6-8895-f6b4a25b2623" xlink:href="uthr-20260331.xsd#uthr_RemodulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_RemodulinMember_019d1dc9-be07-7ac6-8895-f6b4a25b2623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_OrenitramMember_019d1dc9-be07-7051-92e0-0bbdad09bfa7" xlink:href="uthr-20260331.xsd#uthr_OrenitramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_OrenitramMember_019d1dc9-be07-7051-92e0-0bbdad09bfa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnituxinMember_019d1dc9-be07-7d98-914d-aa39dba2f401" xlink:href="uthr-20260331.xsd#uthr_UnituxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_UnituxinMember_019d1dc9-be07-7d98-914d-aa39dba2f401" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdcircaMember_019d1dc9-be07-7ef9-8f9c-defb5f40d737" xlink:href="uthr-20260331.xsd#uthr_AdcircaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_AdcircaMember_019d1dc9-be07-7ef9-8f9c-defb5f40d737" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-7c4e-9efa-a1327ce2183a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-7c4e-9efa-a1327ce2183a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-72af-b5eb-7684a76b7e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-72af-b5eb-7684a76b7e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7eac-a838-b917dbacf805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7eac-a838-b917dbacf805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_019d1dc9-be07-7411-847a-b9e4582c4149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_GrossProfit_019d1dc9-be07-7411-847a-b9e4582c4149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_019dd9e5-467b-7e26-9ebd-c2eddcd6af2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_InventoryWriteDown_019dd9e5-467b-7e26-9ebd-c2eddcd6af2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_019df408-2036-7066-a9f4-e08a3397dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_019df408-2036-7066-a9f4-e08a3397dc0f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationGeographicInformationDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/SegmentInformationGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:to="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7a6d-a813-2c991f10ece4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:to="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7a6d-a813-2c991f10ece4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:to="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019d1dc9-be07-7bcd-b0e8-67fc33e6cd58" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:to="loc_country_US_019d1dc9-be07-7bcd-b0e8-67fc33e6cd58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_019d1dc9-be07-72c5-812f-fb9ce04b9f19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:to="loc_us-gaap_NonUsMember_019d1dc9-be07-72c5-812f-fb9ce04b9f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:to="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:href="uthr-20260331.xsd#uthr_TyvasoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7212-a236-9aea5cbc2afd" xlink:href="uthr-20260331.xsd#uthr_TyvasoDPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:to="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7212-a236-9aea5cbc2afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-72f6-b47d-94699331f6e3" xlink:href="uthr-20260331.xsd#uthr_NebulizedTyvasoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:to="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-72f6-b47d-94699331f6e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RemodulinMember_019d1dc9-be07-7943-b8a5-a42c360d9b9c" xlink:href="uthr-20260331.xsd#uthr_RemodulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_RemodulinMember_019d1dc9-be07-7943-b8a5-a42c360d9b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_OrenitramMember_019d1dc9-be07-77e9-b221-a777b5f4b137" xlink:href="uthr-20260331.xsd#uthr_OrenitramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_OrenitramMember_019d1dc9-be07-77e9-b221-a777b5f4b137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnituxinMember_019d1dc9-be07-7e9c-8f86-e0ad926693aa" xlink:href="uthr-20260331.xsd#uthr_UnituxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_UnituxinMember_019d1dc9-be07-7e9c-8f86-e0ad926693aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdcircaMember_019d1dc9-be07-7bed-be30-965264dec27b" xlink:href="uthr-20260331.xsd#uthr_AdcircaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_AdcircaMember_019d1dc9-be07-7bed-be30-965264dec27b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-72f6-84da-4471d0cb9a91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-72f6-84da-4471d0cb9a91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7fb6-adb4-316c468723e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7fb6-adb4-316c468723e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationConcentrationRiskDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/SegmentInformationConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:to="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_019d1dc9-be07-7d93-b8a1-9558bafa28fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_019d1dc9-be07-7d93-b8a1-9558bafa28fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7837-b0ff-0a7442e9a3b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7837-b0ff-0a7442e9a3b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019d1dc9-be07-7e13-b328-411dc7efacc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019d1dc9-be07-7e13-b328-411dc7efacc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorOneMember_019d1dc9-be07-7ff2-8ce3-3de63f47c515" xlink:href="uthr-20260331.xsd#uthr_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:to="loc_uthr_DistributorOneMember_019d1dc9-be07-7ff2-8ce3-3de63f47c515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorTwoMember_019d1dc9-be07-71bb-b626-57998269ae2c" xlink:href="uthr-20260331.xsd#uthr_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:to="loc_uthr_DistributorTwoMember_019d1dc9-be07-71bb-b626-57998269ae2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019d1dc9-be07-7426-ba5e-4e862d9c59b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019d1dc9-be07-7426-ba5e-4e862d9c59b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.unither.com/role/LitigationDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.unither.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:to="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-77fe-a637-1c4734fb5595_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:to="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-77fe-a637-1c4734fb5595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:to="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SandozIncMember_019d1dc9-be07-7e96-93c7-a5de4a242c51" xlink:href="uthr-20260331.xsd#uthr_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:to="loc_uthr_SandozIncMember_019d1dc9-be07-7e96-93c7-a5de4a242c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LiquidiaTechnologiesInc.Member_019d1dc9-be07-7177-a7e9-7d7b379c2219" xlink:href="uthr-20260331.xsd#uthr_LiquidiaTechnologiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:to="loc_uthr_LiquidiaTechnologiesInc.Member_019d1dc9-be07-7177-a7e9-7d7b379c2219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:to="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019d1dc9-be07-7e10-9134-e1adc4bbe067_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:to="loc_dei_EntityDomain_019d1dc9-be07-7e10-9134-e1adc4bbe067_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:to="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SmithsMedicalASDIncMember_019d1dc9-be07-7ca3-b5b1-037e24ed75e7" xlink:href="uthr-20260331.xsd#uthr_SmithsMedicalASDIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:to="loc_uthr_SmithsMedicalASDIncMember_019d1dc9-be07-7ca3-b5b1-037e24ed75e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_019d1dc9-be07-7194-be47-5d1561704c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_019d1dc9-be07-7194-be47-5d1561704c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_019d1dc9-be07-78bb-bb82-816afe625421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_019d1dc9-be07-78bb-bb82-816afe625421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_019d1dc9-be07-7641-8e93-637e2c7a80ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LitigationSettlementInterest_019d1dc9-be07-7641-8e93-637e2c7a80ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019d1dc9-be07-788d-8a67-3abeed2714a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019d1dc9-be07-788d-8a67-3abeed2714a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019d1dc9-be07-7b88-8daa-0ea22436b8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019d1dc9-be07-7b88-8daa-0ea22436b8e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfPetitions_019d1dc9-be07-7c4f-823b-96034c4af753" xlink:href="uthr-20260331.xsd#uthr_NumberOfPetitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_uthr_NumberOfPetitions_019d1dc9-be07-7c4f-823b-96034c4af753" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>uthr-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019d1dc9-be9c-70d0-873b-6f3c733e5ca9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019d1dc9-be9c-78f0-a1db-8d43aa0cc588_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_019d1dc9-be9c-7b91-84fa-a59821c5f963_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_019d1dc9-be9c-7a70-9857-bedf9af75985_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized gain included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019d1dc9-be08-788e-86d6-b860b9220f22_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-be9c-7b9f-b5ff-5331f6a77de5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units (RSUs) withheld for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-be9c-7ec6-81a6-bdd696d9936e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_019d1dc9-be9c-709e-be0e-c29979ae16a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019d1dc9-be9c-7c0b-8644-8e8a0d3dd3c0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss_019d1dc9-be9c-7fec-9b69-eea8e35a66aa_terseLabel_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairments related to credit loss</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss_label_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Impairment Loss</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss_documentation_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:to="lab_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019d1dc9-be08-7cd8-9c8f-69f1b1272155_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d1dc9-be9c-74a0-9753-cab12166c48b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_RemodulinMember_019d1dc9-be9c-7d03-9053-433cab1d12bd_terseLabel_en-US" xlink:label="lab_uthr_RemodulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remodulin</link:label>
    <link:label id="lab_uthr_RemodulinMember_label_en-US" xlink:label="lab_uthr_RemodulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remodulin [Member]</link:label>
    <link:label id="lab_uthr_RemodulinMember_documentation_en-US" xlink:label="lab_uthr_RemodulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Remodulin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RemodulinMember" xlink:href="uthr-20260331.xsd#uthr_RemodulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_RemodulinMember" xlink:to="lab_uthr_RemodulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be9c-70f4-be75-bb705e24b863_terseLabel_en-US" xlink:label="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table]</link:label>
    <link:label id="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_label_en-US" xlink:label="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table]</link:label>
    <link:label id="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_documentation_en-US" xlink:label="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A table disclosing the revenue, cost of revenue and gross profit by commercial product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:to="lab_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_019d1dc9-be07-7719-8f3b-f4fca336e5c8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019d1dc9-be08-7662-a8f4-e513cd84bb2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_019d1dc9-be9c-75b5-93a0-7fffedad641e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019d1dc9-be9c-7706-bbc2-46a46b8ca36b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019d1dc9-be07-7af7-861a-27a215097c18_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-be9c-7aae-8445-bbbbf3c99f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_019d1dc9-be9c-78bb-a2dd-18de13be3662_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTax_019d1dc9-be9c-7a6f-8531-b77c513dbfed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Excise tax on net share repurchase</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTax_019d1dc9-be9c-7c0c-8bf4-804fb04fe74f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, excise tax</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTax_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramExciseTax" xlink:to="lab_us-gaap_ShareRepurchaseProgramExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019d1dc9-be08-775e-95cc-3eb0775054ff_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019d1dc9-be08-7784-999d-744400901632_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019d1dc9-be08-7501-9b8e-f57364665cbc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-be9c-7fae-9ebe-ef5bdf2b96c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-be08-7f3b-b2d8-d909524f8c36_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense before tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-be08-75b8-a437-975772055385_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense before taxes</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_019d1dc9-be07-78e3-ad14-8e6106e87a28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019d1dc9-be9c-7456-9336-08b311ba3d02_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019d1dc9-be08-7739-b459-e91bb4ff1ae0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-be9c-7848-a048-52d5971ed729_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be9c-7a3d-8ac0-bd5f2e581e10_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-be9c-7742-bef6-18337ea404c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-be07-7e3a-b608-8323a29307e4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019d1dc9-be08-75e4-8e47-5aa40f2444b7_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3297-5a69-7690-af6c-8b3ad9c8cf59_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d1dc9-be08-73bf-9534-20366a786992_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-be08-7953-a41d-9aea4ba266b9_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense, net of taxes</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d1dc9-be9c-7207-9237-3dc2610ad89f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-be9c-7d91-b82b-913f8baba7bb_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be9c-7de7-8c47-bd3a61833e00_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019d1dc9-be9c-7931-992d-70fba185d90c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be9c-7106-ae79-4d989c7231a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_019d1dc9-be9c-7be2-8415-15c2d9d5d4b0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NebulizedTyvasoMember_019d1dc9-be07-7981-a959-12b4a752b3c2_terseLabel_en-US" xlink:label="lab_uthr_NebulizedTyvasoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nebulized Tyvaso</link:label>
    <link:label id="lab_uthr_NebulizedTyvasoMember_label_en-US" xlink:label="lab_uthr_NebulizedTyvasoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nebulized Tyvaso [Member]</link:label>
    <link:label id="lab_uthr_NebulizedTyvasoMember_documentation_en-US" xlink:label="lab_uthr_NebulizedTyvasoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nebulized Tyvaso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NebulizedTyvasoMember" xlink:href="uthr-20260331.xsd#uthr_NebulizedTyvasoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NebulizedTyvasoMember" xlink:to="lab_uthr_NebulizedTyvasoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-be08-7c23-9d44-06c62f9d4518_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019d1dc9-be9c-710f-b72c-a2249f9e2f1c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019d1dc9-be07-706c-92eb-b92ba7381936_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019d1dc9-be9c-7cd0-9e86-fc0daf93280b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019d1dc9-be9c-76ce-94cf-eb5d65db8a40_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-be08-7564-9831-e9b8ed853844_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-be9c-7931-b8ed-8fa9087b8a61_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-be08-7c17-a513-abd69d54ab01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current marketable investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_019d1dc9-be9c-7f46-8679-6f6371c80607_terseLabel_en-US" xlink:label="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options with Performance Conditions</link:label>
    <link:label id="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_label_en-US" xlink:label="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option With Performance Conditions [Member]</link:label>
    <link:label id="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_documentation_en-US" xlink:label="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option With Performance Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:href="uthr-20260331.xsd#uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:to="lab_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019d1dc9-be08-7d16-8e97-8e960da3f675_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation (Benefit) Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019d1dc9-be9c-7b87-b7d7-754293053664_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019d1dc9-be07-79cc-b41f-f1db0f8fdf74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_019d1dc9-be07-7d3e-a74d-733bfb1fe22c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_019d1dc9-be07-7cd4-8f1f-a25184775dbb_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-be08-7286-aff3-855cf0979d31_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_019d1dc9-be08-76e8-adcf-82ac8f8cde8d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_019d1dc9-be9c-7e45-b62a-944b6e0d58b3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019d1dc9-be9c-7081-b254-5b6181b4b8a0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019d1dc9-be9c-7cbd-82c9-dd27a278cc8a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_UnituxinMember_019d1dc9-be08-7c8a-a394-1c3af5a47f09_terseLabel_en-US" xlink:label="lab_uthr_UnituxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unituxin</link:label>
    <link:label id="lab_uthr_UnituxinMember_label_en-US" xlink:label="lab_uthr_UnituxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unituxin [Member]</link:label>
    <link:label id="lab_uthr_UnituxinMember_documentation_en-US" xlink:label="lab_uthr_UnituxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Unituxin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnituxinMember" xlink:href="uthr-20260331.xsd#uthr_UnituxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_UnituxinMember" xlink:to="lab_uthr_UnituxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_019d1dc9-be9c-7a17-998a-3e1e86b2d2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019d1dc9-be9c-71f1-95ad-ce6f288a433e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d1dc9-be9c-7d8e-b991-72161f5cefe1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019d1dc9-be08-7fa3-8d70-3c3a3443aef0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019d1dc9-be08-7407-b056-ce1c5c7ce588_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-be9c-7123-8d0e-ea2add7e13fb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be08-72e0-a431-718819764307_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_019d1dc9-be9c-79c5-b0c3-7ee33c69a9f1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-be9c-784b-a0ab-24db568daabe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019d1dc9-be08-7365-837f-253cc1e6d428_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock_019d1dc9-be07-75d3-bfb3-d0d80c15df1d_terseLabel_en-US" xlink:label="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Exercise Data</link:label>
    <link:label id="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock_label_en-US" xlink:label="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Service Share-based Compensation, Employee and Nonemployee Stock Option Exercise Data [Table Text Block]</link:label>
    <link:label id="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock_documentation_en-US" xlink:label="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of employee and non-employee stock option exercise data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:to="lab_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_019d1dc9-be08-77ab-9952-8eea894b6376_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019d1dc9-be07-7885-8027-e9f11dbd32f8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019d1dc9-be9c-755d-89cb-d0ea479db208_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-be9c-7d84-a568-8dfd40e6f555_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-be9c-7e69-9e23-fc1a9ca25d6d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-be9c-7653-b095-4ab33bd91a58_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_019d1dc9-be9c-7a92-8605-2173945b8096_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_CreditAgreement2022Member_019d1dc9-be08-7f7a-b85a-73d893f7ae50_terseLabel_en-US" xlink:label="lab_uthr_CreditAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Credit Agreement</link:label>
    <link:label id="lab_uthr_CreditAgreement2022Member_label_en-US" xlink:label="lab_uthr_CreditAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement2022 [Member]</link:label>
    <link:label id="lab_uthr_CreditAgreement2022Member_documentation_en-US" xlink:label="lab_uthr_CreditAgreement2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022Member" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_CreditAgreement2022Member" xlink:to="lab_uthr_CreditAgreement2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019d1dc9-be9c-7de9-a9b6-e0798560c3b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_019d1dc9-be08-7464-b1e3-01db28afd859_terseLabel_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one to three years</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_label_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year One Through Year Three, Fair Value</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_documentation_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of available-for-sale debt securities maturing after first fiscal year through third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:to="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_019d1dc9-be07-7f93-8b06-0e69555e6e86_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019d1dc9-be9c-785f-9385-28ce22b9d9ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-be9c-7b40-bb4a-f8a94ec87e51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plan:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019d1dc9-be9c-74f3-85ba-8b03254e7f6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019d1dc9-be9c-79a6-bd94-29e4d4e23b76_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Contractual Maturities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_019d1dc9-be07-7ec4-9b9d-f138cc5a1509_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_019d1dc9-be08-7619-a86b-32e54c595612_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019d1dc9-be9c-7f75-832e-910118a85357_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019d1dc9-be9c-7c8a-bf4b-46b6b246a16a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-be08-7222-9b99-c14be8f9f521_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019d1dc9-be9c-7001-b52b-57923746a533_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2026ShareRepurchaseProgramMember_019d4777-5c0a-742a-b772-47b59221ae6e_terseLabel_en-US" xlink:label="lab_uthr_A2026ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 Share Repurchase Program</link:label>
    <link:label id="lab_uthr_A2026ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_uthr_A2026ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_uthr_A2026ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_uthr_A2026ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2026 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026ShareRepurchaseProgramMember" xlink:href="uthr-20260331.xsd#uthr_A2026ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2026ShareRepurchaseProgramMember" xlink:to="lab_uthr_A2026ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019d1dc9-be08-7d04-a902-7e17866b4f8f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_FurnitureEquipmentAndVehiclesMember_019d1dc9-be9c-7c4f-bcd1-ec520c8249d9_terseLabel_en-US" xlink:label="lab_uthr_FurnitureEquipmentAndVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, equipment, and vehicles</link:label>
    <link:label id="lab_uthr_FurnitureEquipmentAndVehiclesMember_label_en-US" xlink:label="lab_uthr_FurnitureEquipmentAndVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture Equipment And Vehicles [Member]</link:label>
    <link:label id="lab_uthr_FurnitureEquipmentAndVehiclesMember_documentation_en-US" xlink:label="lab_uthr_FurnitureEquipmentAndVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Details pertaining to equipment used to produce goods and services. It also includes long-lived, depreciable assets, commonly used in offices and stores and for road transportation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_FurnitureEquipmentAndVehiclesMember" xlink:href="uthr-20260331.xsd#uthr_FurnitureEquipmentAndVehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_FurnitureEquipmentAndVehiclesMember" xlink:to="lab_uthr_FurnitureEquipmentAndVehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-be08-7707-afd3-3ded66ae8d36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019d1dc9-be07-7ae4-80bb-24a85d4c3377_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-be08-7c94-ab51-9e705ed1c580_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-be08-7071-9af4-364ea67e4043_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-be08-78a8-904b-a00ce0cbefca_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019d1dc9-be9c-78e1-b4a5-1e0ebfc7a9ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019d1dc9-be9c-7e98-90f6-2f5ef6224788_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-be9c-78f4-8758-e017761fd0ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_019d1dc9-be9c-74a6-b289-27de31f8408a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019d1dc9-be07-77d8-ac61-1370a32accf1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_019d1dc9-be9c-71eb-b008-3007e7e29d61_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d1dc9-be9c-75c2-b8e6-50117d4f5b20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-be08-77ec-8365-e52005ae1539_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported under the following captions in our consolidated balance sheets:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-be9c-7d6b-aba2-17eee596687d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_019d3292-a668-7aff-abc0-cb789c3226f7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_019d1dc9-be9c-7368-bbd4-2c58d17908c2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-be08-7e4d-80e6-f4df838c5647_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_019d1dc9-be9c-7cd8-92af-0aab3eedb241_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gain (loss) arising during period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_019d1dc9-be9c-7cdb-983e-2ec5bd86ec4f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-be07-75bb-9c34-0a701e66d0cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-be07-7a05-b1e7-136f451442d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019d1dc9-be08-7f3e-9bb2-fde807e68dff_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_InducementStockIncentivePlan2019Member_019d1dc9-be9c-7cd7-aea5-f262ee566612_terseLabel_en-US" xlink:label="lab_uthr_InducementStockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Inducement Plan</link:label>
    <link:label id="lab_uthr_InducementStockIncentivePlan2019Member_label_en-US" xlink:label="lab_uthr_InducementStockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Stock Incentive Plan2019 [Member]</link:label>
    <link:label id="lab_uthr_InducementStockIncentivePlan2019Member_documentation_en-US" xlink:label="lab_uthr_InducementStockIncentivePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member represents Inducement Stock Incentive Plan, 2019.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_InducementStockIncentivePlan2019Member" xlink:href="uthr-20260331.xsd#uthr_InducementStockIncentivePlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_InducementStockIncentivePlan2019Member" xlink:to="lab_uthr_InducementStockIncentivePlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_019d1dc9-be9c-794c-9057-5270a319f4b4_negatedTerseLabel_en-US" xlink:label="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_label_en-US" xlink:label="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Payment Related to Property Plant and Equipment</link:label>
    <link:label id="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advance Payment Related to Property Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:href="uthr-20260331.xsd#uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:to="lab_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d1dc9-be9c-7739-a7b4-d4d99a420014_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_019d1dc9-be9c-795e-98eb-c3571d9e5bfa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-be07-75a8-bed1-531a9ab7a9b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-be07-7727-a40a-c29a0c400847_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-be9c-7a14-91c8-9529a4da0d5f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d1dc9-be07-7b42-ad39-9f927901e103_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-be9c-7158-a8b7-ce4fc50c3f45_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-be9c-7d54-84fa-bb8e6ac5739f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-be9c-730e-b0ef-70f13599a377_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019d1dc9-be9c-7dc4-ae34-5c61701c46cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_019d1dc9-be9c-78fe-a192-e89bedfbe713_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DistributorOneMember_019d1dc9-be9c-73b9-b392-d6aa0712ce3a_terseLabel_en-US" xlink:label="lab_uthr_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor 1</link:label>
    <link:label id="lab_uthr_DistributorOneMember_label_en-US" xlink:label="lab_uthr_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_uthr_DistributorOneMember_documentation_en-US" xlink:label="lab_uthr_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorOneMember" xlink:href="uthr-20260331.xsd#uthr_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DistributorOneMember" xlink:to="lab_uthr_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be9c-7a19-b8fc-cb2b126b9689_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from external customers by geographic area</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_019d1dc9-be08-74f5-915d-0f993bf78dce_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019d1dc9-be07-7e43-a10d-26150ffcef18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions to Measure the Fair Value of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019d1dc9-be08-7484-bef5-cf34f6de64ac_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_019d1dc9-be9c-7bee-8221-15a7699462fa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3297-5a69-766c-adda-cc26b0740b9d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_019d1dc9-be9c-7f43-8687-ba72b4dcd9d4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d1dc9-be9c-7229-bffc-c61a8af16277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019d1dc9-be07-7f2b-986a-0b2bdbb0f944_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-be08-7359-8b4b-53d6e3067334_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019d1dc9-be9c-7fbf-9f6a-ca26134ea39a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_019d1dc9-be08-78c4-b98d-86f26ad366b6_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROW</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-be9c-7d81-9b7c-41d4f29a7067_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_019d1dc9-be07-702b-8a31-95521dde41dd_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Business Description</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_019d1dc9-be9c-7daa-8467-2beffb4bf4a8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-be07-7d42-85a8-07f05ab6ed77_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-be08-7658-9b5d-8162db73efdd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-be9c-76ef-ae32-a95e3b4b7dd9_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019d1dc9-be9c-78eb-893d-45f8845b5ba6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be08-7a9e-97a7-9e00fa2aedaa_terseLabel_en-US" xlink:label="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales, cost of product sales and gross profit by product</link:label>
    <link:label id="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_label_en-US" xlink:label="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Product Sales, Cost Of Product Sales, And Gross Profit By Product [Line Items]</link:label>
    <link:label id="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_documentation_en-US" xlink:label="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:href="uthr-20260331.xsd#uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:to="lab_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019d1dc9-be9c-7acb-bfb5-64b749c38e17_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-77bb-9885-1781913ea619_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_019d1dc9-be08-773a-a14d-df1d432a8065_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019d1dc9-be9c-74ef-9617-b8a088c3fd7e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_019d1dc9-be9c-7cf0-b22a-292c720d6932_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_019d1dc9-be9c-7100-82bc-415c88d90983_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019d1dc9-be07-781f-a69c-dca509f060bd_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-7538-8940-56800f2df7b0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in value of investment, cumulative amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-be08-7a98-b565-5a402613cef1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_019d1dc9-be08-73ca-98d8-781cf9126641_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019d1dc9-be08-7f41-a4be-2a1184017b89_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareTrackingAwardsPlanMember_019d1dc9-be08-7454-968e-3affb757a776_terseLabel_en-US" xlink:label="lab_uthr_ShareTrackingAwardsPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STAP awards</link:label>
    <link:label id="lab_uthr_ShareTrackingAwardsPlanMember_label_en-US" xlink:label="lab_uthr_ShareTrackingAwardsPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Tracking Awards Plan [Member]</link:label>
    <link:label id="lab_uthr_ShareTrackingAwardsPlanMember_documentation_en-US" xlink:label="lab_uthr_ShareTrackingAwardsPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share tracking award plans (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareTrackingAwardsPlanMember" xlink:href="uthr-20260331.xsd#uthr_ShareTrackingAwardsPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareTrackingAwardsPlanMember" xlink:to="lab_uthr_ShareTrackingAwardsPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_019d1dc9-be07-7ae1-a76e-559d8c4d635c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019d1dc9-be08-7213-9c85-933ddf64e311_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019d1dc9-be08-76e0-90c8-a30e1cafe1c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019d1dc9-be9c-7ca1-9009-c4c8c104b6d1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_SmithsMedicalASDIncMember_019d1dc9-be07-762e-89ae-16a6c29b48c4_terseLabel_en-US" xlink:label="lab_uthr_SmithsMedicalASDIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Smiths Medical ASD, Inc.</link:label>
    <link:label id="lab_uthr_SmithsMedicalASDIncMember_label_en-US" xlink:label="lab_uthr_SmithsMedicalASDIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Smiths Medical ASD, Inc. [Member]</link:label>
    <link:label id="lab_uthr_SmithsMedicalASDIncMember_documentation_en-US" xlink:label="lab_uthr_SmithsMedicalASDIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Smiths Medical ASD, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SmithsMedicalASDIncMember" xlink:href="uthr-20260331.xsd#uthr_SmithsMedicalASDIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_SmithsMedicalASDIncMember" xlink:to="lab_uthr_SmithsMedicalASDIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d1dc9-be08-76a4-af05-f5497a17a7af_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_019d1dc9-be07-70b0-a537-bc25496884ff_terseLabel_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total grant date fair value</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_label_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period, Total Grant Date Fair Value</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_documentation_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the total grant date fair value of option granted during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:to="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_019d1dc9-be9c-7e28-a48a-358cdf258d98_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtInstrumentExtensionTerm_019d1dc9-be08-76cf-834d-255390f04b57_terseLabel_en-US" xlink:label="lab_uthr_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of maturity date extension</link:label>
    <link:label id="lab_uthr_DebtInstrumentExtensionTerm_label_en-US" xlink:label="lab_uthr_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:label id="lab_uthr_DebtInstrumentExtensionTerm_documentation_en-US" xlink:label="lab_uthr_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentExtensionTerm" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtInstrumentExtensionTerm" xlink:to="lab_uthr_DebtInstrumentExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-be08-743a-b1ac-656b4d063cc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-be08-75ae-9919-c3cbd6f3d694_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-be08-7d7d-b497-98b49c8dc1fb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d1dc9-be9c-708c-982f-382ae9e54322_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_019d1dc9-be9c-7192-868b-fc9ca7d5cf53_terseLabel_en-US" xlink:label="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Unsecured Revolving Credit Facility</link:label>
    <link:label id="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement2022 Second Unsecured Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement2022 Second Unsecured Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:to="lab_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-77f0-ab59-11c01a0d649c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in value of investment, cumulative amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_TyvasoMember_019d1dc9-be9c-78cb-97ab-97f7dad482b9_terseLabel_en-US" xlink:label="lab_uthr_TyvasoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Tyvaso</link:label>
    <link:label id="lab_uthr_TyvasoMember_label_en-US" xlink:label="lab_uthr_TyvasoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tyvaso [Member]</link:label>
    <link:label id="lab_uthr_TyvasoMember_documentation_en-US" xlink:label="lab_uthr_TyvasoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Tyvaso, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoMember" xlink:href="uthr-20260331.xsd#uthr_TyvasoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_TyvasoMember" xlink:to="lab_uthr_TyvasoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019d1dc9-be9c-7611-85a8-e92b726a93f6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_OrenitramMember_019d1dc9-be9c-7312-a232-d356a739cf54_terseLabel_en-US" xlink:label="lab_uthr_OrenitramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orenitram</link:label>
    <link:label id="lab_uthr_OrenitramMember_label_en-US" xlink:label="lab_uthr_OrenitramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orenitram [Member]</link:label>
    <link:label id="lab_uthr_OrenitramMember_documentation_en-US" xlink:label="lab_uthr_OrenitramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Orenitram, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_OrenitramMember" xlink:href="uthr-20260331.xsd#uthr_OrenitramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_OrenitramMember" xlink:to="lab_uthr_OrenitramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d1dc9-be07-7bc4-bef4-8db3762b476f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NewlyHiredEmployeesMember_019d1dc9-be9c-7c12-857a-6baa00b99837_terseLabel_en-US" xlink:label="lab_uthr_NewlyHiredEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newly-Hired Employees</link:label>
    <link:label id="lab_uthr_NewlyHiredEmployeesMember_label_en-US" xlink:label="lab_uthr_NewlyHiredEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Newly Hired Employees [Member]</link:label>
    <link:label id="lab_uthr_NewlyHiredEmployeesMember_documentation_en-US" xlink:label="lab_uthr_NewlyHiredEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member represents newly-hired employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NewlyHiredEmployeesMember" xlink:href="uthr-20260331.xsd#uthr_NewlyHiredEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NewlyHiredEmployeesMember" xlink:to="lab_uthr_NewlyHiredEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-be9c-75fc-a026-165b5b7e32cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-77d4-96d7-ee13b2ea25cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-be07-7fed-8719-0f8f4f324376_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_019d1dc9-be9c-7a0f-8931-336829f3aedc_terseLabel_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock entitled to recipient upon vesting (in shares)</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_label_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Entitled To Receive For Each Unit Upon Vesting</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_documentation_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares of common stock entitled to receive for each unit upon vesting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:to="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_019d1dc9-be9c-7564-be8d-14450a6791bb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d1dc9-be07-7bd2-a046-acac8ad80ae4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NetIncomePerCommonShareAbstract_019d1dc9-be08-7766-81f8-d3417d9fbb3c_verboseLabel_en-US" xlink:label="lab_uthr_NetIncomePerCommonShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per common share:</link:label>
    <link:label id="lab_uthr_NetIncomePerCommonShareAbstract_label_en-US" xlink:label="lab_uthr_NetIncomePerCommonShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income Per Common Share [Abstract]</link:label>
    <link:label id="lab_uthr_NetIncomePerCommonShareAbstract_documentation_en-US" xlink:label="lab_uthr_NetIncomePerCommonShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NetIncomePerCommonShareAbstract" xlink:href="uthr-20260331.xsd#uthr_NetIncomePerCommonShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NetIncomePerCommonShareAbstract" xlink:to="lab_uthr_NetIncomePerCommonShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_019d1dc9-be9c-7ac6-9b5c-6f7dc4d864d0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_019d1dc9-be07-744c-83ab-482382f6c486_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NoncashExciseTaxOnNetShareRepurchases_019d1dc9-be07-7984-a2a0-b856cdb40d53_terseLabel_en-US" xlink:label="lab_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excise tax on net share repurchase</link:label>
    <link:label id="lab_uthr_NoncashExciseTaxOnNetShareRepurchases_label_en-US" xlink:label="lab_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Excise Tax On Net Share Repurchases</link:label>
    <link:label id="lab_uthr_NoncashExciseTaxOnNetShareRepurchases_documentation_en-US" xlink:label="lab_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Excise Tax On Net Share Repurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:href="uthr-20260331.xsd#uthr_NoncashExciseTaxOnNetShareRepurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:to="lab_uthr_NoncashExciseTaxOnNetShareRepurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_019d1dc9-be07-7b0a-b5b8-4e177a19247d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019d1dc9-be08-74ac-9c2a-7adbe3c5e8d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_019d1dc9-be9c-7aad-adb2-66ad873b8781_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019d1dc9-be08-74c4-a947-b113cf26fdd9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be08-78dd-bf89-17c2b99f446b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d1dc9-be08-785b-a05d-48cc3312ef42_terseLabel_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Collared Agreement</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_label_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Collared Agreement [Member]</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_documentation_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Collared Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:to="lab_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_019d1dc9-be9c-7780-aa20-b8dc4c0c7ea6_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-be07-7f53-85df-03412b1fa50d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_MarketableSecuritiesCurrentMember_019d1dc9-be9c-7038-94ff-5c08fc9d7da0_terseLabel_en-US" xlink:label="lab_uthr_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current marketable investments</link:label>
    <link:label id="lab_uthr_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_uthr_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities Current [Member]</link:label>
    <link:label id="lab_uthr_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_uthr_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the short-term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesCurrentMember" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_MarketableSecuritiesCurrentMember" xlink:to="lab_uthr_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_019df408-2036-77c8-b3f6-5f21f4e064b7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss related to commercial supply agreement</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_019d1dc9-be9c-7d27-8aec-a94a854dafbb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019d1dc9-be9c-733c-ac8a-efab31d0ce83_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019d1dc9-be08-7bcb-82f4-d7472fef8789_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019d1dc9-be07-7587-bd50-8816eb1930fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_019d1dc9-be9c-7a3d-bcbd-689bc2b1d49d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019d1dc9-be9c-74a4-902d-9d43ac22886f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019d1dc9-be9c-79a0-ae56-412a959078fc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_019d1dc9-be9c-721f-973a-ef3c7dda6a16_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019d1dc9-be07-7e73-b800-7403665bf5e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d1dc9-be07-7d06-a667-2ae114360c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019d1dc9-be9c-7f77-bda5-908e1e9f47d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_AdcircaMember_019d1dc9-be08-7c79-89fd-a982a76ea52e_terseLabel_en-US" xlink:label="lab_uthr_AdcircaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adcirca</link:label>
    <link:label id="lab_uthr_AdcircaMember_label_en-US" xlink:label="lab_uthr_AdcircaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adcirca [Member]</link:label>
    <link:label id="lab_uthr_AdcircaMember_documentation_en-US" xlink:label="lab_uthr_AdcircaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Adcirca, a commercial product of the entity, for treating pulmonary hypertension.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdcircaMember" xlink:href="uthr-20260331.xsd#uthr_AdcircaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_AdcircaMember" xlink:to="lab_uthr_AdcircaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_019d1dc9-be9c-7c52-a85a-98eb10f533bf_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019d1dc9-be08-7e30-ada9-35fa56ad6413_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019d1dc9-be9c-75b4-b185-082863c0a550_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019d1dc9-be9c-717e-b73e-19038e6cd183_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DistributorTwoMember_019d1dc9-be07-72f5-b18b-48176d0e2a91_terseLabel_en-US" xlink:label="lab_uthr_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor 2</link:label>
    <link:label id="lab_uthr_DistributorTwoMember_label_en-US" xlink:label="lab_uthr_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_uthr_DistributorTwoMember_documentation_en-US" xlink:label="lab_uthr_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorTwoMember" xlink:href="uthr-20260331.xsd#uthr_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DistributorTwoMember" xlink:to="lab_uthr_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019d1dc9-be9c-709e-89ba-06defcc220ba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019d1dc9-be9c-75a5-b6c8-7907474dab5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019d1dc9-be9c-7a1e-a2f7-129c0dd1b12b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019d1dc9-be9c-7558-abe3-91845e1f2438_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_SandozIncMember_019d1dc9-be08-782f-b64d-975ee7b4083f_terseLabel_en-US" xlink:label="lab_uthr_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:label id="lab_uthr_SandozIncMember_label_en-US" xlink:label="lab_uthr_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Inc. [Member]</link:label>
    <link:label id="lab_uthr_SandozIncMember_documentation_en-US" xlink:label="lab_uthr_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sandoz Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SandozIncMember" xlink:href="uthr-20260331.xsd#uthr_SandozIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_SandozIncMember" xlink:to="lab_uthr_SandozIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019d1dc9-be9c-778e-bc4f-73469c3d8884_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, RSUs, and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019d1dc9-be9c-7bfd-bab9-9aeaa08e286a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d1dc9-be9c-7a1c-8f44-3a51db1b5bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-be08-77e5-95da-3270bedbd550_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_019d1dc9-be9c-7258-8fc5-9f9b5b72509b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d1dc9-be9c-7808-8fdd-2dccc594d840_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019d1dc9-be9c-7c19-b01e-6473e2e510e6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-be9c-7ea2-8a41-9cc3dd9e53e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-79c4-ab63-969d109adfd8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019d1dc9-be07-7cd6-9b71-295d9316002b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, available-for-sale, unrealized loss position, number of positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019d1dc9-be07-7cd4-a3fc-34a11d371dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in privately-held companies</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019d1dc9-be07-7fa4-8f33-de08bf42d747_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NumberOfPetitions_019d1dc9-be08-76ca-9f14-1648198365dc_terseLabel_en-US" xlink:label="lab_uthr_NumberOfPetitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of petitions</link:label>
    <link:label id="lab_uthr_NumberOfPetitions_label_en-US" xlink:label="lab_uthr_NumberOfPetitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Petitions</link:label>
    <link:label id="lab_uthr_NumberOfPetitions_documentation_en-US" xlink:label="lab_uthr_NumberOfPetitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of petitions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfPetitions" xlink:href="uthr-20260331.xsd#uthr_NumberOfPetitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NumberOfPetitions" xlink:to="lab_uthr_NumberOfPetitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d1dc9-be9c-7a38-bf0e-410e54d8712a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_LiquidiaTechnologiesInc.Member_019d1dc9-be08-7ea0-ac73-57f9b00fbf3b_terseLabel_en-US" xlink:label="lab_uthr_LiquidiaTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidia Technologies, Inc.</link:label>
    <link:label id="lab_uthr_LiquidiaTechnologiesInc.Member_label_en-US" xlink:label="lab_uthr_LiquidiaTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidia Technologies Inc. [Member]</link:label>
    <link:label id="lab_uthr_LiquidiaTechnologiesInc.Member_documentation_en-US" xlink:label="lab_uthr_LiquidiaTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to Liquidia Technologies, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LiquidiaTechnologiesInc.Member" xlink:href="uthr-20260331.xsd#uthr_LiquidiaTechnologiesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_LiquidiaTechnologiesInc.Member" xlink:to="lab_uthr_LiquidiaTechnologiesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_019d1dc9-be9c-7dee-8669-4090a5ae9823_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax (benefit) expense in other comprehensive income for available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-be9c-7161-8437-cbbf07209e5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019d1dc9-be07-7202-9436-a8b965567511_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019d1dc9-be07-7e78-baf9-ac708b83b9cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan (ESPP)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-be07-7aaa-9a9b-e54ce7793538_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be9c-7d38-95f3-9269e0bf7bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_019d1dc9-be9c-747b-8195-4f5151712d76_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019d1dc9-be9c-767b-ba71-0b2ef732505d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock_019d1dc9-be9c-7d83-805b-4ea6a02dd4e2_terseLabel_en-US" xlink:label="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Product Sales, Cost of Product Sales and Gross Profit for Each Commercial Products</link:label>
    <link:label id="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock_label_en-US" xlink:label="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Net Revenue, Cost Of Product Sales And Gross Profit By Product [Table Text Block]</link:label>
    <link:label id="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock_documentation_en-US" xlink:label="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of revenues, cost of revenues and gross profit for each commercial product during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:to="lab_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ExecutivesMember_019d1dc9-be9c-70ba-8f88-ded7d47eff87_terseLabel_en-US" xlink:label="lab_uthr_ExecutivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executives</link:label>
    <link:label id="lab_uthr_ExecutivesMember_label_en-US" xlink:label="lab_uthr_ExecutivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executives [Member]</link:label>
    <link:label id="lab_uthr_ExecutivesMember_documentation_en-US" xlink:label="lab_uthr_ExecutivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ExecutivesMember" xlink:href="uthr-20260331.xsd#uthr_ExecutivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ExecutivesMember" xlink:to="lab_uthr_ExecutivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d1dc9-be9c-7ef7-97f1-002aeb938a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-be9c-76d0-bbbd-7a29110b73bf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019d1dc9-be08-78c6-b1d2-c8a6ef569cd6_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_019d1dc9-be9c-7b1a-8f97-d796ee989fa2_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-be07-7898-8581-93e5c6d1aebd_terseLabel_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in&#160;millions)</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_label_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" xlink:to="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-be08-7335-b841-0a1e30b86805_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Privately-Held Companies and Investments in Equity Securities with Readily Determinable Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-be9c-7ee2-aed6-32ff9dc2cce5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested at beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-be9c-710e-a3d8-11725aaad964_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d1dc9-be9c-7968-836c-794202f87e33_terseLabel_en-US" xlink:label="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_label_en-US" xlink:label="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Fair Value Disclosure, Liability</link:label>
    <link:label id="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_documentation_en-US" xlink:label="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement including cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:href="uthr-20260331.xsd#uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:to="lab_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019d1dc9-be9c-7183-991d-c4da052b2e55_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019d1dc9-be9c-72be-aed4-0a1531fea89a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d1dc9-be07-702c-801d-731ac5a517d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares each eligible employees may purchase in any given offering period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-be07-7995-b4bd-6f268e8ee3ac_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019d1dc9-be9c-782c-a3f1-ea50af33ef3f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019d1dc9-be9c-7f2a-adb5-6f0d61902a78_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-be07-7754-be74-951c539dfc34_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_019d1dc9-be08-74c3-8e4d-dab4d20365e3_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019d1dc9-be9c-73a7-9a75-338f35f02028_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019d1dc9-be08-7a6a-bb2b-ab1093a9351b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d1dc9-be08-7ac6-9c61-46b12ecc7be5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_019d1dc9-be9c-71a0-8270-e5316d2d259d_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_019d1dc9-be9c-74bc-af10-6718e60bdc85_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_019d1dc9-be9c-7396-a8f2-f39331638645_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_019d1dc9-be9c-7a23-84ee-9037af767fc0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_019d1dc9-be9c-7f74-961d-5477c53787fd_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-be08-7008-8f31-448fbcf242fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less&#8212;accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_019d1dc9-be9c-706f-9560-ca66fb30dfe2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019d1dc9-be9c-72ac-83a7-a062a57d90f0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_019d1dc9-be9c-762b-956e-4657486fae3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_019d1dc9-be9c-7187-a6a0-50b294890a23_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_019d1dc9-be9c-712b-b89e-ea095c871b34_terseLabel_en-US" xlink:label="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Unsecured Revolving Credit Facility</link:label>
    <link:label id="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement2022 First Unsecured Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement2022 First Unsecured Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:to="lab_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_019d1dc9-be9c-75a3-9bd2-0afac1b51c10_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019d1dc9-be08-7c58-bed7-d05aeaba7ee2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $.01, 245,000,000 shares authorized, 77,129,770 and 76,452,253 shares issued, and 42,156,223 and 43,643,165 shares outstanding as of March 31, 2026 and December&#160;31, 2025, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_019d1dc9-be08-72fe-aec7-b38eacf83bf2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be08-7850-b3da-df99f030ed00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be08-75de-9e7a-e0a60dbe0c7f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019d1dc9-be07-7cfd-8b5d-0f79ea3a26d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019d1dc9-be9c-76ca-959d-8d98ac199321_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total grant date fair value of employee stock options that vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_019d1dc9-be07-79b1-9c14-8f91249e0870_terseLabel_en-US" xlink:label="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in borrowing capacity</link:label>
    <link:label id="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Contingent Increase, Additional Borrowing Capacity</link:label>
    <link:label id="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contingent increase above the maximum borrowing capacity under the credit facility, if any one or more of the existing banks or new banks agree to provide such increased commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:href="uthr-20260331.xsd#uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:to="lab_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019d1dc9-be07-740d-a4d3-dae7cc5e9fd6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_019d1dc9-be08-7a4b-b7d2-6ec62aeed2ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Revenues from External Customers by Geographic Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be9c-7e71-ae12-6a8e0cf56882_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019d1dc9-be9c-7893-9cd9-dd8b8ea3929e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019d1dc9-be9c-703a-b913-a19b812b4750_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Concentration of Risk Disclosure</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019d32e4-43ef-7683-9e35-d34be48fd026_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-75d3-9b02-35931888314c_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_019d4735-047d-7df5-bd63-d2d8f0fba9eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax (benefit) expense in other comprehensive income for the defined benefit pension plan</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019d1dc9-be9c-7dc7-bc7d-142e05fc6d42_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019d1dc9-be08-7f59-a69a-26b60f79f85d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3297-5a69-75d2-b86b-f2c19fd9a290_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019d1dc9-be08-79e6-975f-8a89cb5beafc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019d1dc9-be08-7293-ad5c-3073548dfd05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4ef7-b0d2-7b60-b572-70f9e13846e7_terseLabel_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Collared Agreement</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_label_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Collared Agreement [Member]</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_documentation_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Collared Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:to="lab_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-be9c-7ce3-9aaa-0ffc55a15217_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2025ShareRepurchaseProgramMember_019d1dc9-be08-7918-a5e4-a3012dd8e973_terseLabel_en-US" xlink:label="lab_uthr_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program</link:label>
    <link:label id="lab_uthr_A2025ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_uthr_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_uthr_A2025ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_uthr_A2025ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025ShareRepurchaseProgramMember" xlink:href="uthr-20260331.xsd#uthr_A2025ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2025ShareRepurchaseProgramMember" xlink:to="lab_uthr_A2025ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d1dc9-be9c-715b-85a6-358732b4a724_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019d1dc9-be9c-7754-8a22-e06c73a5be0f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019d1dc9-be9c-7579-9ef2-c395991ce428_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_019d1dc9-be9c-7b9a-81cb-0d3abdb7a758_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019d1dc9-be9c-7e0a-b120-82e5bb5f2d44_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_019d1dc9-be9c-7d32-9637-543bb684a3b6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7f3b-9fd0-023dfa587438_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7023-84ad-9fd8e57c65f8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_019d1dc9-be9c-7645-a8e7-585551f181c6_terseLabel_en-US" xlink:label="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, percentage of shares to be repurchased</link:label>
    <link:label id="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_label_en-US" xlink:label="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Percentage Of Shares To Be Repurchased</link:label>
    <link:label id="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_documentation_en-US" xlink:label="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Percentage Of Shares To Be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:href="uthr-20260331.xsd#uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:to="lab_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019d1dc9-be08-7079-b2cf-ed2a42afe487_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019d1dc9-be9c-7c36-8da4-3ce03932eb32_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d1dc9-be9c-7766-83f9-10a3aec9fc07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_019d1dc9-be9c-750f-a9ae-d83b1ba675b7_terseLabel_en-US" xlink:label="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings, building improvements, and leasehold improvements</link:label>
    <link:label id="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings Building Improvements And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Details pertaining to buildings, building improvements and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:href="uthr-20260331.xsd#uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:to="lab_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019d1dc9-be07-7a57-a10c-e84bfbe93982_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_019d1dc9-be9c-7e82-a814-52fca4acb777_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement interest</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_019d1dc9-be08-7d54-b05d-02bc95fbd87f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019d1dc9-be08-7205-bbf4-f3ed91ce444e_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d1dc9-be07-77c8-b029-b264a8a5ef2b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award, purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d1dc9-be08-74e1-b162-aab2edaaf340_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-be08-760b-bf21-570a467bec03_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">RSUs withheld for taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_019d1dc9-be07-7a70-abad-c2feb496e737_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_019d1dc9-be07-7525-aa32-e9dfdc5f1e2f_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-be08-7406-af9f-b3bf41cfe8ce_terseLabel_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_documentation_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:to="lab_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-be07-70ab-bb23-de5d3fd9657f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d8f5e-4da1-741d-8d60-e15af228b4a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-be07-753a-9a5a-696c29062402_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-be08-7c33-8629-0710994975ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019d1dc9-be9c-77f2-9c98-3c91a933e76b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019d1dc9-be9c-71f7-99c4-bc710f282c39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain arising during period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019d1dc9-be9c-782f-8b2c-c408be806340_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-be08-7107-a79c-20264bf50e69_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total defined benefit pension plan, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019d1dc9-be07-7e21-874a-ac5e818f9a0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_TyvasoDPIMember_019d1dc9-be9c-7928-9dad-757243177e22_terseLabel_en-US" xlink:label="lab_uthr_TyvasoDPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tyvaso DPI</link:label>
    <link:label id="lab_uthr_TyvasoDPIMember_label_en-US" xlink:label="lab_uthr_TyvasoDPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tyvaso DPI [Member]</link:label>
    <link:label id="lab_uthr_TyvasoDPIMember_documentation_en-US" xlink:label="lab_uthr_TyvasoDPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tyvaso DPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoDPIMember" xlink:href="uthr-20260331.xsd#uthr_TyvasoDPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_TyvasoDPIMember" xlink:to="lab_uthr_TyvasoDPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-77fe-b586-f3bcaa7bcc33_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019d1dc9-be07-7569-9d94-3f5c298b7f41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_019d1dc9-be9c-7822-8acb-e361bc7164af_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, no allowance for 2026 and 2025</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be08-7bb9-bd2d-60dfd132e936_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019d1dc9-be9c-7592-bcd6-2fc51d727c17_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security 12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019d1dc9-be07-7a4d-90f3-2f96ec12960e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019d1dc9-be9c-7e4f-9bd6-4ad60baa26c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_019d1dc9-be07-7160-9d96-e4a2a11babed_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019d1dc9-be9c-7204-98c6-48dc1b617920_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, excise tax, payable</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Excise Tax, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:to="lab_us-gaap_ShareRepurchaseProgramExciseTaxPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-be07-7b58-af14-c403d21883c7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_PrivatelyHeldCompaniesMember_019d1dc9-be9c-7d57-ab61-808a28e22f44_terseLabel_en-US" xlink:label="lab_uthr_PrivatelyHeldCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Privately-held Companies</link:label>
    <link:label id="lab_uthr_PrivatelyHeldCompaniesMember_label_en-US" xlink:label="lab_uthr_PrivatelyHeldCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Privately Held Companies [Member]</link:label>
    <link:label id="lab_uthr_PrivatelyHeldCompaniesMember_documentation_en-US" xlink:label="lab_uthr_PrivatelyHeldCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to privately-held companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PrivatelyHeldCompaniesMember" xlink:href="uthr-20260331.xsd#uthr_PrivatelyHeldCompaniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_PrivatelyHeldCompaniesMember" xlink:to="lab_uthr_PrivatelyHeldCompaniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019d1dc9-be9c-730f-ad8a-4a06de476d9f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4ef7-49e4-7eac-b040-028c1f5a0993_terseLabel_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Uncollared Agreement</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_label_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Uncollared Agreement [Member]</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_documentation_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreement - Uncollared Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:to="lab_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_019d1dc9-be08-789a-9221-7a90630f6f95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019d1dc9-be08-7a07-8961-9bbd75c592f7_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_019d1dc9-be08-7fe6-8de3-540b400305b6_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit (loss)</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_019d1dc9-be07-7f52-82ed-7c1ceb035ab9_terseLabel_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted in period, fair value</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_label_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_documentation_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest_019d1dc9-be07-7d1f-86d6-10642fe5d53d_terseLabel_en-US" xlink:label="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, including interest</link:label>
    <link:label id="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest_label_en-US" xlink:label="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest</link:label>
    <link:label id="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest_documentation_en-US" xlink:label="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:href="uthr-20260331.xsd#uthr_UnrecognizedTaxBenefitsIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:to="lab_uthr_UnrecognizedTaxBenefitsIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d1dc9-be07-7e7b-8e24-7fd42c55a369_terseLabel_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Uncollared Agreement</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_label_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Uncollared Agreement [Member]</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_documentation_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreement - Uncollared Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:to="lab_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4777-ce40-7247-aff5-8991110d51a0_terseLabel_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreements</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_label_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreements [Member]</link:label>
    <link:label id="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2026 Accelerated Share Repurchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:to="lab_uthr_A2026AcceleratedShareRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_019d1dc9-be9c-7612-b03d-2e3baeac89be_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019d1dc9-be08-781e-9b02-430dfa9fcc66_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during period, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_019d1dc9-be9c-7320-bd9b-39fbfacd3080_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-be07-78a4-b452-ba88bf78b02d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock option exercise data</link:label>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_019d1dc9-be9c-77e7-844f-5e08537788b1_terseLabel_en-US" xlink:label="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of accelerated share repurchase agreements</link:label>
    <link:label id="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_label_en-US" xlink:label="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Number Of Accelerated Repurchase Agreements</link:label>
    <link:label id="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_documentation_en-US" xlink:label="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Number Of Accelerated Repurchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:href="uthr-20260331.xsd#uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:to="lab_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d1dc9-be9c-7734-a315-b87990133b86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-be07-746b-b675-c2c728e94eaa_verboseLabel_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_label_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term Disclosures [Abstract]</link:label>
    <link:label id="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_documentation_en-US" xlink:label="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">N/A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:to="lab_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019d1dc9-be08-7f1d-b284-9b2790df8f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventories, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d1dc9-be07-7b6d-8013-cf3839b3aff8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019d1dc9-be9c-7330-b224-3b609693479d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_019d1dc9-be9c-7dd7-976e-17324fe6b0c4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019d1dc9-be08-707d-a124-78f4dc70997b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019d1dc9-be9c-7c7b-9e16-c370cfb0bf56_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019d1dc9-be9c-7993-a4ba-9918e5bcc61b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019d1dc9-be9c-7f3a-8c25-6fed5172bd0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_019d1dc9-be08-77fe-8cc1-4720f59c8d04_negatedTerseLabel_en-US" xlink:label="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of investment in privately held company</link:label>
    <link:label id="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value</link:label>
    <link:label id="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_documentation_en-US" xlink:label="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:href="uthr-20260331.xsd#uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:to="lab_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_019d1dc9-be9c-7771-bf94-c0c9f52b95db_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings under construction</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d1dc9-be9c-7848-9261-945e4d5e037b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-be9c-77a3-9159-66814b087aa9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total (loss) gain on available-for-sale debt securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-be08-7a68-b255-382288b15c71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-be08-76ad-b78c-743edeb227d4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_019d1dc9-be9c-7b62-9ae5-05e33eb3817a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-be08-7ce5-b450-026083e99bce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to repurchase common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-be08-7429-a0ce-5f84447ee322_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to repurchase common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_019d1dc9-be08-7ee3-98bd-a5728c66f398_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019d1dc9-be07-791c-8297-28e3e942426b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of stock under ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019d1dc9-be9c-7679-a926-69798d47b021_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_019d1dc9-be9c-7d52-b9be-58aa3c387c70_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019d1dc9-be9c-775f-bb43-59f28da89033_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019d1dc9-be9c-77c6-b5e2-dbd3fae93c80_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_StockIncentivePlan2015PlanMember_019d1dc9-be9c-7a83-9add-7974897e6675_terseLabel_en-US" xlink:label="lab_uthr_StockIncentivePlan2015PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_uthr_StockIncentivePlan2015PlanMember_label_en-US" xlink:label="lab_uthr_StockIncentivePlan2015PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2015 Plan [Member]</link:label>
    <link:label id="lab_uthr_StockIncentivePlan2015PlanMember_documentation_en-US" xlink:label="lab_uthr_StockIncentivePlan2015PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information relating to 2015 Stock Incentive Plan (the 2015 Plan).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockIncentivePlan2015PlanMember" xlink:href="uthr-20260331.xsd#uthr_StockIncentivePlan2015PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_StockIncentivePlan2015PlanMember" xlink:to="lab_uthr_StockIncentivePlan2015PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019d1dc9-be08-7cdd-9490-aeaf2efb6ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Share-Based Compensation Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtInstrumentAdditionalExtensionTerm_019d753a-eafc-7435-968e-856486107883_terseLabel_en-US" xlink:label="lab_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, additional extension term</link:label>
    <link:label id="lab_uthr_DebtInstrumentAdditionalExtensionTerm_label_en-US" xlink:label="lab_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Extension Term</link:label>
    <link:label id="lab_uthr_DebtInstrumentAdditionalExtensionTerm_documentation_en-US" xlink:label="lab_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentAdditionalExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:to="lab_uthr_DebtInstrumentAdditionalExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019d1dc9-be07-71bf-b58e-cf1c934760fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-be08-7f62-825c-6fbe3a0fa62b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-be9c-77d8-8391-991176e5aa8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-be9c-7547-b60b-fe7a17fc695c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-be08-7a06-8d71-8e77f8097513_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019d1dc9-be07-77ba-b948-b5e3063c6251_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019d1dc9-be08-704b-a25f-2dcb7c028cf4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_019d1dc9-be08-76e4-a43c-1ca2a69791e4_terseLabel_en-US" xlink:label="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs with Performance Conditions</link:label>
    <link:label id="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_label_en-US" xlink:label="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) With Performance Conditions [Member]</link:label>
    <link:label id="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_documentation_en-US" xlink:label="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) With Performance Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:href="uthr-20260331.xsd#uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:to="lab_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d1dc9-be9c-71be-b197-c35088d36d25_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term of awards (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_019d1dc9-be08-7235-b40f-e736828c3875_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-be9c-77cc-9318-b570da002ae2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-be08-769e-842b-92184535e183_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019d1dc9-be07-78d6-8075-849a7d57424b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized to be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019d1dc9-be08-72e2-959f-73391ce6c3c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_019d1dc9-be9c-70f4-b99a-6df79899381c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d1dc9-be08-788f-92c2-4d0d67c1fe16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of compensation employees may contribute for ESPP (in percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_019d473b-5a82-7466-8cc0-96b6a6855f47_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-be9c-7a2e-a93c-7d43946a51fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-be08-729a-a364-9c438f3578af_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-be07-7ae1-ad23-baeb7c8cd020_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019d1dc9-be07-7331-a346-06f6532b479f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Subject to Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_019d1dc9-be9c-72f4-b2f2-029feaa71204_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in equity securities with readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d1dc9-be08-70db-982d-bb71ee86da6e_terseLabel_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreements</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_label_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreements [Member]</link:label>
    <link:label id="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_documentation_en-US" xlink:label="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Accelerated Share Repurchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:to="lab_uthr_A2025AcceleratedShareRepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d1dc9-be07-7206-bff6-22a1fbb5476c_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-7e6b-987f-11172ada17c7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-7f79-83b4-e80b4dd21b73_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019d1dc9-be08-7cb0-a4d2-a21427413bff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019d1dc9-be07-72fd-b40c-0671c9779276_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-be9c-7f90-8fe0-d1bbe96a84d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Related income tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019d1dc9-be07-7d93-9e5a-45ea9fbfd1c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized to be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_019d1dc9-be08-71c7-9806-314ea3c40d45_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, 34,973,547 and 32,809,088 shares as of March&#160;31, 2026 and December&#160;31, 2025, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_019d1dc9-be08-7ef4-87a6-b08db39cec9e_terseLabel_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one to three years</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_label_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year One Through Three, Amortized Cost Basis</link:label>
    <link:label id="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_documentation_en-US" xlink:label="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount after adjustments of available-for-sale debt securities at cost, maturing in the third rolling twelve months following the latest balance sheet. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:to="lab_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-be08-7f6d-8c2f-ac9eb65af78a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_019d1dc9-be08-7bee-bae3-69ac343f4029_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019d1dc9-be07-7905-b236-1ba0424668bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity and Status of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-be9c-7d79-903e-2a8efd6b6ae9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be9c-7a4c-b1a7-5c24da64c5cf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be9c-783d-9ea9-8ed38e5f0a35_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average outstanding shares - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_019dd9e5-467b-72ba-a81f-5eb9a9252162_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-be9c-7fd0-960c-1c93e73b651c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be08-7ce2-8864-36e94d379c16_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019d1dc9-be9c-768c-abcf-e3a306bcd3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d1dc9-be08-7ef5-b749-326b79be37c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_019d1dc9-be9c-76c4-b862-4ea21ef2a644_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-be9c-75d7-bb21-88f858489967_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_019d1dc9-be9c-798c-b202-2c129e1f32fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d1dc9-be07-7acc-9ffd-d453618fb043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019d1dc9-be07-7c6d-931f-8588a3b3d186_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_A2025CreditAgreementMember_019d1dc9-be07-7277-9ac8-5cb5249fa1fe_terseLabel_en-US" xlink:label="lab_uthr_A2025CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Credit Agreement</link:label>
    <link:label id="lab_uthr_A2025CreditAgreementMember_label_en-US" xlink:label="lab_uthr_A2025CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Credit Agreement [Member]</link:label>
    <link:label id="lab_uthr_A2025CreditAgreementMember_documentation_en-US" xlink:label="lab_uthr_A2025CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025CreditAgreementMember" xlink:href="uthr-20260331.xsd#uthr_A2025CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_A2025CreditAgreementMember" xlink:to="lab_uthr_A2025CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_019d1dc9-be07-7e5b-98bd-6e8d004e9ff8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_NumberOfEquityIncentivePlans_019d1dc9-be08-7b77-a81d-0def54721abd_terseLabel_en-US" xlink:label="lab_uthr_NumberOfEquityIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity incentive plans</link:label>
    <link:label id="lab_uthr_NumberOfEquityIncentivePlans_label_en-US" xlink:label="lab_uthr_NumberOfEquityIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equity Incentive Plans</link:label>
    <link:label id="lab_uthr_NumberOfEquityIncentivePlans_documentation_en-US" xlink:label="lab_uthr_NumberOfEquityIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shareholder-approved equity incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfEquityIncentivePlans" xlink:href="uthr-20260331.xsd#uthr_NumberOfEquityIncentivePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_NumberOfEquityIncentivePlans" xlink:to="lab_uthr_NumberOfEquityIncentivePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-be9c-7888-a223-011e97dd86aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-be9c-7234-aad4-5a3345b1398f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-be08-7e7b-b098-6e263b505171_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-be08-7fc0-8451-a522d1a3c938_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019d1dc9-be07-7875-bdea-91eedbefcda6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019d1dc9-be07-7a26-af3d-dad4c063a646_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019d1dc9-be07-7b56-a979-d344656aef18_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019d1dc9-be07-7c4c-9a9a-3f7657b85baf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_019d1dc9-be9c-798e-b86a-ea96e1d4c6a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gain and prior service cost included in net periodic pension cost, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_019d1dc9-be9c-7c9e-911b-5bb195f1ffee_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019d1dc9-be9c-704e-baf9-c88054af1237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_019d1dc9-be07-71f7-9657-c0471e96ce66_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019d8a0f-02b5-7d49-a8bd-3ea175b93d95_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in value of investment, annual amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_uthr_MarketableSecuritiesNoncurrentMember_019d1dc9-be07-78da-a877-72ba2dbe0526_terseLabel_en-US" xlink:label="lab_uthr_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current marketable investments</link:label>
    <link:label id="lab_uthr_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_uthr_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities Noncurrent [Member]</link:label>
    <link:label id="lab_uthr_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_uthr_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesNoncurrentMember" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_uthr_MarketableSecuritiesNoncurrentMember" xlink:to="lab_uthr_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019d1dc9-be9c-7fa9-ae0f-20ec9aae0faa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d1dc9-be07-74d6-b543-32a5eb84c1ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-70c4-bdc4-25394f06dc03_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_019d1dc9-be9c-787b-a414-3fb286ace8c2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_019d3297-5a69-75fa-a143-3de4cef9faba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_019d1dc9-be9c-7b52-99f8-87c5dd96521e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-be9c-7164-b102-e1633d42788b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d1dc9-be9c-7aaa-860d-aab3d2d8bd68_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash additions to property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019d1dc9-be9c-7fa7-a2e4-2e4fd9911942_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-be07-751e-83dc-2d96461b957b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_019d1dc9-be9c-7f0f-b65d-8b5bc3ca97c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019d1dc9-be9c-7bc5-ab25-e84d91c9596f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d1dc9-be9c-73fb-babe-15646050b6f6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019d1dc9-be08-7a4c-be02-8d764d77ae4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional number of shares authorized to be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019d1dc9-be9c-720d-9f55-82a8eb06e457_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d1dc9-be08-7cef-b53e-afa9387a82ef_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3297-5a69-78dc-9785-3cd29e07430c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019d1dc9-be07-7355-a752-c3faf2bd4c23_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-be9c-7d59-a830-b77ea7d492f5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-be08-7b18-bf5e-3c8758f1aed3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>uthr-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019d1dc9-bc28-7738-a60c-cb3403f56a4c,g:9ef47c95-ba6b-4823-ba37-566246fe1199-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.unither.com/role/CoverPage" xlink:type="simple" xlink:href="uthr-20260331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019d1dc9-bd6a-78c3-8f8d-61bd64b4fbdb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentType_019d1dc9-bd6a-78c3-8f8d-61bd64b4fbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019d1dc9-bd6a-7b01-b97d-591a78d7f566" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentQuarterlyReport_019d1dc9-bd6a-7b01-b97d-591a78d7f566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019d1dc9-bd6a-7f70-bc96-cc438c999a07" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentPeriodEndDate_019d1dc9-bd6a-7f70-bc96-cc438c999a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019d1dc9-bd6a-724e-8a78-cf143b9b1924" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentTransitionReport_019d1dc9-bd6a-724e-8a78-cf143b9b1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019d1dc9-bd6a-71f5-9e12-f68dde6c509e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityFileNumber_019d1dc9-bd6a-71f5-9e12-f68dde6c509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019d1dc9-bd6a-7cb8-8b51-50726f930d3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityRegistrantName_019d1dc9-bd6a-7cb8-8b51-50726f930d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019d1dc9-bd6a-7892-a0d9-edb1cc00dc0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019d1dc9-bd6a-7892-a0d9-edb1cc00dc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019d1dc9-bd6a-711d-bd0e-aabb75e90f58" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityTaxIdentificationNumber_019d1dc9-bd6a-711d-bd0e-aabb75e90f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019d1dc9-bd6a-72da-98d2-f7b39bb569f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityAddressAddressLine1_019d1dc9-bd6a-72da-98d2-f7b39bb569f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019d1dc9-bd6a-77dd-89a7-04bd9132a400" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityAddressCityOrTown_019d1dc9-bd6a-77dd-89a7-04bd9132a400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019d1dc9-bd6a-717a-89d3-cd6e74e04352" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityAddressStateOrProvince_019d1dc9-bd6a-717a-89d3-cd6e74e04352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019d1dc9-bd6a-7fe5-a28a-b7eae87ae7bc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityAddressPostalZipCode_019d1dc9-bd6a-7fe5-a28a-b7eae87ae7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019d1dc9-bd6a-79ec-b691-f7cadd157135" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_CityAreaCode_019d1dc9-bd6a-79ec-b691-f7cadd157135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019d1dc9-bd6a-7988-9d1c-2363c536b9ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_LocalPhoneNumber_019d1dc9-bd6a-7988-9d1c-2363c536b9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019d1dc9-bd6a-774a-855b-f88bdc475119" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_Security12bTitle_019d1dc9-bd6a-774a-855b-f88bdc475119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019d1dc9-bd6a-7590-b790-c439ca1e3c12" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_TradingSymbol_019d1dc9-bd6a-7590-b790-c439ca1e3c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019d1dc9-bd6a-7eaf-acbf-80d20a01074a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_SecurityExchangeName_019d1dc9-bd6a-7eaf-acbf-80d20a01074a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019d1dc9-bd6a-7075-95bb-b4c05c21ccf4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityCurrentReportingStatus_019d1dc9-bd6a-7075-95bb-b4c05c21ccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019d1dc9-bd6a-7a43-9fc1-b74c819d79fb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityInteractiveDataCurrent_019d1dc9-bd6a-7a43-9fc1-b74c819d79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019d1dc9-bd6a-7f4b-93a2-272249d18ed1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityFilerCategory_019d1dc9-bd6a-7f4b-93a2-272249d18ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019d1dc9-bd6a-77c9-b7af-7098c043a99a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntitySmallBusiness_019d1dc9-bd6a-77c9-b7af-7098c043a99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019d1dc9-bd6a-78fa-a931-7af10b29f79e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityEmergingGrowthCompany_019d1dc9-bd6a-78fa-a931-7af10b29f79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019d1dc9-bd6a-765c-b155-f1595197aec6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityShellCompany_019d1dc9-bd6a-765c-b155-f1595197aec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019d1dc9-bd6a-7667-9fa7-6bf694ea69a7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019d1dc9-bd6a-7667-9fa7-6bf694ea69a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019d1dc9-bd6a-7957-aa9c-701f0fcbf4e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_CurrentFiscalYearEndDate_019d1dc9-bd6a-7957-aa9c-701f0fcbf4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019d1dc9-bd6a-7318-bd0d-1dfb2bae9a23" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentFiscalYearFocus_019d1dc9-bd6a-7318-bd0d-1dfb2bae9a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019d1dc9-bd6a-756a-bb55-53485d062047" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019d1dc9-bd6a-756a-bb55-53485d062047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019d1dc9-bd6a-7ed0-a2d0-074f10df3dda" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_EntityCentralIndexKey_019d1dc9-bd6a-7ed0-a2d0-074f10df3dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019d1dc9-bd6a-7d6d-9f19-1ad6981b8072" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019d1dc9-bd6a-76bc-9257-fe105f429d5e" xlink:to="loc_dei_AmendmentFlag_019d1dc9-bd6a-7d6d-9f19-1ad6981b8072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7069-b36f-3ed642fe8ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7069-b36f-3ed642fe8ad1" xlink:to="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d1dc9-bd6a-7318-9801-8f2d748b8c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019d1dc9-bd6a-7318-9801-8f2d748b8c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019d1dc9-bd6a-7af7-9797-1e4e497fcfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019d1dc9-bd6a-7af7-9797-1e4e497fcfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019d1dc9-bd6a-7ee7-81cc-182ec12f4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019d1dc9-bd6a-7ee7-81cc-182ec12f4ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019d1dc9-bd6a-76b3-8813-0bc270752910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_InventoryNet_019d1dc9-bd6a-76b3-8813-0bc270752910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019d1dc9-bd6a-737b-aedc-ded15184e512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_OtherAssetsCurrent_019d1dc9-bd6a-737b-aedc-ded15184e512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-7b20-bac7-3645e4df51e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019d1dc9-bd6a-7d15-8c9e-e35ba466e7e0" xlink:to="loc_us-gaap_AssetsCurrent_019d1dc9-bd6a-7b20-bac7-3645e4df51e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_019d1dc9-bd6a-7d1b-aee9-7369ac7cbe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_019d1dc9-bd6a-7d1b-aee9-7369ac7cbe2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_019d1dc9-bd6a-7bd7-af5b-7bd9f95d7d03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_019d1dc9-bd6a-7bd7-af5b-7bd9f95d7d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6a-7605-8a2c-d8f66c8e2a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6a-7605-8a2c-d8f66c8e2a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_019d1dc9-bd6a-7017-b020-c7f0c60ed9df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_019d1dc9-bd6a-7017-b020-c7f0c60ed9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019d1dc9-bd6a-77cf-bd45-fd015c2b6382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019d1dc9-bd6a-77cf-bd45-fd015c2b6382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019d1dc9-bd6a-75c1-8b13-9404e4213947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019d1dc9-bd6a-74a7-8c76-e49a6f84539d" xlink:to="loc_us-gaap_Assets_019d1dc9-bd6a-75c1-8b13-9404e4213947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7069-b36f-3ed642fe8ad1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-bd6a-711e-b236-e8c861ef695f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-bd6a-711e-b236-e8c861ef695f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019d1dc9-bd6a-7680-a7b8-1cb932d04481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-bd6a-711e-b236-e8c861ef695f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_019d1dc9-bd6a-7680-a7b8-1cb932d04481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019d1dc9-bd6a-7b59-9c9b-4f02acfead3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-bd6a-711e-b236-e8c861ef695f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019d1dc9-bd6a-7b59-9c9b-4f02acfead3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-77de-a1d6-f57d687b77ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019d1dc9-bd6a-711e-b236-e8c861ef695f" xlink:to="loc_us-gaap_LiabilitiesCurrent_019d1dc9-bd6a-77de-a1d6-f57d687b77ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019d1dc9-bd6a-7970-8261-f1d27ced6b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019d1dc9-bd6a-7970-8261-f1d27ced6b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019d1dc9-bd6a-7158-a25d-a32a531a0ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_Liabilities_019d1dc9-bd6a-7158-a25d-a32a531a0ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019d1dc9-bd6a-7e1d-a5f9-3c55557364fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019d1dc9-bd6a-7e1d-a5f9-3c55557364fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019d1dc9-bd6a-70c1-8152-ea722a527669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_PreferredStockValue_019d1dc9-bd6a-70c1-8152-ea722a527669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019d1dc9-bd6a-7cca-b50d-86d731dfa6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_CommonStockValue_019d1dc9-bd6a-7cca-b50d-86d731dfa6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019d1dc9-bd6a-7c6f-a013-de5f533aed48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_019d1dc9-bd6a-7c6f-a013-de5f533aed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019d1dc9-bd6a-73b1-b18a-133b91f967df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019d1dc9-bd6a-73b1-b18a-133b91f967df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019d1dc9-bd6a-7f43-832b-4cb7b1362550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019d1dc9-bd6a-7f43-832b-4cb7b1362550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019d1dc9-bd6a-7679-a177-e87f8f351c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019d1dc9-bd6a-7679-a177-e87f8f351c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7bbb-97a7-de17ef77682a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019d1dc9-bd6a-7de4-91af-dad97c6d343a" xlink:to="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7bbb-97a7-de17ef77682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7297-a884-d9824fc18ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_019d1dc9-bd6a-78f6-8c8d-f284bb1d69c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019d1dc9-bd6a-7297-a884-d9824fc18ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019d1dc9-bd6a-79db-957c-83f62671a3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_019d1dc9-bd6a-79db-957c-83f62671a3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1dc9-bd6a-7e5f-958a-2bf60ae6178c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019d1dc9-bd6a-7e5f-958a-2bf60ae6178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_019d1dc9-bd6a-7b63-a1d2-258938814c23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_019d1dc9-bd6a-7b63-a1d2-258938814c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_019d1dc9-bd6a-7e4c-9782-2ff6c09784bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_PreferredStockSharesIssued_019d1dc9-bd6a-7e4c-9782-2ff6c09784bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1dc9-bd6a-7d33-94c6-c94c5bb69f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019d1dc9-bd6a-7d33-94c6-c94c5bb69f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019d1dc9-bd6a-7fd2-91a3-82d3d1f86a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019d1dc9-bd6a-7fd2-91a3-82d3d1f86a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-7d46-b716-79c64d992f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-7d46-b716-79c64d992f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019d1dc9-bd6a-733b-b76d-2043c3019727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019d1dc9-bd6a-733b-b76d-2043c3019727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019d1dc9-bd6a-78c1-9a13-ea78db88eeef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019d1dc9-bd6a-7fbb-af29-646d5cc40e89" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019d1dc9-bd6a-78c1-9a13-ea78db88eeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-bd6a-79e3-b1f4-49774b577703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-bd6a-79e3-b1f4-49774b577703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-bd6a-7117-a6b5-2fd3d259717a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-bd6a-7117-a6b5-2fd3d259717a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019d1dc9-bd6a-702e-beb9-32024d01cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019d1dc9-bd6a-702e-beb9-32024d01cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019d1dc9-bd6a-70f5-bebe-fade3fb437be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_019d1dc9-bd6a-70f5-bebe-fade3fb437be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7068-a685-973a37294327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_019d1dc9-bd6a-7dd1-bb6e-3db9e8238765" xlink:to="loc_us-gaap_CostsAndExpenses_019d1dc9-bd6a-7068-a685-973a37294327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7bde-a7c3-6641f8da1c56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_OperatingIncomeLoss_019d1dc9-bd6a-7bde-a7c3-6641f8da1c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_019d1dc9-bd6a-7a49-b5ab-ff9df0c466f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_InvestmentIncomeInterest_019d1dc9-bd6a-7a49-b5ab-ff9df0c466f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019d1dc9-bd6a-7904-a3e0-06c5880168cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019d1dc9-bd6a-7904-a3e0-06c5880168cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_019d1dc9-bd6a-755d-a17e-07e1b8ad3e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_019d1dc9-bd6a-755d-a17e-07e1b8ad3e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7143-a82a-f7dedab957dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019d1dc9-bd6a-7143-a82a-f7dedab957dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-7475-a083-7e297aff8237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019d1dc9-bd6a-7475-a083-7e297aff8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019d1dc9-bd6a-7a6d-b3f1-7750faf74342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019d1dc9-bd6a-7a6d-b3f1-7750faf74342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7238-9cf1-301fea359415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7238-9cf1-301fea359415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019d1dc9-bd6a-77fc-b50f-9ce2037075b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019d1dc9-bd6a-77fc-b50f-9ce2037075b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019d1dc9-bd6a-7f25-97a7-fa75499aef44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019d1dc9-bd6a-77fc-b50f-9ce2037075b8" xlink:to="loc_us-gaap_EarningsPerShareBasic_019d1dc9-bd6a-7f25-97a7-fa75499aef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019d1dc9-bd6a-786b-81d1-25dbe4ad0b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019d1dc9-bd6a-77fc-b50f-9ce2037075b8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019d1dc9-bd6a-786b-81d1-25dbe4ad0b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-bd6a-78d7-b697-1d13179089a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019d1dc9-bd6a-74ec-9d8b-887c02b1d405" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-bd6a-78d7-b697-1d13179089a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-bd6a-7d58-b239-4d85bbd1d31a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-bd6a-78d7-b697-1d13179089a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-bd6a-7d58-b239-4d85bbd1d31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-bd6a-7985-8ec0-7fcf31a7a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-bd6a-78d7-b697-1d13179089a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-bd6a-7985-8ec0-7fcf31a7a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-bd6a-720d-9613-4227ad90fbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-bd6a-7594-bbeb-2be0f5eb3e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-bd6a-720d-9613-4227ad90fbd3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-bd6a-7594-bbeb-2be0f5eb3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7e44-80b5-36966c08d338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-bd6a-7594-bbeb-2be0f5eb3e58" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7e44-80b5-36966c08d338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7853-ae4f-f74ac560805e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-bd6a-7594-bbeb-2be0f5eb3e58" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7853-ae4f-f74ac560805e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7875-bb3c-707e189b525f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7853-ae4f-f74ac560805e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7875-bb3c-707e189b525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_019d1dc9-bd6a-7617-9bcb-14d6ebd9bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7875-bb3c-707e189b525f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_019d1dc9-bd6a-7617-9bcb-14d6ebd9bda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_019d1dc9-bd6a-7735-8ed3-1b7bc4784a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7875-bb3c-707e189b525f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax_019d1dc9-bd6a-7735-8ed3-1b7bc4784a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-77cb-8f00-740e928943b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7875-bb3c-707e189b525f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-77cb-8f00-740e928943b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-bd6a-7c12-b790-b59ece122c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7853-ae4f-f74ac560805e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-bd6a-7c12-b790-b59ece122c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019d1dc9-bd6a-7ee8-a155-5ee58fba5b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-bd6a-7c12-b790-b59ece122c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_019d1dc9-bd6a-7ee8-a155-5ee58fba5b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_019d1dc9-bd6a-7fb9-b0d2-47da44987a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-bd6a-7c12-b790-b59ece122c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_019d1dc9-bd6a-7fb9-b0d2-47da44987a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-72c7-ac39-5a556fa33716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_019d1dc9-bd6a-7c12-b790-b59ece122c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-72c7-ac39-5a556fa33716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7c8a-80e6-e71200c60f80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_019d1dc9-bd6a-7853-ae4f-f74ac560805e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7c8a-80e6-e71200c60f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-bd6a-710d-9dc7-59a2f1c30e53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_019d1dc9-bd6a-7594-bbeb-2be0f5eb3e58" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019d1dc9-bd6a-710d-9dc7-59a2f1c30e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-bd6a-706d-b00e-b34dc3c12827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_019d1dc9-bd6a-7223-ad50-f089727f0c70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-bd6a-706d-b00e-b34dc3c12827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_019d1dc9-bd6a-7223-ad50-f089727f0c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_019d1dc9-bd6a-7b58-98a1-b8b1c692b287" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_019d1dc9-bd6a-706d-b00e-b34dc3c12827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent_019d1dc9-bd6a-7b58-98a1-b8b1c692b287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019d1dc9-bd6a-77de-a35c-8978e9f08be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019d1dc9-bd6a-77de-a35c-8978e9f08be7" xlink:to="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019d1dc9-bd6a-7ec2-8604-c199adeaf558" xlink:to="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019d1dc9-bd6a-71c1-ae34-9be37923b785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_CommonStockMember_019d1dc9-bd6a-71c1-ae34-9be37923b785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_019d1dc9-bd6a-75f7-9d76-670a388b38a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_019d1dc9-bd6a-75f7-9d76-670a388b38a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019d1dc9-bd6a-7f5d-93a5-87a4fd150981" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019d1dc9-bd6a-7f5d-93a5-87a4fd150981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019d1dc9-bd6a-7861-970b-bf26bb5b0439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019d1dc9-bd6a-7861-970b-bf26bb5b0439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019d1dc9-bd6a-7373-b1ef-2a55b833704d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019d1dc9-bd6a-72c2-8571-9ca99f8d47bc" xlink:to="loc_us-gaap_RetainedEarningsMember_019d1dc9-bd6a-7373-b1ef-2a55b833704d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019d1dc9-bd6a-7fab-90eb-6d7c03bed7c4" xlink:to="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019d1dc9-bd6a-7650-a260-fe15e4f862af" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-785e-bce1-6d7b0fa54111" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-785e-bce1-6d7b0fa54111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7fff-8b97-022fbb0fdd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-7fff-8b97-022fbb0fdd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7dd2-a360-e0d19a6c724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-7dd2-a360-e0d19a6c724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ee9-9611-778590da13dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019d1dc9-bd6a-7ee9-9611-778590da13dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019d1dc9-bd6a-7dda-b52e-fc97bd6d3b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_019d1dc9-bd6a-7dda-b52e-fc97bd6d3b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-79d1-907c-c5c10731297b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-79d1-907c-c5c10731297b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019d1dc9-bd6a-7aae-8ddc-8bec278320f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019d1dc9-bd6a-7aae-8ddc-8bec278320f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax_019d3275-d58f-7dfc-9625-5af7904dccb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTax_019d3275-d58f-7dfc-9625-5af7904dccb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019d1dc9-bd6a-74b5-ad94-9bc0bfeeee86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019d1dc9-bd6a-74b5-ad94-9bc0bfeeee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6a-7fad-b3b2-ad47de2f6737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6a-7fad-b3b2-ad47de2f6737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019d1dc9-bd6a-7aed-9fe4-3a055d6002c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_019d1dc9-bd6a-7aed-9fe4-3a055d6002c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019d1dc9-bd6a-7956-bfdb-759562872006" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019d1dc9-bd6a-7956-bfdb-759562872006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-7687-98c5-2f101776dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_CommonStockSharesIssued_019d1dc9-bd6a-7687-98c5-2f101776dec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-787f-9d2d-2fac8cef9baa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019d327c-e849-74f7-a0cd-3adcf183213a" xlink:to="loc_us-gaap_StockholdersEquity_019d1dc9-bd6a-787f-9d2d-2fac8cef9baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="uthr-20260331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-73a8-a5c8-04bbb7abeb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-bd6a-73a8-a5c8-04bbb7abeb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019d1dc9-bd6a-7b9c-a445-5531880562dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019d1dc9-bd6a-7b9c-a445-5531880562dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019d1dc9-bd6a-77ef-94bb-9d2ce869f6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:to="loc_us-gaap_ShareBasedCompensation_019d1dc9-bd6a-77ef-94bb-9d2ce869f6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019dd9ea-bc58-7c9e-b917-005111c500c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019dd9ea-bc58-7c9e-b917-005111c500c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019dd9e9-4d9d-76c9-ab22-270f22471bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_019dd9e9-4d9d-76c9-ab22-270f22471bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_019d1dc9-bd6a-79d2-9537-5c53043e81c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-72f4-9c98-36844e367698" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_019d1dc9-bd6a-79d2-9537-5c53043e81c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019d1dc9-bd6a-7cf3-9986-48db9f3e9fab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_019d1dc9-bd6a-7cf3-9986-48db9f3e9fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_019d1dc9-bd6a-7f75-8343-2206283eac2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_019d1dc9-bd6a-7f75-8343-2206283eac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019d1dc9-bd6a-78ea-a215-604d6b18ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_019d1dc9-bd6a-78ea-a215-604d6b18ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019d1dc9-bd6a-7d85-9f02-93273c8433ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019d1dc9-bd6a-706d-bc19-b76581b4e08f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_019d1dc9-bd6a-7d85-9f02-93273c8433ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7920-9231-1521cb99669f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019d1dc9-bd6a-757b-aa1b-4340316adccc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019d1dc9-bd6a-7920-9231-1521cb99669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019d1dc9-bd6a-7943-b874-774e030d0313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019d1dc9-bd6a-7943-b874-774e030d0313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_019d1dc9-bd6a-7763-b46d-cacced3893d5" xlink:href="uthr-20260331.xsd#uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment_019d1dc9-bd6a-7763-b46d-cacced3893d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019d1dc9-bd6a-77f9-8666-2fb3c5d96d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019d1dc9-bd6a-77f9-8666-2fb3c5d96d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019d1dc9-bd6a-7453-a47d-3f6bdf6922b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019d1dc9-bd6a-7453-a47d-3f6bdf6922b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019d89ef-3353-7575-a489-b44571baa4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_019d89ef-3353-7575-a489-b44571baa4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_019d89ef-3353-7106-b238-dbabbad42532" xlink:href="uthr-20260331.xsd#uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue_019d89ef-3353-7106-b238-dbabbad42532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7bcc-ae9f-5ebfdc3515f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019d1dc9-bd6a-73c3-a609-c3066b69513c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019d1dc9-bd6a-7bcc-ae9f-5ebfdc3515f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-bd6a-742b-b3aa-621c7c00c925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d1dc9-bd6a-742b-b3aa-621c7c00c925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_019d1dc9-bd6a-7d7c-80a0-21ab2e8eee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_019d1dc9-bd6a-7d7c-80a0-21ab2e8eee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6a-7709-8c61-558198afd2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6a-7709-8c61-558198afd2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019d1dc9-bd6a-7d2e-9ee3-700a36c81640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019d1dc9-bd6a-7d2e-9ee3-700a36c81640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-7400-82b6-aed48e3f1aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_019d1dc9-bd6a-7400-82b6-aed48e3f1aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7885-9bf7-5fb0b8a371d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019d1dc9-bd6a-7e5e-a7af-c867a7db4125" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019d1dc9-bd6a-7885-9bf7-5fb0b8a371d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-72fc-a312-e9f9508baf76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019d1dc9-bd6a-72fc-a312-e9f9508baf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-bd6a-7b50-95e2-8e790063e525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-bd6a-7b50-95e2-8e790063e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-bd6a-7e8a-9b37-731749aca583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019d1dc9-bd6a-7e8a-9b37-731749aca583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-bd6a-711b-bdda-f4b1f216dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019d1dc9-bd6a-77dc-a7b6-687177915ce3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-bd6a-711b-bdda-f4b1f216dc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_019d1dc9-bd6a-7ce2-bc67-7fe2c458c80a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-bd6a-711b-bdda-f4b1f216dc91" xlink:to="loc_us-gaap_InterestPaidNet_019d1dc9-bd6a-7ce2-bc67-7fe2c458c80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019d1dc9-bd6a-758f-9623-489edeadf117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-bd6a-711b-bdda-f4b1f216dc91" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019d1dc9-bd6a-758f-9623-489edeadf117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019d1dc9-bd6a-7805-b11c-3002c09c9010" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_019d1dc9-bd6a-711b-bdda-f4b1f216dc91" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019d1dc9-bd6a-7805-b11c-3002c09c9010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d1dc9-bd6a-7a28-bb98-5ff422423ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019d1dc9-bd6a-7805-b11c-3002c09c9010" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_019d1dc9-bd6a-7a28-bb98-5ff422423ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NoncashExciseTaxOnNetShareRepurchases_019d1dc9-bd6a-7f5e-8e0f-a587d07140af" xlink:href="uthr-20260331.xsd#uthr_NoncashExciseTaxOnNetShareRepurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_019d1dc9-bd6a-7805-b11c-3002c09c9010" xlink:to="loc_uthr_NoncashExciseTaxOnNetShareRepurchases_019d1dc9-bd6a-7f5e-8e0f-a587d07140af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/OrganizationandBusinessDescription" xlink:type="simple" xlink:href="uthr-20260331.xsd#OrganizationandBusinessDescription"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/OrganizationandBusinessDescription" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7bab-b119-91c835c8f7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_019d1dc9-bd6a-7248-b83d-2f03870be63f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7bab-b119-91c835c8f7f8" xlink:to="loc_us-gaap_NatureOfOperations_019d1dc9-bd6a-7248-b83d-2f03870be63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/BasisofPresentation" xlink:type="simple" xlink:href="uthr-20260331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7588-aed3-c4e7e6bc8c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_019d1dc9-bd6a-7a33-9ac8-25d2fe46cc64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7588-aed3-c4e7e6bc8c5c" xlink:to="loc_us-gaap_BasisOfAccounting_019d1dc9-bd6a-7a33-9ac8-25d2fe46cc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/Investments" xlink:type="simple" xlink:href="uthr-20260331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7653-bbfd-532b4019ab17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019d1dc9-bd6a-706a-8206-df9675e97b24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7653-bbfd-532b4019ab17" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_019d1dc9-bd6a-706a-8206-df9675e97b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="uthr-20260331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019d1dc9-bd6a-73c3-b8b7-7007bb33bcda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019d1dc9-bd6a-7c9e-b277-ee1be9ae9503" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019d1dc9-bd6a-73c3-b8b7-7007bb33bcda" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019d1dc9-bd6a-7c9e-b277-ee1be9ae9503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/Inventories" xlink:type="simple" xlink:href="uthr-20260331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6a-7711-a50a-1d99ab5f6ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_019d1dc9-bd6b-7abc-b37b-2a083fe0f64f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6a-7711-a50a-1d99ab5f6ea1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_019d1dc9-bd6b-7abc-b37b-2a083fe0f64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-7479-b9a3-95861df8ccec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019d1dc9-bd6b-709f-854a-1715e773bfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-7479-b9a3-95861df8ccec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_019d1dc9-bd6b-709f-854a-1715e773bfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/Debt" xlink:type="simple" xlink:href="uthr-20260331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019d1dc9-bd6b-795d-9e04-e100a61b32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_019d1dc9-bd6b-7f8b-a7a4-7872a21da9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019d1dc9-bd6b-795d-9e04-e100a61b32aa" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_019d1dc9-bd6b-7f8b-a7a4-7872a21da9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7046-b34d-f1bf38e19c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019d1dc9-bd6b-7ef8-947a-9910d94244bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7046-b34d-f1bf38e19c91" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019d1dc9-bd6b-7ef8-947a-9910d94244bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquity" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-73a1-b8d4-43172091a348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019d1dc9-be07-79f2-8677-1b0cb13d553d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-73a1-b8d4-43172091a348" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019d1dc9-be07-79f2-8677-1b0cb13d553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/IncomeTaxes" xlink:type="simple" xlink:href="uthr-20260331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be07-7b57-a90c-a5911b61e7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019d1dc9-be07-74f5-a04a-d72a472939cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be07-7b57-a90c-a5911b61e7a4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019d1dc9-be07-74f5-a04a-d72a472939cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformation" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-78eb-be4c-a4027421b041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019d1dc9-be07-7d04-8090-6ed80e2c8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-78eb-be4c-a4027421b041" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019d1dc9-be07-7d04-8090-6ed80e2c8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/Litigation" xlink:type="simple" xlink:href="uthr-20260331.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019d1dc9-be07-7722-865d-84f187e3289f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_019d1dc9-be07-73ba-bc88-f49d08b1f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019d1dc9-be07-7722-865d-84f187e3289f" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_019d1dc9-be07-73ba-bc88-f49d08b1f8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="uthr-20260331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7448-a5ec-e89e7d5b25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019d1dc9-bd6a-7287-99f2-fde02ae22246" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019d1dc9-bd6a-7448-a5ec-e89e7d5b25ac" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019d1dc9-bd6a-7287-99f2-fde02ae22246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e30-bbfa-3caff951728f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019d1dc9-bd6a-7786-b7d3-982f5481942b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e30-bbfa-3caff951728f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019d1dc9-bd6a-7786-b7d3-982f5481942b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019d1dc9-bd6a-7efb-9715-cc5820f5b29a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e30-bbfa-3caff951728f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_019d1dc9-bd6a-7efb-9715-cc5820f5b29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019d1dc9-bd6a-75b2-aac3-2a1b87696083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e30-bbfa-3caff951728f" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_019d1dc9-bd6a-75b2-aac3-2a1b87696083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019d1dc9-bd6a-7307-8b4b-2f4437034380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019d1dc9-bd6a-7901-816c-c31101de34f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019d1dc9-bd6a-7307-8b4b-2f4437034380" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019d1dc9-bd6a-7901-816c-c31101de34f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InventoriesTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a8a-a15b-444976d6e4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019d1dc9-bd6b-7e3b-ad1d-a3dd083258fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a8a-a15b-444976d6e4e3" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_019d1dc9-bd6b-7e3b-ad1d-a3dd083258fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-793a-a593-0c348b9a0fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019d1dc9-bd6b-71da-9970-b980342d87c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-793a-a593-0c348b9a0fe4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_019d1dc9-bd6b-71da-9970-b980342d87c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019d1dc9-bd6b-7483-973b-4debfe839fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_019d1dc9-bd6b-7483-973b-4debfe839fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019d1dc9-bd6b-7cbf-b0c9-fdf70a991ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_019d1dc9-bd6b-7cbf-b0c9-fdf70a991ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019d1dc9-bd6b-728b-b7ad-85e70487160c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_019d1dc9-bd6b-728b-b7ad-85e70487160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019d1dc9-bd6b-7f9b-9928-a6d041fec3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019d1dc9-bd6b-7f9b-9928-a6d041fec3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock_019d1dc9-bd6b-7c2f-8b99-f52ab0869110" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock_019d1dc9-bd6b-7c2f-8b99-f52ab0869110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_019d1dc9-bd6b-7ef2-b14d-6960016c3c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7584-b3e2-cf6bc5a88cd8" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_019d1dc9-bd6b-7ef2-b14d-6960016c3c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-7e53-a454-50013cd87922" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019d1dc9-be07-7581-bc2b-09a5e72c358b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-7e53-a454-50013cd87922" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019d1dc9-be07-7581-bc2b-09a5e72c358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-71e0-9460-da39669f4a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock_019d1dc9-be07-7195-9f18-3043191d93e3" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-71e0-9460-da39669f4a0b" xlink:to="loc_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock_019d1dc9-be07-7195-9f18-3043191d93e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_019d1dc9-be07-7d36-a7cf-d5587f05518b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-71e0-9460-da39669f4a0b" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_019d1dc9-be07-7d36-a7cf-d5587f05518b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019d1dc9-be07-763d-a64f-3bd3f2892d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-71e0-9460-da39669f4a0b" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_019d1dc9-be07-763d-a64f-3bd3f2892d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7db8-8cb9-50b9554ae79f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7db8-8cb9-50b9554ae79f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-72cb-a6eb-763db369e7a7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-79be-a372-43b7c167b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-79be-a372-43b7c167b6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-7068-8432-0c1f75e54889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7066-9c06-2705ae445dc8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-7068-8432-0c1f75e54889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7673-90cd-c03dd16bbc03" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7b5d-b737-5a63da8a34a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_019d1dc9-bd6a-7b5d-b737-5a63da8a34a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7345-92d1-56810f7bec15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019d1dc9-bd6a-7345-92d1-56810f7bec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-70c1-8b31-3f009403c505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019d1dc9-bd6a-70c1-8b31-3f009403c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c2d-a9bb-91588137976f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-70dd-af15-7138ec7d01af" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c2d-a9bb-91588137976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7a06-a2f0-0d25bb59f5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7a06-a2f0-0d25bb59f5a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019d1dc9-bd6a-766d-9c18-82f8aed7fc37" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_019d1dc9-bd6a-7f0d-b867-d188aa44ca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_019d1dc9-bd6a-7f0d-b867-d188aa44ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesCurrentMember_019d1dc9-bd6a-7b8e-8151-4bdf4ed6cd3c" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_uthr_MarketableSecuritiesCurrentMember_019d1dc9-bd6a-7b8e-8151-4bdf4ed6cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_MarketableSecuritiesNoncurrentMember_019d1dc9-bd6a-7917-8de4-cf320abee059" xlink:href="uthr-20260331.xsd#uthr_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019d1dc9-bd6a-77e8-9140-5dd5c7abfcf1" xlink:to="loc_uthr_MarketableSecuritiesNoncurrentMember_019d1dc9-bd6a-7917-8de4-cf320abee059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7425-b015-26db3aa06d0c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7366-aaf7-1c78c1a772f2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-747d-ae29-bb488d56b9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_019d1dc9-bd6a-747d-ae29-bb488d56b9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7225-b30e-410420d5e296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent_019d1dc9-bd6a-7225-b30e-410420d5e296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c95-bd78-2d2d4db55e58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_019d1dc9-bd6a-7a1c-8332-cd19c9596340" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_019d1dc9-bd6a-7c95-bd78-2d2d4db55e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-757c-be96-311032f4cecf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-757c-be96-311032f4cecf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7fbf-9b98-e9e8845d04e4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-72b5-a0bd-5575e4517828" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d1dc9-bd6a-72b5-a0bd-5575e4517828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-759c-b404-64d3bdb5ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7e55-b48b-3591b5d29aba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d1dc9-bd6a-759c-b404-64d3bdb5ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019d1dc9-bd6a-7c59-b8de-6af2da967ede" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-785c-baba-ec1cf6deee59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_019d1dc9-bd6a-785c-baba-ec1cf6deee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-73f8-a756-69ba58cfe68a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_019d1dc9-bd6a-73f8-a756-69ba58cfe68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7aeb-a0d5-311a27713a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract_019d1dc9-bd6a-7f2d-a94a-cca104574bed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_019d1dc9-bd6a-7aeb-a0d5-311a27713a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019d1dc9-bd6a-7547-9e97-3e66e21c5d54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-727e-a2c6-19632afd7ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_019d1dc9-bd6a-727e-a2c6-19632afd7ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-752f-a002-67a4e697bd62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_019d1dc9-bd6a-752f-a002-67a4e697bd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-742a-9f2d-9c4b15965fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_019d1dc9-bd6a-7f19-b122-1cd2e016aebb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_019d1dc9-bd6a-742a-9f2d-9c4b15965fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7f2f-bc94-359f71028743" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019d1dc9-bd6a-735e-910e-d38074487d46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7f2f-bc94-359f71028743" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019d1dc9-bd6a-735e-910e-d38074487d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss_019d1dc9-bd6a-7871-a324-cf6dd3320f95" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7f2f-bc94-359f71028743" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss_019d1dc9-bd6a-7871-a324-cf6dd3320f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-75de-8112-687bae5ea19b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-bd6a-7304-9e1e-3262f0ff97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-75de-8112-687bae5ea19b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-bd6a-7304-9e1e-3262f0ff97cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_019d1dc9-bd6a-7958-b70a-1a42481b7545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-bd6a-7304-9e1e-3262f0ff97cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis_019d1dc9-bd6a-7958-b70a-1a42481b7545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_019d1dc9-bd6a-76a3-b88f-0796e51ac301" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-bd6a-7304-9e1e-3262f0ff97cd" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis_019d1dc9-bd6a-76a3-b88f-0796e51ac301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-bd6a-7b4c-b42f-ceb446d11c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract_019d1dc9-bd6a-7304-9e1e-3262f0ff97cd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_019d1dc9-bd6a-7b4c-b42f-ceb446d11c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-bd6a-7b3a-93c3-fdda8fad6ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-75de-8112-687bae5ea19b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-bd6a-7b3a-93c3-fdda8fad6ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_019d1dc9-bd6a-749c-895c-97ba4cac03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-bd6a-7b3a-93c3-fdda8fad6ec8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_019d1dc9-bd6a-749c-895c-97ba4cac03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_019d1dc9-bd6a-7856-ab01-15ff8a83bfc2" xlink:href="uthr-20260331.xsd#uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-bd6a-7b3a-93c3-fdda8fad6ec8" xlink:to="loc_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue_019d1dc9-bd6a-7856-ab01-15ff8a83bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-bd6a-7c4f-b977-7729b6a8f717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_019d1dc9-bd6a-7b3a-93c3-fdda8fad6ec8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_019d1dc9-bd6a-7c4f-b977-7729b6a8f717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e19-946e-43c989c32eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_019d1dc9-bd6a-7f30-b9d8-8fe96afb932e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7e19-946e-43c989c32eeb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_019d1dc9-bd6a-7f30-b9d8-8fe96afb932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7779-a8fd-f76309ee49f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_019d1dc9-bd6a-7779-a8fd-f76309ee49f5" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d1dc9-bd6a-7916-9f5f-15295843ee9c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_PrivatelyHeldCompaniesMember_019d1dc9-bd6a-7bf7-9607-2fbaa98d164b" xlink:href="uthr-20260331.xsd#uthr_PrivatelyHeldCompaniesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d1dc9-bd6a-7224-a597-745ff1028a53" xlink:to="loc_uthr_PrivatelyHeldCompaniesMember_019d1dc9-bd6a-7bf7-9607-2fbaa98d164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_019d1dc9-bd6a-75b7-afd0-63f9e2610493" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019d1dc9-bd6a-795a-8386-673dd0354a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_019d1dc9-bd6a-795a-8386-673dd0354a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019d3292-a668-7f46-8f49-4e8606b77b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_019d3292-a668-7f46-8f49-4e8606b77b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019d8a0f-02b5-72ea-acd4-29eab643ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_019d8a0f-02b5-72ea-acd4-29eab643ba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-79ed-933b-4d4a91d12a86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-79ed-933b-4d4a91d12a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-756b-b0b0-25f28f9053b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_019d1dc9-bd6a-734b-aec9-0f045951a98a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_019d8a0f-02b5-756b-b0b0-25f28f9053b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019d3298-7bb7-797f-a13a-13852d2671f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019d3298-7bb7-797f-a13a-13852d2671f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_019d3298-7bb7-7ccf-9f84-deb5e78cc00e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_019d3298-7bb7-79e9-97be-7802b734c4a2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019d3298-7bb7-796d-bbab-6afc1c049973" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_019d3298-7bb7-792f-becf-1d43b8656e63" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_019d3298-7bb7-796d-bbab-6afc1c049973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019d3298-7bb7-7cb4-98a0-b46adf34ada8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019d3298-7bb7-76f3-898d-2560b514e051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019d3298-7bb7-76f3-898d-2560b514e051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019d3298-7bb7-7aa1-9a61-cfd4499f43cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019d3298-7bb7-7aa1-9a61-cfd4499f43cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019d3298-7bb7-7b85-829c-ed75f56c300e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019d3298-7bb7-7cfc-8202-6a273394eed9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019d3298-7bb7-7b85-829c-ed75f56c300e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d3298-7bb7-72eb-ba51-d10d9263a543" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_019d3298-7bb7-74f7-9d43-b91bcf69ebd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d3298-7bb7-7174-8954-ab57f2978220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_019d3298-7bb7-74f7-9d43-b91bcf69ebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019d3298-7bb7-7678-81b3-847ab5993d57" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019d3298-7bb7-73b1-9b9c-00e7cfb5e321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019d3298-7bb7-73b1-9b9c-00e7cfb5e321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_019d3298-7bb7-78ee-8ff9-8166660adaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019d3298-7bb7-73a3-8f0a-ec4bb3f89773" xlink:to="loc_us-gaap_BankTimeDepositsMember_019d3298-7bb7-78ee-8ff9-8166660adaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019d3298-7bb7-706c-af3b-01be18126800" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_019d3298-7bb7-7b8d-9603-7dd2efa8b472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_019d3298-7bb7-7b8d-9603-7dd2efa8b472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_019d3298-7bb7-76d9-a197-cd9d73192eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019d3298-7bb7-7b83-8794-a6e528d5131e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_019d3298-7bb7-76d9-a197-cd9d73192eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019d3298-7bb7-754d-ba41-c3527408b2c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-764f-ac48-b78477350eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019d3298-7bb7-764f-ac48-b78477350eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7890-98d8-f4fdc26a1e70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019d3298-7bb7-7890-98d8-f4fdc26a1e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7f81-ab26-dc4c1b074234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_019d3298-7bb7-7f81-ab26-dc4c1b074234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7ca3-be0c-18484db82bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_019d3298-7bb7-720d-a433-b46cae8ca709" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019d3298-7bb7-7ca3-be0c-18484db82bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-71a5-9839-3423a8b91ec0" xlink:href="uthr-20260331.xsd#uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:to="loc_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability_019d3298-7bb7-71a5-9839-3423a8b91ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-75f5-ba0c-e5136bc9e783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_019d3298-7bb7-7245-9e6d-33086d4311ab" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_019d3298-7bb7-75f5-ba0c-e5136bc9e783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d3298-7bb7-7065-ae6f-8c903aa389b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019d3298-7bb7-7065-ae6f-8c903aa389b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019d3298-7bb7-7bc8-ad94-e8287bcbd851" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019d3298-7bb7-71b0-bcce-2f5b651fbb15" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_019d3298-7bb7-7bc8-ad94-e8287bcbd851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/InventoriesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a3d-8e83-5e1b3b305ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019d1dc9-bd6b-7547-a2c3-a0b24fe3f216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a3d-8e83-5e1b3b305ea0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_019d1dc9-bd6b-7547-a2c3-a0b24fe3f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019d1dc9-bd6b-7c4e-bd3e-cbd880017395" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a3d-8e83-5e1b3b305ea0" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_019d1dc9-bd6b-7c4e-bd3e-cbd880017395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019d1dc9-bd6b-7d6e-bed3-68c6e963b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a3d-8e83-5e1b3b305ea0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_019d1dc9-bd6b-7d6e-bed3-68c6e963b8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74e9-aca5-8996bb075169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_019d1dc9-bd6b-7a3d-8e83-5e1b3b305ea0" xlink:to="loc_us-gaap_InventoryNet_019d1dc9-bd6b-74e9-aca5-8996bb075169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-7d68-8c8e-96933ae9a43c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d1dc9-bd6b-7d68-8c8e-96933ae9a43c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_019d1dc9-bd6b-730f-9412-cb0e002e7700" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_019d1dc9-bd6b-7045-91db-42505511845f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_019d1dc9-bd6b-7045-91db-42505511845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_019d1dc9-bd6b-7369-a323-a02aaa23582e" xlink:href="uthr-20260331.xsd#uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember_019d1dc9-bd6b-7369-a323-a02aaa23582e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_019d1dc9-bd6b-73f6-b422-6922cbbcd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_us-gaap_ConstructionInProgressMember_019d1dc9-bd6b-73f6-b422-6922cbbcd5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_FurnitureEquipmentAndVehiclesMember_019d1dc9-bd6b-71c8-8364-b2086eb44a04" xlink:href="uthr-20260331.xsd#uthr_FurnitureEquipmentAndVehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_019d1dc9-bd6b-782a-8a3c-6334f5423bc3" xlink:to="loc_uthr_FurnitureEquipmentAndVehiclesMember_019d1dc9-bd6b-71c8-8364-b2086eb44a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_019d1dc9-bd6b-77bf-97a0-1ea2dafc15a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-77de-8cef-1e67b0311e90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019d1dc9-bd6b-77de-8cef-1e67b0311e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7075-a45a-06e52d600a97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019d1dc9-bd6b-7075-a45a-06e52d600a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-7e57-a02d-4a89fbafd430" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_019d1dc9-bd6b-7bbc-a549-0578e16178de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019d1dc9-bd6b-7e57-a02d-4a89fbafd430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d4749-9bb8-7f00-9189-956b29847df5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_019d4749-f3b9-73ea-adcf-3e40434db11f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_019d4749-9bb8-7f00-9189-956b29847df5" xlink:to="loc_us-gaap_Depreciation_019d4749-f3b9-73ea-adcf-3e40434db11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/DebtDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019d1dc9-bd6b-74a5-bada-44c704710fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019d1dc9-bd6b-74a5-bada-44c704710fa2" xlink:to="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:to="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d1dc9-bd6b-7998-ba23-030ad64e7858" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025CreditAgreementMember_019d1dc9-bd6b-78da-bfe2-438401a722b8" xlink:href="uthr-20260331.xsd#uthr_A2025CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:to="loc_uthr_A2025CreditAgreementMember_019d1dc9-bd6b-78da-bfe2-438401a722b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d1dc9-bd6b-73a8-82f3-569e2a089c81" xlink:to="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-72c0-b00e-a84a257d2f69" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:to="loc_uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-72c0-b00e-a84a257d2f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-73c2-821a-c41f88377b63" xlink:href="uthr-20260331.xsd#uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_CreditAgreement2022Member_019d1dc9-bd6b-7a47-97d4-8a7e038e76c3" xlink:to="loc_uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember_019d1dc9-bd6b-73c2-821a-c41f88377b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019d7539-d4e9-7ba1-ad43-c943b7931dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019d7539-f01d-74bf-82c5-f6a1e33cae78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019d7539-d4e9-7e28-8a82-fb88c4b8ee96" xlink:to="loc_us-gaap_SubsequentEventMember_019d7539-f01d-74bf-82c5-f6a1e33cae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019d1dc9-bd6b-76ac-96c0-51c4c8550983" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019d1dc9-bd6b-72aa-925b-baaa4d30044c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_019d1dc9-bd6b-72aa-925b-baaa4d30044c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_019d1dc9-bd6b-7cc0-8a71-7d53381cf80f" xlink:href="uthr-20260331.xsd#uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity_019d1dc9-bd6b-7cc0-8a71-7d53381cf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentExtensionTerm_019d1dc9-bd6b-72cc-abde-254e67c94887" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentExtensionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_DebtInstrumentExtensionTerm_019d1dc9-bd6b-72cc-abde-254e67c94887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DebtInstrumentAdditionalExtensionTerm_019d753a-eafc-7466-a1cd-097c5d761ed4" xlink:href="uthr-20260331.xsd#uthr_DebtInstrumentAdditionalExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_uthr_DebtInstrumentAdditionalExtensionTerm_019d753a-eafc-7466-a1cd-097c5d761ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019d1dc9-bd6b-7e82-97da-0ad3a1d86b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019d1dc9-bd6b-7e82-97da-0ad3a1d86b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_019d1dc9-bd6b-7cce-b0ff-142760b84984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_019d1dc9-bd6b-7cce-b0ff-142760b84984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019d1dc9-bd6b-7210-9736-b1fb4788c660" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LongTermDebt_019d1dc9-bd6b-7210-9736-b1fb4788c660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_019d1dc9-bd6b-731c-b461-f312df9bc977" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d1dc9-bd6b-73bc-93ac-229def8f90b0" xlink:to="loc_us-gaap_LinesOfCreditCurrent_019d1dc9-bd6b-731c-b461-f312df9bc977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationGeneralNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-74ce-b4cd-9dee8d18bc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-74ce-b4cd-9dee8d18bc9e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:to="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019d1dc9-bd6b-7eb7-b0fe-010301df1fda" xlink:to="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockIncentivePlan2015PlanMember_019d1dc9-bd6b-7325-94c0-b00a05d20341" xlink:href="uthr-20260331.xsd#uthr_StockIncentivePlan2015PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:to="loc_uthr_StockIncentivePlan2015PlanMember_019d1dc9-bd6b-7325-94c0-b00a05d20341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_InducementStockIncentivePlan2019Member_019d1dc9-bd6b-7cea-984f-47e53908e95e" xlink:href="uthr-20260331.xsd#uthr_InducementStockIncentivePlan2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019d1dc9-bd6b-7802-8edd-3eda93c94607" xlink:to="loc_uthr_InducementStockIncentivePlan2019Member_019d1dc9-bd6b-7cea-984f-47e53908e95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:to="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019d1dc9-bd6b-7e56-ac84-8bbf41d1878b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NewlyHiredEmployeesMember_019d1dc9-bd6b-7c2b-b4cf-446f4eaaad89" xlink:href="uthr-20260331.xsd#uthr_NewlyHiredEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d1dc9-bd6b-77ff-8807-b40ff2dfd7f8" xlink:to="loc_uthr_NewlyHiredEmployeesMember_019d1dc9-bd6b-7c2b-b4cf-446f4eaaad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7efb-94fa-e76e1e3d5999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfEquityIncentivePlans_019d1dc9-bd6b-7427-b7bb-ba008c4e9627" xlink:href="uthr-20260331.xsd#uthr_NumberOfEquityIncentivePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_uthr_NumberOfEquityIncentivePlans_019d1dc9-bd6b-7427-b7bb-ba008c4e9627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019d1dc9-bd6b-7b2c-b694-7c38118c747d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019d1dc9-bd6b-7b2c-b694-7c38118c747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019d1dc9-bd6b-71a7-8e34-084ed1236f56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019d1dc9-bd6b-71a7-8e34-084ed1236f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-789f-8157-cfa3a8e09d69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-74b0-b2c9-c91aadd1f3bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-789f-8157-cfa3a8e09d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-78f4-9687-616aa9081d14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-78f4-9687-616aa9081d14" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-765f-b872-7030cba8b31f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-745b-b6ae-5e68e18d4245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-745b-b6ae-5e68e18d4245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7e9a-83ce-6921251db517" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7e9a-83ce-6921251db517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareTrackingAwardsPlanMember_019d1dc9-bd6b-74e7-b0a2-4a939924d005" xlink:href="uthr-20260331.xsd#uthr_ShareTrackingAwardsPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_uthr_ShareTrackingAwardsPlanMember_019d1dc9-bd6b-74e7-b0a2-4a939924d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d1dc9-bd6b-7e6c-b835-b8cb0b0c4d03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-72d3-9eb3-e0fa7e5fff17" xlink:to="loc_us-gaap_EmployeeStockMember_019d1dc9-bd6b-7e6c-b835-b8cb0b0c4d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7be2-87bc-68888c553b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-75ac-aa60-becfc8a07175" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-78f3-b20c-88f459b61173" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-75ac-aa60-becfc8a07175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d4758-0a73-7fb4-a250-83e307f8021a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d4758-0a73-7fb4-a250-83e307f8021a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:to="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d4758-5978-7329-86fb-f68dcf9717ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_019d4758-5978-7efe-a22e-4bdabfd796c0" xlink:href="uthr-20260331.xsd#uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:to="loc_uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember_019d4758-5978-7efe-a22e-4bdabfd796c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d4758-9381-750c-912a-d34352280d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d4758-5978-781c-b757-eaa976a67fcd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d4758-9381-750c-912a-d34352280d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d4758-5978-7e8c-8ab1-87cdfe98a0fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d4758-5978-76f0-b58b-21f9993a56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d4758-5978-76f0-b58b-21f9993a56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_019d4758-5978-78b0-9ed0-36351f1f907a" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue_019d4758-5978-78b0-9ed0-36351f1f907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d4758-5978-784f-a9eb-3ade91cd2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d4758-5978-784f-a9eb-3ade91cd2a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d4758-9381-7301-9ae1-9a1fa6e1ecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d4758-9381-7301-9ae1-9a1fa6e1ecc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019d4758-9381-70d6-84c1-dd84b36951af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_019d4758-9381-70d6-84c1-dd84b36951af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d4759-046f-7470-b49b-9a9c75bd4012" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_019d4759-046f-7470-b49b-9a9c75bd4012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d4759-046f-7cbd-b456-83e431d9605b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d4758-5978-7777-bc78-ebedf3ab2aa2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d4759-046f-7cbd-b456-83e431d9605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationAssumptionsForStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7641-9ece-d1148006f2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7641-9ece-d1148006f2c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-74b2-9b54-3c23dbf015d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-736e-b69a-1d159639432a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7982-a17f-418c13c246ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-736e-b69a-1d159639432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-799b-9ca7-673fabbaa3b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d1dc9-bd6b-7cdc-9c5a-c711e58311e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019d1dc9-bd6b-7cdc-9c5a-c711e58311e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019d1dc9-bd6b-72d8-ae47-2a68625c93b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_019d1dc9-bd6b-72d8-ae47-2a68625c93b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d1dc9-bd6b-7631-ba78-0e80efbfb81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019d1dc9-bd6b-7631-ba78-0e80efbfb81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d1dc9-bd6b-7374-ab17-5f3ea78a86d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-764c-9bab-2ade531e19b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019d1dc9-bd6b-7374-ab17-5f3ea78a86d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStatusofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7ff2-8fee-cd0c72bacb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7ff2-8fee-cd0c72bacb3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c1f-82f2-b0ca9f02ca66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-79cc-a4cb-e801454bc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7b2e-a7c6-e333a8e22667" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-79cc-a4cb-e801454bc8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7433-84fd-d00a0e802e71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7d38-83f6-ba00e05f71a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7d38-83f6-ba00e05f71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-7b33-82b7-4d60430f6a38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_019d1dc9-bd6b-7b33-82b7-4d60430f6a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-7115-8cbe-77232bd93470" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-7115-8cbe-77232bd93470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019d1dc9-bd6b-7b1e-a68d-02b5b73827fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_019d1dc9-bd6b-7b1e-a68d-02b5b73827fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7058-8bd3-3ad6571c087c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019d1dc9-bd6b-7ced-b590-e03e09f32515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019d1dc9-bd6b-7058-8bd3-3ad6571c087c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d1dc9-bd6b-7f00-91c9-8f1d9a36e916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_019d1dc9-bd6b-7f00-91c9-8f1d9a36e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d1dc9-bd6b-7c1b-9467-f0009836812e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_019d1dc9-bd6b-7c1b-9467-f0009836812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7ca9-ad5f-fc6cb5b89efd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7ca9-ad5f-fc6cb5b89efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-72e9-b055-77c9d62b124e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-72e9-b055-77c9d62b124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-7e38-8b37-960fa7f808d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-7e38-8b37-960fa7f808d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-711b-a317-07761523d5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019d1dc9-bd6b-711b-a317-07761523d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7322-ac18-7466f8cccca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_019d1dc9-bd6b-7bba-943c-5227f977bc23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7322-ac18-7466f8cccca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d1dc9-bd6b-75f6-8d8b-32f6c8f190e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_019d1dc9-bd6b-75f6-8d8b-32f6c8f190e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7e40-b381-dd073230a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_019d1dc9-bd6b-7e40-b381-dd073230a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d1dc9-bd6b-7b33-ba71-cbe7de78172a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019d1dc9-bd6b-7b33-ba71-cbe7de78172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-77e8-a3c8-83eec38b0e28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-77e8-a3c8-83eec38b0e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-7694-999a-36cc78979b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract_019d1dc9-bd6b-7851-8c34-41d166719d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_019d1dc9-bd6b-7694-999a-36cc78979b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-766d-86ed-81681c37ed23" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019d1dc9-bd6b-7993-afd4-9eea55727a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019d1dc9-bd6b-7993-afd4-9eea55727a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d1dc9-bd6b-7e3a-ba03-5441e2bfc267" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019d1dc9-bd6b-7e3a-ba03-5441e2bfc267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019d1dc9-bd6b-700b-a3f5-13ec325e1781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract_019d1dc9-bd6b-751c-9f49-0b377b86f1d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019d1dc9-bd6b-700b-a3f5-13ec325e1781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-76ad-843e-aa90057d1147" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-76ad-843e-aa90057d1147" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019d1dc9-bd6b-7e51-9722-48f961af1d04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_019d1dc9-bd6b-7919-9d7f-9f921a1ac180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_CostOfSalesMember_019d1dc9-bd6b-7919-9d7f-9f921a1ac180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d1dc9-bd6b-7e46-a52f-4ab761a7152a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019d1dc9-bd6b-7e46-a52f-4ab761a7152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019d1dc9-bd6b-7185-9043-74321a0b12aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019d1dc9-bd6b-78c0-b662-7a58b78c8258" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_019d1dc9-bd6b-7185-9043-74321a0b12aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7c3d-b591-d44f2a0f36cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7f4c-81be-778da2e8b4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7f4c-81be-778da2e8b4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7a8c-8dfb-68f23c511ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-74fc-8bef-f65f4754e5bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7a8c-8dfb-68f23c511ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019d1dc9-bd6b-736c-a51c-476f4a2ed238" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7301-b24f-c743c60ab56d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d1dc9-bd6b-7301-b24f-c743c60ab56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-737f-8390-1b633fc17cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_019d1dc9-bd6b-737f-8390-1b633fc17cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-768e-a586-ea4dc9554cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-bd6b-7c13-b33e-15ac0fbd9cdd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_019d1dc9-bd6b-768e-a586-ea4dc9554cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationStockOptionsExerciseDataDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7e97-b273-455c5b9ec191" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7e97-b273-455c5b9ec191" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7be8-aec7-9056ac93c36e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7905-a353-453edc1df37d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7110-a562-bb3c27cac285" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019d1dc9-bd6b-7905-a353-453edc1df37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7bb1-8462-d0892732222f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-7a5d-b61c-a911d3d5157f" xlink:to="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-79a9-9bca-3150ff69658a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019d1dc9-bd6b-79a9-9bca-3150ff69658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6b-7545-bf4e-416b35925b15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019d1dc9-bd6b-7545-bf4e-416b35925b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d1dc9-bd6b-7efe-be08-9a4771e20b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_019d1dc9-bd6b-70ff-99a6-ed9680251e3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019d1dc9-bd6b-7efe-be08-9a4771e20b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d475a-f3f7-7441-bbbb-5ccca3a02771" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d475a-f3f7-7441-bbbb-5ccca3a02771" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:to="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d475c-c882-76d5-ba9b-73bbd889af3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d475c-c882-7512-91ae-6704baf971aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d475c-c882-7512-91ae-6704baf971aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_019d475c-c882-7596-8633-1c92d9ab763b" xlink:href="uthr-20260331.xsd#uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d475c-c882-7561-b6ac-deda6ea91415" xlink:to="loc_uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember_019d475c-c882-7596-8633-1c92d9ab763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:to="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019d475c-c882-70ab-9bd4-bf90cc637af7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ExecutivesMember_019d475c-c882-73e3-94dc-5b9ea04fc82f" xlink:href="uthr-20260331.xsd#uthr_ExecutivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019d475c-c882-7164-b95f-5456d8a1af51" xlink:to="loc_uthr_ExecutivesMember_019d475c-c882-73e3-94dc-5b9ea04fc82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d475c-c882-733c-b387-2b70d32a41a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_019d475c-c882-72a2-b396-347cad77ddf4" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting_019d475c-c882-72a2-b396-347cad77ddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d475c-c882-7c72-bb7f-6fccb1715bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d475c-c882-7c72-bb7f-6fccb1715bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_019d475c-c882-7bbb-9171-5958eb5e22f8" xlink:href="uthr-20260331.xsd#uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_019d475c-c882-7bbb-9171-5958eb5e22f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d475c-c882-7539-a9b6-e9c9bd9e7983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019d475c-c882-7539-a9b6-e9c9bd9e7983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019d475c-fbe7-7e07-8c26-15ed3a3ef112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_019d475c-fbe7-7e07-8c26-15ed3a3ef112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d475c-fbe7-704f-8cc2-78eb7d949c51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d475c-c882-72ab-9001-ba7e4a3ae1e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019d475c-fbe7-704f-8cc2-78eb7d949c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationRestrictedStockUnitsStatusDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7407-b55c-dc363434e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-bd6b-7407-b55c-dc363434e45b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-bd6b-7907-90c1-d470d29a0eae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7141-89df-e41f1951dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-bd6b-7dc6-96a6-9cafade73d33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019d1dc9-bd6b-7141-89df-e41f1951dfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-bd6b-7ba0-b678-24ddc2565bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-7e3b-9922-4cd46d9873fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-7e3b-9922-4cd46d9873fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d1dc9-bd6b-7976-869d-6d327aa835a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019d1dc9-bd6b-7976-869d-6d327aa835a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d1dc9-bd6b-75e4-876b-33d5d0916f64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019d1dc9-bd6b-75e4-876b-33d5d0916f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d1dc9-bd6b-729b-906c-f5d0a4c0d157" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019d1dc9-bd6b-729b-906c-f5d0a4c0d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-78d9-bf86-915bf2d51ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_019d1dc9-bd6b-73e2-b9b5-6c9a76484bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d1dc9-bd6b-78d9-bf86-915bf2d51ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019d1dc9-bd6b-79ef-ab6d-fb552ef6d9a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-77a2-9eec-7476e8f22e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-77a2-9eec-7476e8f22e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-7762-b551-201e544708de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-7762-b551-201e544708de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-743d-a7f2-fcf79f5fdc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019d1dc9-bd6b-743d-a7f2-fcf79f5fdc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d1dc9-bd6b-765e-8ea2-63ca0e18c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019d1dc9-bd6b-765e-8ea2-63ca0e18c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-72a7-997f-0410b96b13f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_019d1dc9-bd6b-7317-89c6-94cdb45ebb66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019d1dc9-bd6b-72a7-997f-0410b96b13f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#ShareBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-be07-7c73-83b1-a33044a1e14c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019d1dc9-be07-7c73-83b1-a33044a1e14c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:to="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019d1dc9-be07-70ca-ab97-819b6e4f85c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019d1dc9-be07-7697-a977-2cc719777c79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019d1dc9-be07-701a-9754-44371736ec76" xlink:to="loc_us-gaap_EmployeeStockMember_019d1dc9-be07-7697-a977-2cc719777c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019d1dc9-be07-7886-ae12-5195b7df3c75" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d1dc9-be07-7de1-8854-90b16b20a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_019d1dc9-be07-7de1-8854-90b16b20a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d1dc9-be07-73ec-b4c1-074f5f632464" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_019d1dc9-be07-73ec-b4c1-074f5f632464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d1dc9-be07-7531-82f0-2ad46fff92eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_019d1dc9-be07-7531-82f0-2ad46fff92eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019d1dc9-be07-7e43-ad5b-bff0b9577aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019d1dc9-be07-7124-9264-e63b716fb09a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019d1dc9-be07-7e43-ad5b-bff0b9577aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-7def-a729-b7cd9ae6195e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019d1dc9-be07-7def-a729-b7cd9ae6195e" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019d1dc9-be07-76ce-aa81-61430276a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019d1dc9-be07-76ce-aa81-61430276a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019d1dc9-be07-772a-9148-0cd53ccaf931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_019d1dc9-be07-76ce-aa81-61430276a7b4" xlink:to="loc_us-gaap_NetIncomeLoss_019d1dc9-be07-772a-9148-0cd53ccaf931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-784e-9791-0dd827606281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-784e-9791-0dd827606281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be07-721a-8619-733fbad6a4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-784e-9791-0dd827606281" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019d1dc9-be07-721a-8619-733fbad6a4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_019d1dc9-be07-7251-b129-a45588db7e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-784e-9791-0dd827606281" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_019d1dc9-be07-7251-b129-a45588db7e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019d1dc9-be07-75b0-bd8c-06bc17516120" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_019d1dc9-be07-7251-b129-a45588db7e40" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019d1dc9-be07-75b0-bd8c-06bc17516120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be07-7fc9-b853-11ad2e849789" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_019d1dc9-be07-784e-9791-0dd827606281" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019d1dc9-be07-7fc9-b853-11ad2e849789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NetIncomePerCommonShareAbstract_019d1dc9-be07-7833-a9b6-c8c3a047a125" xlink:href="uthr-20260331.xsd#uthr_NetIncomePerCommonShareAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:to="loc_uthr_NetIncomePerCommonShareAbstract_019d1dc9-be07-7833-a9b6-c8c3a047a125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019d1dc9-be07-73ea-9f60-9ee70e9e0f11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetIncomePerCommonShareAbstract_019d1dc9-be07-7833-a9b6-c8c3a047a125" xlink:to="loc_us-gaap_EarningsPerShareBasic_019d1dc9-be07-73ea-9f60-9ee70e9e0f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019d1dc9-be07-770b-9d25-29b4a43a8a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetIncomePerCommonShareAbstract_019d1dc9-be07-7833-a9b6-c8c3a047a125" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019d1dc9-be07-770b-9d25-29b4a43a8a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d1dc9-be07-7a9e-9579-fe2c40deb58f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_019d32e3-cb43-7ac8-90a6-50a90f910f6d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019d1dc9-be07-7a9e-9579-fe2c40deb58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019d4778-15dc-72ac-9d1b-da7f86db6b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019d4778-15dc-72ac-9d1b-da7f86db6b6a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019d4778-91ea-7b11-bfc5-53262a8296f5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:href="uthr-20260331.xsd#uthr_A2026ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:to="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2026ShareRepurchaseProgramMember_019d4778-91ea-79bb-ae39-ff0e2b44102c" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4ef7-49e4-763b-94b1-f42f33af0fe2" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4ef7-49e4-763b-94b1-f42f33af0fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4ef7-b0d2-75eb-908b-c7033b26d87a" xlink:href="uthr-20260331.xsd#uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2026AcceleratedShareRepurchaseAgreementsMember_019d4778-91ea-781d-96eb-71a8040022c7" xlink:to="loc_uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4ef7-b0d2-75eb-908b-c7033b26d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:href="uthr-20260331.xsd#uthr_A2025ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019d4778-91ea-7d41-9796-639a099bfc60" xlink:to="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2025ShareRepurchaseProgramMember_019d4778-bab9-70cf-9585-df6ed8b7da2b" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4778-91ea-7508-b94d-df16b77c5d0e" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember_019d4778-91ea-7508-b94d-df16b77c5d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4778-91ea-79d0-b1f8-92e710a5a86a" xlink:href="uthr-20260331.xsd#uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_A2025AcceleratedShareRepurchaseAgreementsMember_019d4778-bab9-7a6a-a0d6-cfa1e61f92fd" xlink:to="loc_uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember_019d4778-91ea-79d0-b1f8-92e710a5a86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019d4778-91ea-7a77-aff7-f7d9c477679b" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019d4778-91ea-70ce-950f-a10929cdf273" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019d4778-91ea-70ce-950f-a10929cdf273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_019d4778-91ea-7e9c-8b5f-a04b7fd91695" xlink:href="uthr-20260331.xsd#uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements_019d4778-91ea-7e9c-8b5f-a04b7fd91695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d4778-91ea-763c-b5c5-f1417025f594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019d4778-91ea-763c-b5c5-f1417025f594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019d4778-91ea-745b-b382-99e72e8f2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019d4778-91ea-745b-b382-99e72e8f2e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_019d4778-91ea-7b9b-abca-c68519663d31" xlink:href="uthr-20260331.xsd#uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased_019d4778-91ea-7b9b-abca-c68519663d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019dd244-6347-7dee-b366-bdda2931e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTaxPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTaxPayable_019dd244-6347-7dee-b366-bdda2931e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramExciseTax_019dd241-a02a-7c8c-94e3-97823b26db3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareRepurchaseProgramExciseTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019d4778-91ea-765b-80a9-f717fa823542" xlink:to="loc_us-gaap_ShareRepurchaseProgramExciseTax_019dd241-a02a-7c8c-94e3-97823b26db3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be07-7538-ab7c-c3e699ddda2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019d1dc9-be07-73ee-90d2-9f0a82e82a89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be07-7538-ab7c-c3e699ddda2d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019d1dc9-be07-73ee-90d2-9f0a82e82a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnrecognizedTaxBenefitsIncludingInterest_019d1dc9-be07-7bd5-b6d9-1cfe7307c98b" xlink:href="uthr-20260331.xsd#uthr_UnrecognizedTaxBenefitsIncludingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019d1dc9-be07-7538-ab7c-c3e699ddda2d" xlink:to="loc_uthr_UnrecognizedTaxBenefitsIncludingInterest_019d1dc9-be07-7bd5-b6d9-1cfe7307c98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationGeneralDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/SegmentInformationGeneralDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-73eb-a006-11d11a0a9344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019d1dc9-be07-7a05-9080-22bca6ab48b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-73eb-a006-11d11a0a9344" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019d1dc9-be07-7a05-9080-22bca6ab48b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:href="uthr-20260331.xsd#uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-73eb-a006-11d11a0a9344" xlink:to="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:to="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-7c74-a0d2-75ab28e9f944" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7a14-9e86-371e895d0389" xlink:href="uthr-20260331.xsd#uthr_TyvasoDPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7a14-9e86-371e895d0389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-7c57-999d-d5723d1cf109" xlink:href="uthr-20260331.xsd#uthr_NebulizedTyvasoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-7c57-999d-d5723d1cf109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RemodulinMember_019d1dc9-be07-7ac6-8895-f6b4a25b2623" xlink:href="uthr-20260331.xsd#uthr_RemodulinMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_RemodulinMember_019d1dc9-be07-7ac6-8895-f6b4a25b2623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_OrenitramMember_019d1dc9-be07-7051-92e0-0bbdad09bfa7" xlink:href="uthr-20260331.xsd#uthr_OrenitramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_OrenitramMember_019d1dc9-be07-7051-92e0-0bbdad09bfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnituxinMember_019d1dc9-be07-7d98-914d-aa39dba2f401" xlink:href="uthr-20260331.xsd#uthr_UnituxinMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_UnituxinMember_019d1dc9-be07-7d98-914d-aa39dba2f401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdcircaMember_019d1dc9-be07-7ef9-8f9c-defb5f40d737" xlink:href="uthr-20260331.xsd#uthr_AdcircaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_uthr_AdcircaMember_019d1dc9-be07-7ef9-8f9c-defb5f40d737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-7c4e-9efa-a1327ce2183a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7055-beac-526e7522a41a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-7c4e-9efa-a1327ce2183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:href="uthr-20260331.xsd#uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable_019d1dc9-be07-72ff-8733-cd87bbbbd993" xlink:to="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-72af-b5eb-7684a76b7e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-72af-b5eb-7684a76b7e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7eac-a838-b917dbacf805" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_019d1dc9-be07-7eac-a838-b917dbacf805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_019d1dc9-be07-7411-847a-b9e4582c4149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_GrossProfit_019d1dc9-be07-7411-847a-b9e4582c4149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_019dd9e5-467b-7e26-9ebd-c2eddcd6af2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_InventoryWriteDown_019dd9e5-467b-7e26-9ebd-c2eddcd6af2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_019df408-2036-7066-a9f4-e08a3397dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems_019d1dc9-be07-7c4c-9200-c6bd21de7189" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_019df408-2036-7066-a9f4-e08a3397dc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationGeographicInformationDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/SegmentInformationGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-79bb-9c68-ffa843eb128a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-79bb-9c68-ffa843eb128a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:to="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019d1dc9-be07-7a6d-a813-2c991f10ece4" xlink:to="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019d1dc9-be07-7bcd-b0e8-67fc33e6cd58" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:to="loc_country_US_019d1dc9-be07-7bcd-b0e8-67fc33e6cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_019d1dc9-be07-72c5-812f-fb9ce04b9f19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019d1dc9-be07-7296-8008-b78d4572ce85" xlink:to="loc_us-gaap_NonUsMember_019d1dc9-be07-72c5-812f-fb9ce04b9f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:to="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019d1dc9-be07-77d9-a8d3-2b53c98f5c2d" xlink:to="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:href="uthr-20260331.xsd#uthr_TyvasoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7212-a236-9aea5cbc2afd" xlink:href="uthr-20260331.xsd#uthr_TyvasoDPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:to="loc_uthr_TyvasoDPIMember_019d1dc9-be07-7212-a236-9aea5cbc2afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-72f6-b47d-94699331f6e3" xlink:href="uthr-20260331.xsd#uthr_NebulizedTyvasoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_uthr_TyvasoMember_019d1dc9-be07-7030-a5c7-8778fcca01ed" xlink:to="loc_uthr_NebulizedTyvasoMember_019d1dc9-be07-72f6-b47d-94699331f6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_RemodulinMember_019d1dc9-be07-7943-b8a5-a42c360d9b9c" xlink:href="uthr-20260331.xsd#uthr_RemodulinMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_RemodulinMember_019d1dc9-be07-7943-b8a5-a42c360d9b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_OrenitramMember_019d1dc9-be07-77e9-b221-a777b5f4b137" xlink:href="uthr-20260331.xsd#uthr_OrenitramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_OrenitramMember_019d1dc9-be07-77e9-b221-a777b5f4b137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_UnituxinMember_019d1dc9-be07-7e9c-8f86-e0ad926693aa" xlink:href="uthr-20260331.xsd#uthr_UnituxinMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_UnituxinMember_019d1dc9-be07-7e9c-8f86-e0ad926693aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_AdcircaMember_019d1dc9-be07-7bed-be30-965264dec27b" xlink:href="uthr-20260331.xsd#uthr_AdcircaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_uthr_AdcircaMember_019d1dc9-be07-7bed-be30-965264dec27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-72f6-84da-4471d0cb9a91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d1dc9-be07-7d37-bf53-fbe5af3acd09" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_019d1dc9-be07-72f6-84da-4471d0cb9a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_019d1dc9-be07-7cfe-99c9-e1d56a55f574" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7fb6-adb4-316c468723e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_019d1dc9-be07-7eba-8c3b-1440269ea7f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d1dc9-be07-7fb6-adb4-316c468723e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/SegmentInformationConcentrationRiskDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#SegmentInformationConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/SegmentInformationConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-711e-95f3-d0f7bd9ab378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019d1dc9-be07-711e-95f3-d0f7bd9ab378" xlink:to="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019d1dc9-be07-7b4e-8f66-4de70c3a1c4e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_019d1dc9-be07-7d93-b8a1-9558bafa28fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019d1dc9-be07-7f86-bc53-24bca4e46533" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_019d1dc9-be07-7d93-b8a1-9558bafa28fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019d1dc9-be07-7837-b0ff-0a7442e9a3b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019d1dc9-be07-7e13-b328-411dc7efacc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019d1dc9-be07-7ae4-b667-78b66648c823" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019d1dc9-be07-7e13-b328-411dc7efacc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019d1dc9-be07-7bbe-84ff-4b9f4f9f4af6" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorOneMember_019d1dc9-be07-7ff2-8ce3-3de63f47c515" xlink:href="uthr-20260331.xsd#uthr_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:to="loc_uthr_DistributorOneMember_019d1dc9-be07-7ff2-8ce3-3de63f47c515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_DistributorTwoMember_019d1dc9-be07-71bb-b626-57998269ae2c" xlink:href="uthr-20260331.xsd#uthr_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d1dc9-be07-74b8-86b9-2d65e1c7131f" xlink:to="loc_uthr_DistributorTwoMember_019d1dc9-be07-71bb-b626-57998269ae2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_019d1dc9-be07-77e1-b6a5-92dd1a42451c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019d1dc9-be07-7426-ba5e-4e862d9c59b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_019d1dc9-be07-72b0-938c-de1f28e5637c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019d1dc9-be07-7426-ba5e-4e862d9c59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.unither.com/role/LitigationDetails" xlink:type="simple" xlink:href="uthr-20260331.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.unither.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019d1dc9-be07-7faa-8538-c0c19287809f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019d1dc9-be07-7faa-8538-c0c19287809f" xlink:to="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:to="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_019d1dc9-be07-77fe-a637-1c4734fb5595" xlink:to="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SandozIncMember_019d1dc9-be07-7e96-93c7-a5de4a242c51" xlink:href="uthr-20260331.xsd#uthr_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:to="loc_uthr_SandozIncMember_019d1dc9-be07-7e96-93c7-a5de4a242c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_LiquidiaTechnologiesInc.Member_019d1dc9-be07-7177-a7e9-7d7b379c2219" xlink:href="uthr-20260331.xsd#uthr_LiquidiaTechnologiesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_019d1dc9-be07-755f-baf5-3d27b3fc5a99" xlink:to="loc_uthr_LiquidiaTechnologiesInc.Member_019d1dc9-be07-7177-a7e9-7d7b379c2219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:to="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019d1dc9-be07-7e10-9134-e1adc4bbe067" xlink:to="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_SmithsMedicalASDIncMember_019d1dc9-be07-7ca3-b5b1-037e24ed75e7" xlink:href="uthr-20260331.xsd#uthr_SmithsMedicalASDIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019d1dc9-be07-7f4f-8d5f-4b3b3acc5e73" xlink:to="loc_uthr_SmithsMedicalASDIncMember_019d1dc9-be07-7ca3-b5b1-037e24ed75e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019d1dc9-be07-731a-957e-b9f1b8c0367e" xlink:to="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_019d1dc9-be07-7194-be47-5d1561704c08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_019d1dc9-be07-7194-be47-5d1561704c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_019d1dc9-be07-78bb-bb82-816afe625421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_019d1dc9-be07-78bb-bb82-816afe625421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_019d1dc9-be07-7641-8e93-637e2c7a80ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LitigationSettlementInterest_019d1dc9-be07-7641-8e93-637e2c7a80ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019d1dc9-be07-788d-8a67-3abeed2714a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_019d1dc9-be07-788d-8a67-3abeed2714a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019d1dc9-be07-7b88-8daa-0ea22436b8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_019d1dc9-be07-7b88-8daa-0ea22436b8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_uthr_NumberOfPetitions_019d1dc9-be07-7c4f-823b-96034c4af753" xlink:href="uthr-20260331.xsd#uthr_NumberOfPetitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019d1dc9-be07-732e-b0db-6c6ffc0babf3" xlink:to="loc_uthr_NumberOfPetitions_019d1dc9-be07-7c4f-823b-96034c4af753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 29, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">United Therapeutics Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-1984749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1000 Spring Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Silver Spring<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">608-9292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTHR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,446,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001082554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,279.7<span></span>
</td>
<td class="nump">$ 1,557.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investments</a></td>
<td class="nump">874.0<span></span>
</td>
<td class="nump">1,363.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, no allowance for 2026 and 2025</a></td>
<td class="nump">312.0<span></span>
</td>
<td class="nump">350.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">178.3<span></span>
</td>
<td class="nump">183.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">228.0<span></span>
</td>
<td class="nump">248.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,872.0<span></span>
</td>
<td class="nump">3,702.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable investments</a></td>
<td class="nump">1,317.4<span></span>
</td>
<td class="nump">1,776.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangible assets, net</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">116.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">1,840.7<span></span>
</td>
<td class="nump">1,729.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">335.4<span></span>
</td>
<td class="nump">357.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">233.2<span></span>
</td>
<td class="nump">196.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,714.2<span></span>
</td>
<td class="nump">7,880.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">498.3<span></span>
</td>
<td class="nump">488.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">100.8<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">599.1<span></span>
</td>
<td class="nump">560.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">214.0<span></span>
</td>
<td class="nump">223.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">813.1<span></span>
</td>
<td class="nump">783.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.01, 245,000,000 shares authorized, 77,129,770 and 76,452,253 shares issued, and 42,156,223 and 43,643,165 shares outstanding as of March 31, 2026 and December&#160;31, 2025, respectively</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,520.3<span></span>
</td>
<td class="nump">2,798.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(10.2)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, 34,973,547 and 32,809,088 shares as of March&#160;31, 2026 and December&#160;31, 2025, respectively</a></td>
<td class="num">(5,441.6)<span></span>
</td>
<td class="num">(4,260.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">8,831.8<span></span>
</td>
<td class="nump">8,556.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">5,901.1<span></span>
</td>
<td class="nump">7,096.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 6,714.2<span></span>
</td>
<td class="nump">$ 7,880.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">245,000,000<span></span>
</td>
<td class="nump">245,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">77,129,770<span></span>
</td>
<td class="nump">76,452,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,156,223<span></span>
</td>
<td class="nump">43,643,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">34,973,547<span></span>
</td>
<td class="nump">32,809,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 781.5<span></span>
</td>
<td class="nump">$ 794.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">138.2<span></span>
</td>
<td class="nump">149.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">184.1<span></span>
</td>
<td class="nump">170.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">455.7<span></span>
</td>
<td class="nump">411.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">325.8<span></span>
</td>
<td class="nump">382.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">51.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(46.3)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="nump">40.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">318.3<span></span>
</td>
<td class="nump">423.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(43.4)<span></span>
</td>
<td class="num">(101.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 274.9<span></span>
</td>
<td class="nump">$ 322.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 6.32<span></span>
</td>
<td class="nump">$ 7.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="nump">$ 6.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">44.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">47.2<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 274.9<span></span>
</td>
<td class="nump">$ 322.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Defined benefit pension plan:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Actuarial gain (loss) arising during period, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax', window );">Actuarial gain and prior service cost included in net periodic pension cost, net of tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Total defined benefit pension plan, net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized (loss) gain arising during period, net of tax</a></td>
<td class="num">(9.2)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Realized gain included in net income, net of tax</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Total (loss) gain on available-for-sale debt securities, net of tax</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 263.8<span></span>
</td>
<td class="nump">$ 324.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent', window );">Tax (benefit) expense in other comprehensive income for the defined benefit pension plan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent', window );">Tax (benefit) expense in other comprehensive income for available-for-sale debt securities</a></td>
<td class="num">$ (3,500,000)<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax expense (benefit) for gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 6,444.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 2,698.9<span></span>
</td>
<td class="num">$ (3.4)<span></span>
</td>
<td class="num">$ (3,474.5)<span></span>
</td>
<td class="nump">$ 7,222.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">322.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan (ESPP)</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock units (RSUs) withheld for taxes</a></td>
<td class="num">(15.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for RSUs vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 6,807.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">2,737.7<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(3,474.5)<span></span>
</td>
<td class="nump">7,544.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">76,452,253<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">$ 7,096.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">2,798.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(4,260.4)<span></span>
</td>
<td class="nump">8,556.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">274.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(11.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued under employee stock purchase plan (ESPP)</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock units (RSUs) withheld for taxes</a></td>
<td class="num">(58.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Share repurchase</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,172.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTax', window );">Excise tax on net share repurchase</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued for RSUs vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="nump">77,129,770<span></span>
</td>
<td class="nump">77,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 5,901.1<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 2,520.3<span></span>
</td>
<td class="num">$ (10.2)<span></span>
</td>
<td class="num">$ (5,441.6)<span></span>
</td>
<td class="nump">$ 8,831.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 274.9<span></span>
</td>
<td class="nump">$ 322.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">19.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized losses on equity securities</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">25.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">38.2<span></span>
</td>
<td class="num">(42.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(40.1)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(12.7)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">134.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">463.3<span></span>
</td>
<td class="nump">461.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant, and equipment</a></td>
<td class="num">(100.8)<span></span>
</td>
<td class="num">(74.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment', window );">Deposits</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale debt securities</a></td>
<td class="num">(701.7)<span></span>
</td>
<td class="num">(692.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of available-for-sale debt securities</a></td>
<td class="nump">269.0<span></span>
</td>
<td class="nump">611.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of available-for-sale debt securities</a></td>
<td class="nump">1,307.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue', window );">Purchase of investment in privately held company</a></td>
<td class="num">(25.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">743.7<span></span>
</td>
<td class="num">(164.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments to repurchase common stock</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of line of credit</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from the issuance of stock under ESPP</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">RSUs withheld for taxes</a></td>
<td class="num">(58.3)<span></span>
</td>
<td class="num">(15.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,484.4)<span></span>
</td>
<td class="num">(93.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(277.4)<span></span>
</td>
<td class="nump">202.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">1,557.1<span></span>
</td>
<td class="nump">1,697.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">1,279.7<span></span>
</td>
<td class="nump">1,899.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash additions to property, plant, and equipment</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">47.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NoncashExciseTaxOnNetShareRepurchases', window );">Excise tax on net share repurchase</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance Payment Related to Property Plant and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_NoncashExciseTaxOnNetShareRepurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Excise Tax On Net Share Repurchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_NoncashExciseTaxOnNetShareRepurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business Description</a></td>
<td class="text">Organization and Business Description<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. In 2021, we converted to a Delaware public benefit corporation, with the express public benefit purpose </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have approval from the U.S. Food and Drug Administration (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FDA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to market the following therapies: Tyvaso DPI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Powder (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Tyvaso DPI</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Tyvaso</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Inhalation Solution (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nebulized Tyvaso</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Injection (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (treprostinil) Extended-Release Tablets (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Orenitram</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), Unituxin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dinutuximab) Injection (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Unituxin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), and Adcirca</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (tadalafil) Tablets (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Adcirca</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We also derive revenues outside the United States from sales of Nebulized Tyvaso, Remodulin, and Unituxin, and within the United States from sales of commercial </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> lung perfusion services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">us</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, &#8220;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">our</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, as filed with the SEC on February 25, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In our management&#8217;s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March&#160;31, 2026 and December&#160;31, 2025, and our statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for the three-month periods ended March&#160;31, 2026 and 2025. Interim results are not necessarily indicative of results for an entire year. Certain prior year amounts have been reclassified to conform to the current year presentation. In the consolidated statements of cash flows, we reclassified prior amounts within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">net unrealized losses on equity securities </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to conform with the current period presentation.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Adopted During the Period</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items in the notes to the financial statements. Public business entities are required to apply the guidance prospectively and may elect to apply it retrospectively. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, although early adoption is permitted. We are evaluating the impact of adopting this guidance on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Marketable Investments</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Available-for-sale debt securities are recorded at fair value, with the portion of the unrealized gains and losses that are not credit-related included as a component of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive (loss) income</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in stockholders&#8217; equity, until realized. Available-for-sale debt securities consisted of the following (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,723.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,722.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,433.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,443.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">603.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">606.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,036.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,050.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,236.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,776.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,050.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:3.6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair value for those available-for-sale debt securities that were in an unrealized loss position as of March&#160;31, 2026 and December&#160;31, 2025, aggregated by investment category and length of time that the individual securities have been in a continuous loss position (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">822.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">822.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">119.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">119.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">942.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">942.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">234.6&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we held 98 and 87 available-for-sale debt securities, respectively, that were in an unrealized loss position. In assessing whether the decline in fair value as of March&#160;31, 2026 of any of these securities resulted from a credit loss, we consulted with our investment managers and reviewed the credit ratings for each security. We believe that these unrealized losses are a direct result of the current interest rate environment and do not represent an indication of credit loss. We do not intend to sell the investments in unrealized loss positions prior to their maturity, and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. There were no impairments due to credit loss on our available-for-sale debt securities during the three months ended March&#160;31, 2026 and 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of available-for-sale debt securities (in millions). Actual maturities may differ from contractual maturities because the issuers of certain of these debt securities have the right to call the securities or prepay their obligations under the securities with or without penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">807.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due in one to three years</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,319.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in Equity Securities with Readily Determinable Fair Values</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We held investments in equity securities with readily determinable fair values, in the aggregate, of $65.3 million and $126.9 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively, which are included in current </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. Changes in the fair value of publicly traded equity securities are recorded in our consolidated statements of operations within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. See Note 4&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Investments in Privately Held Companies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we maintained non-controlling equity investments in privately held companies of $91.6&#160;million and $53.8&#160;million, respectively. We invested $25.0&#160;million and zero in privately held companies during the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. We measure these investments using the measurement alternative because the fair values of these investments are not readily determinable. Under this alternative, the investments are measured at cost, less any impairment, and adjusted for any observable price changes. We include our investments in privately held companies within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other non-current assets</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When an observable price transaction occurs that is identified as similar or identical to our investment, we perform a valuation analysis to assess the fair value of our investment using various inputs, such as the discount rate, time to a liquidation event, and price volatility of peer company stocks. We adjust the fair value of our investment based on the valuation analysis and recognize the gain or loss in the period in which the observable price change occurred. During the three months ended March 31, 2026, one of the privately held companies in which we invested raised additional capital by issuing equity securities similar to ours at an increased valuation compared to prior financing rounds, which resulted in an increase of $12.8&#160;million in the value of our investment. This gain was recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other expense, net </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These investments are subject to a periodic impairment review and, if impaired, the investment is measured and recorded at fair value in accordance with ASC 820, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For non-controlling equity investments in privately held companies in which we held an investment as of March 31, 2026, cumulative impairments and downward fair value adjustments were $5.3&#160;million and cumulative upward fair value adjustments were $14.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We account for certain assets and liabilities at fair value and classify these assets and liabilities within the fair value hierarchy (Level 1, Level 2, or Level 3). Our other current assets and other current liabilities have fair values that approximate their carrying values.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets and liabilities subject to fair value measurements are as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">397.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">397.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">205.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">205.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,722.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,722.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">403.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">403.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">65.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">65.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">668.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,126.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,794.4&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">753.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">753.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,443.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,443.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">606.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">606.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">880.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,050.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,930.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Marketable Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Available-for-Sale Debt Securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> for further information. The fair value of these securities is principally measured or corroborated by trade data for identical securities for which related trading activity is not sufficiently frequent to be considered a Level 1 input or comparable securities that are more actively traded.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of these securities is based on quoted market prices for identical instruments in active markets. During the three months ended March&#160;31, 2026 and March&#160;31, 2025, we recognized $61.6&#160;million and $5.3 million of net unrealized losses, respectively, on these securities. These net unrealized losses are recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other expense, net </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments&#8212;Marketable Investments&#8212;Investments in Equity Securities with Readily Determinable Fair Values</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> other current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of our contingent consideration obligations is estimated using probability-weighted discounted cash flow models (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DCFs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">). The DCFs incorporate Level 3 inputs, including estimated discount rates, that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. The fair value of our contingent consideration liabilities increased by $1.7&#160;million during the period from December 31, 2025 to March&#160;31, 2026. The loss was recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">research and development </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">The carrying amounts of </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">accounts receivable</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">, and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">accounts payable and accrued expenses</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"> approximate fair value because of their short maturities. The fair values of our marketable investments and contingent consideration are reported above within the fair value hierarchy. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following, net of reserves (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Raw materials</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.6&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">30.6&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Work-in-progress</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">35.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">35.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finished goods</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">108.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">117.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">178.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">183.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text">Property, Plant, and Equipment<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following (in millions):</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">266.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">266.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings, building improvements, and leasehold improvements</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">949.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">944.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings under construction</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">704.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">592.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Furniture, equipment, and vehicles</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">509.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">493.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,430.0&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,297.5&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(589.3)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(567.8)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,840.7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,729.7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March&#160;31, 2026 and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025 was $21.6 million and $19.6&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2025 Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2025, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Wells Fargo Bank, National Association (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Wells Fargo</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) as administrative agent and a swingline lender, and various other lender parties, which provides for an unsecured revolving credit facility of up to $2.5&#160;billion (which facility may, at our request, be increased by up to $750&#160;million in the aggregate subject to obtaining commitments from existing or new lenders for such increase and other conditions). In accordance with the terms of the 2025 Credit Agreement, in May 2026, we extended the maturity date of the 2025 Credit Agreement by one year, to April 2031. The 2025 Credit Agreement provides the lenders with the ability to extend the maturity date by <span style="-sec-ix-hidden:f-476">one</span> additional year, to April 2032, if we request such an extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At our option, amounts borrowed under the 2025 Credit Agreement bear interest at either an adjusted Term Secured Overnight Finance Rate (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Term SOFR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) or a fluctuating base rate, in each case, plus an applicable margin determined on a quarterly basis based on our consolidated ratio of total indebtedness to EBITDA (as calculated in accordance with the 2025 Credit Agreement). To date, we have elected to calculate interest on the outstanding balance at an adjusted Term SOFR plus an applicable margin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 25, 2025, we borrowed $200.0&#160;million under the 2025 Credit Agreement, and used the funds to repay outstanding indebtedness under the 2022 Credit Agreement, as discussed below under the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the second quarter of 2025, we paid down the entire $200.0 million balance under the 2025 Credit Agreement, which brought our aggregate outstanding balance to zero as of June 30, 2025. Our aggregate outstanding balance under the 2025 Credit Agreement remained zero as of March&#160;31, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The 2025 Credit Agreement contains customary events of default and customary affirmative and negative covenants. As of March 31, 2026, we were in compliance with these covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The interest expense reported in our consolidated statements of operations for the three months ended March&#160;31, 2026 and 2025 relates to the 2025 Credit Agreement and 2022 Credit Agreement, respectively.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2022, we entered into a credit agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2022 Credit Agreement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Wells Fargo, as administrative agent and a swingline lender, and various other lender parties, which provided for: (1) an unsecured revolving credit facility of up to $1.2&#160;billion; and (2) a second unsecured revolving credit facility of up to $800.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2024, our outstanding aggregate principal balance under the 2022 Credit Agreement was $300.0&#160;million. During the first quarter of 2025, we paid down $100.0&#160;million of our balance under the 2022 Credit Agreement, which brought our aggregate outstanding balance down to $200.0&#160;million as of March 31, 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 25, 2025, we terminated the 2022 Credit Agreement and entered into the 2025 Credit Agreement. We repaid in full all our obligations under the 2022 Credit Agreement in connection with the termination of the 2022 Credit Agreement and our entry into the 2025 Credit Agreement. There were no penalties associated with the early termination of the 2022 Credit Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we have one shareholder-approved equity incentive plan: the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2015 Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). The 2015 Plan provides for the issuance of up to 14,770,000 shares of our common stock pursuant to awards granted under the 2015 Plan, which includes 950,000 shares that were added pursuant to an amendment and restatement of the 2015 Plan approved by our shareholders in June 2025. We also have one equity incentive plan, the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2019 Inducement Plan</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), that has not been approved by our shareholders, as permitted by the Nasdaq Stock Market rules. The 2019 Inducement Plan was approved by our Board of Directors in February 2019 and provides for the issuance of up to 99,000 shares of our common stock under awards granted to newly hired employees. Currently, we grant equity-based awards to employees and members of our Board of Directors in the form of stock options and restricted stock units (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RSUs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) under the 2015 Plan, and we may grant RSUs to newly hired employees under the 2019 Inducement Plan. See the sections entitled </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> RSUs </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">below for additional information regarding these equity-based awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, we issued stock options and RSUs to certain executives with vesting conditions tied to the achievement of specified performance criteria through the end of 2028 and 2027, respectively. Additionally, during the three months ended March&#160;31, 2026 and 2025, we issued RSUs to certain other employees with vesting conditions tied to the achievement of specified performance criteria during specified performance periods, with the latest performance period ending in 2028. Throughout each performance period, we reassess the estimated performance and update the number of performance-based awards that we believe will ultimately vest. Estimating future performance requires the use of judgment. Upon the conclusion of the performance period, the performance level achieved and the ultimate number of stock options and RSUs that may vest are determined. Share-based compensation expense for these awards is recorded ratably over their vesting period, depending on the specific terms of the award and anticipated achievement of the specified performance criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We previously issued awards under the United Therapeutics Corporation 2011 Share Tracking Awards Plan (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">STAP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). We discontinued the issuance of STAP awards in June 2015 and all remaining outstanding STAP awards were exercised during the first quarter of 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2012, our shareholders approved the United Therapeutics Corporation Employee Stock Purchase Plan (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which is structured to comply with Section&#160;423 of the Internal Revenue Code. See the section entitled </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ESPP </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">below for additional information regarding the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table reflects the components of share-based compensation expense recognized in our consolidated statements of operations (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.5&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.5&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSUs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">21.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">23.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">STAP awards</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.8)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ESPP</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense before tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">33.9&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">31.8&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We estimate the fair value of stock options using the Black-Scholes-Merton valuation model, which requires us to make certain assumptions that can materially impact the estimation of fair value and related compensation expense. The assumptions used to estimate fair value include the price of our common stock, the expected volatility of our common stock, the risk-free interest rate, the expected term of stock option awards, and the expected dividend yield. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, in addition to time-based stock options, we granted 0.3&#160;million performance-based stock options in each period with grant date fair values of $53.9&#160;million and $38.0&#160;million, respectively, calculated based on the assumed achievement of the relevant financial performance condition. During the three months ended March&#160;31, 2026 and 2025, we recorded $10.5 million and $7.7 million of share-based compensation expense, respectively, related to performance-based stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following weighted average assumptions were used in estimating the fair value of stock options granted to employees during the three months ended March&#160;31, 2026 and 2025:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected term of awards (in years)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.0&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.0&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity and status of stock options under the 2015 Plan during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Exercise</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Remaining</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Contractual</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Term (in Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Value (in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4,636,330&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">166.11&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">289,956&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">536.12&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(495,147)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.00&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(365)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.26&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4,430,774&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">193.46&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.6</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,770.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercisable as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,243,872&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">142.88&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.2</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,460.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,186,902&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">331.72&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">7.2</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">310.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The weighted average fair value of a stock option granted during each of the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $190.42 and $110.11, respectively. These stock options have an aggregate grant date fair value of $55.2&#160;million and $39.0 million, respectively. The total grant date fair value of stock options that vested during the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $36.7&#160;million and $1.2 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to stock options was recorded as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.2)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.2)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, unrecognized compensation cost related to stock options was $97.0&#160;million. Unvested outstanding stock options as of March&#160;31, 2026 had a weighted average remaining vesting period of 2.3 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock option exercise data is summarized below (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">495,147&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">131,474&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash received</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">68.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">16.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">182.9&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">29.1&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each RSU entitles the recipient to one share of our common stock upon vesting. We measure the fair value of RSUs using the stock price on the date of grant. Share-based compensation expense for RSUs is recorded ratably over their vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, in addition to time-based RSUs, we granted 0.2&#160;million performance-based RSUs in each period, with total grant date fair values of $88.7&#160;million and $67.3 million, respectively, calculated based on the assumed achievement of the relevant financial and non-financial performance conditions. During the three months ended March&#160;31, 2026 and 2025, we recorded $5.2 million and $8.3 million of share-based compensation expense, respectively, related to performance-based RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity with respect to, and status of, RSUs during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Grant Date</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,416,871&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">252.86&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">295,640&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">520.38&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(274,965)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">234.77&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(16,515)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">248.71&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,421,031&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">312.06&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to RSUs was recorded as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.0&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.0&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">15.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">15.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">21.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">23.4&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(3.5)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(3.8)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">19.6&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, unrecognized compensation cost related to the grant of RSUs was $273.4 million. Unvested outstanding RSUs as of March&#160;31, 2026 had a weighted average remaining vesting period of 2.4 years. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ESPP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ESPP provides eligible employees with the right to purchase shares of our common stock at a discount through elective accumulated payroll deductions at the end of each offering period. Eligible employees may contribute up to 15 percent of their base salary, subject to certain annual limitations as defined in the ESPP. The purchase price of the shares is equal to the lower of 85 percent of the closing price of our common stock on either the first or last trading day of a given offering period. In addition, the ESPP provides that no eligible employee may purchase more than 4,000 shares during any offering period. The ESPP expires in June 2032 and limits the aggregate number of shares that can be issued under the ESPP to 3.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Earnings Per Common Share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of our outstanding stock options, outstanding RSUs, and shares issuable under the ESPP, as if the RSUs were vested, the stock options were exercised, and the shares expected to be issued under the ESPP at the end of the current offering period were issued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The components of basic and diluted earnings per common share comprised the following (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">274.9&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">322.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average outstanding shares &#8212; basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of dilutive securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options, RSUs, and ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average shares &#8212; diluted</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7.18&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.82&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options and RSUs excluded from calculation</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Calculated using the treasury stock method.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">The common shares underlying certain stock options and RSUs have been excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2026 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract), </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">which program expires on March 9, 2027</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Pursuant to this authorization, we entered into two accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citibank, N.A. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Citi</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) on March 9, 2026 to repurchase approximately $1.5&#160;billion of our common stock in the aggregate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the 2026 ASR agreements, comprised of a $750&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $750&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2026</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we made an aggregate upfront payment of $1.5&#160;billion to Citi on March 11, 2026. Under the 2026 Uncollared ASR, we received an initial delivery of 992,120 shares of our common stock, representing approximately 70 percent of the total shares expected to be repurchased under the 2026 Uncollared ASR, measured based on the closing price of our common stock on March 9, 2026. Under the 2026 Collared ASR, we received an initial delivery of 708,657 shares of our common stock, representing approximately 50 percent of the total shares expected to be repurchased under the 2026 Collared ASR, measured based on the closing price of our common stock on March 9, 2026. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2026 Collared ASR, we received an additional 463,682 shares of our common stock on March 30, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final number of shares that we will ultimately repurchase pursuant to the 2026 ASR agreements will be determined based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2026 ASR agreements. As discussed above, under the 2026 Collared ASR, the final number of shares we will ultimately repurchase will also be subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the final settlement of the 2026 ASR agreements, we may be entitled to receive additional shares of our common stock, or, under certain limited circumstances, be required to make an additional cash payment to Citi or, if we so elect, deliver shares of our common stock to Citi. The scheduled termination date of the 2026 Uncollared ASR is in the second quarter of 2026. The scheduled termination date of the 2026 Collared ASR is in the third quarter of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The initial repurchase of our common stock under the 2026 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2026 ASR agreements was accounted for as a reduction to stockholders&#8217; equity in our consolidated balance sheets. The hedging period under the 2026 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on March 30, 2026. The final settlement of the transactions under the 2026 ASR agreements is accounted for as an unsettled forward contract indexed to our common stock until the final settlement occurs. The forward contract related to the 2026 ASR agreements was equity classified, in accordance with ASC 815, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, upon inception and we expect equity classification to remain appropriate through final settlement under the 2026 Uncollared ASR and the 2026 Collared ASR. During the three months ended March 31, 2026, we recorded a liability of $8.4&#160;million for an excise tax imposed under the Inflation Reduction Act of 2022 (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IRA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) as a result of our repurchase of shares under the 2026 ASR agreements.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2025 Share Repurchase</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2025, our Board of Directors approved a share repurchase program authorizing up to $1.0&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract). Pursuant to this authorization, we entered into two accelerated share repurchase agreements (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025 ASR agreements</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) with Citi on August 1, 2025 to repurchase approximately $1.0&#160;billion of our common stock in the aggregate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the 2025 ASR agreements, comprised of a $500&#160;million uncollared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Uncollared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a $500&#160;million collared share repurchase agreement (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">2025</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Collared ASR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), we made an aggregate upfront payment of $1.0&#160;billion to Citi on August 4, 2025. Under the 2025 Uncollared ASR, we received an initial delivery of 1,274,296 shares of our common stock, representing approximately 75 percent of the total shares expected to be repurchased under the 2025 Uncollared ASR, measured based on the closing price of our common stock on August 1, 2025. Under the 2025 Collared ASR, we received an initial delivery of 849,531 shares of our common stock, representing approximately 50 percent of the total shares expected to be repurchased under the 2025 Collared ASR, measured based on the closing price of our common stock on August 1, 2025. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2025 Collared ASR, we received an additional 514,789 shares of our common stock on August 25, 2025. The final settlement of the 2025 Uncollared ASR occurred in November 2025, and we received an additional 3,882 shares of our common stock upon settlement. The final settlement of the 2025 Collared ASR occurred in January 2026, and we received no additional shares of our common stock upon settlement as a result of a collar provision that established the minimum and maximum number of shares to be repurchased, as well as other adjustments. In total, we repurchased 2,642,498 shares of our common stock under the 2025 ASR agreements that we currently hold as treasury stock in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final number of shares that we ultimately repurchased pursuant to the 2025 Uncollared ASR was based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2025 Uncollared ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The initial repurchase of our common stock and final settlements under the 2025 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2025 ASR agreements was accounted for as a reduction to stockholders&#8217; equity in our consolidated balance sheets. The hedging period under the 2025 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on August 25, 2025. The final settlements of the 2025 ASR agreements were accounted for as unsettled forward contracts indexed to our common stock until the final settlement occurred. The forward contracts related to the 2025 ASR agreements were equity classified, in accordance with ASC 815, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, through final settlement. Excise taxes imposed under the IRA as a result of our 2025 ASR agreements were $1.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">Our effective income tax rate (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%">ETR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">) for the three months ended March&#160;31, 2026 and 2025 was 14 percent and 24 percent, respectively. Our ETR for the three months ended March&#160;31, 2026 decreased compared to our ETR for the three months ended March&#160;31, 2025 primarily due to increased excess tax benefits from share-based compensation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OBBBA</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) was enacted in the United States. The OBBBA includes provisions that allow both the immediate deduction of domestic research and experimental expenditures and the full expensing of the cost of certain qualifying assets in the year placed in service. The impacts of the OBBBA were reflected in our consolidated financial statements beginning in the period of enactment and continue to be reflected in the period ended March 31, 2026, resulting in decreases to both our deferred tax assets and cash tax liabilities. The OBBBA provisions did not have a material impact on our ETR for the period ended March 31, 2026.</span></div>We record interest and penalties related to uncertain tax positions as a component of income tax expense. As of March&#160;31, 2026 and December 31, 2025, our unrecognized tax benefits, including related interest, were approximately $30.6&#160;million and $28.7&#160;million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Chief Executive Officer, as our Chief Operating Decision Maker (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CODM</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), manages our company as a single operating and reporting segment at the consolidated level. Our operating segment focuses on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. The accounting policies of our one operating segment are the same as those described in Note 2</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Summary of Significant Accounting Policies </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February&#160;25, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our CODM is regularly provided with revenue and expense forecasts, including product development plans, to manage the operations of our operating segment. Our CODM monitors forecasted to actual results for net income when assessing performance and allocating resources across the operating segment. Significant segment expenses are presented as </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">operating expenses </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The measure of the operating segment assets is reported in our consolidated balance sheets as </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">total assets</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other sources of revenues were as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tyvaso DPI</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nebulized Tyvaso</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Orenitram</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unituxin</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adcirca</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">781.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">247.1&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">648.1&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">302.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">163.8&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">794.4&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">701.9&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">During the three months ended March 31, 2026 and 2025, we recorded $44.9&#160;million and $9.0&#160;million of inventory reserve expense, respectively. Tyvaso DPI inventory reserve expense accounts for $39.2&#160;million and $5.8&#160;million of the total inventory reserve expense recorded during the three months ended March 31, 2026 and 2025, respectively. The Tyvaso DPI inventory reserve expense increased in 2026 mainly because we recorded an estimated $26.8&#160;million loss related to a commercial supply agreement. This agreement is intended to provide us with sufficient inventory to meet the needs of our patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Total revenues and cost of sales include sales of infusion devices, including the Remunity</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and RemunityPRO</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pumps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Geographic revenues are determined based on the country to which our products are shipped. Total revenues from external customers in the United States and rest-of-world (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ROW</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for each of our commercial products were as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net product sales:</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tyvaso DPI</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nebulized Tyvaso</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">112.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">127.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">163.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total Tyvaso</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">442.9&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">457.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">441.1&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">466.3&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">108.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">17.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.0&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unituxin</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">49.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">53.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">56.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">58.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adcirca</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">744.2&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">37.3&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">781.5&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">749.6&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">44.8&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">794.4&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues. Revenue from these two distributors as a percentage of total revenues is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation <div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Sandoz Litigation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April 2019, Sandoz Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Sandoz</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and its marketing partner RareGen, LLC (now known as Liquidia PAH, LLC, a subsidiary of Liquidia Corporation) (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RareGen</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), filed a complaint in the U.S. District Court for the District of New Jersey against us and Smiths Medical ASD, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Smiths Medical</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), alleging that we and Smiths Medical engaged in anticompetitive conduct in connection with the plaintiffs&#8217; efforts to launch their generic version of Remodulin. In particular, the complaint alleged that we and Smiths Medical unlawfully impeded competition by entering into an agreement for Smiths Medical to produce cartridges used with the CADD-MS</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3 (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">MS-3</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) infusion system specifically for the delivery of subcutaneous Remodulin for our patients, without making these cartridges available for the delivery of Sandoz&#8217;s generic treprostinil injection. In March 2020, the plaintiffs filed an amended complaint to add a count alleging that we breached our earlier patent settlement agreement with Sandoz by refusing to grant Sandoz access to cartridges purchased for our patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Smiths Medical was dismissed from the case in November 2020, based on a settlement resolving the disputes between the plaintiffs and Smiths Medical. As part of this settlement, Smiths Medical paid the plaintiffs $4.25&#160;million, disclosed and made available to the plaintiffs certain specifications and other information related to the MS-3 cartridges, and granted to the plaintiffs a non-exclusive, royalty-free license in the United States to Smiths Medical&#8217;s patents and copyrights associated with the MS-3 cartridges and certain other information related to the MS-3 pumps and cartridges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March 2022, the court granted our motion for summary judgment with respect to all claims brought by the plaintiffs except the breach of contract claim. As a result, all antitrust claims, all claims under state competition laws, and the common law tortious interference claim were resolved in our favor. These were the only claims in the case that gave rise to any potential for trebling of damages, punitive damages, disgorgement, and/or the award of attorneys&#8217; fees. The court also denied the plaintiffs&#8217; request for injunctive relief.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The court granted Sandoz&#8217;s motion for summary judgment with respect to Sandoz&#8217;s breach of contract claim. The issue of what, if any, damages Sandoz is entitled to based on the court&#8217;s decision on the contract claim went to trial. On November 1, 2024, the court entered a final judgment in favor of Sandoz, ordering us to pay to Sandoz (a) approximately $61.6 million in damages; (b) prejudgment interest in the amount of approximately $9.0 million; and (c) post-judgment interest. All parties appealed the final judgment, including the court&#8217;s March 30, 2022 summary judgment decision. The appeal is pending before the U.S. Court of Appeals for the Third Circuit, and oral argument was held in November 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We accrued a liability of $71.1&#160;million during 2024, an additional $3.0&#160;million during 2025, and an additional $0.8&#160;million through the first quarter of 2026, reflecting, in the aggregate, the damages and pre-judgment interest amounts awarded in the final judgment, as well as post-judgment interest accrued through March 31, 2026. We currently do not expect that the amount of any loss in excess of these accruals would be material to our financial results; however, the amount ultimately payable, if any, could be higher or lower than this amount depending on the amount of post-judgment interest, and the outcome of appeals. We recorded this liability within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">other non-current liabilities </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in this litigation. Among other things, we believe our settlement agreement with Sandoz did not provide Sandoz any rights with respect to delivery systems such as the MS-3. We also believe that the plaintiffs, who were on notice that Smiths Medical would discontinue the MS-3 system, failed to fulfill their duty to properly mitigate their exposure as a result of such discontinuation, and any damages they incurred are the result of market conditions and their own failure to properly plan their own product launch. However, due to the uncertainty inherent in any litigation, we cannot guarantee that appeals will not result in an outcome adverse to us. This litigation has involved, and will likely continue to involve, substantial costs to defend, and an adverse appellate outcome could result in substantial monetary damages in excess of the liability we have accrued to-date.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Litigation with Liquidia Technologies, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since March 2020, we have been engaged in litigation with Liquidia Technologies, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Liquidia</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) regarding its efforts to obtain FDA approval for Yutrepia</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a dry powder inhalation formulation of treprostinil. That litigation has included two petitions for </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> review (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">IPR</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) filed by Liquidia with the Patent Trial and Appeal Board (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PTAB</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) of the U.S. Patent and Trademark Office (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">USPTO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), as well as multiple lawsuits we have brought alleging infringement by Liquidia of several of our patents. Most of these cases have now been finally resolved, and Liquidia received final approval from the FDA to market Yutrepia to treat pulmonary arterial hypertension (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PAH</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and pulmonary hypertension associated with interstitial lung disease (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">PH-ILD</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) in May 2025 and launched commercial sales in June 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have an ongoing patent infringement lawsuit against Liquidia, which was originally filed on September 5, 2023 in the U.S. District Court for the District of Delaware, alleging infringement of U.S. Patent No. 10,716,793 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8217;793 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), a patent related to Tyvaso with an expiration date in May 2027 that was later invalidated as a result of an IPR proceeding, and therefore is no longer at issue in this litigation. On November 30, 2023, we filed an amended complaint to assert a new patent: U.S. Patent No. 11,826,327 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8217;327 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), which expires February 3, 2042, and is the only patent remaining at issue in the case. The claims of the &#8217;327 patent generally cover improving exercise capacity in patients suffering from PH-ILD by inhaling treprostinil at specific dosages. Trial took place in June 2025, and the parties are awaiting the court&#8217;s decision. If we prevail in this lawsuit, we believe that we will be entitled to a court order requiring Liquidia to remove the PH-ILD indication from Yutrepia&#8217;s product labeling, and that we may also be entitled to damages.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2021, we filed a motion in one of our earlier patent cases against Liquidia in the U.S. District Court for the District of Delaware to file an amended complaint adding trade secret misappropriation claims against Liquidia and a former Liquidia executive, Dr. Robert Roscigno. The court denied the motion based on a finding that adding the additional claims would impact the case schedule. Thus, we filed those claims as a separate case against Liquidia and Dr. Roscigno in North Carolina state court. Discovery is complete. On January 5, 2024, Dr. Roscigno filed a motion for summary judgment, which was denied on July 31, 2024. On July 3, 2024, Liquidia filed a motion for summary judgment, which was denied on July 23, 2025. The court has scheduled trial to commence in January 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We filed a new complaint on May 29, 2024, to commence a separate, related case against Liquidia and Dr. Roscigno in North Carolina state court. That case is in its early stages, and the parties are currently engaged in discovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 21, 2025, Liquidia filed a lawsuit against us in the U.S. District Court for the Middle District of North Carolina, alleging that Tyvaso DPI infringes U.S. Patent No. 10,898,494 (the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8216;494 patent</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). This patent&#8217;s claims are directed to the treatment of pulmonary hypertension by administering specified amounts of treprostinil via a dry powder inhaler in a specified number of breaths. The patent expires May 5, 2037. Liquidia seeks damages and attorneys&#8217; fees. We filed a motion to dismiss or, alternatively, a motion to stay the case based on the argument that we co-own the asserted patent based on Liquidia&#8217;s and Dr. Roscigno&#8217;s alleged trade secret misappropriation subject to the pending North Carolina state court litigation. The court granted our motion to stay and denied the motion to dismiss. On May 9, 2025, we filed a lawsuit against Liquidia in the U.S. District Court for the Middle District of North Carolina, alleging that Yutrepia infringes U.S. Patent No. 11,357,782. This patent claims a method of treating pulmonary hypertension using inhaled treprostinil delivered using a specified dosage regimen. The patent expires May 14, 2027. We moved for a preliminary injunction, but the court denied that motion. Liquidia moved to dismiss or, alternatively, transfer the case to the U.S. District Court for the District of Delaware. The court denied Liquidia&#8217;s motion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We plan to continue to vigorously enforce our intellectual property rights related to Tyvaso DPI and Nebulized Tyvaso. In addition, we believe we have meritorious defenses and intend to vigorously defend ourselves against the claims made by Liquidia in its patent infringement lawsuit against us.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MSP Recovery Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July 2020, MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; and Series PMPI, a designated series of MAO-MSO Recovery II, LLC, filed a class action complaint against Caring Voices Coalition, Inc. (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CVC</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and us in the U.S. District Court for the District of Massachusetts. The complaint alleged that we violated the federal Racketeer Influenced and Corrupt Organizations (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">RICO</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) Act and various state laws by coordinating with CVC when making donations to a PAH fund so that those donations would go toward copayment obligations for Medicare patients taking drugs manufactured and marketed by us. The plaintiffs claim to have received assignments from various Medicare Advantage health plans and other insurance entities that allow them to bring this lawsuit on behalf of those entities to recover allegedly inflated amounts they paid for our drugs. In April 2021, the court granted our motion to transfer the case to the U.S. District Court for the Southern District of Florida.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October 2021, the plaintiffs filed an amended complaint that includes state antitrust claims based on alleged facts similar to those raised by Sandoz and RareGen in the matter described above. The amended complaint added MSP Recovery Claims Series 44, LLC as a plaintiff and Smiths Medical and CVC as defendants. In December 2021, we filed a motion to dismiss all of the plaintiffs&#8217; claims in the amended complaint, including the new antitrust claims. Smiths Medical also filed a motion to dismiss the plaintiffs&#8217; claims against Smiths Medical. In September 2022, the court dismissed all of the plaintiffs&#8217; claims against us and Smiths Medical without prejudice.</span></div><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">In October 2022, the plaintiffs filed a second amended complaint, which added federal antitrust claims and consumer protection claims under other states&#8217; laws to the claims previously asserted. The second amended complaint also named Accredo Health Group, CVS Health Corporation, Express Scripts, Inc., and Express Scripts Holding Company (collectively, the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%">Specialty Pharmacies</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">), and the Adira Foundation as additional defendants. In March 2023, we filed our motion to dismiss the second amended complaint. The Specialty Pharmacies filed their own motion to dismiss, as did Smiths Medical. On March 22, 2024, the magistrate judge recommended dismissal of the plaintiffs&#8217; complaint against all defendants in its entirety with prejudice, and for administrative purposes, issued an order dismissing the complaint. On April 12, 2024, the plaintiffs filed an objection to the magistrate judge&#8217;s recommendation. On May 10, 2024, we filed a response to the plaintiffs&#8217; objection, as did the other defendants. If the district court judge adopts the magistrate judge&#8217;s recommendation and dismisses the case, the plaintiffs will have the right to appeal.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in this lawsuit.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Litigation with Humana and United Healthcare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Humana Inc. (</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Humana</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and United Healthcare Services, Inc. (</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">United</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) filed separate lawsuits against us in the U.S. District Court for the District of Maryland in December 2022 and November 2022, respectively. Each of these lawsuits includes allegations similar to those in the </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery</span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> matter discussed above concer</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ning our charitable </span><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">contributions</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to CVC. In particular, these lawsuits allege that our donations to CVC violated RICO and various state laws. We filed motions to dismiss both of these lawsuits in March 2023. On March 25, 2024, the court dismissed both the Humana and United complaints in their entirety. In both cases, the RICO claims were dismissed with prejudice. In the Humana case, the state law claims were dismissed without prejudice, and in the United case, some of the state law claims were dismissed with prejudice, while others were dismissed without prejudice. Neither Humana nor United filed an appeal to date, and their deadlines for filing appeals have passed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 24, 2024, Humana and United each filed lawsuits against us in the Circuit Court for Montgomery County, Maryland. These lawsuits include allegations similar to those in their lawsuits discussed above concerning charitable contributions. Humana and United allege that our donations to CVC give rise to common law causes of action, violations of state consumer protection statutes, and violations of insurance fraud statutes under the laws of various states. On July 22, 2024, we filed motions to dismiss both of these lawsuits. Oral argument on these motions to dismiss took place on October 24, 2024. On September 23, 2025, the court dismissed both lawsuits with prejudice. On October 20, 2025, Humana and United each appealed the court&#8217;s decision to the Appellate Court of Maryland, and those appeals are currently pending.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend ourselves against the claims made in these lawsuits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Adopted During the Period</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items in the notes to the financial statements. Public business entities are required to apply the guidance prospectively and may elect to apply it retrospectively. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, although early adoption is permitted. We are evaluating the impact of adopting this guidance on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities</a></td>
<td class="text">Available-for-sale debt securities consisted of the following (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,723.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,722.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">403.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,433.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,443.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">603.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">606.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,036.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,050.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Reported under the following captions in our consolidated balance sheets:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,236.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-current marketable investments</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,776.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,050.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following tables present gross unrealized losses and fair value for those available-for-sale debt securities that were in an unrealized loss position as of March&#160;31, 2026 and December&#160;31, 2025, aggregated by investment category and length of time that the individual securities have been in a continuous loss position (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">822.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">822.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">119.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">119.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">942.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">942.2&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12 months or longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">234.6&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of the Contractual Maturities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of available-for-sale debt securities (in millions). Actual maturities may differ from contractual maturities because the issuers of certain of these debt securities have the right to call the securities or prepay their obligations under the securities with or without penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">807.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">808.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due in one to three years</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,319.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,317.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,126.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Subject to Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets and liabilities subject to fair value measurements are as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">397.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">397.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">205.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">205.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,722.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,722.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">403.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">403.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">65.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">65.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">668.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,126.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,794.4&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Money market funds</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">753.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">753.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">U.S. government and agency securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,443.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,443.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">606.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">606.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Equity securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">880.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,050.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,930.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liabilities</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">cash and cash equivalents</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Marketable Investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Available-for-Sale Debt Securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> for further information. The fair value of these securities is principally measured or corroborated by trade data for identical securities for which related trading activity is not sufficiently frequent to be considered a Level 1 input or comparable securities that are more actively traded.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">current marketable investments</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of these securities is based on quoted market prices for identical instruments in active markets. During the three months ended March&#160;31, 2026 and March&#160;31, 2025, we recognized $61.6&#160;million and $5.3 million of net unrealized losses, respectively, on these securities. These net unrealized losses are recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other expense, net </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations. See Note 3&#8212;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Investments&#8212;Marketable Investments&#8212;Investments in Equity Securities with Readily Determinable Fair Values</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt">Included in</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> other current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">other</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">non-current liabilities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The fair value of our contingent consideration obligations is estimated using probability-weighted discounted cash flow models (</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DCFs</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">). The DCFs incorporate Level 3 inputs, including estimated discount rates, that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. The fair value of our contingent consideration liabilities increased by $1.7&#160;million during the period from December 31, 2025 to March&#160;31, 2026. The loss was recorded within </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">research and development </span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories, Net of Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following, net of reserves (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Raw materials</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">34.6&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">30.6&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Work-in-progress</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">35.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">35.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finished goods</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">108.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">117.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">178.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">183.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant, and equipment consists of the following (in millions):</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">December 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">266.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">266.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings, building improvements, and leasehold improvements</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">949.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">944.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Buildings under construction</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">704.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">592.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Furniture, equipment, and vehicles</span></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">509.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">493.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,430.0&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,297.5&#160;</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(589.3)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(567.8)</span></td><td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,840.7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,729.7&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Components of Share-Based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table reflects the components of share-based compensation expense recognized in our consolidated statements of operations (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.603%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.5&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.5&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSUs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">21.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">23.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">STAP awards</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.8)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ESPP</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense before tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">33.9&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">31.8&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions to Measure the Fair Value of Stock Options</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following weighted average assumptions were used in estimating the fair value of stock options granted to employees during the three months ended March&#160;31, 2026 and 2025:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected term of awards (in years)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">32.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.0&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.0&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity and Status of Stock Options</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity and status of stock options under the 2015 Plan during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Exercise</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Remaining</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Contractual</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Term (in Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Value (in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4,636,330&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">166.11&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">289,956&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">536.12&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(495,147)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.00&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(365)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.26&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4,430,774&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">193.46&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3.6</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,770.2&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Exercisable as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,243,872&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">142.88&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.2</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,460.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,186,902&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">331.72&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">7.2</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">310.1&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation (Benefit) Expense Recognized</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to stock options was recorded as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.1&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.4&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.2)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(0.2)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">8.3&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total share-based compensation expense related to RSUs was recorded as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cost of sales</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.0&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.0&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">15.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">15.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense before taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">21.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">23.4&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Related income tax benefit</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(3.5)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(3.8)</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense, net of taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.0&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">19.6&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock', window );">Schedule of Stock Option Exercise Data</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Stock option exercise data is summarized below (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended </span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">495,147&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">131,474&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash received</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">68.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">16.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total intrinsic value of options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">182.9&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">29.1&#160;</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of the activity with respect to, and status of, RSUs during the three-month period ended March&#160;31, 2026 is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Weighted</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Grant Date</span></div><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of January 1, 2026</span></div></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,416,871&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">252.86&#160;</span></div></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">295,640&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">520.38&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(274,965)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">234.77&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(16,515)</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">248.71&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unvested as of March 31, 2026</span></div></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1,421,031&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">312.06&#160;</span></div></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee and non-employee stock option exercise data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The components of basic and diluted earnings per common share comprised the following (in millions, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">274.9&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">322.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average outstanding shares &#8212; basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of dilutive securities</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options, RSUs, and ESPP</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Weighted average shares &#8212; diluted</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7.18&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.82&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock options and RSUs excluded from calculation</span><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Calculated using the treasury stock method.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">The common shares underlying certain stock options and RSUs have been excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock', window );">Schedule of Net Product Sales, Cost of Product Sales and Gross Profit for Each Commercial Products</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other sources of revenues were as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tyvaso DPI</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nebulized Tyvaso</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Orenitram</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unituxin</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Adcirca</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">781.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">247.1&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">648.1&#160;</span></td><td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">302.5&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">163.8&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">794.4&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit (loss)</span></div></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">701.9&#160;</span></td><td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">During the three months ended March 31, 2026 and 2025, we recorded $44.9&#160;million and $9.0&#160;million of inventory reserve expense, respectively. Tyvaso DPI inventory reserve expense accounts for $39.2&#160;million and $5.8&#160;million of the total inventory reserve expense recorded during the three months ended March 31, 2026 and 2025, respectively. The Tyvaso DPI inventory reserve expense increased in 2026 mainly because we recorded an estimated $26.8&#160;million loss related to a commercial supply agreement. This agreement is intended to provide us with sufficient inventory to meet the needs of our patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt">Total revenues and cost of sales include sales of infusion devices, including the Remunity</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and RemunityPRO</span><span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pumps.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Net Revenues from External Customers by Geographic Area</a></td>
<td class="text">Total revenues from external customers in the United States and rest-of-world (<span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ROW</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) for each of our commercial products were as follows (in millions):</span><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2026</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">U.S.</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">ROW</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net product sales:</span></div></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tyvaso DPI</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">330.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">302.5&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nebulized Tyvaso</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">112.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">127.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">163.8&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total Tyvaso</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">442.9&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">14.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">457.5&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">441.1&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">25.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">466.3&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Remodulin</span><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">108.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">17.8&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">126.6&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.0&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">138.2&#160;</span></div></td><td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Orenitram</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">135.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">120.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unituxin</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">49.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">53.6&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">56.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">58.2&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adcirca</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.9&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.7&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">0.3&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.0&#160;</span></div></td><td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total revenues</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">744.2&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">37.3&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">781.5&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">749.6&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">44.8&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"><span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">794.4&#160;</span></div></td><td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;text-align:right"></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk Disclosure</a></td>
<td class="text">Revenue from these two distributors as a percentage of total revenues is as follows:<div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.511%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Distributor 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenues, cost of revenues and gross profit for each commercial product during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,126.8<span></span>
</td>
<td class="nump">$ 3,036.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">2,126.1<span></span>
</td>
<td class="nump">3,050.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,723.3<span></span>
</td>
<td class="nump">2,433.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">1,722.7<span></span>
</td>
<td class="nump">2,443.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">403.5<span></span>
</td>
<td class="nump">603.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 403.4<span></span>
</td>
<td class="nump">$ 606.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Current and Non-current of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Reported under the following captions in our consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,126.1<span></span>
</td>
<td class="nump">$ 3,050.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Reported under the following captions in our consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Current available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesCurrentMember', window );">Current marketable investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Reported under the following captions in our consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Current available-for-sale debt securities</a></td>
<td class="nump">808.7<span></span>
</td>
<td class="nump">1,236.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesNoncurrentMember', window );">Non-current marketable investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Reported under the following captions in our consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent', window );">Non-current marketable investments</a></td>
<td class="nump">$ 1,317.4<span></span>
</td>
<td class="nump">$ 1,776.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=uthr_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">$ 942.2<span></span>
</td>
<td class="nump">$ 234.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">942.2<span></span>
</td>
<td class="nump">238.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">822.6<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">822.6<span></span>
</td>
<td class="nump">218.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">119.6<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">119.6<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt Securities, available-for-sale, unrealized loss position, number of positions | investment</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss', window );">Impairments related to credit loss | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtSecuritiesAvailableForSaleImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtSecuritiesAvailableForSaleImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis', window );">Due within one year</a></td>
<td class="nump">$ 807.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis', window );">Due in one to three years</a></td>
<td class="nump">1,319.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">2,126.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due within one year</a></td>
<td class="nump">808.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue', window );">Due in one to three years</a></td>
<td class="nump">1,317.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 2,126.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the third rolling twelve months following the latest balance sheet. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing after first fiscal year through third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities with readily determinable fair value</a></td>
<td class="nump">$ 65.3<span></span>
</td>
<td class="nump">$ 126.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Investments in Privately-Held Companies (Details) - Privately-held Companies - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Investments in Privately-Held Companies and Investments in Equity Securities with Readily Determinable Fair Values</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Investments in privately-held companies</a></td>
<td class="nump">$ 91,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to acquire long-term investments</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Increase in value of investment, annual amount</a></td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Decrease in value of investment, cumulative amount</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Increase in value of investment, cumulative amount</a></td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=uthr_PrivatelyHeldCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=uthr_PrivatelyHeldCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized losses on equity securities</a></td>
<td class="nump">$ 61.6<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in fair value of contingent consideration liability</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized losses on equity securities</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">668.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">397.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">205.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,126.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,722.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">403.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability', window );">Contingent consideration</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,794.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,930.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability', window );">Contingent consideration</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Balance | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,722.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Balance | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">403.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Balance | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">397.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Balance | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">$ 205.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement including cash and shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 34.6<span></span>
</td>
<td class="nump">$ 30.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-progress</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">117.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 178.3<span></span>
</td>
<td class="nump">$ 183.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,430.0<span></span>
</td>
<td class="nump">$ 2,297.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation</a></td>
<td class="num">(589.3)<span></span>
</td>
<td class="num">(567.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">1,840.7<span></span>
</td>
<td class="nump">1,729.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">266.5<span></span>
</td>
<td class="nump">266.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember', window );">Buildings, building improvements, and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">949.7<span></span>
</td>
<td class="nump">944.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Buildings under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">704.2<span></span>
</td>
<td class="nump">592.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_FurnitureEquipmentAndVehiclesMember', window );">Furniture, equipment, and vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 509.6<span></span>
</td>
<td class="nump">$ 493.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_FurnitureEquipmentAndVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=uthr_FurnitureEquipmentAndVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="nump">$ 19.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2025</div></th>
<th class="th"><div>May 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=uthr_A2025CreditAgreementMember', window );">2025 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity', window );">Increase in borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=uthr_A2025CreditAgreementMember', window );">2025 Credit Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtInstrumentExtensionTerm', window );">Term of maturity date extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_DebtInstrumentAdditionalExtensionTerm', window );">Debt instrument, additional extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022Member', window );">2022 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember', window );">First Unsecured Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember', window );">Second Unsecured Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtInstrumentAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtInstrumentAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_DebtInstrumentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_DebtInstrumentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent increase above the maximum borrowing capacity under the credit facility, if any one or more of the existing banks or new banks agree to provide such increased commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=uthr_A2025CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=uthr_A2025CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - General Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>plan </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=uthr_StockIncentivePlan2015PlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of shares authorized to be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,770,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares authorized to be issued (in shares)</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=uthr_InducementStockIncentivePlan2019Member', window );">2019 Inducement Plan | Newly-Hired Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shareholder-approved equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=uthr_StockIncentivePlan2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=uthr_StockIncentivePlan2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=uthr_InducementStockIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=uthr_InducementStockIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=uthr_NewlyHiredEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=uthr_NewlyHiredEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense before tax</a></td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense before tax</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense before tax</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=uthr_ShareTrackingAwardsPlanMember', window );">STAP awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense before tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense before tax</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=uthr_ShareTrackingAwardsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=uthr_ShareTrackingAwardsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember', window );">Stock Options with Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue', window );">Total grant date fair value</a></td>
<td class="nump">$ 53.9<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">289,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue', window );">Total grant date fair value</a></td>
<td class="nump">$ 55.2<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options (in dollars per share)</a></td>
<td class="nump">$ 190.42<span></span>
</td>
<td class="nump">$ 110.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair value of employee stock options that vested</a></td>
<td class="nump">$ 36.7<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining vesting period (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total grant date fair value of option granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions For Stock Options (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of awards (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="nump">32.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Status of Stock Options (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the period (in shares)</a></td>
<td class="nump">4,636,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">289,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(495,147)<span></span>
</td>
<td class="num">(131,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,430,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">3,243,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Unvested at the end of the period (in shares)</a></td>
<td class="nump">1,186,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 166.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">536.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">138.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">120.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">193.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">142.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Unvested at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 331.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period (in Years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period (in Years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Unvested at the end of the period (in Years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value (in&#160;millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 1,770.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period</a></td>
<td class="nump">1,460.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Unvested at the end of the period</a></td>
<td class="nump">$ 310.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Related income tax benefit</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense, net of taxes</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Related income tax benefit</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense, net of taxes</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options Exercise Data (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Summary of stock option exercise data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received</a></td>
<td class="nump">$ 68.3<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Summary of stock option exercise data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="nump">495,147<span></span>
</td>
<td class="nump">131,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received</a></td>
<td class="nump">$ 68.3<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 182.9<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting', window );">Number of shares of common stock entitled to recipient upon vesting (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">295,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 273.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining vesting period (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember', window );">RSUs with Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense before taxes</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember', window );">RSUs with Performance Conditions | Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Awards granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Awards granted in period, fair value</a></td>
<td class="nump">$ 88.7<span></span>
</td>
<td class="nump">$ 67.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock entitled to receive for each unit upon vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=uthr_ExecutivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=uthr_ExecutivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units Status (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of the period (in shares) | shares</a></td>
<td class="nump">1,416,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">295,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(274,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(16,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the end of the period (in shares) | shares</a></td>
<td class="nump">1,421,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 252.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">520.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">234.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">248.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 312.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Employee Stock Purchase Plan (Details) - ESPP<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of compensation employees may contribute for ESPP (in percentage)</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, purchase price of common stock, percent</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares each eligible employees may purchase in any given offering period (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized to be issued (in shares)</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 274.9<span></span>
</td>
<td class="nump">$ 322.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average outstanding shares - basic (in shares)</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="nump">44.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options, RSUs, and ESPP (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">47.2<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetIncomePerCommonShareAbstract', window );"><strong>Net income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 6.32<span></span>
</td>
<td class="nump">$ 7.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="nump">$ 6.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and RSUs excluded from calculation (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_NetIncomePerCommonShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_NetIncomePerCommonShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 25, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2026 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Aug. 01, 2025 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments to repurchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTax', window );">Share repurchase program, excise tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2026ShareRepurchaseProgramMember', window );">2026 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementsMember', window );">2026 Accelerated Share Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements', window );">Number of accelerated share repurchase agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments to repurchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable', window );">Share repurchase program, excise tax, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember', window );">2026 Accelerated Share Repurchase Agreement - Uncollared Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased during period, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased', window );">Stock repurchase program, percentage of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember', window );">2026 Accelerated Share Repurchase Agreement - Collared Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased during period, shares (in shares) | shares</a></td>
<td class="nump">463,682<span></span>
</td>
<td class="nump">708,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased', window );">Stock repurchase program, percentage of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2025ShareRepurchaseProgramMember', window );">2025 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementsMember', window );">2025 Accelerated Share Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements', window );">Number of accelerated share repurchase agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments to repurchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased during period, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,642,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramExciseTax', window );">Share repurchase program, excise tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember', window );">2025 Accelerated Share Repurchase Agreement - Uncollared Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased during period, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased', window );">Stock repurchase program, percentage of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember', window );">2025 Accelerated Share Repurchase Agreement - Collared Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased during period, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,789<span></span>
</td>
<td class="nump">849,531<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased', window );">Stock repurchase program, percentage of shares to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramExciseTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramExciseTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Number Of Accelerated Repurchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program, Percentage Of Shares To Be Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2026ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2026ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2025ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2025ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_UnrecognizedTaxBenefitsIncludingInterest', window );">Unrecognized tax benefits, including interest</a></td>
<td class="nump">$ 30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_UnrecognizedTaxBenefitsIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Including Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_UnrecognizedTaxBenefitsIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - General (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 781.5<span></span>
</td>
<td class="nump">$ 794.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">648.1<span></span>
</td>
<td class="nump">701.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserve</a></td>
<td class="nump">44.9<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_TyvasoDPIMember', window );">Tyvaso DPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">247.1<span></span>
</td>
<td class="nump">254.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserve</a></td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss related to commercial supply agreement</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember', window );">Nebulized Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">127.2<span></span>
</td>
<td class="nump">163.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">118.6<span></span>
</td>
<td class="nump">155.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_RemodulinMember', window );">Remodulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">126.6<span></span>
</td>
<td class="nump">138.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">124.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_OrenitramMember', window );">Orenitram</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135.6<span></span>
</td>
<td class="nump">120.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">128.2<span></span>
</td>
<td class="nump">112.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_UnituxinMember', window );">Unituxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">58.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">48.6<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_AdcircaMember', window );">Adcirca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems', window );"><strong>Net product sales, cost of product sales and gross profit by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="num">$ (6.8)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_TyvasoDPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_TyvasoDPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_RemodulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_RemodulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_OrenitramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_OrenitramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_UnituxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_UnituxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_AdcircaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_AdcircaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Geographic Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 781.5<span></span>
</td>
<td class="nump">$ 794.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_TyvasoMember', window );">Total Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">457.5<span></span>
</td>
<td class="nump">466.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_TyvasoDPIMember', window );">Tyvaso DPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember', window );">Nebulized Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">127.2<span></span>
</td>
<td class="nump">163.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_RemodulinMember', window );">Remodulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">126.6<span></span>
</td>
<td class="nump">138.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_OrenitramMember', window );">Orenitram</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135.6<span></span>
</td>
<td class="nump">120.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_UnituxinMember', window );">Unituxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">58.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=uthr_AdcircaMember', window );">Adcirca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">744.2<span></span>
</td>
<td class="nump">749.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Total Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">442.9<span></span>
</td>
<td class="nump">441.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Tyvaso DPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">302.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Nebulized Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">112.6<span></span>
</td>
<td class="nump">138.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Remodulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">120.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Orenitram</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135.6<span></span>
</td>
<td class="nump">120.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Unituxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Adcirca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Total Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Tyvaso DPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Nebulized Tyvaso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Remodulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Orenitram</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Unituxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Adcirca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">ROW | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from external customers by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_TyvasoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_TyvasoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_TyvasoDPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_TyvasoDPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_NebulizedTyvasoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_RemodulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_RemodulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_OrenitramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_OrenitramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_UnituxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_UnituxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=uthr_AdcircaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=uthr_AdcircaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Concentration Risk (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Distributor 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Distributor 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=uthr_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=uthr_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=uthr_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=uthr_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>petition</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=uthr_SandozIncMember', window );">Sandoz Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 61,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation settlement interest</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">Additional accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=uthr_SandozIncMember', window );">Sandoz Inc. | Smiths Medical ASD, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=uthr_LiquidiaTechnologiesInc.Member', window );">Liquidia Technologies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Litigation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_uthr_NumberOfPetitions', window );">Number of petitions | petition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_uthr_NumberOfPetitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of petitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">uthr_NumberOfPetitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>uthr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=uthr_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=uthr_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=uthr_SmithsMedicalASDIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=uthr_SmithsMedicalASDIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=uthr_LiquidiaTechnologiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=uthr_LiquidiaTechnologiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>276</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Organization and Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/OrganizationandBusinessDescription</Role>
      <ShortName>Organization and Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Property, Plant, and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant, and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/Investments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/Inventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/ShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.unither.com/role/SegmentInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Investments - Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Investments - Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Investments - Current and Non-current of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Investments - Current and Non-current of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails</Role>
      <ShortName>Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails</Role>
      <ShortName>Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Investments - Investments in Privately-Held Companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails</Role>
      <ShortName>Investments - Investments in Privately-Held Companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.unither.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.unither.com/role/InventoriesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Property, Plant, and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant, and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.unither.com/role/Debt</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Share-Based Compensation - General Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - General Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails</Role>
      <ShortName>Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Share-Based Compensation - Stock Options Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Share-Based Compensation - Assumptions For Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions For Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Share-Based Compensation - Status of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Status of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Share-Based Compensation - Stock Options Exercise Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options Exercise Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Share-Based Compensation - Restricted Stock Units Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Share-Based Compensation - Restricted Stock Units Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stockholders??? Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.unither.com/role/IncomeTaxes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Segment Information - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/SegmentInformationGeneralDetails</Role>
      <ShortName>Segment Information - General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Segment Information - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/SegmentInformationGeographicInformationDetails</Role>
      <ShortName>Segment Information - Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Segment Information - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/SegmentInformationConcentrationRiskDetails</Role>
      <ShortName>Segment Information - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="uthr-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.unither.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.unither.com/role/Litigation</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="uthr-20260331.htm">uthr-20260331.htm</File>
    <File>uthr-20260331.xsd</File>
    <File>uthr-20260331_cal.xml</File>
    <File>uthr-20260331_def.xml</File>
    <File>uthr-20260331_lab.xml</File>
    <File>uthr-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="696">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "uthr-20260331.htm": {
   "nsprefix": "uthr",
   "nsuri": "http://www.unither.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "uthr-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "uthr-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "uthr-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "uthr-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "uthr-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "uthr-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 256,
   "keyCustom": 20,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 36,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://www.unither.com/20260331": 1
   },
   "contextCount": 232,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 566,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 696,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://fasb.org/srt/2025": 8,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.unither.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.unither.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.unither.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952156 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.unither.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.unither.com/role/OrganizationandBusinessDescription",
     "longName": "9952158 - Disclosure - Organization and Business Description",
     "shortName": "Organization and Business Description",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.unither.com/role/BasisofPresentation",
     "longName": "9952159 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.unither.com/role/Investments",
     "longName": "9952160 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.unither.com/role/FairValueMeasurements",
     "longName": "9952161 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.unither.com/role/Inventories",
     "longName": "9952162 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.unither.com/role/PropertyPlantandEquipment",
     "longName": "9952163 - Disclosure - Property, Plant, and Equipment",
     "shortName": "Property, Plant, and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.unither.com/role/Debt",
     "longName": "9952164 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.unither.com/role/ShareBasedCompensation",
     "longName": "9952165 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.unither.com/role/StockholdersEquity",
     "longName": "9952166 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.unither.com/role/IncomeTaxes",
     "longName": "9952167 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.unither.com/role/SegmentInformation",
     "longName": "9952168 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.unither.com/role/Litigation",
     "longName": "9952169 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.unither.com/role/BasisofPresentationPolicies",
     "longName": "9955511 - Disclosure - Basis of Presentation (Policies)",
     "shortName": "Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.unither.com/role/InvestmentsTables",
     "longName": "9955512 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.unither.com/role/FairValueMeasurementsTables",
     "longName": "9955513 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.unither.com/role/InventoriesTables",
     "longName": "9955514 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.unither.com/role/PropertyPlantandEquipmentTables",
     "longName": "9955515 - Disclosure - Property, Plant, and Equipment (Tables)",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.unither.com/role/ShareBasedCompensationTables",
     "longName": "9955516 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.unither.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.unither.com/role/SegmentInformationTables",
     "longName": "9955518 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "uthr:ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "uthr:ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
     "longName": "9955519 - Disclosure - Investments - Available-for-Sale Debt Securities (Details)",
     "shortName": "Investments - Available-for-Sale Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails",
     "longName": "9955520 - Disclosure - Investments - Current and Non-current of Available-for-Sale Debt Securities (Details)",
     "shortName": "Investments - Current and Non-current of Available-for-Sale Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails",
     "longName": "9955521 - Disclosure - Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details)",
     "shortName": "Investments - Available-for-Sale Debt Securities in Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.unither.com/role/InvestmentsNarrativeDetails",
     "longName": "9955522 - Disclosure - Investments - Narrative (Details)",
     "shortName": "Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "investment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "investment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails",
     "longName": "9955523 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)",
     "shortName": "Investments - Contractual Maturities of Available-for-Sale Marketable Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails",
     "longName": "9955524 - Disclosure - Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details)",
     "shortName": "Investments - Investments in Equity Securities with Readily Determinable Fair Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails",
     "longName": "9955525 - Disclosure - Investments - Investments in Privately-Held Companies (Details)",
     "shortName": "Investments - Investments in Privately-Held Companies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.unither.com/role/FairValueMeasurementsDetails",
     "longName": "9955526 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.unither.com/role/InventoriesDetails",
     "longName": "9955527 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "longName": "9955528 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant, and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "longName": "9955529 - Disclosure - Property, Plant, and Equipment - Narrative (Details)",
     "shortName": "Property, Plant, and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.unither.com/role/DebtDetails",
     "longName": "9955530 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
     "longName": "9955531 - Disclosure - Share-Based Compensation - General Narrative (Details)",
     "shortName": "Share-Based Compensation - General Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "uthr:NumberOfEquityIncentivePlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "uthr:NumberOfEquityIncentivePlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
     "longName": "9955532 - Disclosure - Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details)",
     "shortName": "Share-Based Compensation - Allocation of Compensation Expense (Benefit) by Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
     "longName": "9955533 - Disclosure - Share-Based Compensation - Stock Options Narrative (Details)",
     "shortName": "Share-Based Compensation - Stock Options Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
     "longName": "9955534 - Disclosure - Share-Based Compensation - Assumptions For Stock Options (Details)",
     "shortName": "Share-Based Compensation - Assumptions For Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
     "longName": "9955535 - Disclosure - Share-Based Compensation - Status of Stock Options (Details)",
     "shortName": "Share-Based Compensation - Status of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "9955536 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
     "longName": "9955537 - Disclosure - Share-Based Compensation - Stock Options Exercise Data (Details)",
     "shortName": "Share-Based Compensation - Stock Options Exercise Data (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "uthr:ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
     "longName": "9955538 - Disclosure - Share-Based Compensation - Restricted Stock Units Narrative (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Units Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
     "longName": "9955539 - Disclosure - Share-Based Compensation - Restricted Stock Units Status (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Units Status (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails",
     "longName": "9955540 - Disclosure - Share-Based Compensation - Employee Stock Purchase Plan (Details)",
     "shortName": "Share-Based Compensation - Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails",
     "longName": "9955541 - Disclosure - Stockholders\u2019 Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.unither.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955542 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-147",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.unither.com/role/IncomeTaxesDetails",
     "longName": "9955543 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.unither.com/role/SegmentInformationGeneralDetails",
     "longName": "9955544 - Disclosure - Segment Information - General (Details)",
     "shortName": "Segment Information - General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.unither.com/role/SegmentInformationGeographicInformationDetails",
     "longName": "9955545 - Disclosure - Segment Information - Geographic Information (Details)",
     "shortName": "Segment Information - Geographic Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails",
     "longName": "9955546 - Disclosure - Segment Information - Concentration Risk (Details)",
     "shortName": "Segment Information - Concentration Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.unither.com/role/LitigationDetails",
     "longName": "9955547 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "uthr-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "uthr_A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Accelerated Share Repurchase Agreement - Collared Agreement",
        "label": "2025 Accelerated Share Repurchase Agreement - Collared Agreement [Member]",
        "documentation": "2025 Accelerated Share Repurchase Agreement - Collared Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Accelerated Share Repurchase Agreement - Uncollared Agreement",
        "label": "2025 Accelerated Share Repurchase Agreement - Uncollared Agreement [Member]",
        "documentation": "2025 Accelerated Share Repurchase Agreement - Uncollared Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2025AcceleratedShareRepurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2025AcceleratedShareRepurchaseAgreementsMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Accelerated Share Repurchase Agreements",
        "label": "2025 Accelerated Share Repurchase Agreements [Member]",
        "documentation": "2025 Accelerated Share Repurchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2025CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2025CreditAgreementMember",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Credit Agreement",
        "label": "2025 Credit Agreement [Member]",
        "documentation": "2025 Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2025ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2025ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Share Repurchase Program",
        "label": "2025 Share Repurchase Program [Member]",
        "documentation": "2025 Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Accelerated Share Repurchase Agreement - Collared Agreement",
        "label": "2026 Accelerated Share Repurchase Agreement - Collared Agreement [Member]",
        "documentation": "2026 Accelerated Share Repurchase Agreement - Collared Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Accelerated Share Repurchase Agreement - Uncollared Agreement",
        "label": "2026 Accelerated Share Repurchase Agreement - Uncollared Agreement [Member]",
        "documentation": "2026 Accelerated Share Repurchase Agreement - Uncollared Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2026AcceleratedShareRepurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2026AcceleratedShareRepurchaseAgreementsMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Accelerated Share Repurchase Agreements",
        "label": "2026 Accelerated Share Repurchase Agreements [Member]",
        "documentation": "2026 Accelerated Share Repurchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_A2026ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "A2026ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 Share Repurchase Program",
        "label": "2026 Share Repurchase Program [Member]",
        "documentation": "2026 Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, no allowance for 2026 and 2025",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less\u2014accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r153",
      "r645"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r61",
      "r157",
      "r642",
      "r669",
      "r670",
      "r1163"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r19",
      "r498",
      "r501",
      "r556",
      "r665",
      "r666",
      "r1017",
      "r1018",
      "r1019",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "uthr_AdcircaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "AdcircaMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adcirca",
        "label": "Adcirca [Member]",
        "documentation": "Represents Adcirca, a commercial product of the entity, for treating pulmonary hypertension."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1164",
      "r1222"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Restricted stock units (RSUs) withheld for taxes",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "uthr_AdvancePaymentRelatedToPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "AdvancePaymentRelatedToPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deposits",
        "label": "Advance Payment Related to Property Plant and Equipment",
        "documentation": "Advance Payment Related to Property Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r936",
      "r946",
      "r978"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r939",
      "r949",
      "r981"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r974",
      "r982",
      "r986",
      "r994"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense before tax",
        "terseLabel": "Share-based compensation expense before taxes",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r445",
      "r446"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based compensation expense, net of taxes",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r256",
      "r298"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options and RSUs excluded from calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r107",
      "r155",
      "r187",
      "r190",
      "r191",
      "r223",
      "r233",
      "r244",
      "r247",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r476",
      "r478",
      "r541",
      "r627",
      "r628",
      "r638",
      "r705",
      "r842",
      "r843",
      "r854",
      "r885",
      "r902",
      "r903",
      "r917",
      "r1123",
      "r1124",
      "r1180"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r161",
      "r187",
      "r190",
      "r191",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r476",
      "r478",
      "r541",
      "r885",
      "r1123",
      "r1124",
      "r1180"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r873"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported under the following captions in our consolidated balance sheets:",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract",
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract",
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101",
      "r1186"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101",
      "r1185"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r304",
      "r513",
      "r534",
      "r536",
      "r537",
      "r538",
      "r624",
      "r817",
      "r873",
      "r876",
      "r883",
      "r1093",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r540",
      "r870",
      "r871",
      "r1006",
      "r1189"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r540",
      "r870",
      "r871",
      "r1006",
      "r1189"
     ]
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://www.unither.com/role/BasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting [Text Block]",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "uthr_BuildingsBuildingImprovementsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "BuildingsBuildingImprovementsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings, building improvements, and leasehold improvements",
        "label": "Buildings Building Improvements And Leasehold Improvements [Member]",
        "documentation": "Details pertaining to buildings, building improvements and leasehold improvements."
       }
      }
     },
     "auth_ref": []
    },
    "uthr_BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Acquisition, Contingent Consideration, Fair Value Disclosure, Liability",
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement including cash and shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r1065"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash additions to property, plant, and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r151",
      "r820"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, fair value disclosure",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r75",
      "r186"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r98",
      "r639",
      "r692"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r909",
      "r910",
      "r912",
      "r913",
      "r914",
      "r915",
      "r1074",
      "r1075",
      "r1077",
      "r1164",
      "r1220",
      "r1222"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r693"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r693",
      "r711",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value $.01, 245,000,000 shares authorized, 77,129,770 and 76,452,253 shares issued, and 42,156,223 and 43,643,165 shares outstanding as of March 31, 2026 and December\u00a031, 2025, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r369",
      "r375",
      "r641",
      "r885"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r167",
      "r169",
      "r173",
      "r625",
      "r651",
      "r652"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r254",
      "r672",
      "r673",
      "r806",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r254",
      "r672",
      "r673",
      "r806",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r254",
      "r672",
      "r673",
      "r806",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r806",
      "r834",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r254",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r806",
      "r834",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r254",
      "r672",
      "r673",
      "r806",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings under construction",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r861",
      "r863",
      "r873",
      "r886",
      "r905",
      "r1217"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/SegmentInformationGeneralDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r588",
      "r827",
      "r832",
      "r869",
      "r1059"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "uthr_CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Unsecured Revolving Credit Facility",
        "label": "Credit Agreement2022 First Unsecured Revolving Credit Facility [Member]",
        "documentation": "Credit Agreement2022 First Unsecured Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_CreditAgreement2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "CreditAgreement2022Member",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Credit Agreement",
        "label": "Credit Agreement2022 [Member]",
        "documentation": "Credit Agreement2022"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Unsecured Revolving Credit Facility",
        "label": "Credit Agreement2022 Second Unsecured Revolving Credit Facility [Member]",
        "documentation": "Credit Agreement2022 Second Unsecured Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r1081"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r187",
      "r189",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r327",
      "r328",
      "r338",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r354",
      "r361",
      "r362",
      "r364",
      "r496",
      "r552"
     ]
    },
    "uthr_DebtInstrumentAdditionalExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtInstrumentAdditionalExtensionTerm",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, additional extension term",
        "label": "Debt Instrument, Additional Extension Term",
        "documentation": "Debt Instrument, Additional Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r42",
      "r43",
      "r96",
      "r97",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r884",
      "r1067",
      "r1068",
      "r1069",
      "r1073",
      "r1115",
      "r1116",
      "r1117",
      "r1177",
      "r1178",
      "r1184"
     ]
    },
    "uthr_DebtInstrumentExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtInstrumentExtensionTerm",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of maturity date extension",
        "label": "Debt Instrument, Extension Term",
        "documentation": "Debt Instrument, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r496",
      "r631",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r884",
      "r1067",
      "r1068",
      "r1069",
      "r1073",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r884",
      "r1067",
      "r1068",
      "r1069",
      "r1073",
      "r1115",
      "r1116",
      "r1117",
      "r1177",
      "r1178",
      "r1184"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r32",
      "r33",
      "r40",
      "r86",
      "r87",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r496",
      "r631",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r884",
      "r1067",
      "r1068",
      "r1069",
      "r1073",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r309",
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "12 months or longer",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r309"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r309",
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r309"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current available-for-sale debt securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current marketable investments",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Noncurrent",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "uthr_DebtSecuritiesAvailableForSaleImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments related to credit loss",
        "label": "Debt Securities, Available-For-Sale, Impairment Loss",
        "documentation": "Debt Securities, Available-For-Sale, Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one to three years",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year One Through Three, Amortized Cost Basis",
        "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the third rolling twelve months following the latest balance sheet. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsContractualMaturitiesofAvailableforSaleMarketableInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one to three years",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Year One Through Year Three, Fair Value",
        "documentation": "Fair value of available-for-sale debt securities maturing after first fiscal year through third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails",
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r306",
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r307"
     ]
    },
    "uthr_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract]",
        "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r847",
      "r1113"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.unither.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, available-for-sale, unrealized loss position, number of positions",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r308"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r119",
      "r1067",
      "r1072"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r30",
      "r176",
      "r826",
      "r827",
      "r829",
      "r831"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r177",
      "r223",
      "r238",
      "r247",
      "r826",
      "r842",
      "r843"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r411",
      "r440",
      "r441",
      "r443",
      "r864"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_DistributorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DistributorOneMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor 1",
        "label": "Distributor One [Member]",
        "documentation": "Distributor One"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_DistributorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "DistributorTwoMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor 2",
        "label": "Distributor Two [Member]",
        "documentation": "Distributor Two"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per common share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r174",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r211",
      "r213",
      "r218",
      "r219",
      "r220",
      "r222",
      "r367",
      "r444",
      "r471",
      "r475",
      "r510",
      "r511",
      "r626",
      "r653",
      "r833"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r174",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r213",
      "r218",
      "r219",
      "r220",
      "r222",
      "r367",
      "r444",
      "r471",
      "r475",
      "r510",
      "r511",
      "r626",
      "r653",
      "r833"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share Reconciliation [Abstract]",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.unither.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate (as a percent)",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r866"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining vesting period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Related income tax benefit",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r145",
      "r146",
      "r147",
      "r170",
      "r171",
      "r172",
      "r195",
      "r196",
      "r197",
      "r199",
      "r206",
      "r208",
      "r210",
      "r224",
      "r296",
      "r297",
      "r314",
      "r366",
      "r391",
      "r444",
      "r461",
      "r462",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r554",
      "r556",
      "r649",
      "r665",
      "r666",
      "r667",
      "r679",
      "r730"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinEquitySecuritieswithReadilyDeterminableFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity securities with readily determinable fair value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r534",
      "r822"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r513",
      "r534",
      "r536",
      "r537",
      "r538",
      "r636",
      "r637",
      "r873",
      "r904",
      "r907",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net unrealized losses on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r1110"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in privately-held companies",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in value of investment, cumulative amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in value of investment, annual amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in value of investment, cumulative amount",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r936",
      "r946",
      "r978"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r933",
      "r943",
      "r975"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r536",
      "r537",
      "r539",
      "r817",
      "r850",
      "r851"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "uthr_ExecutivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ExecutivesMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executives",
        "label": "Executives [Member]",
        "documentation": "Executives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and liabilities subject to fair value measurements",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r524",
      "r873"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r524",
      "r873"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r523",
      "r524",
      "r526",
      "r536",
      "r561",
      "r562",
      "r563",
      "r817",
      "r850",
      "r851",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r873",
      "r876",
      "r883"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r817",
      "r850",
      "r851",
      "r1175"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r850",
      "r851"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r519",
      "r521",
      "r522",
      "r523",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r623",
      "r873",
      "r877"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r395",
      "r400",
      "r402",
      "r514",
      "r524",
      "r536",
      "r561",
      "r817",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r873",
      "r883"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r395",
      "r400",
      "r402",
      "r404",
      "r514",
      "r515",
      "r524",
      "r536",
      "r562",
      "r817",
      "r850",
      "r851",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r873",
      "r883"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r514",
      "r515",
      "r516",
      "r517",
      "r524",
      "r536",
      "r563",
      "r817",
      "r850",
      "r851",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r873",
      "r876",
      "r883"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r523",
      "r524",
      "r526",
      "r536",
      "r561",
      "r562",
      "r563",
      "r817",
      "r850",
      "r851",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r873",
      "r876",
      "r883"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails",
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r310",
      "r311",
      "r363",
      "r389",
      "r496",
      "r507",
      "r531",
      "r540",
      "r543",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r635",
      "r650",
      "r847",
      "r873",
      "r874",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r886",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1165",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r982"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r982"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r982"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r982"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r982"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "uthr_FurnitureEquipmentAndVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "FurnitureEquipmentAndVehiclesMember",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, equipment, and vehicles",
        "label": "Furniture Equipment And Vehicles [Member]",
        "documentation": "Details pertaining to equipment used to produce goods and services. It also includes long-lived, depreciable assets, commonly used in offices and stores and for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/SegmentInformationGeneralDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit (loss)",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r66",
      "r106",
      "r187",
      "r190",
      "r191",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r541",
      "r838",
      "r842",
      "r1079",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1123"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r100",
      "r106",
      "r627",
      "r629",
      "r647",
      "r828",
      "r830",
      "r832",
      "r838",
      "r842",
      "r1079",
      "r1087",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r321",
      "r322",
      "r481",
      "r486",
      "r487",
      "r495",
      "r518",
      "r520",
      "r525",
      "r542",
      "r543",
      "r544",
      "r663",
      "r664",
      "r715",
      "r816",
      "r817",
      "r867",
      "r868",
      "r871",
      "r872",
      "r875",
      "r883",
      "r1161",
      "r1162",
      "r1190"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r481",
      "r486",
      "r487",
      "r495",
      "r518",
      "r520",
      "r525",
      "r542",
      "r543",
      "r544",
      "r663",
      "r664",
      "r715",
      "r816",
      "r817",
      "r867",
      "r868",
      "r871",
      "r872",
      "r875",
      "r883",
      "r1161",
      "r1162",
      "r1190"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r192",
      "r449",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r463",
      "r465",
      "r466",
      "r467",
      "r634",
      "r671",
      "r678",
      "r866"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120",
      "r187",
      "r209",
      "r210",
      "r223",
      "r239",
      "r247",
      "r452",
      "r453",
      "r464",
      "r655",
      "r828",
      "r830",
      "r832",
      "r866"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r185",
      "r459",
      "r460"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, RSUs, and ESPP (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r220",
      "r410"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r974",
      "r982",
      "r986",
      "r994"
     ]
    },
    "uthr_InducementStockIncentivePlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "InducementStockIncentivePlan2019Member",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Inducement Plan",
        "label": "Inducement Stock Incentive Plan2019 [Member]",
        "documentation": "This member represents Inducement Stock Incentive Plan, 2019."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r998"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r998"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r998"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill and other intangible assets, net",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r828",
      "r832",
      "r1021"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r184"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r823"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss related to commercial supply agreement",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r175"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.unither.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets",
      "http://www.unither.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r821",
      "r885"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r825"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-progress",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r824"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r236",
      "r247",
      "r842",
      "r1020"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Contractual Maturities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r121",
      "r257",
      "r259",
      "r532",
      "r533",
      "r1183"
     ]
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and land improvements",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.unither.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r42",
      "r43",
      "r44",
      "r46",
      "r47",
      "r48",
      "r49",
      "r187",
      "r190",
      "r191",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r477",
      "r478",
      "r479",
      "r541",
      "r691",
      "r837",
      "r854",
      "r917",
      "r1123",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r99",
      "r644",
      "r885",
      "r902",
      "r903",
      "r1067",
      "r1071",
      "r1111",
      "r1176"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r150",
      "r187",
      "r190",
      "r191",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r477",
      "r478",
      "r479",
      "r541",
      "r885",
      "r1123",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r1166"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in borrowing capacity",
        "label": "Line Of Credit Facility, Contingent Increase, Additional Borrowing Capacity",
        "documentation": "The contingent increase above the maximum borrowing capacity under the credit facility, if any one or more of the existing banks or new banks agree to provide such increased commitment amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r45"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r96"
     ]
    },
    "uthr_LiquidiaTechnologiesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "LiquidiaTechnologiesInc.Member",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidia Technologies, Inc.",
        "label": "Liquidia Technologies Inc. [Member]",
        "documentation": "Represents information pertaining to Liquidia Technologies, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement interest",
        "label": "Litigation Settlement Interest",
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r97",
      "r188",
      "r194",
      "r351",
      "r365",
      "r631",
      "r850",
      "r851",
      "r884",
      "r1187"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r323",
      "r324",
      "r325",
      "r326",
      "r447",
      "r848",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r323",
      "r324",
      "r325",
      "r326",
      "r447",
      "r848",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r1004"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional accrual",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r855",
      "r858",
      "r896",
      "r900",
      "r1188",
      "r1191",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable investments",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "uthr_MarketableSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "MarketableSecuritiesCurrentMember",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current marketable investments",
        "label": "Marketable Securities Current [Member]",
        "documentation": "Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the short-term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable investments",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "uthr_MarketableSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "MarketableSecuritiesNoncurrentMember",
     "presentation": [
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current marketable investments",
        "label": "Marketable Securities Noncurrent [Member]",
        "documentation": "Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1130"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r855",
      "r858",
      "r896",
      "r900",
      "r1188",
      "r1191",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.unither.com/role/OrganizationandBusinessDescription"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business Description",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r225",
      "r835",
      "r836"
     ]
    },
    "uthr_NebulizedTyvasoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NebulizedTyvasoMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nebulized Tyvaso",
        "label": "Nebulized Tyvaso [Member]",
        "documentation": "Nebulized Tyvaso"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r77",
      "r101",
      "r147",
      "r148",
      "r165",
      "r168",
      "r172",
      "r187",
      "r190",
      "r191",
      "r193",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r217",
      "r295",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r367",
      "r370",
      "r372",
      "r376",
      "r444",
      "r471",
      "r475",
      "r511",
      "r541",
      "r648",
      "r712",
      "r728",
      "r729",
      "r828",
      "r830",
      "r832",
      "r916",
      "r1123"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_NetIncomePerCommonShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NetIncomePerCommonShareAbstract",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per common share:",
        "label": "Net Income Per Common Share [Abstract]",
        "documentation": "Net Income Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NetProductSalesCostOfProductSalesAndGrossProfitByProductLineItems",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product sales, cost of product sales and gross profit by product",
        "label": "Net Product Sales, Cost Of Product Sales, And Gross Profit By Product [Line Items]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.unither.com/role/BasisofPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "uthr_NewlyHiredEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NewlyHiredEmployeesMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newly-Hired Employees",
        "label": "Newly Hired Employees [Member]",
        "documentation": "This member represents newly-hired employees."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940",
      "r950",
      "r974",
      "r982"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROW",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1225",
      "r1226",
      "r1227"
     ]
    },
    "uthr_NoncashExciseTaxOnNetShareRepurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NoncashExciseTaxOnNetShareRepurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise tax on net share repurchase",
        "label": "Noncash Excise Tax On Net Share Repurchases",
        "documentation": "Noncash Excise Tax On Net Share Repurchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "uthr_NumberOfEquityIncentivePlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NumberOfEquityIncentivePlans",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity incentive plans",
        "label": "Number Of Equity Incentive Plans",
        "documentation": "Number of shareholder-approved equity incentive plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r1086"
     ]
    },
    "uthr_NumberOfPetitions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "NumberOfPetitions",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of petitions",
        "label": "Number Of Petitions",
        "documentation": "Number of petitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r828",
      "r832",
      "r838",
      "r1079",
      "r1087",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "uthr_OrenitramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "OrenitramMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orenitram",
        "label": "Orenitram [Member]",
        "documentation": "Represents Orenitram, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r885"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale debt securities:",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total (loss) gain on available-for-sale debt securities, net of tax",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r94"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax (benefit) expense in other comprehensive income for available-for-sale debt securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities, Tax, Portion Attributable to Parent",
        "documentation": "Amount, after reclassification adjustment, of tax expense (benefit) for gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r94"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total defined benefit pension plan, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r12",
      "r60",
      "r61",
      "r94"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit pension plan:",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Actuarial gain (loss) arising during period, net of tax",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r401",
      "r405"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax (benefit) expense in other comprehensive income for the defined benefit pension plan",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent",
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r94"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain arising during period, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive (loss) income, net of tax",
        "verboseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r94",
      "r166",
      "r169",
      "r206"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized gain included in net income, net of tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r164",
      "r291"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gain and prior service cost included in net periodic pension cost, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax",
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r89",
      "r164"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r885"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r869"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r938",
      "r948",
      "r980"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r941",
      "r951",
      "r983"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r941",
      "r951",
      "r983"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for legal settlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to repurchase common stock",
        "terseLabel": "Payments to repurchase common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs withheld for taxes",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of available-for-sale debt securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r178",
      "r258"
     ]
    },
    "uthr_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of investment in privately held company",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value",
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire long-term investments",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r817",
      "r1175"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r378"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r693"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r378"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r369",
      "r374",
      "r640",
      "r885"
     ]
    },
    "uthr_PrivatelyHeldCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "PrivatelyHeldCompaniesMember",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Privately-held Companies",
        "label": "Privately Held Companies [Member]",
        "documentation": "Information pertaining to privately-held companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r675"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of stock under ESPP",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of available-for-sale debt securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r1094"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of available-for-sale debt securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r178",
      "r258",
      "r290"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the exercise of stock options",
        "terseLabel": "Cash received",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1128"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r144",
      "r250",
      "r588",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r818",
      "r827",
      "r830",
      "r832",
      "r855",
      "r856",
      "r895",
      "r897",
      "r898",
      "r901",
      "r906",
      "r1005",
      "r1015",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1121",
      "r1122",
      "r1188",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and Services [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r144",
      "r250",
      "r588",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r818",
      "r827",
      "r830",
      "r832",
      "r855",
      "r856",
      "r895",
      "r897",
      "r898",
      "r901",
      "r906",
      "r1005",
      "r1015",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1121",
      "r1122",
      "r1188",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r555"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r115",
      "r117",
      "r118"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r152",
      "r646"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets",
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, net",
        "totalLabel": "Property, plant, and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r555",
      "r633",
      "r646",
      "r885"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r555"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r933",
      "r943",
      "r975"
     ]
    },
    "uthr_RemodulinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "RemodulinMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remodulin",
        "label": "Remodulin [Member]",
        "documentation": "Represents Remodulin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r1067",
      "r1069"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of long term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r676"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r816",
      "r828",
      "r829",
      "r842",
      "r1182"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r934",
      "r944",
      "r976"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r935",
      "r945",
      "r977"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r942",
      "r952",
      "r984"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "uthr_RestrictedStockUnitsRSUsWithPerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "RestrictedStockUnitsRSUsWithPerformanceConditionsMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs with Performance Conditions",
        "label": "Restricted Stock Units (RSUs) With Performance Conditions [Member]",
        "documentation": "Restricted Stock Units (RSUs) With Performance Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r88",
      "r643",
      "r668",
      "r670",
      "r677",
      "r694",
      "r885"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r195",
      "r196",
      "r197",
      "r199",
      "r206",
      "r208",
      "r210",
      "r296",
      "r297",
      "r314",
      "r366",
      "r444",
      "r461",
      "r462",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r497",
      "r499",
      "r500",
      "r502",
      "r509",
      "r553",
      "r554",
      "r665",
      "r667",
      "r679",
      "r1222"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.unither.com/role/SegmentInformationGeneralDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenues",
        "terseLabel": "Total revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r223",
      "r234",
      "r235",
      "r243",
      "r247",
      "r250",
      "r252",
      "r254",
      "r392",
      "r393",
      "r394",
      "r588",
      "r828",
      "r832"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Revenues from External Customers by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues from external customers by geographic area",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "uthr_SandozIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "SandozIncMember",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sandoz Inc.",
        "label": "Sandoz Inc. [Member]",
        "documentation": "Sandoz Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails",
      "http://www.unither.com/role/InvestmentsCurrentandNoncurrentofAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Share-Based Compensation Expense Recognized",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Basic and Diluted Earnings (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Share-Based Compensation (Benefit) Expense Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Subject to Fair Value Measurements",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories, Net of Reserves",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Privately-Held Companies and Investments in Equity Securities with Readily Determinable Fair Values",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "uthr_ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Product Sales, Cost of Product Sales and Gross Profit for Each Commercial Products",
        "label": "Schedule Of Net Revenue, Cost Of Product Sales And Gross Profit By Product [Table Text Block]",
        "documentation": "Tabular disclosure of revenues, cost of revenues and gross profit for each commercial product during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.unither.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r555"
     ]
    },
    "uthr_ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ScheduleOfRevenueCostOfRevenueGrossProfitByProductTable",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table]",
        "label": "Schedule of Revenue, Cost of Revenue Gross Profit by Product [Table]",
        "documentation": "A table disclosing the revenue, cost of revenue and gross profit by commercial product."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r62"
     ]
    },
    "uthr_ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Exercise Data",
        "label": "Schedule of Service Share-based Compensation, Employee and Nonemployee Stock Option Exercise Data [Table Text Block]",
        "documentation": "Tabular disclosure of employee and non-employee stock option exercise data."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r443"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity and Status of Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions to Measure the Fair Value of Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Concentration of Risk Disclosure",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1085"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r227",
      "r252",
      "r253",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r629",
      "r630",
      "r682",
      "r683",
      "r684",
      "r744",
      "r757",
      "r778",
      "r797",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r819",
      "r834",
      "r855",
      "r857",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r899",
      "r910",
      "r1188",
      "r1191",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r223",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r839",
      "r840",
      "r841",
      "r842",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r827",
      "r828",
      "r829",
      "r832",
      "r1059"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868"
     ]
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of stock option exercise data",
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted in period, fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of the period (in shares)",
        "periodEndLabel": "Unvested at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning of the period (in dollars per share)",
        "periodEndLabel": "Unvested at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "terseLabel": "Awards granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of compensation employees may contribute for ESPP (in percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares each eligible employees may purchase in any given offering period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number of shares authorized to be issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares authorized to be issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum number of shares authorized to be issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock entitled to recipient upon vesting (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Shares Entitled To Receive For Each Unit Upon Vesting",
        "documentation": "The number of shares of common stock entitled to receive for each unit upon vesting."
       }
      }
     },
     "auth_ref": []
    },
    "uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant date fair value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period, Total Grant Date Fair Value",
        "documentation": "Represents the total grant date fair value of option granted during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueDisclosuresAbstract",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in\u00a0millions)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value of stock options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of the period (in shares)",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of the period (in dollars per share)",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "uthr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermDisclosuresAbstract",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term (in Years)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term Disclosures [Abstract]",
        "documentation": "N/A."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsStatusDetails",
      "http://www.unither.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "uthr_ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options with Performance Conditions",
        "label": "Share-Based Payment Arrangement, Option With Performance Conditions [Member]",
        "documentation": "Share-Based Payment Arrangement, Option With Performance Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_ShareRepurchaseProgramExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareRepurchaseProgramExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Excise tax on net share repurchase",
        "terseLabel": "Share repurchase program, excise tax",
        "label": "Share Repurchase Program, Excise Tax",
        "documentation": "Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_ShareRepurchaseProgramExciseTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareRepurchaseProgramExciseTaxPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, excise tax, payable",
        "label": "Share Repurchase Program, Excise Tax, Payable",
        "documentation": "Amount of excise tax payable on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "uthr_ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of accelerated share repurchase agreements",
        "label": "Share Repurchase Program, Number Of Accelerated Repurchase Agreements",
        "documentation": "Share Repurchase Program, Number Of Accelerated Repurchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_ShareTrackingAwardsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "ShareTrackingAwardsPlanMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAllocationofCompensationExpenseBenefitbyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STAP awards",
        "label": "Share Tracking Awards Plan [Member]",
        "documentation": "Share tracking award plans (STAP) is a long-term, equity-based compensation plan for eligible participants. Awards granted under this plan are non-dilutive as they are not settled in shares of entity's common stock and convey the right to receive in cash an amount equal to the appreciation of entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term of awards (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at the end of the period (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested at the end of the period (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant date fair value of employee stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award, purchase price of common stock, percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "uthr_SmithsMedicalASDIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "SmithsMedicalASDIncMember",
     "presentation": [
      "http://www.unither.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Smiths Medical ASD, Inc.",
        "label": "Smiths Medical ASD, Inc. [Member]",
        "documentation": "Smiths Medical ASD, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r54",
      "r55",
      "r145",
      "r146",
      "r147",
      "r170",
      "r171",
      "r172",
      "r195",
      "r196",
      "r197",
      "r199",
      "r206",
      "r208",
      "r210",
      "r224",
      "r296",
      "r297",
      "r314",
      "r366",
      "r391",
      "r444",
      "r461",
      "r462",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r554",
      "r556",
      "r649",
      "r665",
      "r666",
      "r667",
      "r679",
      "r730"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r227",
      "r252",
      "r253",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r627",
      "r628",
      "r629",
      "r630",
      "r682",
      "r683",
      "r684",
      "r744",
      "r757",
      "r778",
      "r797",
      "r802",
      "r803",
      "r804",
      "r805",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r819",
      "r834",
      "r855",
      "r857",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r899",
      "r910",
      "r1188",
      "r1191",
      "r1192",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r224",
      "r368",
      "r369",
      "r371",
      "r373",
      "r554",
      "r588",
      "r674",
      "r680",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r830",
      "r832",
      "r911",
      "r1221"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r224",
      "r255",
      "r368",
      "r369",
      "r371",
      "r373",
      "r554",
      "r588",
      "r674",
      "r680",
      "r681",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r693",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r830",
      "r832",
      "r911",
      "r1221"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r937",
      "r947",
      "r979"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "uthr_StockIncentivePlan2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "StockIncentivePlan2015PlanMember",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Plan",
        "label": "Stock Incentive Plan 2015 Plan [Member]",
        "documentation": "Information relating to 2015 Stock Incentive Plan (the 2015 Plan)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for RSUs vested (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.unither.com/role/ShareBasedCompensationStatusofStockOptionsDetails",
      "http://www.unither.com/role/ShareBasedCompensationStockOptionsExerciseDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Number of options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r88",
      "r420"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under employee stock purchase plan (ESPP)",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r54",
      "r55",
      "r88"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "uthr_StockRepurchaseProgramPercentageOfSharesToBeRepurchased": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "StockRepurchaseProgramPercentageOfSharesToBeRepurchased",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, percentage of shares to be repurchased",
        "label": "Stock Repurchase Program, Percentage Of Shares To Be Repurchased",
        "documentation": "Stock Repurchase Program, Percentage Of Shares To Be Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets",
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r79",
      "r695",
      "r711",
      "r731",
      "r732",
      "r885",
      "r917",
      "r1067",
      "r1070",
      "r1071",
      "r1111",
      "r1176",
      "r1222"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r496",
      "r508",
      "r733",
      "r734",
      "r801"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r557"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r557"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.unither.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r557"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1179"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.unither.com/role/ShareBasedCompensationGeneralNarrativeDetails",
      "http://www.unither.com/role/ShareBasedCompensationRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Entity [Domain]",
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.unither.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails",
      "http://www.unither.com/role/InvestmentsInvestmentsinPrivatelyHeldCompaniesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r363",
      "r389",
      "r496",
      "r507",
      "r531",
      "r540",
      "r543",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r635",
      "r650",
      "r873",
      "r874",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r886",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1165",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.unither.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 34,973,547 and 32,809,088 shares as of March\u00a031, 2026 and December\u00a031, 2025, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r54"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased during period, shares (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r88"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchase",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r88"
     ]
    },
    "uthr_TyvasoDPIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "TyvasoDPIMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tyvaso DPI",
        "label": "Tyvaso DPI [Member]",
        "documentation": "Tyvaso DPI"
       }
      }
     },
     "auth_ref": []
    },
    "uthr_TyvasoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "TyvasoMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Tyvaso",
        "label": "Tyvaso [Member]",
        "documentation": "Represents Tyvaso, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH)."
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.unither.com/role/FairValueMeasurementsDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesDetails",
      "http://www.unither.com/role/InvestmentsAvailableforSaleDebtSecuritiesinUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r859",
      "r861",
      "r886",
      "r905",
      "r1217"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "uthr_UnituxinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "UnituxinMember",
     "presentation": [
      "http://www.unither.com/role/SegmentInformationGeneralDetails",
      "http://www.unither.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unituxin",
        "label": "Unituxin [Member]",
        "documentation": "Represents Unituxin, a commercial product of the entity, for treating pulmonary arterial hypertension (PAH)."
       }
      }
     },
     "auth_ref": []
    },
    "uthr_UnrecognizedTaxBenefitsIncludingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.unither.com/20260331",
     "localname": "UnrecognizedTaxBenefitsIncludingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.unither.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, including interest",
        "label": "Unrecognized Tax Benefits, Including Interest",
        "documentation": "Unrecognized Tax Benefits, Including Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r220"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding:",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.unither.com/role/ConsolidatedStatementsofOperations",
      "http://www.unither.com/role/StockholdersEquityScheduleofComponentsofBasicandDilutedEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average outstanding shares - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r220"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001082554-26-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001082554-26-000020-xbrl.zip
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M]S*[VM4-&W CZ;C 8W5C#-S@<44P:L4(QNH&#CC16%PP6'6C#)Q@\5#L5=W
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ME%2Y/AN^^I6:=-2G?FQW)5_I=0GV.::P[1?J;"NN%D9S1@=LCE(3BWG9,NZ
MER42]<^#6+9X6!F(1>>-6,XT<?,25HZ0)PXX(K;5L%W))&,[)([(VMR[E'<*
MVWL [8U[%0-VCCMR=GSIM'%VEJZT3K' 5]!7[DK8PNG+0/HRNI6JCSVOV-&E
M:4:CR,&P23+#Q?1&8Y\.J1N P2M]<+P@^"C9K)7N61N_'_:2Y 'L 7Y+*3Z?
M@)^E5E_- S_N7_P=$'!+P[O!$WE+83%6T)J28_U1B&[>*:K8)@9[TE$7#>@J
M=7$]*S']Y%,21/[[),A?<-1K\GBFY!-]GSPH5]"HBVWXM7K74.NZMMI2_1 A
MK\*6CHW@E7JGU:VW.JN.Y#1$/0L>+82)1 3I"$IT*^93#E^W&JE=I=;3ZYHF
MIY2F"B5Z6A2U18L615$8.J\K[5;*.))2*.I,8U$/-"3PH251XKNP!U$XO+?,
MG8#T.H'HG-WYE0YLT\X[RZJ+57+UCBIS%;P5(K@D/Z9X^M*1OG2]6A,J\M?T
M5:0'6ER&G*%WM:A*WEE&SU?S7#.HYN69-EK$W98L:I?/B*JV2.;]J<K \0*M
M;GN?AA E5#AO&6X0/VBU=?TY#!-R\L\DR#<Y8E_@GLT8E+T!=9)34K*W[[AT
MK?T%7.= @XR*$C&'GW.TSTIW&(,DQ(,0#T?IUE*(>.@>:+Q2&>*!&4V?0FR8
MGI+O.R+^L^U.%H9^:?()KF7)334IH,1/"*?W6]_'IZ_)(][YN4>VO1765(%2
MG-+AC>#][Y@>[7HAV$FAAU3(4,&2+@:V2US39EXQ?,"::S370B!Y@XZFXM@+
M6+K.A4\=@F=+GU]M*QQ.&&'NK@1@K=DMI \KB,+UMRR"NKL1U(Q6X'9&#DM6
M.T#<(>. 7DQ^^3PIY;)=!C-VT^?%UR& ETB/O2[^>K;F9BM>=V*])V].OF["
M5Y]6/^]J3;W53OVJU913/U_W*+6I=+6-3]KB6_#3X2&3;/U[1'S@*>==>J!C
MSU\_XC[3#K,>Q*<0VJ&WGSZ!34TYN4V1@_,_<1LH_6TR $"H?6)0TM:T@=XW
M+=WL6P91-4/OJ^9_R]W:Y*:A/X/>,VWT?4I^-<@ (']!G%?R'B!ES;,J,,Z\
M7,C&TJO2<SU@!X.#RLJ8*D!Q>CYAT@E4'9 97 5+(ERM1QKZ:#O\93M"#7"2
MF3ST!A)V2D*Y_MLGLKMR*U&5W0/?2S=-Z=M45]VXL>T#T%GBBES;DM=FU9CP
M9E7;<5_R5GFFQ'6S<WKX<:I]$6-W8QKC/F 6R8<;5X(U./A!7:)O)@6;"2Z)
MLT(D> +YN VQN%]]7!D]:<A-Q=BJ)[DL#L^Z15EIJHJ>RQ18_[ENY+MCXZ(Z
M![(JCGHF)&?2JIG[;>U/,=TL((K]AJ,!R<@X_O4)% ^5?L!UPT"Z!GUD24PR
M3<L8\[3=$A1RU*LJ,>$V*R%BKF/V[GA%!00/\X8J 5T7#%ZH"MB1/CA5#Q]^
MNB2R;#!D/^:A$UXE9OE7"< )P'$%N!WE%<=98#Z%YT:9^JJ7CYWMZ2@E'BX>
M86!PV:>#1SP6E+>EJ#*R_>9[(XSKX1/_88?#JRB +5+_^LUT(@3-91!0^)^5
M6FX'J\)I#P#68G*A#GCDO^/1O>"2T^82_2A<@OW NEI*'4UI7')> U&2.+C[
M+-&W,74!5UDF G"AK@M.%19S1LIL_E^ELK,K+PCQ#"D 8589XU:4*N6U Q'-
M=X,_/,]BZ6'4?[%-&CQZCI6FR)1:3\84;XZ*D$216TFV43[*46N]KK*/GR#*
MB8LJ)PXH.VW#4@<+[%O'&V/"@!#Q7*&I4%<_QCAPZ=<9OJ]C2SB-5S64\AVN
M)MX**5^:!YR3>'0@'JU[JJWRJB3I'ZD#'S[7I6?J@O_KQ)W&B36R73L(?99L
M+:0^5R@K4.HGV/\CQCVP[^4"XC=P<!LXN*/M4S4MQ']EJ&B+^-^=B@R@(J/%
M%16)0]WC'NJ>2J,/;R5\?")J\SQ;1&2(B&%$(Y%M09IPZ]1ZFJXW5WM#BL8B
MITHU&:)AVZBF"U0CIS5HY+EQR*F>!"[U A>"G \$%2C(I[B>=8Y.X4H9F_TJ
M^CZ-^X0LKQCA;)'E&0D'6RUW%,X(9[=8EU7U6-<-YK/3(#PML7Z. 8DM0OW&
M?0$T8PPZ9LX)XM,8%"<7BHZLYT$V6T1Z'K)1:SU]KZ:1G!Q@G(Y03\(N0JIS
MA9Y</>NWBO48U8G[?.NYTZ!;&HMJ8'JE'#&*00>G131;A7HNHM%KO7:*6*_Z
M+(/JCP5BLYXF0KXNN726C)0^74;(>^Y9=T7>KQD=QW _S[FQ?;;^8%%N@U7?
M3AGU*83_:5'0BO OC((,H"!>"$B<28L*;:X =Z #GW7&AR(W2^L*-W_$STR0
M#XD-,ID4>WJVR.G$^P]BC>12(YU:STBI:,BB1L2)$0<45* GFHMN, V@Q5GN
MR'EE <0HDOITX/DTD?522-Y$8A=WJ"HTQC@YS9W4\]MN!""9=4G]P@@BONX)
MR>'Z+?0)P-5VB?]^$])1 )R.+_4]EA>[X1A!P;P"N9/B9XB\@E,EP*WQRJ,2
MH QZ1E&+ZLU2:G["?H'/DM4,*!9Q@L4E;Q=[@I4P;6+Y?:$N'=BIC(EY"6E%
M]"*">5H4DTD=9*(8M=:36W)%8I;;)OWPT?ROF$%-M[1J*6=%(>ELIHYQT1+M
M^&/%MJ@[(/R-V;&*5NLIAI9[7G4!LN-(4P*+'@,H..[,.6Y;C'$;Q^E8R* 4
M/;:3I_:#I1@*A5D(;-0._#(".F 3=TZQ">$6%/%IU6=NW5_<P(>3!=P1G(.C
MYC 7HP>^D, VJ\+NPF 1!DN:P7)/_4?46QM=!679;KDFO@MP""9W,U:8VB^M
MF?W2QOQ<M0KFBW 8!/]QQ']Z,?QG8#Z+G+=<CD?WX3QMC*\VSL*VA)7!.9Z$
ME#N"E9$P0YJ<Z]1Z>K,C[ S!@8(##VAG;.# +EKZ[;R943Q:&B<4J/P'^X-:
M$H&5D6<JN=&H3WV< 3$?M PD+PJ#D+AL<U4Q-LXP$"<BF"<1P1S9EN70\A5&
MI2*8:=E(![%RJJGC8T&>\\1_HA\N8_5PR[3#W8#I^N!NIA,6XPNS\TFUQ=+>
M\J:CGJ#=+:AS!^K<<CJ^-W5BMG0UTE7VU$\%C)H7P3$.%=B^>#UY";*;?DL(
M9T60I,D03.PVBD[ *8I?#Z\ ]UGIGOI1$/]!U&<>XE>!^#NYFUMS2/Q,OWX*
M2=^ADZK_N>X%(^(_VRY[LSYM7-#[K>_CG<D>U]R3; 8''\P]96D.@DFQI.O
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M0##!&HMWQ[!B&_29W&SQ$E<4\6P.U=H!R<_8T]4ZI= V7S4DB=(Z<7_J=.3
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M3GYFB)IF-(H<=!/6FMD<+9=%C:NPT(7(=A46_.$[2V&^6<PC6YNV?'!>XE,
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MK1;1;$OASDPT&A"-7"4IRWUS&;% L4"QP*HO\+R,.3Q"B%R?PGK_!'O.\8*
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M^+D]0UC7=*)MX7]3WXY%9!40P;=9:S9SRN,M4#I1_MG>C #[Q]PGH/[R_C/
MY(8IVUQ.H9W&-MU:3VNK^V2Z923=8F7QAI?FD,;G24_;"^MWIR<-#W+;::&)
M,NFI4$',O?1=[B9ENR\T*+";U':P\,DC>S>4RB)HS@I\9^IAWD>^.22L)&2
M)@Y(QO"]+HT=XH9UYG)BG<@86UN<J<-9Y*'*/7EG34*>O$L3P.K3^P3B]PCO
M2]>ZG@ [31_)X!:TTJ;_BEC?:5'1%JMF/RK"0?)I[;QXC.MQGYHF%GB@Y#ZU
MJW<[55:L7RF;1;-'F'85!*<J[]9IS7#H7UQ:+\0U:2+S'G 2$+6>O%PB3\4"
MN+V/R-:3Y,'4YN(K=U.;YT-&Z]1F462DU7K=_1,5BB&CJHM][A=XJGIIP>$C
M+\1V\%"X,?#\1@ $#QS4#].: @CU59C3=SF!^C?/?P28SVJZOP+PTR2/#C9[
M2Q8J[.1)*:_GEY^4VK5>NZND')((-7:*:HS[!9ZJGOU!PH03A:(]SN$Q+,:D
MU J^^=YH!OU[GXX3J0GV_15QG.!NL%YLIHE,3/!I=PO*\!$JF&\BVZ:!#T5D
M.#!;3C/QRB.R<U(MU6_3@R265]?LV+SG;(1!#HV#X-_$\[$]/M^/Q8U&#<MC
M$WGQ#6E"H5OKR76U9134[4?H'K[)+8?NR4]N&]O_Z*UBV_\(!93WZ+3Z"F@2
M640=%.=IH4&$C2[&OOU"0NJ\2T/J(*1&L,3WLVXA5]CYV$I(:+E/Y#_L<.A%
M\"ABP5:^TI#Z(]ME0H/8_G\2)TJK:-=EUF5NU><1N2;<TU919V;%D%9V':14
ML 5=I710@0G!Z[20(F-5!V_U&A^B@/4O_9B:0+R3(CK/?/O=ZC=N)D#?F&^O
MJYB9INX3 A'U&QS0TT'*FO>C+.PQT=9V/#\511P%%W$,P$9P35'$(8HX1!%'
M,9YW8JC'LT?'$S\<_.R1APORS%^B>*.P/)YOGO\P!?+=X(I!^1&!G#>^JV/S
MEKK>:@D_NXK$=8#$GJRTM=F1;@M'6B2J9*7BA\G1-<9M\6O\U_2I9>]1\7<V
M1S9;=,84N,'=X#N\"/ZY8J#-P\X&CV<SXA2PK"30#32U2CN=N&9T;_M"'.A5
M8H&GJJ0F1]]Q "$<4HF^4=^TX]-&YN%(WA@)6R12%IO6@J"]BR%[G8#<2A,T
MW5JOW2EHRIS04'S33YX\E8STTVYAB+:@D9='458G&TQ:$;5V$$18/#D3M9$+
M6Y>N'^_OSS2N="!I>Y- ^F[ QKP'/Q'.-_"!&]HOV+DU??H[5J^FG7NT92Q\
M%F-DSX'*<LCDHJD,AU]P-8_R3"7WP^//0'JUPR'+LAMX_M*HUO,2T8<(_4_[
M!CR1-TQ^&GH.@@:S;U-9)HU;L!E%FJ$L OZG15(9(_Y%D!2F-Z1-^.:QI=/9
MYJ,E*6BIV0]GGH%VD!$;:S*&ODW /Y\QE._8MLV.;;6.UM1X22@266H\9ZFE
MTMPJ6;5KO:ZZ8WO'XR>I\1\+)^:O9]^+7*N1$!9M4X-V/J^#&Q+=8:IRXL?8
MX&>Y\-&>93K2#VK9T:@ O?3!2L838%YT_!MJ**:NL/4K^P7[O[X J;KA&C55
M%+A3A<=A'*UB0/COZ_AR;T@<07P6 X*#:&X4H?C_ZQGE/= @]&T3#&7\XM*U
M%C^8N_(>=N)9J_,W3"="^%Z_F6P \P,8W=># 3733DW;;*2+D4>]%R!KBE+Z
M^RQEWA00?'V^?%V@HUL^-W> FUMI,_(V1RC+8.D=G>>$-"I9&)!F:-2E/GVV
M71>]9.Q+SZA@CP$[*?"ID*N2AQFU S)C;C^9M:_0=2-E*O!.)5WI9'Y@9WGI
MI3LZR^=#@4J;(Q(T,*V@WNX:14WQ*8@$>7)=2S8U-B@!"I^N%?_"/!7F:19Y
MI/(DCG"$2UTQNI4P1H5_*1B8!P;FRJ!0D(,[W6[NA)=JN9.5\R4?H_'8H7BD
M3IS8E,"*<\EV8_P"?O8I,=\"$3ZM]KWKR[?Z/><#N",8[$=--2O0=A\3.\XV
MLT%J^R!HA:4N%/T!$J5O$O*Z!WI+'YQNJ*"<*Z&8A6DM.(X#CMMR=).!XS2L
M,%@])^6/XX0"SZ+ 36]$T[/&A4@1(J40)8XD]H04MD&J8()E4Z^ 5!%Z7# =
M!TRW58]G8;IVK=>J!-,5%]6J4G77K><V6%QKKH6M:Q7>3+'@F$^1CSB6":<H
M6#-2%5$YI0O<":NSQS: XV2P;5T:XVC;.J,5.IEN*XP[H6<.8-Q=D;$=$N?Z
M;4Q=H,4(?$=0/9'O4^M+%-YZX3\I\R73M(]1ZW6[N6O5A<TG>/%,>7%KVNWN
MO-BI];3\&5,<FH*5KU&*=[H*M],V::[?6&>OD+Q)P 0NA>UA+?1<;^,=:7!?
M<)Z-3-T;4"<I<C?-80(S'*WPF'3!U;YSP<UF)?RSAKYI59]&M];K%!U!+TIL
M'-XLVF>E.UA-0@ ( 7"@:5D9!4#FMK^=G4<R<B@<JFZG<;+ 3R$.5YL48,_5
MG(^(_VR[#'>S=B>]W_H^WCE?M+WVGGED8B<PZI<3ZU18,A^E$C&3.9$8VW2]
MD+*X%O C(TOLF3.)?1('U@@?L'XZS;7[3=Z@:["$L1>P6-F%C^UW[!?Z^=6V
MPN%$),S=E7!+:W8+Z<,*HG#]+0E@DSN[\+KUH&9\ [<SQ"Y%10'B#AD']&+R
MR^<)4=@N@QF[Z?/BZQ# 2VS(7A=_/5MSLQ6O.Z'YY,W)UTWXZM/JYUVMJ;?:
MJ5^UFG+JY^L>I3:5KK;Q25LXDI^DPDQ:YN\1\8&GG'<)M('GKV^MGVF'65M1
MI!#:H;=OI&[?2&D=D2+1YG_B-E 5VF0 @%#[Q*"DK6D#O6]:NMFW#*)JAMY7
MS?]6Y=KDIJ$_@]XS;?1]2GXUR  @?T&<5_(>(&7-LRHPSKQ<R,;2[1667@_8
MP>"@LC*F"C!*/#].<F:M6?$J6!+A:CW2T$<KZB_;$6K4>D],'GH#Z0H-,-9[
MA&Q593N@Y^"J[![X7KII2M^FNNIFEI*^Q!4;-/3ZIC$FO$?5=MR%O%5Z*?$9
M4Z)^K^;5[VQ+CU/URTR.'P3,W=A&5>6ZI+24MO3AITLBRX;[/BY9KWFY7:OE
MI0!Y+0FT+3"-]W0T\.D98"@WI<35N(U&\ AS-;BPU$R*8-3V;G WIC$O!3/?
M0(X]$]N-J'49)I_A(RCX$6.4_'X$$N#.?R:N_2>[FYT ?HD"G!@12%_A0M\>
MQT2XL*PE+H/ODC?%3YFNH"$7)2(/SH,_7:0[Z6D(@!S3"+1F )3LCQ,9)=F!
M1*2^#41N#EU8U_/[9$8YN&LF:]P'5V$K;(N^4,=C9ZAQS:HW&F%3<]"Q"939
M\'/7>V%6)1[#6I$93V8#NO81]/B<R!W14!H!68$"EUS6;QLK7>$N-L@-N[A*
MYM#W7* 3?)%C#\#> PD*C,;:(@!2DN/>)D@4Y#'@M%<<^N:B80!+QE<"GAWR
MBK'3<=1WX%E]ZM*!'<)ET^W7X[?%0Q7&;(E+%X/["M8OE2:4<4 \LJ=>X,F%
M;6; ;'S2C<W6$(/,QJ&^-(B0<UA*XQ2B #LO>AY*'\C'%4P"Y %CU)'&X*Z/
MB,E(!/ 2,H*Q:?"9X>!#'VZ=D(B- G%(0H09?HG/)"_$=DC?=NSP'1\:^K!;
M=OX>:S/DQN (0-P(LO4.$L<<_ \J#0GP$QDCN@$UT^;T/YN/H%P]SV(H^NI'
MS]*E!6:='80)=W\X'L17C%^V^&]?+\M&^D>4!H#-7R!U$&H#\"B]5Y0C4QJ_
MD)[>7TC@25_O;PZU7+VI*UF,R%7W'$FPH32[QJI[VR<!C0U>,"P,[7/9L)8^
MA#X%,L4<+=OY"-)Y2)R8%.^]5QR<4#I%'A[3F0FSGI"=(+G#D-PCQJJX$(.W
MM!^!F82&V$$QGH/T'N@([#/X2E!?H=3W/]3D@^8.CN <Q';GPS/!*!D)8BN0
MV*[?P"&RJ-5XH YK8,LB1V#PETY[!\=W#MI##SAZ$W)N3]*S;#=".(Y(GRLQ
M=VCTYJ T],(N+=/V32*(;3\Y1RPPX@8HY+B1:0?&;&8Z:TK_H!)QP(<!?PH#
M;3Z%=T0TD+PH## <Q&(#<=R/1:>3>78!<2@+M2U;HW/&8$S$$YZ*_\(0F>UN
M?>HL'LAAL(R^22_V2^EVM^1$[C,V]1M$ 4I/>,Z+;=(-)_<<!Z8N@^E@%Z -
M,#^FF0I>Y&_/5JA+D>M,@L+)>8#D84SF%3-@?:S8\2E<AM^'U!\%$N8$*:TC
MRJ=T2?!*RZ8C!@CY<YT7B$2EAW9Y@PBP #<@02$>V/ 6XB>,Y-,!]9%3MQT/
MX:TV:-\%;@ZB/N@9F_CVBN3ZM'1FENMTTZCFZ::2]W3S"PGLX&YP:9I>A*!Z
MGAUN*BF'F\KJX29[ BK=>Y"0V/=M]\-,I4*'F4_#I=RX:'*POEW=Q(<H?4I=
M:0Q>-/%CS86/\RTVXG=Z%.A'H)?BDWJD?Y\^1W%$D8%\>O+R2,W(9T7'C$TF
M#?F!?T8C.PBX\(X>KZ_*%D,?9PW2[-$<:N;:$S:E2X8&0*GSSA3^NV1Y:$]@
M7Q8GPB-.QYD ?^[&B95@2?WW&"G/U 51YCCOB%DZ1FH@4SX#S,/S[#%:K+@H
MI"1P+FAZ-B5*Q8!FH*Q@Z$4.+ &-%L*H"N[YG\B-/61&5F@192?5Z:%J:AYH
M)NN*B1$"R&#KP5LN76!])\G!PT/];P#%F,KE5N/_QD-3X:7O%-0$BRM)7ZE)
M1WWJ+^2SZ*!0 'RV0ZT9RP"=L4?2OA\1_UW"JS#WI9*&[4T,L!%QR3.#)LM%
M-SX#^X]MEZ4-K& G,T(8)1/K?Z(@3,Q@>S+2 U ,=.W4@8RP6I$U-IB_T 5T
M! &"%ZA@0&Q,J1S'"H M>/;:B?N/F *N24M*8D?&Z_"+S<<C?W[U\!1OFHQ3
M9YSCTR%U _1 X^9)=8E-2,<IGM0/$IBQPGNLQ9^V.<?>I,&4VC"O@S9& )MA
MTNP\2(AOW:)QB9CW$<L3V'[D(,OXS/^8P@@H Y:%.28L&066/[D2WPQTA1.?
M_9C:F](5]1EN0#[ MXP#R B%QKS: *PX!.3ZP(XS3 "A*(CP5^;"8($I8(+=
M/9[3RRQ))7%RYHRH!=C.(,,R619>%2]JLI[$&^?/Q6:N6]G*!I'!'VBPC#-R
M03G$41?'"P*,F;@)<TC!S)(H&X!S=#T5[A/*COESD;97C,P<27[T=68"P\I=
M^-6,6>(>V,1\CW\^P2.^."!89E:RNFP/9W<8M,/DDFJ9@/M L;P$)!..H0="
MF&T?0VJN17QK1@$Y/:'6050F/C9+*"AM(Y>6Q^ROKY&?9-M(]XOC+"ID$]QZ
M+MW1F.$0-;>@*?\)0BE!4141 CKUUGMAY@N:!%ILDWV[?/PBV0EW/?YDWS1:
M:IU#I1!W)IOECY<M^:<%E[P!*O98D("O%JS.&( ";&L6QMJ?@/_ZU0[(\[-/
MGV./&?XTP0#!IBC2AR=P:$Q)45H?+Y:O Z-TF4*EY)&E!WO!1A[:YI _F)=N
MODU.3:9I[).B!W1WF($)!IX5DP X;"S""_]CD0$6ZTW<JCX&&.MXY80F6"!A
M%G@A?2\*)3/QFY+NN5.?!C/#&?'A"B4;/@R28Z)9&(/EXJ;&7>[7K3UNA))$
M?##'?SP&8PH?]!S9<1 /TV/&F)OP0C$&!%L:D7>).O#1[ X[A,>$\U=BL,<.
MF,J ?RB;IXDR)G86&7@FWNEL/",KKILZT9*<Q#SJ"Y#,>IL!MSGAD"7J@P>)
MBT?EG-1HP%-&=@A(B$]_ 0[TA3@8RDTL*WLT)B9+YX]O8Q_#C5/ >&ZVP%%*
M0'\AIIP:X"^WS#C5+JE$53&6 JN%%!6S^F3C0%7%VVINRRJM[:1/92]P<X?>
M5WK%=,JI'$B'#75,J_-:BB@NUEJBN%@4%V]"3UH[A[),GP*JC3D^9%;S'C+?
ML%;)3*7?N%]I/[QTK1^L"@HIX)H%'F<GF/!E$@-_\@E*RLL@H&$P<Q92HG!:
MREFUMGI6/;>0W4ZHV3-3WJ14)NXW@[NT (T*1I/B,D^'-H"U&H\$=H2T-7<6
M7L58TN*N,*-1LG!7<W'YV/7 0VH\40[9\9N$)CB=JR%F<8K8=XXKG:<A_V?@
MK/A<-PG^L_K9R:&5"?Z,'3:8I<S\+';F;>'I'6%';9Z;U.KRY_(2TXQ&4;QP
M=@2T=#;X 3?\,?$0RW:/T0G==$B)@5)'FF MK\A%3I@3J1.B^N;YR"A,\Z:(
M43U%N.FK8C0#C:)O9P<,$8.E4M</L'& J8.GMQ\OULGA=1)83Y7 .I/ E?"S
M]&ZSHQ?3O:D#[]_<O2G[Y[J1[X[U:Y+UKEA3)MQM7M.!?.2BY9VQ/?VKE:1H
M3](_I$D2Q7[MMX[;8"SS/D>H>4%DLQX\5][J(,X-N]PRIZ-RP/C#!XW+ /%S
M:H"P/_] (T0 9A4PWYE-=L:0^0;6+(/$?Z)%FVOZ[PG-T8X32#U8ECOM<D2>
MJ6O.9^BLZSS+7Q?E0[5/YJ@-\A'['ZO&YJ$3FXW_J8)"W73]EB1\7IHFV/;6
M9-;H)<93+]%DQQ,;N/.*^84HG1:;)[O1J&%Y+!R(ZTGKH-RN]>2ZH:A--6<'
MY>.W2=^QW;E@N/-FN&466V+ 65B"J?V9QD<KZ L%=L).Y6FL8V!)CR'81K -
M+UO\P /?H!K:R#<=/*5853<?!<OP1D]GP#+',^W667.Y3;9N;+)QI7MR>'^S
M%W?5KM[M5,[]F]0]KP36UP8&E/R 2!42)\!"G7*]HQ5NZK9J/:VEYA[JG(.@
M#Z"5UKXR-> DR"\K^1W*5^C*.#A\#WDM:*Q"AO6!B&R;8=U5D,@Z.QG6@KY.
M1H;M:H6NTI,:J\:\@Q</25;<SR#C]:KRA^SN,IPI>40#KP=6::Z=\)*-2XN9
MAOCDA<1)SR@_$C3%B$V. A#''[&I5NF$J:O5>DI=5MHIEDGE9G2* ;X\\HZ0
M+D>4+@=SD74\%A!#OH6,$#*B% CEBW&4%.)H@TO:E+.'.(1\$/)!R ?>;(CC
M')1VC8GGL2HP*F=5+!1K5Z*6IMUJ&AVED'H,H]G1T[\IKT9$K"G[FO3\M32*
M5N20]T6J[R[6E';+JBEMS;I644MBA?I+Y7@F&<?]I.V4KBQ]XK".+<&0TC"X
M6#<^_ERR,K SZK1Y+!9JOH ^F"^?7E^NL?NQE'A&8<\HY'B/2]+,DD:W>:LG
M=H+9/81Y>!5WGUVT$@?V&[4:?U+?2S,0.W-M^:IRQ'E:0COI&#R:-;ZP4QI?
MG(CDKDPZ0CKQ"]#Q 3J1"C-1)%KKH(ID56%T:[U.J\-5(M\YJ8M;SVV80F7P
MR+9"9? ,.J$RIBI#/H3* ,%DIKD?6X/4:JN%U3RJ;%0IS5)D"Q:2+5CB,>#Y
MO/IX4JP8>LFN#02^!+[$";\XX3_;$WZU)9_J"?_J^(3-O8_U29?CBB0'B$:;
M8DWGVVAS.M-E,DI5]-I<VN6I-4X4O39%KTW1:W,'FU3TVA0-F=8'<Y4*54*J
M+06]%4U5FRU^&C?M+D%$!S3!<$<J#E1;:JTGM_9ITB3X1O!-B3V!#L4X6PKF
MU):&/8%$LTW!,CQL\7BV76$19IW9;)K:5/C1/>>4\B6:;>[!0B4WBEGEIG:M
MUVZIN4]K1*.Z4R2_@SD+!G82X2E'5]!8U6ALR:[.6E*DMK@L*1+TQZ>*S=Z,
M4VUU477F;Z(FFG%R>)5(KQ7-.$4BW&DDPFE5.H*26V :UUOJ223,B31;'GE'
M2)<C2I=#N="R7.O)6NZ8IQ 20D@((7'\;IP'DA+;#A=E)>?AHI /0CX(^<";
M$7&<DU199:Z'WLJ=_<:AU%BLU6%1A^K4WHC&G&)-I3;F+"NP7WRK3=%D4S39
MK-0S"CFVXY(T19/-):/O(%;?VMYHJJR!?6?L4]H@6J.)3IJBMY< G6B+5H*V
MT(_6DCE#J$#'GFB*VDZ)+0IM<@S2$8TVN>5JH5%X!IW0*%.-TN:KT:;<1J5B
M&&VN,L-%)J!HM'DBKQ:-&P6^S@I?XO!>'-Z?R^&]<=J']ZOM-N>L'?9DV[7
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MM@!+?7CX^K6+?<Z_ Q?CW,G&=9Y,@WJ$@@ TL3H"#5'CA=VJL<4P_I(UE0T
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M=%MC_O8PXB?,3WOP@:'"PP.;;'CJ \MIZ]T*?0F:93G/!&"Q8@.8ZS4H;50
M1OSD9@"?>C[H7KS@8,'5*!70VP_HQ6L'B_T#S^2!&]J4S (/K/ ;YL@/SP"Z
MXS$#+<H%_BL LW7)2@Z#04W];>+K"T5_G*7I?(5 JB=3CPYPK%+P]ES!E\E,
M.Y<N+1I1)7' 6FY3ESRD$C<)%Q18 8^+T9O#HQ8,SBB\C@1AI,BW'K[8JV*_
M2P]#YZ9I^)9(B'!G(=(?IVK0)66^663ZD!CLO9CUC)]%P>OF_O[&MM4P#6([
M/B_/K!'T$KFXW+"TLF,G)-6127<@RWA6*&.N$VG'+%EX7$G>,68PJS6E'=?4
M/^&LS-S_XMGQH$;@&.:X?H'.36<D5D=#7"(ULUC&]>2 446^L<@W[IPE6#J]
MN!O+.N(;D'OS/Z/D-,QD /O%XY8&V$R:A6H^[I4,[,AF0EL@TI@>]WSA2<"Q
MPZO?V'F>VU^4E>N!;[(.KN^ISJ_4HZ,)3ZH);)S=HXW!GWM'D?A50C3%: 7A
M5< 9,?5*AL,-(V#^B$T)3H]OPPE]BJ;S*9Q%FMMMUILKPT$RZ&P_2A7I46JZ
M:CW3'0WA/#L=)(O:[4WWX%B;M-)2CH4%O89J1[V&4EFOX0-]1".?&P^P*<><
MAZ,4C]Y(2CH/PS'WA=@)/D0^=LH;NU-# 3TM[U8F79(//ZG.NKE@ETXXS;DL
M-,+9?A]Z?T"H@$#B<1B_:S] +#5^['_WY?WOC9_Z^W"@L\%<\Z*+KPTF\#'Y
MCT=LM .V!$0IYD: AM,S1Z/FAX?PV*'8HB YN#]L]_/H!TM'#SS>?H/%!^"S
MSB9V)%X#EE%;A]EYJ&1 [J/[P.,W^H;+_%CL!G)-?6)3:C!=M($?A$7TX "L
MKUS'#J]Q+7,)YZ\5NTMF!_/=C3\_]X;WA>Q>%-:AF[M0D^R8&;ZBHZ[7E)"9
M*.MO"\V0L<OF^8V 7T%!)]V329IC: 6[GX>)L,"7E>,AZ3W=-1=1")Q/B=R^
MNT5VR2W_^A"L648I[,D#G(]8B0!8V/UNV[Y&V]8T4VUOD?/<1 @;C55X##U+
M]S:(:BL\<B*#? 0\$&EX]_^VSA7FP^*NE10+"[9V:>(=-V, ?/[APSLV$%VX
M&)G'%7UXN=[-$IQ,]H/LQ+(B+GT,+)8;S#Q61K1R%X0*NM4BMR+8JTA!JFO>
MOJ49"I8]*;2Q8'I]7B\092,/--G>(D1B(<%E7."QJ:U!\+"$\>BEW-X&!@U8
MD @Z[MB7(+O\R+A^7E&;.>D\+PS/8.(  P!86I8%5@-_(0P ,]#1,ZJ[3B@+
M4^83YY1(%(3D\)A,""/,>6A'^WA_MZ3MK)MF[C0?<(RE$1M;I'22O5 9AO'S
MVR"KI#X)_>I>:!!D.,?WHX_:B3&><, 7U#2X!@G[O<")@R5QA 5!ORP_4WB"
M";]WCN=_67[E NX!; ?OWC;^@>("/H,3X]N7\#OF[TDYEBB'!Y"N()CM:*@"
M6#(WOQ_RD 8\*OV12<T-HP-Y!0<SCU_.4TU?Q0/WN"&Z,S_QMSS<.A+ \'#T
MIM!)@7(=;\$\\@IX(CQ3>Z_?Y D#)-RH.S5-)74P4V>E+A>R/U>EXS5-BTYJ
M.I@IZ=\T.:>Q++=L3K.!K+1O[]I'I^E@,BEW@7:K<VKCWHWEZ3E7EI& !1U,
ML[O='SY5RZ#B*?&4@*-XJO-/"3B*IUKTE("C>*I%3PDXBJ=:])2 HWBJ14\)
M.(JG6O24@*-XJD5/"3B*IUKTE("C>*I%3Q7,3AMBYM;AJ.HT\5Q*CI?.&DA<
M+(UMDA]E/.3A/)@V_CM/&_]PD)*9;"=9?=_0IA:.\8T%LO;"\ J6:H C$Q:]
M1'".OQY%1;DA&D][+(R7ER?-<\C[KY]:3;P69506I>QGN@@LEO;$:5RXIZV@
M<@DJ?Z-KQP ZVW7%\JF#Z:3 3%)2UI'Z=_)@+">CLK#V!D\<?26_[@ PVBF[
MOK@PH.]JZU:+KG;2#DM]!#]-6Y"N-.GN#=UT=4U0KCS#8BBMH%MY(PTCG,L8
M[W7H_ZH77R"\>Y@,[ZX!/25I-B1=H=POA\0JN](&J[847&*Y,IS2\3*<82+%
M1]=98RD,'/-/TU^]8^TMJ?OA9YA%=L]RME@V?B\EZ5[MS15E.% RLN[/W!0
M'BFU.6>)2,$GM\@G\D7X!$O8RI-!LGF%X!/!)YW@$^4B?(*MX.1Q9M$9P2=M
M Y'@DP,^R2IO5"V?8"%B923X1/!)>Y98CD]&%^&3:6\^4@2;"#9ISQ++L<GX
M(FPRZ\WE0;)-H> 2P26=X)+));ADC%U>A:M+<$E[EEB*2R["(U)O/ID"6=O#
M)26NCW8OGBFST6QZ3OQ(<Z!X%Z\)5%>HR&@PD@O,)CM49#8Y&BHBG18JDKF#
MJ5>H<GD4I(J_*Q .>?=%O.+6/QS'P%);#[R]B/?@6$::%)![\ZERCK<[CQ-K
MT)4".C5=H92#C@+0.>? +I#3(>3D7"J40X[:FTOC@22@<Q/0R?&SEX/."*S6
M0;(9GD#.-2(GQ_-<#CEC] D,!7)N CDYSMARR,$K/(&<&T%.CH.R''*F&"0A
M#)W;@$Z5P)EAU(#2*D,GSSNGZ3\>72>PC;MPA^B83NCTUPJCOM>F85A'2X!+
M!WV;SBL!?KQM4]%*X/](EODN[C$[AZII=P?G[E+A2X7M7C5'_>-W"V=3(I=W
MVD*"2MV+L=K]*8)K@KW=U$EIE5>!\"@HT,)-R5:%@N,$QUV6XW*\LCD<)V%G
MP/*.6,%Q@N-NEN-RO-DY'"<CQPU+WYP+CA,<=[,<EW,)D,-Q"OI1IJ6OJ07'
M"8Z[68[+N3S)X3BU-U>%42D83C!<57=..0R'><>E _L%OPE^NR)^>W7F59T'
MBX&_E>2\<6\^'DP3G/=:,)U@NAM@N@KO.',8;0*,!D9E%^X&PLO.: X1P53>
M&;?)\F!B"#&$&.+6AKB^LMBC C7S"E)2/"8>*_F8J%0I*E6*M.2R'J[I)1*3
MX2US92BW*3%9\(G@DS)\,KL(GV",\%A)\5P)/A%\T@4^F0XOP2?PEKFDE \>
M$'PB^*0E?'*1@C!3#"25AX.)X!/!)VU98CD^N4B%<'C+?"34B6"3%BVQ')M<
MI$ XO&4^/B=K6G")X)(FN>0BY<'A+>=5I1!<(KBD.2ZY2&GP*=;\F:GG),.+
M2I6B4J6H5-FV^Z)2)3&F8Y:1(&JIW 9T<JY0RD%G@I4JS[A/%,CI#G+R+A7*
M(0<+.)UUQ2:@TR'H5%G":3I#H7-&#P*!G XAI\K"RC/6O4*4Y+X-Y%196'DF
M87<@49+[-I!395WEF7RFMUX@IS/(J;*J\DSIS6=GQ6I6#IPSZU1&A20/78:B
MC&6-92S/(?H)>:SG[O'-I+F>3:CKS(+-<VP>SX.=J6"EC<K?9]0ON"Z4EBZX
M77![E[@]QQ>=P^U8V&54OANEX';![8+;+\_M>?<'.=P^QB!JH=L%MPMN[P2W
MGU719H:=@219<+O@=L'M7>#VLRKMSZ:]^4@I[207S"Z873![ \Q^5I'_V:PW
M+]]_2_"ZX'7!ZPW4@DU>AI]2"W8R'*:W^CRU%JQ@>,'P@N$O'L*0P^12;PY_
M5%ULO0E>9[$.?_.UA46C6_C,F(+Q?DP!_C-\_1TRSAM)':@1/YFV06W_S1W_
MK(ZXED(A![&,G28FL$\?E:47]>;O Q<^(_Z*PO^[E)(U#+/R" 6:&>1WS=57
M1)'Z1![*8Z+9!OYEU"?/E+A41RP8Y)<*:RY_LF')ON.^_.F:/GWO/-MID)=[
M<U7-1#S0SL)IX&Q+S2V'#XO-#4.(,D_5T=2<)3&CT8"0L)U/E-"?&VI[M(\?
M;*B.J6#6RX!\?WG2/(>\__HI^S=$TW7@9=\C2\<MN2%Y+3*++5N% \8L,\SW
MY"W)#4XH-KL1QB!GY3W$-H6Q :LPF4WJ+>Z-TUCG8'?AUX5VV+1UEVH>C&S:
M?,BU9MK6"UE070O@@3A+@G2AG@]$\TOS9V$X?#3=]=< %@F3>N>LUZ:_AB]^
M UV5M@/CWEQ.ZTNPOP48AT58'B3,VW>(!K-;KZFKF[ E7K#9P'JU1Z UO@J)
M9WJ[?Q/XAPEK8>2''V]<Y\DT* D\\FSZ*_C]<FGJ)GMR2V9X;DVISW;1IM3P
M$ 9.X)*-YN.CWF _+.RJ%)+<0H6T7^"5\8T>3]=%1K "V%;^+R9)EX&'Z#$H
M"^[LAX]$S/F-KA'Q+R77:@>6E9G:FYO9*Q_+[)T>2^P%CIBHOS:Y,;TY(WM$
MMZ_?O@C2%2?=UV"].90:H=3['( L,W7^;Y2[IAUH3 S&Y4HXW C%19(.SZ;A
MKZ)#1NQ7H1@:[GZB+< V#_SLG^0),&P.@<;X0: ST-+2-AY]$_WE5\/T-I;V
M\@;T$=*#_>C7_=%'R7UCHI!_O9OB8,BG&88\AV\.OQ[ 5W]+?JX,Y)F2^LUP
M(*5^GC723!V,AI.C0]54N[Z>>@B%RM=+T\*1SZVI%E[H#/X'2"\P!<#$<K4-
M#6!FH!LTL@D6EJF#W613#/X&DVGCN(P-]\[**:?1^)\K=T>41WJW ./LQYVV
M]*G[1K.>M1</P1)G-N"%.&>?P909U%PNZTO+0)G,-MM $Y,1ZTT 5HS+!>_?
MM5;-AX Y#M;L?YC:$@"K++0)U<:JNAPM=&.D+XR)IJB3T4+1_V<"!@<3<6!'
M8%$7M/C^_C=M?KK1=^CN:":-AJFBKYKKDT\#\M&T-9N9T)]L.!^N][$>P_2!
M5HINCT;2G5P52&M?]#^H\PCLO@(.WQF1+@7C$%@3F! $PH(=HV!]:!VR<S,_
M"#S#CU;<^'<=(]!]_DMO96XVU!B0O^]I\:1C([-<T(>?\&Y;LZ)20=[;E]TT
M[_%8QT#X'49[:SGZC]VQ:<+/9[ CU+CWP\_P712.6!MXF^\&-&$T+^&=<'#D
M+R5Z]%8\.>*20[GXX,,QBUO8<-CT[YSEW;/C6@9YE;17.%;2\1'.*&6>\D5P
MD-!J# ??OOQ9FR%8$(JOF3>&:@@J?JB,G6:W$'NF@#$-/3>6Y3Q[Y!7L4G@>
M]EZ_V;)IPF(\QK(1\:_0V%/EP40^;J(5'6HZD$:SSH^4_;DJ736=QKGT2+%@
M(_2"=*,%S/G#QZM\JL%7BV5TYBE!7D'>[CXER"O(V]VG!'D%>;O[E""O(&]W
MGQ+D%>3M[E."O$V2]WCI-&D71GX\UO6,N]SH#7F%L.)CZM3VJ=M,'W/FK_[.
MHMA^YU%L'_:CV I?$5>Y5;/#G2I;KXR3].HV"L/_3BK^7R3G05 _G_JC1MBA
MW)[>SH;\,7@XC+<ZCQUNAW2Q6U)!N7+*$J_<2P=.";X6?"WXNLV4*\?7)=5[
MA65W3R%T@V%9GZD?A;SPR/TW]1NP;1NB4Y.M8(@SF*/*/G.%Q=!^OLX0<PT:
MY)A=5E@ZIY2E6OFVE">*\*;#7G^IB%[%Z^1WE%#E:E)<HCOF9#CMS15EF%]?
M]JRM+5V(_^PM%JPK6+<YUAW7P+H\D>#_],R?_INE^9,:=_]+72>-I6>8F#>5
M)?E7P=2"J0535\/4>7GZU>AC:7@+^KC@64UPN.#P2ZKMR44X7 (.'Q9H>M5I
M#A>L*UCWDJR;4[6H7HM;DH7%+9A:,'75%G<=3)UD7N46]+&X+:C\?FT16/ #
M(ZPFEW.[=IG^L;<@%:8Y_=0JD@HJ[\V2VPW[.J2"@&=5\)SE- "K")[8%E 5
MZ!3H+&E2Y;2PJ0B=K(W=)+,Z[97!LV@>A$!Q53+V,JYX;,^F3(60%? L"<_+
M"-DI]@&_%1DKT%F9"7"9\],,A.=8R2Q ?F7PK#Q >6S@_R[O5U$&S5:3Y(45
MSW"IY!!1"(5TE:5<0BC(0^PC(N>WSLD3"OF<T@ZQ("!:(403/=IJ@:A4C6-%
M(/0&$7J1B&T9FS&-)N??5W4%HJ6-I1+>%P'TDX!>1WQS$N@*6@O20+H5H N(
M5@C1B\3RR6HU/AB!T!M$Z$6B6^01"-'Q^/QX\JY 5'AB*@+S-[IVC  ^KZNK
MPV@P.J\U&?:OR^Y-%NO^*J19_=+L(EYE&2^6A]/SO<I=D68"HI5!5!Y>)#)'
MQEOCB4"H0.@)5W.7\<)/,3IG?#L^3N% :AG0Y>%% GADO(.6A^)X+B!Z D0O
M$L2C#+$=[& H$"H06CH1XB+VK"+Q*,B;$:)7DB#5M/OHBPL# NC6(C'J4AKK
M(J<'149Y,!)1T0*>)>%91_Q.X11]1;F-%'T!W.J],A<)/%/4FY*K(F?JTN+W
M(L%IRHB[7":W@6(!S\K@V6C)3&4LK ,!W-.\,!=Q92N3FY*KP@=3"9#_ . &
M/W<1/$(8U*W%+A)UJDQ[<W5V_J5!-V2!0&=EZ+Q(Q*DR W3>RC%6@+,R+\M%
MSJ?JL#<?*;>"3N%DN;2$O4@4K"H!B,?G9U%W \0"G56A4[I(P("*%X2WTK]
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M_>):ZN$YZZOV@F_V/CHN.W(];"?CI45%8K?7P?_/WKOP-HYC::!_1>B=722
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M]?GJ@G+J1 K,29I6RM\ [W\^O^Q^OKXL7G!Q(;$/-91?"$:=(_/F# >P5''
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MJM<+8T@G8B02U6;43+EFD/($:S4R!SY'31NC)H1*O97U$W\@4B8!LCCS.%<
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M@: <*J9;B1Q$6/ITGB(X&=)+KV*QO^!A^>TNI37(O*PE$_ 0A-S7GUY]O52
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MUN_T;Y,Z1/HI&\'G14>#3KDH>R71D!"W+JG^"FN&^V>:%6Q3=XSWO8YEH%'
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M8THO5DOEZ74</R<8C2*HZ%5\7#@=U1-(0A^8_EI":D/H# X$EI*N,0Q(Q)+
M#)7%E%S+I&R3119$90JQO:ABC1*ESMB=5**-%=E4IO$IE]+66,.&RNY";4LI
MZMZT MQ:&^%* [=_8&2:E^^A^\/-4OCW)W>(%R#!?K8%.)JGUC2S[E:]E^@;
M?)!K;N%0#K%5L)"Y&QH<#Y,;I!R442JJ>)$P>3WG-XK34RZ$]JYUU#ZB>P)$
M^33(Y(SEA$P;?M64ZK.M4T>XJ-;#/_[N1JHNYZCC8.H9^MC(I/4IA2W(R.V
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MC@JEZ\Y3VF]&L%'SF:P67<!6HV0I>=?X\IZA^U:JT'P3&ZY]4C\U]; ?!-%
M(>K%&.AW_N145F1:ONITV96B>1R-8UC:UE[D>3@O\F&X-HJ5&P66IRYWXY9"
M^0LDI$./'[7QQKIYWX(;JY1;45Q=II6E[Z]J>E)5J2)FA3WI,'PA'B<%8 CV
M#>,:*78V(O&R[$RE(:B>+4'$#3?,"%5;J@ALWXS7VC?CQ/;-L'TS;.V [9NQ
M'?I3ZL4S8<WVM<QVL$V\)!BB:CF,;T4Y'2A010=&;:/I9415E-UF946* 8B4
M"K6E*O@',4R4,^V@PT%S53+JZHX5&-ISP9@:BX@0^)LWA]\UWS]RMY2E^GN
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MMJ1:Y<1'E70H4JO+LD3>3R@MNJ4O9$:M.IKJ0E5R0^8?H&^G7E1_8AR4.-D
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M*I#Y"F2%FJY*/=CM._3==_#'R\9=\F/RO%*W+:G4*I0\W7F60 =)4UB*DFC
M])GX_88:5UY)SSE?.I:RKBCZ4(-!.,PS W\>QIWKGXCO H%?2!13 4^JD5[P
M"<%!W5S.]]^(B4^IH=Y$^#E\L\.YB,4"/#"?=^DLFF>3U7X*5$A4"$P0Q\6K
M;"QY<CO&;=ZI2"R'>O+1DK?U>,4S0065A.8X@>^D0D-:VJU*><>O>1-2Y%%2
MNC +N-*Q5VMQW)8P#G7/X*SH:(L@ .<?"SW-U \_ UV_U8) E3ID_1%$8.TC
M\-,.GEXPZ+&78M=+DV^['._$AE_XEL (4!Q0U5*Z8M84%1?(92DZ@8)T4E0#
MJP1( NODU.\Q-65.L+<Y)T]T^)YBMF'#$W_$ZC>W 4L9'@68WX\I?J(.9$?K
MN$L;K]%BN".'#.'!^Y5I5&[#;.C)LD@+!V5-6?AEDR_ 3A^1H'%[SCO=H)G:
M!\KL:S83E>Y>:CPO_2XR#%T2S^K=>/F/8M X^ R;_;#18N_(-D%8>A%2WCV+
M326/B&=^ZUWWU";$I$[D$4I]),0]CLE%;"DF4H7^NN+<"+H8C8GB5E8=G;_[
M_?S+V_?.Y6\W;R\_-Y\\W&DAC6[>WUQ^Z?:;)XW94*5MY!DT31Y'=G22('M:
MZZLV6ES?<U\O#*1+7OO,50A*%54HUU!5R)@0P\K77&,6L8WCN3[WS^%>NJU+
MX;9M=%YI&YW]/=M&9_,V.NLG'IP,?K+9WC;;^[7WWFE%,LW70GF_)#.7HAH/
M!)PX>!+X,AQV'15M@J&=S_#<)'7>$R@GF;7L5-_O=PI/[>+GAX^]XO58\YXM
M7+>? 1N7*Y33YZ#_ YFFX=J B=2(T52/[R@5A+%@9/ NCNA/5%KCK,B@2)T=
M'Y6]A'RD,E20[K[Y$1ILA6IY!+_JU^N0AFY9HRFI>4= 4?M4Y:FU2'_2ZQ^>
M;J35+__\H+]:J;=S>O0Y':U^MS2C*C;OH,^BH=7&Q_']A?M[LAT$W+AKU,"V
MXDP^R5.GZVP>UQ^U;OMJ%*R_#I.??^'@ 2A2&U0W[^&::TB8Q'?\[T'[2K[7
MI=,[4@R8-F\)?=,2A@ASA3&H"..5RVA3+P3[ RL$M^TIJ;^2D824D3BP2..S
MK6-<-!S7V+%UUKSL?+]0LAT^@NA;]M@]CN<'DO)YW;;WFZE$R2]"]Q[CNIDW
M+UZ M%-D/<+QM4,\S1 ;B(-BI-/]T\/3DP?+ \/!4P;:70$J_BP"@[4,\W^+
M_(^U@UMM/:BM>&I3MMISMN6R^4OU;MEXJ0W"<JVYQOW]O=Y^O2K^ 'GA;+3J
MM<3=TE>:(M/RX%;SX-Z@=VAYT/)@@VL<'/=.MIX%]1B#S;6]6G9LYUZ=-K11
MS:WXO^N<@U;!KU?PET%-6#7_49YZV;*E#Q?!P%X$6[)91_OVUMZ6S=K9/^H=
M[=I]:OT^#0;/OTM;J%J9?M@C'_^_E@3]?N]D"VR\&TKJJRA,5E5Z"E7I'L;9
M(E%Q<'B\@>-FS0/SN))]Q4LWD.TO:,N.CC;P]]HM:\&6[9ST3M:YD>UFM6&S
MUE*>'GNK7J3ZM/V^J:]B&OLY?/Y4Y=*'O</!&C.I*1;&/>@.>J?'BR42"/#-
M=7@[_5WK/+,:X4;N,S#RK7JQ55NV?[*!Q]-N60NV;*??7\^59G>K#;O5B/:^
MA2KA6B[%+?&G:?QTZTRS<<>U;N'##10G&R)I6,O=ZQW;S=J2S3KH-94P9/=J
MXX-E4[M>H[:$>%SY]R"RRI)5EM9@E\-]JRMMS5YMXEVR>]6LI^+ 9FAMPS:M
MY5"R"M(+4I#.?2](/-?J1U8_6J>8R5J\V[)51[T]NU7;L54[^[V^U8[:OTV'
M-G_]64L#&PNQ85<@JQ%9C6@=+\0+ +EX-5ME-:(MV:J7 !WS2K:J*7_YMBA&
MKO=MG,1YY'?E',61.!8G9Y(R$E!^ 7QM VQ%HMM@T#MZ#M5J=3^%S8H"DTI;
M!:MJ_1A0VA.SVC/B"CT.ERV%%WIJ0CV##'L<"AV?].^KLWPF^?4(%_03SK0.
MCLN>-GO:-CQMIP>] WO:[&FSI^T9*+33'_1.ESIL[4%;PUQMXM"UFZ>61P#:
MQE"-TZK&3"ZW-EW:NXVZ$)?JK>'>5%P21+Z(LC==_JR)1J\#EBZ:$YJ80)D^
M!U1N7=/$P DB+\Q](?^*1_#!*$^#.')\<1MXV.>:'PEDO^FO8LK-IK&+H_KC
MZNNE<Y5/9^GR#M)M[D!H(! YT0*)?.$EV+?;=[*[V)EQ!QTGBYV_$ J-:CU(
MW;>10ADU:9K&U*1)%%TP'=4 L^.XJ8.=#=T$!\6!$!ME8:#4G0I\7Q#[V.(0
M>WET'#\)8/W.$#9 SPR_76@@OK"0C@,OS (W#.>PT:,4OH=10";=91,<H8"G
M7_QM;^6WR"*21 \GPM(5SY( 6 6VWO&QEWD,G*=?B$_]F6,;]BR >8!LI.[F
M?^D?]?8T/8%3._0[!^8*3,(=V3/JNYP C^O1>FM0T6"'9UEK:9-_ZUWW:M>[
MOV_PSXKUFH,%V.(LHG:SP/YKLLL"R;;QP&MTC)9M;RTG]WM]M;-;26Q=C[H5
M<F.O-UA.[4:(V!_<UR276K;[\5U4TR-W*+([ ?<%/B=[SU]G;@;?X/T-HV3=
M>-2]BQ,@P,Z3*2SW=ZNB57Z]_./YIE!/Z%UGYW5U$SX8](X'375];>-(;>R.
M^RPCK=<=]W&#4T\RZ*N:8%N?LH2SA+.$VXJG+.$LX2SAMN(I2SA+.$NXK7C*
M$LX2KE6$6QW4[U>3T)<%I!\!*[OLW>J7?6>5,3'8)I(G\%\?W^^4Y.@@>:0_
MLT?Z?=DC78-1_2.;<%I;"+#!!C"Q7MP6H-]_;3CP!^>U6.HOI?[A(S/Z9KOU
M>DB-\=U'9?370SHC=F0IM]D%AQ'#M6EGS[4]U_9<;P/EEIWK![;*>2;=O\%,
ME87LR#=/KW2V;8BMFNQ&0S3<N_Q>T=&:!E(L/'2Z9_T9V)1JF]?//%#L4LI[
M@X3[RR/1:_TT_BTEU/[^(HC##Y'L 140/T@Z>R3LD7A,0OW/?YT,^H,S>RCL
MH;"'XL7>$VMJW?;DV)/S@R=G;[  WK'5)\<>"7LDK(9E#X4]%/:>6'HDK)]O
M,Y]WN>#Y'H_W\T!5;NDYZO<'"]VAMO<<V6U?=]L/[*Z_PET?'"^T%WL9V[YN
MQJCECA7<L7]BA<+KV_;!X0N5"7;75QWVH_W>R8O9]@>F!QWY^/_/;T'M]]H#
M'O8@X^D>(KZ>8W1PL-@][KYC=#\'MEE^VJU_N EE=_Y%[#Q!*+[0K=_XTMS
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MP4BQC<6[R%&19%&AD>0ZR6XGIACE15 AL045/DVY\$E3X1/5/+$8'>Z' 58
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MLO%=&^-EY/RADJR%08H.O0KBI(S("T-A L'['4X")0GCWVL3"6[/#L=?TA?
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MRLDN"@6H0]CC/!.#5"QRMF%=C*"=#D>-<S%120&F32D6S\4DT:/@S6<=U72
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M>1?ZWEJ!+,+'FPV1\*F2!$7T"O^9L5:^2^NDO2GC]$V<!'TCSL'KY4RH'P5
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M5_A;/ N$YC?UGUA7"2]U)U5E>'/3Q&&T55*R0">(]()OXZ7-'^'41S-5X(;
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MI-A]M!\U@<0.J[!HR!2Q-(+@>L!FR11# -(?REJ,PR8"M0;?NFAT*+[1-L9
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M&LFO69YBHOBQZ"3NN&>:Y75T<D-.+#B,:JPMZP'G8!.,T5+*'*50;J]HPM(
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M6>4W_39MK%JJI5T7X,/A;&V ">5:!)!085EP :L#9VU;CV8GC8F?*=Y=2KB
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M(6$\D'7Y-VAY&(KE7 Y[D6Y@@,B]YCWE\CB\VD:57?13CDO<PK.6(,YD*7$
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M; I.PT5H"/(C_DF\)I2KLM&HREM/=#73S""* '*R8(9+$8Z[@CBC1C #PC<
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MXB1TD=P++NX"T2,[S'@&'4W _[9NUP:*1W%_\PC_'&>& B(P$)3.H,Y&=L^
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M2W#&*Z(Q\B$'59#L!V$Z/$I$1<&SK'-11;F]GN'ZD\>-8+PD828D/.QE@88
M<5"W3%\]/="]Q5.D],Q](20)$S VW4V2$0T/1\4H ,\1*A33$H#_7% !TB":
MZR8M]\50&N:C3A,DLF8R:H@>,/5E(\RL,#Z7A[MD3.7)2*7_IM&W9 I.M +K
MZ5P6D6XSRUE"J'=\( \I+!6W?(N1>9AU/0PB4ZI:48&:\\@P]//A8^2;%;I
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MNIX.1S4=43,'-G012D@XE3M154ZR//EO9-)"08^?A[U^YYQ;3S:0SQ;ICZ9
MJXKM,T#1515V?J'^!#VE]LLHQ6#*,N6>2]=PH&09@+'+> 8Q\^TRD2[.O&.
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MY=0AMDP5+I$CER;/$XP%+^WN//H"]Y^=G1P>G$CW/X/?\-+_$2LCX&7XS':
M"-Y'#*R:8$% SW7123+30G58'BKC?8+W#RV%;NDM3D>/,-(JU>ITJAQ&6LB.
MBB"+F!IT9$1L=V"-KN@4#)M@EY,YOG,!D_(S3WF.6OB.R\.7X&_X G9 9KE]
MW2&T$GLMQ"?K0;P;:%.8/ MJ?9U0Q\:,W_SA$;%8$^0,AEI83\O#&F?_;\,7
ML(-Q=(7XY-:AK^M.EQ$?+6@?*O1%X&HHMBV"ZI&-D4O^5%H@U[[T.'$QY]>8
M6XS,Y-626)5@I 7KH\S;"+<<RCV&X4><J0%<C9"M$>/;(K0N$2<0__V8$27A
MR:+4XG&VBH?B(OM*G$^+_'_GSC$7:L0HZ?<XA<[?I_NK_HY1M\C+MXBP7Y#C
MX2\824=4\7<VK=;S!ZN>EWP,Q<B(<VH1"C+V7$$9P55B/:30>OPP*]8#ZA9Y
MN>^7:Q=]!X$-KBW7BC,9:B5]GD^O1>!H%8&0UX^&XO:CFG&7#%L$RC4>EO6_
M:JIU]?&JJR59BQSZ/(&,%A8/V)8)+V2[598N.<1:IY^L.ETQ,A4G(\ZJ34#4
M3:1K),RGIRD 8DS^]<^/AP<?_M.^Y-@O\@S06X5Y-:+0.OU#>EY5125%WB(W
M/^.QG+7N7+DCKM)PDR;4.CV5N 9,C!B7%OG^'AB-J_@\1J#U=2HIC8A;Y.*,
M?+Y/'6*57ZT7<2@&X>3D()4O958&C/<AQS85L6-)^P -G4KI4Y)."T-F$A7P
M,-[[7-KD^LSLOQ((11RT<*0RJIPJ0ANAB:7WE7M%DDX+0RK;BO%HH^MS:P25
M@-!QT<*2RL>*ZPUM1"H[U:T$4R$++4;IE"TG9VXE.JD<N!HR>>1:5%(Y77XB
MW4I<4AE;-5SRR+6XE$G[V@A(;!7:FR/B2 > 0YZ1@V7A\QE;'B-RB_(U%G"[
MQ@*Y'%LM@*E<,KY^-HVE%!/$F%*.*MP:D23C?2"KI?!>>4QN58*)^X&ZEO^#
MCK8$^CK"=*%P6/3L5>X;\<6I)0I(-P/Q,N/=1<EZ@P!Q7UR&D4/^Q/8]Y;Q/
MN=)A2X.#3IPV4E*UC\J#!G&-2 =#*F&$6K0]5!X0DUN6Y[@V^BD.6D +JRBF
ML638=FRNJ"L8LH2'G"](!,&<'H"_(/85_ 078K3U!_T-"-5&0*IPLS+X1SH8
MD1(Y8W^D2;(:U^[8B?U)7#]5B09$^2:#)XQLXBS 2YA-B2O]MZS%U8^>S8C5
MQD]FQ2F*G_@O&/N#3"TV(:A7.02J&'%=8A7$70C%L>PS,D<".XO_8D=5.I"[
MSM*R F]M,*3J7(7!L!1F2FG&4EPKT<ZLOE<#M9"%%KM4_2NW@M]"=&)E].H=
M;850BT3&/H98$;^%WL^MO\L7Z=B>@^6SW)PFU>#:A"0MOJG:F>9I@&F$TOVG
MS(G&JT\.=N$1(5(SHRK/3PMUJLJFA;K=*9<L%U0#*TZA@^,H5>E2Y8DV.CK[
M6=G/V,4,.37[336>6K!2Q:;<!W*F$0AI>>_)!J#G.,&;C?P3ON'UFS?Y)[X$
MUXV(&*KA;A. UY&G#894H:H@&"(%PG/&RYN!#L;[0(L?C.%"C<2[>%DZ23UA
M?53G"^O6)&LPUD9 JE!5$ %*DA&(V@T*69V4<V_J^^>6LC@R&QD"M-RU<*?J
M2D4=/A)G@+P5^'>@1QT0"2]\!< &X2[BJP6Z]%F5X#B[%[UF8 =Q&HK,J\&T
MMQ&LRPC0@EY^LU7!K>5DOD,_8X:]></,(H )$FC3LW<6;RWFZ:U<92?P4)PA
MY>W@7CKJ"7/!B*5>$0+^>@%QFUVQE1*@!3Z]5RP?^$AB$ -*YFX)5Q(<?X+<
M%O1)[EK<4\6OZK@'$_X.].5$.YTY=(&Q<E+?8]8$6FPJ<]<RUT%^G"JP%4 >
M2@L #^6U.!U/[9*.GCI(WU$7JW= R0-G%G+M:^)XT&%N$'.).^9J1Q=FT'(:
M+-,JQL2VQ&NC)EWIR]_DG7P8$NDE?RG-5$4]T,T(E3/>2_5^,$!!P]?0C\Q=
MG"FOUETTZ!EIL4\7]HJP;_<Z('8:ONI3Z!2A%IB,C6'1:?I6NC]]6B)X[%"Q
MU^C8:*%)U\8R#E]$#T5V6/E.IF.&9A-BQ2ZNCUP!4RV.Z=)7#HZAD.3IFAVL
MP/2*NA:6>U15TD+XUW4AS66HA3-=U,J$,R' D!):"67T[HIJB*7IM,"D*D\1
MC[^[ZS]UD]^A\7\GOE4COU03?'5+ 2._DO%[SY[+%^#WT4)>?\*.?&OL@":V
MQO02[VQ#0ZYVBE]T1LB17]Z0G]^YZ%1GY!)'[2N_Z CFR2]XR&^8G4-K0NV!
M^L2&[?F=)[PW]-_6?]&Q&+:)_&R2!\H0X:DAFE%O=M'Q6Q*!IQW#_U"'?P52
M 0@ MKB#.Y)[]$6?E$\"&_B ]BQ0E^'57=6_0JA23Q1MK,[UTV:8-]9W\M@:
MXI.;-UG'A27DH_N A4K!GO LR/QYKG-*4C?6^C!E?1P]8S8G\HL51?67GCKF
MA^/5&+\4'J^[J[.U _PF+AVXG^NZOT)T%;^7<O#R,X3G(I12R<L0'4]XCET/
M7U$N'N6>3=NSA#RDPL%"D,LY7!L1<;D([E5VYP9D-,1OT;&=:+0)#GU^P=,A
M9G%O^)KZSBA!N$43;3I%Q*UI7W2,MKJ):=HF6)D\ZKD\G77K'Q++/OBYG#EZ
M@?%Y;M@0\XW[R;\B'QVXX[5]=#>=@<J20IJ1.P148[+&G&3CX?:FI&(K@J-^
MBV K';9A1'L&'T=W8![ 3]2!)>?X?QBQ1Q</)J#<> +_P30RI4S(@)!CHWI!
M6DUW;D,1/23^%TW%WP01^4LY0[\*_4MU:"@.V6?@BJ>)8IHF3 _AYR-4=N$/
MT/)L+P %S>2G08@=?#%KB5"4,M\3-"2.>F5N3N!LBGW]F-CN"O[2(X[\/CD/
M_X!QGM&Y?R0.NL$]AA6U?&H1OUX<,VNQ;$)(W7K,!;9^JJJ2=]#Z%SPAEJ/K
M+Z5(FV!C3W[I]TJ%5F\,P]=4NV(LHFB"12NJ@;:'Q085$#34GEO"N'AQN9S(
ML U9&G7FT+_\EK?(4F--9:,K<6VH9V!NIZZ]<==48]L$W]S#;/4X2NH735AW
M+LPF,/KV;%M-9<BYI(S15VD2FD'S@IEP YR;.@G*U>$=2&;J\\(W;T)^O(^Z
M \RFA2O*7)HMY8,A4663(E3J&)=+_>W-5(6\._7<B<S5EJ[#_8,3^7]Q7]?3
M-:$SW[FV9ZEKF?J>%=M8EKH)EC[@5\@Q"/3RL&"K66@5$#3"'D_J\CCR'W8D
M7%_P-*"0J,+@6:&O$5?@,69ENIJLKP] [:\PIO=>$;-YB7Y63-0$J*+G!L&C
MJAYC".8T^:?_B$ ^H>ICIIYU R@PZ?GCH29$-\"X6?Y)G(2+;+E<I"V52/LV
M_@SMY,MX^K[25"!'79(5%7W=YJ\1WM1:YIK6\U\Q&4]D.6N.&1KC)RPAERNR
MZ.5G<B*/"A9<5R__EAI]ZR+[NK;WQI!:C"'R[EPIDA-KI5RT=>]7T>!;>SOK
MG,;3\PNO.1C79M>$(?CF#?)/N130&)ENUP3M:T=MN!Y2=_D-+(:$(_?8/&$+
M@Y&WE-T@:R*A?)E1]Q= &$)K\U-)336VLU[C2HEM>CU<?8;9'W^4^]0&$^0&
MHXB:0;$=SJI;G,374*6Q6V8>L/ WG"?/E.B&?BW9MQZO97GX=&7K4I_)#;Y3
M?5U90]B$44RIV;,LN,'4Q^N3&B_+AIHANC*;[\GV%XA0T!;Z3X5G"FLR_I[\
M<[4=[^2R;8IO3NJ."QK"QMBWF7&A$IOOR?9:X\*:C+\G_]08%]9BVP3?9/?L
M<*T=LRZK$Q0O->MS_>8U5IF;IM2')9\L!:,Q#I.0 ;V,66GGNZ,NOTT[(@J0
MF2^\A#/D[DN+CEVYRVV WH(WVW%8!CN>VE8";@7=\X]HE&?0U >3T:[LQ);L
MX$?N5NS<^E%==AL8,&QQ/EE(\+TAOJN?9@P6<\3I=?^N>(A,-6O"D/> AY[:
M3>QKIWO E=FX"78\X2D$AT,TSWY2S9J@^R/#+A':Q6>J61-TER4F[TWG]M56
M3="\9UN$64BSK$DV:H+>#UC$C[^4/A C]\I(]KR@G+,NXV]=\"DSB#5O[+HF
MTL"A)ZC<Q%VL?7;;AEDQ>-5@D-VV"58\(]>F?\)R3/,<?;59$W2_)W]XQ"9H
M@*V)2QTZ)E@N+/>*3=%1-<&RYRD1$_X%EK46<GK/UWI\\@F:8$^8_/6Q\)_L
M:???Q%IN:9#-R C5 78."_0I^OSN_U!+ P04    " #5,Z9<FVJ%FB@9  "<
M&P$ %0   '5T:'(M,C R-C S,S%?8V%L+GAM;-U=6W/;QI)^SZ_0^KSNQ'._
MI$YR2I:=E*N<V&4[F[-/J;E*V%" %R!E:W_]SH"418L7462#@E)E2R)% =]T
M?^C+3$_//__UY7)R<A7;KFKJ'Y^1[_&SDUC[)E3U^8_/?O_X,]+/_O73=]_]
M\S\0^O>+]V].7C9^=AGKZ<E9&^TTAI//U?3B9'H13_YHVK^J*WOR;F*GJ6DO
M$?JI_[.SYM-U6YU?3$\HIO+F8S>_;7_ Q 02O$'.4XV48AI9B3WRCG',DI"6
M^_\\_\'$Q)4W CDK'>*:LOP34TA(2;E,D1!C^HM.JOJO'\H79[MXDH=7=_W+
M'Y]=3*>??GC^_//GS]]_<>WD^Z8]?TXQ9L]O/OUL\?$O*Y__S/I/YWN8Y_UO
MOWZTJ]9],%^6//_WKV\^^(MX:5%5=U-;^W*#KOJAZ]]\TW@[[:5^+ZZ3C9\H
MK]#-QU!Y"Q&*&/G^2Q>>_?3=R<E<'+;U;3.)[V,Z6?SX^_O7\QMW^;I+UZ3L
M^>(3S[O9Y66/$%73>)FA]Y>:7G^*/S[KJLM/DWCSWD4;T^W5[J#,5_1VXF>3
M^;7(]SVX?]RY^O-;L#=(OX&YN.ZLSG2+[?>^N7S>@SQKZJZ95*%P\86=%"%_
MN(AQVMV/=S:]:%'A)&9S@?UC\\66X"T-YDU^O;AD 0."-'Z9QCK$N?9N[CEI
M_#<?FA3N-.W-7TZLBY/^W3]G'3JW]M.?IUV7+WTV:]O\L/YY^XP%:9'"-B ;
M/494<^>%3E9RNEZ9O2*3[5ROS<75BU;%\SB9=C?O%#F*7H9K <SEM_]HSFQW
M<5J'\NW5_\ZR^9CDBW:GTS/;MM?95/V7G<SBW5$:39&QB2*"(Y%82,/8!LKN
M/<J=@'T[^B7^G+;^I&E#;+/E?7;R.18KN3#"7Y:?V_V>U-0VEU"DF#9#*V1.
MA3RB0[GRJVW_BE/K)O%#]+.VFE9QTY -\4@G)E$BQII@O$G2 C-D"YQ=>$&?
M%B^@A _&AE/OFUFFYOOH8Z9I!O9;G&Y Y#1&SOB 0G1)<Y6=O8,V&-OP[,('
M]K3X "9^,$*\KJ_RO9OV.@.YBX!E!(89BS"WGE./E24!F #+]]]%X?QI*7QO
M\8(I^&T)N[8.R'N)+'$*)48LD=GZ4 QM]E=1[*)L\;24?:"HP53^IK*NFO3.
M9L6HT Q 913&X& PPUH*":SKI=L#CF2#1'.ZDA/?0) .(6C.+4^&##>@!Y#W
M*"'LOJJ^2]T#!0UKK9; _-;4?CT>81AR7 FD%1;<6.4LXT-8K;5H1A.K0A$
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M!J/)=*8G]O$!\?%N]O /5]&P7Y:_C!^=COX^7?S[#X75LX6!MHKP4^,GJI_
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MRQWDT7=?+YFJ[B,FQ #JJ%;((:QEZO1!/FF>.Y%S&#U#/4^J(;I-+L8-,-!
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MU])&VBHP8'2<:CU#A!NKO)"I:U+:$9T7C](;H2?7^?&JL5^C#A_N%7NRA\^
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MELAPS.#+W$S]?\TC\K??[Y) #SZ28$0!1[T"PF@$=-7YW"I*C% D0DZ=(FV
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MZRE7#TRL+CO! XVQ!]0X;8(35=/^[OM\AT 98/B=G0X;>X&]V3)#;J(]:;(
MIHA$0#!H@4)8 T<H81A+&+&]9+?RTRRIH89TD*"YHG9%1SQ 8)@T *.@E"*:
M<>_[7G2?1TGUWB'U\0B0^C3@@:(\E>1K,=/CQ5MO],R_TZ/RGWH\WP@:I8%
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MI^;<<RCLZ6SK?8^MMQHJ5SO<?;:B'W:=5X+4*DM9':BN+N=$&QV?772O+=/
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M40;DE";<*Y0ZB9-<B!.:4881K!]&@P'&+LON),N9<%GU6U1O;9U$+#) 42Y
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MSLGA$]X]VUD1E#B@1< @V"!48,%9=#J#>4?A7P;S, =S3@Z?X@[>O/33G;7
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MW29QHXVJ:E "4$PRX +W3AKA-#:=V=/ZJ'/Q9-+I,\=,PO89$DNLFFN@H>/
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M"LU'?>,_A2>8&J+F.E )2W0;@?1?HGNHA8I<ZDU<H-L9'#422&X4P(XSCZQ
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M^O1-?;C&&AN4--13W+U=_6$B5_[CW_X_4$L#!!0    ( -4SIER!AJ'OR^\
M (02"@ 5    =71H<BTR,#(V,#,S,5]L86(N>&ULU+U[<^,XLB?Z_WX*W#D1
MN]T10C??C]D]>\/UZN.XU;;#Y>K9N1TW*D 2M#DCDSXDY2J?3W\!D)(HB0\D
M!-*>/[K+EDEDYH_*9"*1C__U?_]X7*-G6E99D?_[7\Q?C+\@FL=%DN7W__Z7
MKW>?</"7__M__[?_]K_^+XS_S[O;S^A#$6\>:5ZC]R4E-4W0]ZQ^0/4#17\K
MRG]FSP3=K$F=%N4CQO];W/:^>'HIL_N'&EF&Y6TOV_ZU_*MAAHF9Q"&.8BO
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M&H<S#.[@%N0#?>+]BV7/!I70E @AS *.FJ?=<+*;TM?RPHN*M]ST=1R8$S]
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M-#]Q9AA\/Z,=/ZAEZ&7%LX?7&Y&QR+_5S?1<=ODU<V$;_V@.NZ6.ER;CI<#
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M_,<.)M1VL!M[IF^8L>/%T(FN( 9F-OR<H$BG(P?*5_'9Q@E7T&K'S1G]"66
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MR(I,RXM"+PAAG>Y568%\794:X&\9:SQ_VK*&XBUO/&!]3XO[DCP]9#%B=IS
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M'KQ@AF /5<,$8EP@SL91:>R*%\W&6DOJX.+KRK21)[QLY@P8D)-,&/@*JLG
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M>P9B<KLX[3C WH."/&KIBZS7 PXTIZ@I":UK(($4S65G%$!@.!E; +I988_
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M)SAR0A^' ?LG#I+83*-OS[2,BK?Q'>ZR(@WMU88?T^VWX15[+[\&V')N_+P
MJA^H#,:VHC:V=7SPTIRPM,SREV##;B4:B0B9]&T#U$'3M"=08&#1#8(Z0,>[
MA3-64GPQ\Y6CZ<!'U!_XV/+!V\M<YC7CN,IB$>TPCT,11A SRV>EV XL0D/J
M.K8%ZCH_'ZO+O.A%"QY2B\ D93MX9C+YCT_CVKKT4Y.THV_B6;RZO>7\\[R?
M5H*)TP.XX9T=95T&>CY&ES7DLP-^8O#GIZ@04WI?TB2K+^Y+*GA@S]OZPLM<
MDJ]YQ=N'TN26/A?K9_:":B[]1&)14MD_A<@,+1QX0833.(R)G[AQZLH-'-#
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M?NN>Q0!(H\[%\3W+^1<#W!ZX&$/7J'D9NVW01571FJ?Q?LZ:'I)L]_0[)=R
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M@VC'8=.I<-\VI^U?J)2D>.8SDMO9+8<\S @L #K\4%P+5KH.R\]C9ME#="W
MG1RNZUD5_LK_Q!,@+ZKK]*8L_UY^S)/K].-_UB\7W\ND^JW,Z^0R%W^I/JV3
M/ZHZOW]?Y$GUH60_/)?)W\NVE9^DQZ"'VMP.1YD5)?H[)25B'':& W'];3OZ
MB"*^"OU6DISWK,C^?^[^M#=R'$D AO\*@7VP3S60W%?WL?O)=?4:Z"[[=;EG
M,.@/#4JB;.VD)8^D=)?WUS^DI,Q49NI@4*3L7F!WVF5+C(.*8##.'%WEKZCW
M9OU(^)BV;,OK3W^EM$97S\_;+&XJLKIZ/L2IR]HQWNW\8?:;%\KCXWP-<8-'
MT2;.VTOK[Q_0W'HG6S??)Q-D]ZEENY39J B%U:Q.M2SK&ZV*5Y;(L;CB.W,5
MQW1+2][+Y"P\>9@R^*G8;ME?DL,O+OOQ-A:O&V%BN EV@CBV;=.BJ2,61U"
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M-)\MM9K1/$Q"WV@>>4*VK.UKMJ7E)V8^/C 9.S_W;)L=>7% ,$U)9)N)$=-
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MEE[[;OBOR'7V=G2LZI![\^TZ=_.]/4*2[1]V447_M6/R^(7[*>_9*E<_LHL
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MTXA<DUV&[\NGO$Z^;LF#:*+S\-N:;44.%'&HV#QQ,=W3\BG+":A#\PCYTSI
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MVS)[83>0[>M_TVWC="4YLQ:':_\2U\>$&6<X, )B!=2R4L<1KOV;@J39,#N
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M +"J.(X3>"Z%$T\N;4#>BU!7]\5-Q(NU?RZ*I+K*DVX<7S76Z24@#HX<EUU
M2!!$J1^PLU@L&KP(#=U'\^[IB; 3B-G%;3UP\=R-%&T:W%*4D)K(MO\&L5M,
MYO4S$:87!E-U^F-"-?=!7<8/Y<VM04B\46=J&4:-MY666DTV0_>B259[7;E)
M>PZ=(5_.N;'A4Q\'CI-BEUTM7-OWF483F^:Y&!7-^NQXS2<]1V1UWD>/R/C!
MEVV!@%=\-<9*Z+B^&_?07:_C]DUZXO9=&F]8QF=HCND:_%Z0+JJ-[Q+)GDM9
M-9^W*0UAY13,I9RXS*9<O**FX3S5S("$;A("K?8IFV<.M?W?;TMV$EZ<0[:#
MB6VZ. K\,#1,VXX"D$]K7?1UN_\[6&K&5:^\LU#S_;WME[S9/Y;)7XD.W#G0
MQ,M\]NGZ%P&,_5.H(6W%"3M:MF2ML3IJD7]?LW2T; QX@(X>+.#CT1N8]T\/
M_,+]2Y;3ZYH^S5G=H^_ITQP-.'2?/?'XQ]$Y4*'?.7#40%<T$GR2,JF9X,,K
MKC84?)*@_E3PZ0?7K(_MA.#LF[^C3VV;R$]%WG@&=F1[3\NGWO<PYH9TO A'
MGN_BV(I]*Z"A0PD1;#C]MI1 9$JJ0?7%D7E #O6P0QR]QL+B\S"$(XUO_!6(
M>@_>_<[*V%G1=,7DP<R*)LTLR.=QHICGW;;OZE-9H\AVU4]&SGOR[?]WI:K1
M[MNS24_%ZW+T_@*5K\KV0$T%K#IT)!T^\2--=EMZD_+Q;#G[ZE\_[4K>_/V^
MZ01/?]0?&=/_>=$WQTQP9 4.#B/+#XTD#=* @%PU@H!U!SP[-'B(8(](,W*K
MF[%P1RM:OD!S&(2Y*N@FT< KX,$[P*;7#>JP0+\W>""."&HP41G2!!*ORI4@
M"G9=)P"0&1?7=^C[;^1&;NK^P3[D9@*/E^# ,&T<IW9@AY%-TC18U8<LCKMF
MW;;O^O$NW,> '5W)=ZQGG][0<=P2]-?T&L,WX[VXC &8_[7\Q? M4>XLED!!
M[L"Z+7GCR?KUEDEGS<>[_VN7/7-LCA;WH"G<I.K:!C.%+0?;D6>$7F@[?@C*
M!(0 UWQD[%'9H :933-1]H /[,@ \51,Y^OB%$QIGS'IE$<G&7Y:#&(9)BA2
MEB#0JVH[&::<JRNI-23U3:OKJJ]%^0M](-OOM*ZWP\EY2>+CT/<H-GW;<E+J
M148L-A1M'I9N;=)!;BH"MAPVJH[ @=ID@F."RD,-'X"ZHL^"!BSZ+L "N%*8
M)TZ5#IB M*[(SY-\(>$"KTC>>'FV_&.Q96]4;5>[;T5-9ZP'[D@S_ 03D[<[
M"E(GB7TC#/T(=%\5A:S;D];#X]__+;!,_[^Z]I3 FZ8P)P7OB3KX U,"79=.
M/>8 F#Y5%R=AN.M>>Z#LN+BT@!>0G"M!Z^,PUO-#/_8C'%+3P['M&W$:&5'J
M@MK2GZP.DGQX8_KCW!?@H(@I#H2AC8D3$1R&9D#=*(X]$Z07Y3FP9/+-$@Z(
MZ3-INF ZBY-T,G9Z9,*TPND80X2IFHAQLO:Z4S"&R+J8?#'XD)QB^4RC^ONA
M3\C5"\FV?,N8S?.=;"GO"4FVO",D!W5;5!GWM!P:ZXY'_;A0IC;!06RYV$MI
MXIJ^%24&2"@5XK9B8/" )V96/.:8(DX(.E+"G:XD1T<"T"_-4(N.!)A64+F!
M8CKEC;8%II'.6+X9V);-Z [T&YYK#5=J8*4B':@2LU4UJ :6GNM?'2#@.<OW
M):\?_?+C.2L;3_EG4@NULQI[5[.*/ )#')J8DANE<UI3J2 1IF[N2](TK.ZG
M%HI2#,K+GB)+*BU[<,'5LK*GR.DG94\^)Y&3O??MW!==DY;V\G:4ZK]G]6.Q
MJ^\HV]?MZV?*OOBG+&_$?' *48!]/Z7,WHE-[/B6D;IA'"2&\T=.'WCYW;U@
M?;0*Q(0^\[#]S"_0$W=6[NM%F<V3Y2^TZWS&IPV5V0M;=/N*'NDVX:,]GTDN
MZMA1MCLSQLRJS%[F#;XO]EV=]B-<>K9DAR+J<$1]).5F^RCA/B"1>.U=D$L)
M7F<W8+G%*CDWF26L!-!Z^;XJ^7*2N:MT8;D+^Z>B&8 3\X_W.F_JO6E574Y'
M:$JD?1-':>C@V(C#U+6BT$U -_ I8)KMQ8^[;)LT4Y)W>=(,B#ZB KLA3W),
M[,JKB@^P Z /M4G4ZN#.]Y(&7T1%"%1TLYP$M>I5483H\[N?T#N2$]_/=,G7
MEV_9\3+Y,\GR(==WX 0XM/@@:<>E3N)2P_8CB-4)@KZ.:<G=R;NC;X9/KV5G
M*^\LUAZXQ\;&P$GQ8AP6TPD*&;8D3MCW<7W]&_YV?>+6XFAT+GF%@^5!E*L:
M,R\&=-VA\R!&7(R@A[TMIU2:&7D\H;*DCS2OLA?:A@X.7JNT*"NRI3U_UJ%/
M,1/#F_2>_+@MRB85LQ?2N2_:@,Z%Q4%L')INB#TO,)W("'Q"0D@H4C.^FH.;
M]_R5;MPV>N"RQY06.?$\<^11PKW354]R\[: J"8_8!I-]_:*J<)WM&DP'=J.
M/SW!_#2..10WZ-_WCG0<BL 8+1O44:,]#+H2YQ7I<-W8KJK\5V+]^:FQ%EC%
MJ?%G7:NYOY1X 8XLU\5V8%F\B:0;^V*-) 6 Z4Y6/61U/Q]3W^D>?J//%>6_
M#S#.(PF._( =MXY-V5%B67[B0 Y998R#GY#K,D[L^%+%#J![=ZHP0'&'<!$*
M=6?]K]XU7(1HX:S^Y9W$;QE_:5G2I#\A8%<_%B4W]\\-Z<BS<$BHBPV7VC:-
M[,#T027ST^"TJ\<.>-L8_#"D@QP0D)_7,<-'49%7Q1VHT.\9<S*V QUAJQ1Z
M$1J5B?TDL)4%7X3P2]$7>FMQ"<^Q$>M-RNRXIR)O )X?\C&3_<AQ#<R#,8%-
MPS"*J81?;Q[R2N'B??R,W8)ZS;3C!H]634C7^ BRU+%"3(R88C<-',?Q*;4M
M2[(X:@DO%=1(K<A$086JE#5 I=HOF^HULF:7\19^JVRUU$_-$*N^C&H,X%M5
M4\TP8**H:NY-V92XJZ2=0P)/B.N_J5F2]Z"DDN%.*)R6S^7$P61Q*!%.C%:)
M-+@ADA8DP9TLMW(*W! IEPEP@T_!Y82[CZZ:/F';5SXFZ6_5H:3@F PN*#DB
M:VF6I=->*!TNS: M]%+]!SH6IXC+F1"'YB5/-7-@LBC,%\7%AE#*I416",!J
M0@PAMR_6H/>DQP?RT83T,VW_>YU?Q7&Q8V?P'8UI]L*]O^>6,K.,<1A$"2:N
M;P6QYZ5V&.PO'V*VL@A8B9L'\)3M0#)C>0\3/%]PGGEB%K(RALC.(&R@H@][
M^#_QE*(#@^[F&20SEU"88G63"N=!KCV[4)@) ],,Q=^5#MC$E";55X;X=57M
M""/J)FV]'[_QQ#N& [/ALA?*9Y(-MFCBOM+JO+->:,8XL$(?6P&U:>A8CN6!
M4@]5(:8_$-2@B?C.H_J1HJQ#]C@6L4U@_/+]]A8<VE"S-\)AD-4Y#@Z9-!AN
MT'6/R?O)Q[/C%+_\B+>[YG;2=@P[-+A3ZG15RT1U41DU:*T=P5'*S(%HC]KU
M83HXH=D?7]CR];ZMZAU]YI'Y_.%[3>K=1:JGYX>8A):'O= /@\3Q(\,2"IC/
M =*L(UO0A_Z_!^"HA2ZF%&>9-:WD5+( IK1DJ1=6/:*D35RSV!*M%F$_')7'
M[,*K* -1\O;"+?P\3%BKLO[C5_(_1?EIQT[U)R8%5S^RR_YK?,9S&%'L!H38
ML1WXL2\TB7UX>=V.DPX6^IT#$QQ1,<*(:?%;3A[0]2%(F;"031,P=4JS-WLG
M-/O74<!&%EU%K*8)V@O3S%.2D[:J3]NBHO?%K_ESQGLE-37QH@['\15TN^P;
MP*B!S._.]]E3D]/YZ[?;Z_[0%W$OXP0SYGV+:O@ $RM1%G1-,U3.(IND5'X@
MV?"RZTXEFR3M8C39]-.250+/?$@L.R+'6VSY;HJCR+&Q&Z96D) @-&P;E-E_
M"0,DL/!<PP-$J79;0SP1NT@OI!0FDD<B3Q+7%::8CU.C*BU\ ,*ZJ=SC)%ZD
M7T\\*B=[=[0F64Z3+Z3D0WRJJSC>/>VVW-G]F:99G%T6V<0>CEQJX21*[)30
MT(X#(2-3'*3FHW2/ *(=!C#1%&"9F*2J901,< \\V -''WK@40=?H2"+$ZM(
MK@4 KBKFX@PXEWK FS(#0KF7^.!JXAXERS!=_M_ALGX2V#@D28+]T'>"T*>>
MY[M"\B\"3;/H<V!-QCMD(.(<@V:D7379,$%O(*,#Z(9X=&##?#&_!#\@8QP5
M\D6NL\IUGA;E4YNE4-)M:\RP2T7#HD'F?>!QE@,'?U(VJE&0%=,#%><667'L
MH2 ]I\,)15]:.D*P[T7_5%0U;Y]W,=ZE-_WE:MML'WNZ<]%?^.+Y*M7'IG9C
M>AYAS'1GZ(0&)I2D%DTC+TUA;=3?@@K-BKG?PY3C4^1-3NT^P#8T=^K+#_XS
M'X8;%P_Y9/7"._H8Q$S#=[_%P$-H+CC*<>*SP]HS:941C6_ 6.7S'M>DX8V&
M1[[!-HU/HGP+9"1,>MXB]KKI%-0@E"1-$UBR_?*CYD7;1<X']#;'DN_:!+-C
MJ*GF=7'H!10'KN<$GFGX06 +V_5"(#6?(4W7Y>R Q :1 QJ([O% O"D:P-H5
MXZ7 %4 YAV JN&'.=8\Y1PS0 85FA+QRY@#N \J9)'<I4, LF/$/HGOR!B"V
MTGK7 !!E)W<!V)MR%X*O64[R."/;'J"SP#K/)S2C%$<NTXUQ:L9\:J)GI#'$
M9!^!HUDA'J#VOF50M'V.36+&K +B8;I.AFZP)3E#E2);;PS*JM;8#*GG]M+<
MXW*B>FPD4WUC:)/J\;JF3]5]P>]_#-R6GDPFN2\^L4=NR^(E2VCR\?4W9GA=
MYX< RE5<9R]M@YJ((4GBBSXGJ6?AP')C[*41M8F1$L\"7=-U(ZP[X>"(?EOP
MVR'== MK0YK\]_Q?G#;TW&'.KW'%(2Q(#FC_)TSE:-]N,=WUGC81I@2/F/-M
M.J#;+[QBO^?HHMO>UGW@*+/]_0D=8[L=VJ\;U/$ <28PC=H1H5"KKL5O1>I9
M.[JKZOFUF']^8*P&5W9@)JF;^_Q->CC:]I-5ADZ/)DJ>!#BP0Y//A#-]C[J$
M!* ..B) =?MD]RAP-^S1IMIC(2+_\OP4]),JYA(TMK:801(S-,4I5C8^4P#D
MRI,SQ9EP.303\"X\Q?0?Y9<\^<J;[=^D7_Y5OU[]62;5SV5>,Q7UZ:5,_E'>
M[.HJ86HJ3W[+7ZHZZ:*F@@FHLNMKUA7_H*3$-$_ZL\N84'1MHKO,S9]+DM>-
M=8$^%2^4-Z+B[Z'ZD=2(E!1QU&N2-U52O"/=;\UD%]' SB+V3^N;M3@/TS]Z
MF:ZPT;\*]DEEV4H#72T'=RE;^AFZB]>"J[LO/VB\X['Z3TRK/A3E:^,7$M1E
M@R]K5E0'F&@/5/!B.D[MO.I83"A,+US2J,S[-4N-E)@.K[B:#$X2U!>PZ0<E
M;Q>#<<%>%/'CZV6,D:OVMHRX:O1[=9W?TC(K+CIYNHZ/(\^(<$I]8OII[(4N
MR'.M%CW-PKT_ZZ3;>RK>#,%+S)NQ&'C=&<O$Z;?;BEZ'2^$YOINN]+W:M%9)
M,XNXQ?K0P/YK4:8TJR=+F>"7)BT<5G6]4HO<NA<Q+8R]N++I@:)C9OFG(J^S
M?%?LJN%)O*;U*WOBL;HI?RD8\F4OE_N\[JGI4F]X.$A\$P?4]]/ "'W7M"7Z
ML&I%6DCC+&[A:EKHJ<&"[1;:-GBHG%6^=./$5/W;[X.^>>9'["=&F[-=_/6P
MBRT5&]2O/.'/KS7B7!&_5QEZOA37=S0&71';88/150%5V>B*0^))+!SS\Y03
M/R(X"IV U]K9AF?'GN5"YY/,@-1LC)\VI^HWIN+:&_,\O&84E8JV5"><%%/%
M:OD#TZ>GK.FWD^+P,4< ?9YBC:+.4$/4:NWY= +P'71S&F* 6)^FP3?A'9BZ
M+C%?LRHF6^Z7_9(G36/E,T/0<"),+#?%5A)'?FQ809PZHMV7QH!H5@#[ID,M
MW-;KS" #FDY/<FA:S%71#1-L*9)!O9;F:)+JLS2ZZ&H]EN;(ZO=7FGU6(F7^
MCE9UF<5U-X#CMSRKJ[OOOS4CM=FUL:D19$0P*Z)-0QV8>=T,QZ(.)HX=8S,F
M%N&=TDPJ)*9+D- LQAP#]"=# ?5P0$<D /GBLER>.=%7XAU,%1P1ZLI(&Y30
M!X[43^COX_R4J<F592P@-7\%!LLEZTLS6E'N_D+&3&;SRZZ]7G[_0NI/,OZ7
MKK4@ !/->Q>C<^\BC[HW0?<K9A4^M:Y&7I0:MPZN)_,\&&-&%$=FZ./8=HT@
M2&POL=P_7F@9%:!PC!9D(8+:1QD0E6RA-158_*Y#V@0%'JQY9:>X5*Q&S[X!
MXC9OOA>KQW!ZR28]_#?HL+^*ZJ)6X[+*.(X>1->/Z6AE^&!\1R]$R:-A%U7T
M7SL&[LL+^Y][MLKGXHED^;G=;]E\7IZ18NK;7L NYW8@V!1G#I+N'-\#7-0
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MAY2$:E?E&L0M+WG!#&IQ4P7ZT8$?=& ( /$+U?#(BK>L-Y@E@*A,!QX9JCL
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MWTW4@>+3<&*6SC'QJ8N)Z_ANY#L>/ZE"G"< ;=OKL^8$/5>LR ,HJ9AI@!N
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M0N;'OL@T@7?R*JL3!,')(IS$\Q![CL^(E_ESZ@>-ZZMFI_M(:?BQ,(/;$*[
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M%L?SP">YXWK1'VOV( )&]Y!.;+TDE59+4JV6,\+**V=?TUU7<D ;L_5K3,V
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M$S(_>9K6]!/3E>]U!2[Z=K_V[_XS_]O?_M)\PO^7\L'_]I?_!U!+ P04
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M1-1F5^"8 $U.4&M[V4Q\2@V_ZD5TC[2;3&]?^?C>JTFU9%Y/FH=RW36&$>3
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M'JS&Z^^^28,Y7NFY?F)OQ %(H^+>R+ V4'*%-J=+=8Q'&9[6<0?5CK$<"L1
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M^'/3 7K@+,:+_NW<7[5V&NABH!X0 P(1Z:UP$.G<,==>!(Z<+CRP0SF<K@H
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MO_35TOOKE(MD'&@#$4 L!*DE,<'B<>.$-M'G$2(,LRY*QL<9;1MM@;2J$FD
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MCY6C%+L3*'M+N3B<O-=7'2>Z1$L@<2" <>6QAE)9F3L'N8N6DC"SOXYW0N9
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M>O@1 <\T(V@W"#9;]A^LD0+@=+C@'MBNW.Y;<>P(4-X0X&'0PK,0 LH^!'@
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MBG%FC&(5PAHX0@G#6,+(2U'WG>=WT[0W1+,JK0#T93IQ69-C_ \8&S_SQKM
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M\(QVUME3@X$RC )B,7$F0,1<[B9YSS9-LC<(]FFHL5,C!<#I%.5^2F*@D0B
M(FE1% 3E)G?._A\A3;(WK$9HJ+%3QP7@O'=O!L)]:KJJ 7*(*4X4)3@W6/_
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M,.-( :SZ:*UVTU4=1)V^]:2]L,@ 1;D 44!021)5A4OKUMR7MS,-:<I808,
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MU7RY5NKSY,H-$^;,>7(0FO=J5 1$H# 3A+((=]V4^Y0G=Z30QB4#2PB87BH
M"86 - [C!-I.*F_FY&WDM75:P'$MRV25>[#K.Y+BP_,'F?/[!UK^V72]Q6*I
M#[X( 7T0P@&/*.2QG-N$#GAR:TPV<.\SI2D@>&E4+](TG[E,((5Q?>8*8\9I
M+&.41(->;IMD5/L\>694DRR@U[PFP.&!>?7L"MM:B:P"\E [^"1E5-$P5;8=
MUR#&?#.T*;9PVG9]!# >6%O#U+S5_VO3K$Q-["A0"@04QW$H"8V8[?J"#G8<
M/VUZEG5QE.I]M"(C2/.4HS+6*D)&*/T7BE.>'C:"FV&7OF7'-_\T$O+>W?HX
M_?M@2AMW>B12RU45U/XU"E,00_U=+!7EW'JK@VZ6/#.IL= ?FI1%'!PG>_Y*
M_UV4K]&\I@TGTQO.6$\VD^D<*_T?56B(%?5D>1Z/[#9&;W$5LZ!8QV;QC3[(
M*[4G0_.\B5D*4L0(" 5*).081G!0)7F/=;0RX"XI="JBA6WUNLXV^)A5=9FQ
MI?Z5JUPV^SZE0I!R&8%(2!2I&/,$#GL@NXFZ._ M(5;85)]'^-_^U9+^"!G3
M_C)$(,&$I"$B5!YV,^G'?TO=71[AO/B/4Y\/.]+#1;/U]B]D 2!1:KI\0A6F
M,D$1GOT&XNM)U_^S/2M]C@/R.,5[<7%_),OKJ\7P:'KIN<!H(D$L4Q0*PA-B
M_86H+GX\.]",1+W/F,8"X&D?FJ]9G=U-;35S3,3&#7D/:Y8NPE];"YF$C?73
ME7<RYYFL^E\Y5)2"U#QUR ,.29CB-""VFT6=Q.!4?V/:*^T-T>B.(T@!2; $
MIL"7I3R($+9];=#,B6L?,Y>M'+H="S@X/B:_SMY+6C47A2H)J/:] /(81[%B
M24)L-.<X'MFMU=C LK"F6*_,HCWHF"1*KZ4JT:>[$+-(\802&P74;>.[.SY/
MQ;/5-$8JU_71^8;FHOB_+SEO*S)!>O?&,:")D#$-XU"?^P>=F@\(^X+X6)@*
M2SISC??7[#_+3&3T5O+[O%@4=]I#:DG^N^74C[44IJP,"ZT23'@8'C9O:8&_
M>QQWX1/[UF!1HPZ-0\CL7U_E'5U\TDMG_=SD&"74)SD8Q4!"*GC,]'<1[E@D
M7MHX:=+K-4)_>%T>&@9TFSQ@<>,P59F.[6#-=4LR3JQ *A)SLQ"QR-P?2MR5
M&=!O!+NCN5DE)L-56-"=ZX7A1I^U[JM?I5AULKOYV+J\<1H!EC (@@C+,)8"
M:S&&;0G:AG '^WBX"NNZ\R"*?N0#6\-Z4:A=8" 80!PIQ0-&F;*=(=3.C=L+
M>HLKA67%>V!"U_1Y%;+Y7)0KGWHCZWJQ:I5Y) HDL?X48Y (F""(@Y@'MJM=
M.MCQ+$XQ$O'#<F!+ZO? DEZWZJ]"7#R8'ID7?U&-CK@M5K7.U[2LGX\R\\Q]
M)4M#D$)$E41A$H>V"RA/8M"SS:T=:YL/(D_M[TNNZ<OJ*-R,8@A222* S,+.
M,4T#:OM2N8L?SQ;$^:QK%  ^&-.>BIXO."^7>J]87]*R?-;?_)TNED=;B#05
M(*4(@T@3E"+$,*:V[Y@',>8V:V$N\[(.B;=VMB?2M2RS0N@S2BEI)3_*]=]'
M*81IJD\_E() TC",(\12&9[%]@8PZ^B]'A?V:!LZUW&&;TMS,+Y2UU*?O#5@
M#>\7Z6-W&#% 4!#%/*8*)P.;.QZ2=M/K9RXSF:X]]UDQ>S%!R<6:_&JS>)L]
M:$V]WNSWI\8T!AH-T;7KX>+5XS2/<&+>S&CF)R;/Z*'^M1[E837$:QADK#K:
M*8Z<VKL$?\T?,T/T5HO]0?_P3RML'E-U<GSOQ>)EN@[2B$-GO,>?K.\+81FO
M YI.CK_CT&K6AB=87>MAZ_(A%Y\7],X*4OL4G1PD1^'4J E/4#(S_C*O1&D/
MI@.23DYDH[W?L2X\ >H?Q5^O_-GU@"VDG1Q=1@'7K1O' &[7U.Q!BL]%>5D\
M/.HSTN3IUD77R7'B).@&:,6'B5==ZFVRO"VV[)H+-(NSKX?^$!RQ^RDX3$O>
MXCD3C(/02SU%SQ/0ON0B>\K$<O,TYQ2@#DBY/91UZ[SH4X#KJ;18O/+U\I[=
MI$G41- 90BTZ+X8IP(/8^GK^OW0ZLAL*WZ?M]K \:!9U*L4#L&[NM; ?:"6%
MV0/)O-KHKZ3YW3H?XL/SZ^]LTB96PKQ*E(OK!<U-Q?4F/=$NYK.PZ#2II=D8
M#E_CGA$9#PSOT\/CHGB6\J;6F[2K1R-;KRL?8SWMX[AM=#LGNL6)JO; '%:\
M73SJX7FV*6N^NZ^KFXOO-[.81?]X;I]"/:-Y#%:]ZWU?TZ*K-T)&0ON'J!?"
M0\R S+;'&'V,.M"+#]#]EHMR\7QW(_FRS.I,5A</]73<&JD.<NV!>]2Z5.(#
M9)]^E/RZS+B%^?5*:A X'MQ('@GO R*_Z!6@_DAK^9EFY3KI;#(T#30'8>3!
M/62[.AR#M3^SGW_]LUZ9TN5]?G?-I[F]'M*#H'-[-3E,.;ZFX7PJ5_<%,Z7@
M'%.WDG[3P[2%U)OODA=/LGR^4D=C'1G#*+L?-,"$*;NA^C+,].!\(T%G<<53
M\-F=K%UJ<>QDO\M*ZVYU'C)KP.0@?1,]9WAUZKT8I(2_]?7)++N3H:#\O#CY
M>7%R$C;?BOR;+&R LD_)W45CEZZ+'L$]6E>D)OF0Y>N6?_J;UA:8(\+.G-K8
MG<$0-;EV>7=W]4:HR=&F?5+.$D#'HM6L"L?XO#"4T\5SE55V<IM:B3I+!IVX
M]VY5CV/T;NH_KTM^5=Y6Y:>JSM8OAMK,DA\T@+-,T;&HGJ(VQPA?+6OMX_/5
MR[WV7&D[56>IHV.Q[%60/PO@MZ+^0VY7:FDKC7O( ,XR22TLEKUJ<XSP9TVT
MR.6+I#8N1%M(.LLH'8MBMVK\PNWC4MX6GWZ8NWZIY30O</--HY!ISO:4<9Q=
M=EM">(@2/83]]ZQ8K-1\I?Y1/,A+TQFF?/Y*_YH#^\[!W%V<V[2 (?KTT RT
MQ/]9TD6F,K[A_I;^^"!SJ;)Z<K+$J '=7=7;-(>A>O7+)+0;6]!\P_"7AT?3
MOE\+P+)%5C_;V;N-&]%=;H EHSA-L_Z<P&QN\3K(NDL@L' (\W.OU\"@Y7/T
M(=E!('H5Z^K7D4>W H6L]+GPN_S/,BNW?L6.4SYAF$$@>Q7Z.EV'OF8!73_-
ME0&T3]E*]D\'LQ8R?Z[I\^_5M2SU:>N!YES:3OP90G_"O-;*F9[KLR7B[,+U
M!!1V9^2A]*XOA'Y(OJRS)WFIW<1=43Y/3AUIIN@.ID-]%P.%=QU(7BP.V<ND
MI222=L+NLJ\ZH2A.TXMCZ*YE80&G5RHN<TKZ=5UT".X^R4>S],T*'(>TW-5"
MGPA*BQ)^YBJ><Z7YF9_X,S_Q-&S$OV^+U7E\ZO38I^0LC:IK=C0*ZQJ Q6++
MEIVI<4C.W;+>J.YBB.RN0;F[JU=52WF5_T[UY+U9/CRLXU95G=^RQ>>BO'A<
ML,4?I0W,3A[-Y4ZM#;'"@OH\@-WPK$6L;I[X955;0K>1J,N=W4 0NY3A^O!C
M&Z?1&,TST?JT7PQ3A2<H79>E=: .:;J;3R.P:E&(ZRC=?^KGB[]*41D6+4#5
M1,]=A^5!;J]#!;Z ,_-VY)1QW,7Q.F!J0O/-[$'V!/OT@R_,TR??'\M:'(M@
M>X8.&\Y=D>:)F)^L0<?0_U%^RL5GT^[B2FV%^*7,#>.73Z7XHS1WZ2*_N\C%
M;_E350L+!C!Z4#^F_FGX%O:4[=A6S/'J2[[A_Y#30WGT9N./TL9Z/GY4/YS&
M:&N9K&['YO*[%O#N8]UH[UH._>.MV5LPD]-'<[8IM&,>H]7KCQ>YJ*[41HPK
MM;+@K1B6K6/TH,[*/*W[D%'*=IW&_,+XFM]<'*^;:\?W>2%6LET6N:@^EOJ#
M+<NQQ(*SPE([=F07",=6]?%)B.JJO*KORT^:P^I:7.5;:;[5YOM_5=_5@ANQ
M;NN%49!YV,.62=D8WUEQJQU[L@B!ZT=Q)#5Y<9.O,G?I.%MTNBXR&P1U'>C=
M<&LG5_J8FKMLBVGIE[Z5G5P6-W(A>2W%QH8F5YPT4W1W_S\.KTZ]N$XOTZR(
M;2[6E5(9UW0_YW;F6C]U=RYP'):#]>7:9TI9_E(6R\<O5;6TB&@776=[W[%^
MM%]'KCWJO>G=+[:,VD*QBZZS'>=8[]JO(^=SL;@M:KJP4;YW2,M9EY31<ZY1
M%^X1NN#UDBX6S]<T$Y: :B+IK!_*>+PZ-.,ZI\I<N6L.5Z=&2ZZQC::S-B<C
M@>O1C>MMYTM"_\73G37?V$K478>2L;O,'O5XA-Z*LQT/81/$)MKNVHM8P+)#
M63ZXTBVKUAUJ*V5WC4&F^-4^13G/\UEF];-YVF2M2GV\>5@]X?8Q4YH9J:6U
MA>Z)0[GK$S(2[G&J='UL/' SOU>K163U^-M]L=!:_E[;.DF>-I2[%B.C8W=C
M5.D=_M]D_27GQ8.E&/J@ =QU&K&&=;O:O$/X*,@\%](= PU"W*O8T0@U.D:^
MP?T8R3?!+SN@#QUC$-X^19].5)YWD_RJOI?ES/.[>8Q!4/L4N#I1>:YG-67+
M!2V_9E5M\:J[G>H@.'T*9_4JR#6 QYYE:B2DA>2@; 6?@EG=JG$>^7]Q_O8!
M[*,]"$F?0ED#E>5\V3S8PDW%L9'@(/!\BF1TJ<5UJU.S,AN)+ '61&\07CY%
M'CJ4XD.LV,KS6+N$!@'D4[B@20W.5[-B<L[="XU!>/ATF#\0WH]\X<EPG)KX
M&/ITWO8PW['(?Z'T<</81UGQ,EO%\RTE//:3'P2B3R?IX2ISOBZ)S/!%%W$0
M/KU*9^L>LX_Z(&1].E0/5ICK92VO\@^YJDTMBK5$UA::@Y++?3I>]RC'^57T
M:QF1O3OG9IJ#H//I/-VC'%_;V'_)JTPK\[:DJR<,R](DX)KV_ <%0Q-[VG<,
M8Z7!_5 Q+'2[/QKJR"Q&=HUM)3LEE+DE]\$\B3*]SWTC08<M5?NPV M>=BC#
M=<AYR]KDHL0#4LZPZ=1V(RH>E2E>+!8-OL1.W]5VPAY@U=&"M5<A/UMXNYI#
M/]MY_VSG?5I$JRX7M[)\J*[4;2FT?=G9S7>0=3:'3MLC]"O&^4[!<&7C"<!]
M2LX*L4_=PS6([PLDMUD]>7N]1\I91?5(4/84X/JYON5"PH ET.QJ1/%82_%Y
M0>\FP=-&TUFU]&DX]:C$?3A_#LPZR#HKCSX-MG[%>.$ 5WR9:@I:VW"">^2<
ME4:/<81-BO#(&=Z6#WEMUQ?ND'16%#W>%1XKQ"]/: FP=JK.ZJ$G^4'O8'LY
M,)0/V?IU<4N>\)"BNQ+H,=ZP11]>8/7IQV-6VH3J@*"[ N<Q2#5KPPN@/B[7
MC%F :$O*7;GR&' .-> %+#>2+\NLSF1U<7=W\42SQ>1$^0ZZ[@J.QP#6J9NW
M<1U\72PRK@6X+@L^XW7PWC S7 >WBV'].GAWJ",;L7 OW$Q_TJ7)AKS8)6WK
M[-U/W9.KXT[<]F]:!NK+^658$Y_?BGK#JIUX__!1/ G_3\2Y0W_S>_3-#\P?
MC%;R?__K_P%02P,$%     @ U3.F7 ^FG%(N"   +"X  !4   !U=&AR97@S
M,3$P,S,Q,C R-BYH=&WM6MUNV[@2OM^GX*8XW02P'<L_B>ND =S4/370)MW4
MP>[=@I)&%A%9U)*4'9^GWQE2\D_LM,YNMG&"4Z".)0Z',YR/WPQIGL9FG)R=
MQL##LY].?ZY6V7L9Y&-(#0L4< ,AR[5(1^RW$/0-JU8+J7.9S908Q88UZHTC
M]IM4-V+"7;L1)H&S4L_IH7L^/;2#G/HRG)V=AF+"1/AV3T2<!U'4J?-FH]WR
MZAW>;#:\5K/9CNI^U&SX?WA[V!7%71]M9@F\W1N+M!H#C=]M-6K'[<R<3$5H
MXJY7K_]GSXJ>G48R-3B>PO[NJU.SKHRK$>KSI3%RW"5=!FY-E2=BE':MDWM.
M6=DAD(E4W5=U^^^$6JH1'XMDUOVE-X%4*':!"MBG(?NBY"\5S5-=U:!$Y&2U
M^!]T.S4:R#Y/G2/'J"L1*92.>0URI?_[Q\&[P9 UO9JWZL>2!TOV!CCEH)[0
MX//^U7#P87#>&PXN+]B7ZZNOU[V+(1M>LJOK3WWF-7G5:^WS@V?AS.4'-OS8
M9U_[Y]=7@^&@_Y7U?S__V+OX;Y_USH<,F[TWS=:#7=F RF_BL7AC9$://V0^
M6AOG8U!AG[DR^)Y=21/["3>FP@+ 5]&,F9B;UZ_:G9._[=I)QL,0Z:::0&2Z
MS:-R+8HTQ/GK5KW.D[KOU4K/GL:"U>GQZK7.,<W'@,5\ DS!1, 4&=O$0K,_
M<PP4J&2&[S.I#),I^R#5F'GUZJ],1NPZ%43OPQ@4SR W(M!(ZPIEN1$RQ4"^
M>;&!;.QF(-]QC1'!0(UG[":5TP3"$51</(LHAA(T2R6F9QR"BY3Q=,;RU*@<
MT U,V#9W8W@Y&^.3$CQA$0_PE6)R+ PSTLFM":00@-9<S4ADS&\ QUW2J?%=
MB,;@D(E-_#@&"01"8:)'L12[HR4A*#:-11 SG=/'HO\4%!1*R(&QT E6!%1<
M3(6)T4&=06 -)+T9FB9#='."W4+FSY:GX46#L_G,P DL$BF&GY"T"'<%D8GB
MV*R6VD4:(0=9@L'O09*'J!,AM13;"L)1$&]EB @",X$\219H+8"B[PR-"R(4
MI+A"$GF" @A1B3BRPVEK3\!US*)$3G6)7P4CH8WB.!"GE\YNM+*R!$-=&K-F
M[8M&8FLWD3A<"=OK5YV&=WRB"ZP5Q0C1BHPB@8_[^L#&=,"X HL>1(/P$Z H
M,T#(^HG0,?4@L3&R*C$K/8="!XG4.?8COE4R<3#*E P@Q->:[2-J0D 8.FCT
M;X.8IR-@/:2RJSQ!"5ORMO?!6>&U0_?D'@65A:F#+^EGQ'=+J'8H(UNV'BA:
M&2C"@<C/NUA'":H:'K->.V[L&'[Y;N'7JS6.:#[>@\8M 8;19LCO8ZQ"R3O@
MN=Z^"V51'Q OQ4@N+\M<H0*DM(G0EBA1"E*KAVKW!<4NT[0"K/()@$5B7H"H
M4E X-0JD6[1%RT2$]MA Y[X6H>!*D /"E0\V<:2D*=>4TNV2U3;_6UJ5&M @
M@S1.G3+::@1YPBD;H%O6B$5I@#U<H;%<'^$W'T@0"1O[0_B8!+US /=W"^#U
M6K.S#O"M*6X-Y]N3X]9PQR4R$2&AF&N9<LH"7.,*H/*5H,U56,(,@2^X+Q)A
M9E0L;!J6%IU%I 6;6R\KHDOEKTTVMX5#68X;+8WKE(J;() JM ;80G@$*=8L
M"6(>6R"CQ40B6.0[7..B$QGR_8M&=K!;R/9J[1;-1W_"D]SR&X4=H@@+48$C
MX\YIO:"<5R9;\+5[W%QC6B!C1^1:[2I97^;F?@NVR2A\+@U4ID??WW,QO]P
MV+4);B;*DP(:X*5B,=PM+,Y9UH5Y'2YT)% 4A[9E(R8?P*U4&L@@R!6!8BD/
M;] ZEMK@>SKM1%TZ0$7%013;OZ=+A.A&UKLC71B.^S6PIQETT)'F<[L.G%4Q
MU_.BA?C2K@8(;2*Q\U&0_(PEX@:2XFCCCGSE'T_18Z^ G=L(MG=M!?S#C: ]
M+PW+]5-94!LQ[3*&%RQ'*'Q );-6+,^MXU@P&ZGTO'BP+U#E>"R, ?A&'O$E
MEB?4'@JTSRK91Z0C;6M*"_B7RO9R><*?N4#S[5+,T\ >@AS\?[_WX_=[O00+
M02Q,!:*0]MZTBP\$(&:*Q#_?=TV!WU F=X6AS>6VI+6GM^5)UH.06&R1W,G'
M!C;D(7;4,"?#>U%;%,+8!:&']6K%E1,::PF=CQ$F.$W6F2();3SS>_&EPHYN
MR'I8$40*B::"> !+CX@H>PI?0*_B$JI()S*9 &75E(^*'Q-4P:@PSA(Y VR=
MQM)Q*%\!-@+Q44J.VO?@48)ATP^LQF[J"GD?D0JJB@%(>*:A6WXY0?+/$C[K
MBM1.H>UTL@Z^"241K$N*0>QXKKFX</#F3>VX?DQW#HS"_V$Y<'$=H6:O(QR:
M<+VM56LVVO>VUFO>O6W?U-JI-;WFXZNM'7F=1]?:1&-;K:W4'MKI=5.,0=09
M3]_N-??*#@7LNXWLEGFKP*"5<#>.+H1/PQ/VALI[7':KJ;B8@!?@VV<^8T<5
M>S'H =[5R;>]AXL6P"AEYEQH)?Z=(?]51WZ$)4?/%ENO7[4PD]A/]KEW-1Q<
M]-G5Y?#CNT^]X7 %;3]P.A>B1;JA](2RS)Z&LW)FGMM<OYMMRU ORNT-%YR^
MQ+7WM:='UW.;R2%=_'S&6<YJ[0J#(P9;N'L><Z'<7MQNA,YC 1'KWT*0TPDM
MNW2G$+N#H^<)N0=&9?^+^\$$]Q=KH3A8C\6AW0ELLS']YEW.;>YYWKG G$EM
MKZ]TW0^N$UB[TKR@6VM#?=&%^\BYN;F_RP-NHJY\NMO:A_:6^%]02P,$%
M  @ U3.F7%XL8T@O"   ,BX  !4   !U=&AR97@S,3(P,S,Q,C R-BYH=&WM
M6FUS&CD2_GZ_0N?49>TJP Q@@['C*F*3#5L;.^?@VOUVI1EI0&7-:%;20-A?
M?]W2#"\&)_C6&V/7I2J8&;5:W>I'3[>$SL8VD>=G8T[9^3_._EFMDDL5Y0E/
M+8DTIY8SDAN1CLAOC)L[4JT64A<JFVDQ&EO2J#>.R6]*WXD)]>U66,G/2SUG
MA_[Y[- -<A8J-CL_8V)"!'NW)]KUL-UJT6:'!>U6,VR'<71\PL-&_:1]W(H;
M[#_!'G0%<=_'V)GD[_82D5;'',?OMAJU]E%F3Z>"V7$WJ-?_M>=$S\]BE5H8
M3T-__]6K65=&]0CTA<I:E711E^5?;95*,4J[SLD]KZSL$"FI=/=-W?T[Q99J
M3!,A9]V?>A.>"DVN0 'Y=4@^:_53Q=#45 W7(O:R1OS)NYT:#N2>I]Z1-NB2
M(N6E8T$#7>G__G'P?C DS:#66/5CR8,E>R.8<JZ?T>"+_LUP\&%PT1L.KJ_(
MY]N;+[>]JR$97I.;VU_[)&C2:M#:IP<OPIGK#V3XL4^^]"]N;P;#0?\+Z?]^
M\;%W]7.?]"Z&!)J#DV;KT:YL0.4W\5B\L2K#QQ\R'ZV-\S&HD%]HP@VYJ)$^
M&_%$I:Q"(JZMB&?$CJE]^^:H<_H_NW::4<: ;JJ2Q[;;/"[7HD@9S%^W&G2>
MU?V@5GKV/!:L3D]0KW7:.!\#,J833C2?"#X%QK9C8<@?.=6 .#F#]YG2EJB4
M?% Z(4&]^F^B8G*;"J3WX9AKFO'<B@C"JC3(4BM4"H$\>;6!;.QF(-]3 Q&!
M0"4S<I>JJ>2PQBH^GD44F8+5ERI(SS $%2FAZ8SDJ=4Y!S<@8;O<#>&E)($G
M+:@D,8W@E28J$998Y>76!%(><6.HGJ%(0N\XC+NDT\ [!L; D-(E?A@#!2*A
M(=&#6 K=P1+&-9F.130F)L>/1?\IU[Q0@@XDPDBH"+"XF H[!@=-QB-G(.K-
MP#3%P,T)=&,DG"U/PZL&9_.%@9.36*00?D32(MP50":(0[->:A=I#!SD" :^
M1S)GH!,@M13;"L!1(&]E@ @$,X)<R@5:"Z"8>T/#@F "%5=0(I<@ !!5@",W
MG''V1-2,22S5U)3XU7PDC-44!J+XTML-5E:68&A*8]:L?=5(;.TF$H<K87O[
MIM,(VJ>FP%I1C""MJ#@6\+AO#EQ,!X1J[M #:!"AY!AEP@&RH11FC#U0+ %6
M16;%9R9,))7)H1_RK5;2PRC3*N(,7ANR#ZAA'&#HH='_&HUI.N*D!U1VDTN0
M<"7OT3[W5@1'S#_Y1X%E8>KAB_H)\MT2JCW*T):M!XI7!HIA(/3S/M9! JN&
MIZS7VHT=PR_=+?S"%NX8Y^.2&]@20!A=AOP^QBJ8O".:F^V[8!8-.>"E&,GG
M995K4 "4-A'&$25(\=3IP=I]0;'+-*VYI Z 16)>@*A24#@V"J!;L,4H*9@[
M-C!Y: 035 MT0/CRP26.%#7E!E.Z6[+&Y7]'J\IP,,@"C6.G#"I8$>628C8
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MZHLN- 3FS>W#71YQ'W7ET]_9/G1WQ?\+4$L#!!0    ( -4SIEPE4FWE&04
M /06   5    =71H<F5X,S(Q,#,S,3(P,C8N:'1M[5AM;YM($/Y^OV+.T;6I
M9 C8CAUC-Q*Q26/),3F#U?;3:0U+6!4#7=9)?+_^9A?(F^LV54^7YM1\B#"S
M\_;,L[/##F.Q2HZ',27A\6_#WS4-QEFP7M%40, I$32$=<'22W@?TN(3:%JU
M:I3E&\XN8P$MH]6%]QG_Q*Y(*1=,)/2XMC,\*'\/#Y23X3(+-\?#D%T!"]\V
M6&BV#[O+-C6/S&6G8[:6W7X_HBVC3V@0];OF7V8#57%YJ5.(34+?-E8LU6(J
M_5N=EMX[S,7@FH4BMDS#^*.AEAX/HRP5Z(^C?OE8FMDV1O@EVEMF0F0K2]H2
M]$9H)&&7J:62;)3&:H4@2S)N[1GJ;R E6D16+-E8K^TKFC(.,S0 4Q\N>/:Z
M69"TT K*652N+=C?U#K2I2/U^[I,I(>V$I;2.C&S)5-Q/IQ-3B8^M%NZ^3"/
M>QG<BS= R"E_QH!'SMR?G$Y&MC]Q9W"QF'L+>^:#[[Z(Z,TC6.B>/M+!<T8J
M ^2GT7P1L=L>V&/WPG?&+P[V&NR^T07W%/PS!SQ[?F+/'$]S/TR=CV"/?"EI
M&49K*Z.=6_UQMBP-,5/+/,K_FRW=^6*RDQ2"+$UI(%B6PC43,8B8PN<UX5B%
M9 .<YAD7D$6P2)ELP7Y,.<GI6K"@P-;+44R4\KY4?+77[@Q&V2HGZ48]OP$4
MG69\!::A_0E1QI6#'./-0J (0@CGA ?QJSVS:PS:9K/LXJ2 B"4HO(W)H\&:
M,\%H 20-P;D)8I)>4HQAM6)%\3"$N0J[C* )DZ;T(3![F&<B7B9$B":,8L(X
M!E*@IK0XBAF-T"[Z$>R*@AM%+*!<YB[M5EDU =\)%N&#R)1@20L%T&H#G]+L
M&H.^I$W(U[Q8$ZPJKKJWDRNDU4Z629(PRR6L]Y?7BR0#*^<>X4N2TD)S;Q*Z
M 3M0'B4#,8R88*:'1X.=A-L^5:HW(LO5SYR$(9ZL6D(C8;6[];%3<51[9I*:
M>IW9\T3P$![3T(]Z$@_<"5#R#*)U@GLE0(8DDI^WG.7T\YIQ*F>/0A;LKOS[
M!'<&!_-P/WQS6^0[AM^RNZJTV6]WL,;]@63J_[7.K9^WSBS%SK4J&QTV3$%0
M-<2WJFXU";"=( MR3@M9[Z84DR0!5,-P2()L*'(D0-%46A%+21K(]V@P9,JT
M;$.X:IV4=,FP.RF?Q:,FI'^+ G7!OW2P"K),:+U^F?&0<@U!3DA>4*M^&(2L
MR!.RL5BJ8%)*@VV"7<EF&)"D<J+\E>)J"N[W]9[1DX.PP"-1A+7C:D;6U8Q\
M(,)M6:>C=SN]G6)#-W?*OF:VKQOFOV^UT]:-=O=)9@\4$"48"'>!!7W;:#=J
MA8J$5BN_ ?-A"24O'R->@OT\NU9]X)R3#73+4_N6E14$7\G.D+DUGK3TI0#Q
M:J_3&Q3J/YS;^.4Q<V#N^F<G4]OW'T#S1 9\!T9/6%KM=-D9<"T46<)"J)%Y
M:5A_89R[B/6Q_OPP_X1(*JL6$^@Q> *V3YR+?T']XU#O7W"&,T".0\ 6OF]^
M ?SC '_CHW4;X@,UZ'SG!_TWY^Z?Z(M?WF><NG/GG3N9O8.'-V03#TX<^?IT
M,9]-O#-G#)X[=:8?[U_BP'==D( ]&TN[,]>O;4^F:-?VX +/R-H 1G1>WA"X
M<RFST0O*;=^!\<0;35UO,<='=[0X=V;^[O'WT45LGA5JL+8XQ4,"-]?6U>S=
MZ:AJ9]RID"4>D6NQ6V77I=7.>][J?WGK?*!NN_\!4$L#!!0    ( -4SIEQ2
MM(2V) 4  ',7   5    =71H<F5X,S(R,#,S,3(P,C8N:'1M[5A?;]I($'^_
M3S%'=&TJ8<<& L'02"XX*56"<]BH[=-IL=>PJK'=]9*$^_0WN[:3$)J&J*=+
M<VH>(IOY_YO9V?'T%V(9'_<7E(3'O_5_US08IL%J21,! :=$T!!6.4OF\#&D
M^1?0M))KD&9KSN8+ 0VCT8:/*?_"+DE!%TS$]+C2TS\HWOL'RDA_EH;KXW[(
M+H&%;VLL:)#((-1LM(Z:+=HD,Z,]"\@LZG;,3N?0:/QEUE 4V0N97*QC^K:V
M9(FVH-*^U6KHG<-,]*Y8*!:6:1A_U!3K<3]*$X'V.,H7CX6:;66$SU'?+!4B
M75I2EZ#70B,QFR>6"K)6**L$@C1.N;5GJ+^>I&@16;)X;;VV+VG".(Q1 9SY
M<,'3U_6<)+F64\ZB@C=G?U/K2)>&U/M5$4@'=<4LH55@9D.&XGQZ/WHW\J'9
MT!N;<=R)X(Z_ 4).^3,Z/' F_NAD-+#]D3N&B^G$F]IC'WSW17AO'L%4]_2!
M#IXS4!&8S4.C_B)\MSVPA^Z%[PQ?'.P5V%VC#>X)^.\=\.S).WOL>)K[Z<SY
M#/; EY2&83S]&'RC"=R78DF($I9YE/TWA[WU31A&"01IDM! L#2!*R86(!84
MOJX(QVCB-7":I5Q &L$T8;(Y^PO*2497@@4Y-F6.9**$]Z7@J[UFJS=(EQE)
MUNKY#2#I).5+, WM3XA2K@QDZ&\: D400C@G/%B\VC/;1J]IUHO^3G*(6(S$
M&Y\\&JPX$XSF0)(0G.M@09(Y11^62Y;GFRY,E-N%!W48U>$#6:(@GC(GG--E
MFH1U&"P8C>"$)20)&(G!C2(64*ZT^W@5Y2N.;QBYU%K&5 ?D$"S"!Y$JPHSF
M"I[E&KXDZ16Z/*=UR%8\7Q',*7+=.>$ESNJ$RQ!)F&82U+OL%9.LS-*X1_B,
M)#37W.N8KL$.E$59F>C&@F"<AT>]!\MM^[8I?Q%IIEXS$H9XXVHQC835;%?7
M45FAVC.7J*E7D3V/!YOPF(9^U)%XX#F HLH@6L5X4@*LD%A6YTW%<OIUQ3B5
M,TDN$W:;_GV"YX*#>;@?OKE)\FU]W]1VF6FSVVQACKL]69O_USPW?MX\LP3[
MUK)H<]@N!4'1$']5>:N*@##9+S-.<YGONB23. 840W>PO2 APP+(ZTHJNFD[
MJ#!D2K5L/,BUBHMR2;%)*IOYO2:D/U8"5<*_=3T),HMIQ3]+>4BYAB#'),NI
M53WT0I9G,5E;+%$P*:'>=H%=RF88D+@THNP5Y'(Z[G;UCM&1 [+ "U&$E>%R
M=M;5['P@PFU:JZ6W6YT'R89N/DC[GMJN;IC_OM964S>:[9W4'B@@"C 0[AP3
M^K;6K%4"91%:C>P:S,T4RKJ\CW@!]O.<6O7A<T[6T"[N[)NJ+"'X3G2&C*VV
M$^M+ >+57JO3R]5_^&"?.YX:-H:GSKD['FY LV,%/ &C'5C+DRX[ _)"GL8L
MA J9EX;UUC#W_/C^A! JK183:#'8 =2=QN%?0/\XT/L7G"'$&6)\B[9$V0Z"
M=)4(N?PJP7_S"^\?Q_N1#]=MB _4N'-GO-KEH_[1Z?LG^NJ7VXX3=^*<NJ/Q
M*6SNST8>O'/DSR?3R7CDO7>&X+EGSMGGNRL>>-+Z!.SQ4.H=NWZE>W2&>FT/
M+NR)7RE C\Z++8$[D30;K2#=]AT8CKS!F>M-)_CH#J;GSMA_= A^,!/?W='L
MDNI[>^ LS=7\;G$:8T5=TJW-\.TEK%PR;D7(#&_BE7A8Y D;IHW_Q=+[0"W;
M_P%02P$"% ,4    " #5,Z9<V*O&E3'O 0 %Y1@ $0              @ $
M    =71H<BTR,#(V,#,S,2YH=&U02P$"% ,4    " #5,Z9<AU%\]+,/  !*
MK   $0              @ %@[P$ =71H<BTR,#(V,#,S,2YX<V102P$"% ,4
M    " #5,Z9<FVJ%FB@9  "<&P$ %0              @ %"_P$ =71H<BTR
M,#(V,#,S,5]C86PN>&UL4$L! A0#%     @ U3.F7)2!NB# /P  XI4# !4
M             ( !G1@" '5T:'(M,C R-C S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( -4SIER!AJ'OR^\  (02"@ 5              "  9!8 @!U=&AR+3(P
M,C8P,S,Q7VQA8BYX;6Q02P$"% ,4    " #5,Z9<_Q+BG49X   ,U08 %0
M            @ &.2 , =71H<BTR,#(V,#,S,5]P<F4N>&UL4$L! A0#%
M  @ U3.F7 ^FG%(N"   +"X  !4              ( !!\$# '5T:')E>#,Q
M,3 S,S$R,#(V+FAT;5!+ 0(4 Q0    ( -4SIEQ>+&-(+P@  #(N   5
M          "  6C) P!U=&AR97@S,3(P,S,Q,C R-BYH=&U02P$"% ,4
M" #5,Z9<)5)MY1D%  #T%@  %0              @ '*T0, =71H<F5X,S(Q
M,#,S,3(P,C8N:'1M4$L! A0#%     @ U3.F7%*TA+8D!0  <Q<  !4
M         ( !%M<# '5T:')E>#,R,C S,S$R,#(V+FAT;5!+!08     "@ *
+ )8"  !MW ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>uthr-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:uthr="http://www.unither.com/20260331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="uthr-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <instant>2026-04-29</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">uthr:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">uthr:PrivatelyHeldCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:BuildingsBuildingImprovementsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:BuildingsBuildingImprovementsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:FurnitureEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">uthr:FurnitureEquipmentAndVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:A2025CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022FirstUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022SecondUnsecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">uthr:CreditAgreement2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:StockIncentivePlan2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:StockIncentivePlan2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:NewlyHiredEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:InducementStockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:NewlyHiredEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">uthr:InducementStockIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareTrackingAwardsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareTrackingAwardsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:ShareBasedPaymentArrangementOptionWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:ExecutivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">uthr:ExecutivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">uthr:RestrictedStockUnitsRSUsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-09</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-09</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-09</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-11</startDate>
            <endDate>2026-03-11</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-11</startDate>
            <endDate>2026-03-11</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-11</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-11</startDate>
            <endDate>2026-03-11</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-11</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-30</startDate>
            <endDate>2026-03-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2026AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-04</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-04</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-25</startDate>
            <endDate>2025-08-25</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementUncollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementCollaredAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">uthr:A2025AcceleratedShareRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoDPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:NebulizedTyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:TyvasoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:RemodulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:OrenitramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:UnituxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">uthr:AdcircaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">uthr:DistributorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">uthr:SmithsMedicalASDIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001082554</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">uthr:LiquidiaTechnologiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="investment">
        <measure>uthr:investment</measure>
    </unit>
    <unit id="plan">
        <measure>uthr:plan</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>uthr:agreement</measure>
    </unit>
    <unit id="segment">
        <measure>uthr:segment</measure>
    </unit>
    <unit id="petition">
        <measure>uthr:petition</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-25">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-28">0001082554</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <uthr:DebtInstrumentAdditionalExtensionTerm contextRef="c-102" id="f-476">P1Y</uthr:DebtInstrumentAdditionalExtensionTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-26301</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">United Therapeutics Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">52-1984749</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1000 Spring Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Silver Spring</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">20910</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">608-9292</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">UTHR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">42446733</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-30" unitRef="usd">1279700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-31" unitRef="usd">1557100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-5" id="f-32" unitRef="usd">874000000.0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-5" id="f-33" unitRef="usd">1363200000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="INF" id="f-34" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-3" decimals="INF" id="f-35" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-5" id="f-36" unitRef="usd">312000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-37" unitRef="usd">350200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-5" id="f-38" unitRef="usd">178300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-39" unitRef="usd">183100000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-5" id="f-40" unitRef="usd">228000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-5" id="f-41" unitRef="usd">248900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-5" id="f-42" unitRef="usd">2872000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-5" id="f-43" unitRef="usd">3702500000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-3" decimals="-5" id="f-44" unitRef="usd">1317400000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-5" id="f-45" unitRef="usd">1776700000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-3" decimals="-5" id="f-46" unitRef="usd">115500000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-4" decimals="-5" id="f-47" unitRef="usd">116500000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-48" unitRef="usd">1840700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-49" unitRef="usd">1729700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-3" decimals="-5" id="f-50" unitRef="usd">335400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-5" id="f-51" unitRef="usd">357700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-5" id="f-52" unitRef="usd">233200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-5" id="f-53" unitRef="usd">196900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-5" id="f-54" unitRef="usd">6714200000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-5" id="f-55" unitRef="usd">7880000000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-56" unitRef="usd">498300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-57" unitRef="usd">488000000.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-58" unitRef="usd">100800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-59" unitRef="usd">72600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-60" unitRef="usd">599100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-5" id="f-61" unitRef="usd">560600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-5" id="f-62" unitRef="usd">214000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-5" id="f-63" unitRef="usd">223200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-5" id="f-64" unitRef="usd">813100000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-5" id="f-65" unitRef="usd">783800000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-73" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-5" id="f-74" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-5" id="f-75" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-76"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-78" unitRef="shares">245000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">245000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-80" unitRef="shares">77129770</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">76452253</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-82" unitRef="shares">42156223</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-83" unitRef="shares">43643165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-5" id="f-84" unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-5" id="f-85" unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-5" id="f-86" unitRef="usd">2520300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-5" id="f-87" unitRef="usd">2798000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-5" id="f-88" unitRef="usd">-10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-5" id="f-89" unitRef="usd">900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-90" unitRef="shares">34973547</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-91" unitRef="shares">32809088</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-5" id="f-92" unitRef="usd">5441600000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-5" id="f-93" unitRef="usd">4260400000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-94" unitRef="usd">8831800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-95" unitRef="usd">8556900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-96" unitRef="usd">5901100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-97" unitRef="usd">7096200000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-5" id="f-98" unitRef="usd">6714200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-5" id="f-99" unitRef="usd">7880000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-100" unitRef="usd">781500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-5" id="f-101" unitRef="usd">794400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-102" unitRef="usd">133400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-5" id="f-103" unitRef="usd">92500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-104" unitRef="usd">138200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-5" id="f-105" unitRef="usd">149000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-106" unitRef="usd">184100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-5" id="f-107" unitRef="usd">170100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-108" unitRef="usd">455700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-5" id="f-109" unitRef="usd">411600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-110" unitRef="usd">325800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-5" id="f-111" unitRef="usd">382800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-112" unitRef="usd">41800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-5" id="f-113" unitRef="usd">51100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-5" id="f-114" unitRef="usd">3000000.0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-5" id="f-115" unitRef="usd">6100000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-116" unitRef="usd">-46300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-5" id="f-117" unitRef="usd">-4300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-118" unitRef="usd">-7500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-5" id="f-119" unitRef="usd">40700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-120" unitRef="usd">318300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-5" id="f-121" unitRef="usd">423500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-122" unitRef="usd">43400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-123" unitRef="usd">101300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-124" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-125" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">6.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">7.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">5.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">6.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-130" unitRef="shares">43500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-5" id="f-131" unitRef="shares">44900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-132" unitRef="shares">47200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-5" id="f-133" unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-134" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-135" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-5" id="f-136" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-5" id="f-137" unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax contextRef="c-1" decimals="-5" id="f-138" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax contextRef="c-5" decimals="-5" id="f-139" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-140" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-141" unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-1" decimals="-5" id="f-142" unitRef="usd">-9200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-5" decimals="-5" id="f-143" unitRef="usd">5400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-1" decimals="-5" id="f-144" unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-5" decimals="-5" id="f-145" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-146" unitRef="usd">-11000000.0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-147" unitRef="usd">5400000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-148" unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-149" unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-150" unitRef="usd">263800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-5" id="f-151" unitRef="usd">324400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent contextRef="c-1" decimals="INF" id="f-152" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent contextRef="c-5" decimals="INF" id="f-153" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-154" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-155" unitRef="usd">1700000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-5" id="f-156" unitRef="shares">76500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-5" id="f-157" unitRef="usd">800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-5" id="f-158" unitRef="usd">2798000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-5" id="f-159" unitRef="usd">900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-5" id="f-160" unitRef="usd">-4260400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-5" id="f-161" unitRef="usd">8556900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-5" id="f-162" unitRef="usd">7096200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-5" id="f-163" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-164" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-5" id="f-165" unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-166" unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-5" id="f-167" unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-5" id="f-168" unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-5" id="f-169" unitRef="usd">58300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-170" unitRef="usd">58300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-13" decimals="-5" id="f-171" unitRef="usd">327200000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-14" decimals="-5" id="f-172" unitRef="usd">1172800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-173" unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:ShareRepurchaseProgramExciseTax contextRef="c-14" decimals="-5" id="f-174" unitRef="usd">8400000</us-gaap:ShareRepurchaseProgramExciseTax>
    <us-gaap:ShareRepurchaseProgramExciseTax contextRef="c-1" decimals="-5" id="f-175" unitRef="usd">8400000</us-gaap:ShareRepurchaseProgramExciseTax>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-5" id="f-176" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-15" decimals="-5" id="f-177" unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-5" id="f-178" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-5" id="f-179" unitRef="usd">68300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-5" id="f-180" unitRef="usd">68300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-5" id="f-181" unitRef="usd">33900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-182" unitRef="usd">33900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued contextRef="c-16" decimals="-5" id="f-183" unitRef="shares">77100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-5" id="f-184" unitRef="usd">800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-5" id="f-185" unitRef="usd">2520300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-186" unitRef="usd">-10200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-187" unitRef="usd">-5441600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-5" id="f-188" unitRef="usd">8831800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-5" id="f-189" unitRef="usd">5901100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-21" decimals="-5" id="f-190" unitRef="shares">75000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-5" id="f-191" unitRef="usd">800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-5" id="f-192" unitRef="usd">2698900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-5" id="f-193" unitRef="usd">-3400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-5" id="f-194" unitRef="usd">-3474500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-5" id="f-195" unitRef="usd">7222200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-5" id="f-196" unitRef="usd">6444000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-197" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-198" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-5" id="f-199" unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-5" id="f-200" unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-29" decimals="-5" id="f-201" unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-5" id="f-202" unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-29" decimals="-5" id="f-203" unitRef="usd">15300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-5" id="f-204" unitRef="usd">15300000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-30" decimals="-5" id="f-205" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-30" decimals="-5" id="f-206" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-5" id="f-207" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-5" id="f-208" unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-5" id="f-209" unitRef="usd">16600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-5" id="f-210" unitRef="usd">32600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-5" id="f-211" unitRef="usd">32600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesIssued contextRef="c-31" decimals="-5" id="f-212" unitRef="shares">75200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-213" unitRef="usd">800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-214" unitRef="usd">2737700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-215" unitRef="usd">-1200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-5" id="f-216" unitRef="usd">-3474500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-5" id="f-217" unitRef="usd">7544400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-5" id="f-218" unitRef="usd">6807200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-219" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-220" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-221" unitRef="usd">22600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-5" id="f-222" unitRef="usd">19800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-223" unitRef="usd">33900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-5" id="f-224" unitRef="usd">31800000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-225" unitRef="usd">-61600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-5" decimals="-5" id="f-226" unitRef="usd">-5300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-227" unitRef="usd">25900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-228" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-229" unitRef="usd">-32000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-5" id="f-230" unitRef="usd">-4100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">-38200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-5" id="f-232" unitRef="usd">42700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-233" unitRef="usd">40100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-5" id="f-234" unitRef="usd">11200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">-12700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-5" id="f-236" unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">-27000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-5" decimals="-5" id="f-238" unitRef="usd">-134500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-239" unitRef="usd">463300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-5" id="f-240" unitRef="usd">461200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-241" unitRef="usd">100800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-242" unitRef="usd">74900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-243" unitRef="usd">5700000</uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment>
    <uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-244" unitRef="usd">9200000</uthr:AdvancePaymentRelatedToPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-245" unitRef="usd">701700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-5" id="f-246" unitRef="usd">692300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">269000000.0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-5" decimals="-5" id="f-248" unitRef="usd">611700000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-249" unitRef="usd">1307900000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-5" id="f-250" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue contextRef="c-1" decimals="-5" id="f-251" unitRef="usd">25000000.0</uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue>
    <uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue contextRef="c-5" decimals="-5" id="f-252" unitRef="usd">0</uthr:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">743700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-5" id="f-254" unitRef="usd">-164700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-255" unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-5" id="f-256" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-5" decimals="-5" id="f-258" unitRef="usd">100000000.0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">68300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-5" id="f-260" unitRef="usd">16600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-5" id="f-261" unitRef="usd">5600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-5" decimals="-5" id="f-262" unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">58300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-5" id="f-264" unitRef="usd">15300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">-1484400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-5" id="f-266" unitRef="usd">-93800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">-277400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-5" id="f-268" unitRef="usd">202700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-5" id="f-269" unitRef="usd">1557100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-5" id="f-270" unitRef="usd">1697200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-271" unitRef="usd">1279700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-36" decimals="-5" id="f-272" unitRef="usd">1899900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-5" id="f-273" unitRef="usd">1900000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-5" id="f-274" unitRef="usd">5400000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">1500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="-5" id="f-276" unitRef="usd">500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">99600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-5" id="f-278" unitRef="usd">47200000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <uthr:NoncashExciseTaxOnNetShareRepurchases contextRef="c-1" decimals="-5" id="f-279" unitRef="usd">8400000</uthr:NoncashExciseTaxOnNetShareRepurchases>
    <uthr:NoncashExciseTaxOnNetShareRepurchases contextRef="c-5" decimals="-5" id="f-280" unitRef="usd">0</uthr:NoncashExciseTaxOnNetShareRepurchases>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-281">Organization and Business Description&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. In 2021, we converted to a Delaware public benefit corporation, with the express public benefit purpose &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We have approval from the U.S. Food and Drug Administration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;FDA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) to market the following therapies: Tyvaso DPI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (treprostinil) Inhalation Powder (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Tyvaso DPI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), Tyvaso&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (treprostinil) Inhalation Solution (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Nebulized Tyvaso&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (treprostinil) Injection (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), Orenitram&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (treprostinil) Extended-Release Tablets (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Orenitram&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), Unituxin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (dinutuximab) Injection (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Unituxin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), and Adcirca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (tadalafil) Tablets (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Adcirca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;). We also derive revenues outside the United States from sales of Nebulized Tyvaso, Remodulin, and Unituxin, and within the United States from sales of commercial &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; lung perfusion services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As used in these notes to our consolidated financial statements, unless the context otherwise requires, the terms &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;we&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201d;, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;us&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201d;, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201d;, and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccounting contextRef="c-1" id="f-282">Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;SEC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, as filed with the SEC on February 25, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In our management&#x2019;s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March&#160;31, 2026 and December&#160;31, 2025, and our statements of operations, comprehensive income, stockholders&#x2019; equity, and cash flows for the three-month periods ended March&#160;31, 2026 and 2025. Interim results are not necessarily indicative of results for an entire year. Certain prior year amounts have been reclassified to conform to the current year presentation. In the consolidated statements of cash flows, we reclassified prior amounts within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;net unrealized losses on equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;to conform with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Adopted During the Period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items in the notes to the financial statements. Public business entities are required to apply the guidance prospectively and may elect to apply it retrospectively. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, although early adoption is permitted. We are evaluating the impact of adopting this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Adopted During the Period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;requires public business entities to disclose, on an annual and interim basis, disaggregated information about certain income statement expense line items in the notes to the financial statements. Public business entities are required to apply the guidance prospectively and may elect to apply it retrospectively. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, although early adoption is permitted. We are evaluating the impact of adopting this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-284">Investments&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Marketable Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Available-for-sale debt securities are recorded at fair value, with the portion of the unrealized gains and losses that are not credit-related included as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive (loss) income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in stockholders&#x2019; equity, until realized. Available-for-sale debt securities consisted of the following (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,723.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;403.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Reported under the following captions in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Non-current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,433.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;603.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;606.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,036.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Reported under the following captions in our consolidated balance sheets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Non-current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,776.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:3.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following tables present gross unrealized losses and fair value for those available-for-sale debt securities that were in an unrealized loss position as of March&#160;31, 2026 and December&#160;31, 2025, aggregated by investment category and length of time that the individual securities have been in a continuous loss position (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12 months or longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;822.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;822.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12 months or longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;234.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, we held 98 and 87 available-for-sale debt securities, respectively, that were in an unrealized loss position. In assessing whether the decline in fair value as of March&#160;31, 2026 of any of these securities resulted from a credit loss, we consulted with our investment managers and reviewed the credit ratings for each security. We believe that these unrealized losses are a direct result of the current interest rate environment and do not represent an indication of credit loss. We do not intend to sell the investments in unrealized loss positions prior to their maturity, and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. There were no impairments due to credit loss on our available-for-sale debt securities during the three months ended March&#160;31, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of available-for-sale debt securities (in millions). Actual maturities may differ from contractual maturities because the issuers of certain of these debt securities have the right to call the securities or prepay their obligations under the securities with or without penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;807.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Due in one to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in Equity Securities with Readily Determinable Fair Values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We held investments in equity securities with readily determinable fair values, in the aggregate, of $65.3 million and $126.9 million as of March&#160;31, 2026 and December&#160;31, 2025, respectively, which are included in current &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;marketable investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. Changes in the fair value of publicly traded equity securities are recorded in our consolidated statements of operations within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. See Note 4&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Investments in Privately Held Companies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, we maintained non-controlling equity investments in privately held companies of $91.6&#160;million and $53.8&#160;million, respectively. We invested $25.0&#160;million and zero in privately held companies during the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. We measure these investments using the measurement alternative because the fair values of these investments are not readily determinable. Under this alternative, the investments are measured at cost, less any impairment, and adjusted for any observable price changes. We include our investments in privately held companies within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When an observable price transaction occurs that is identified as similar or identical to our investment, we perform a valuation analysis to assess the fair value of our investment using various inputs, such as the discount rate, time to a liquidation event, and price volatility of peer company stocks. We adjust the fair value of our investment based on the valuation analysis and recognize the gain or loss in the period in which the observable price change occurred. During the three months ended March 31, 2026, one of the privately held companies in which we invested raised additional capital by issuing equity securities similar to ours at an increased valuation compared to prior financing rounds, which resulted in an increase of $12.8&#160;million in the value of our investment. This gain was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These investments are subject to a periodic impairment review and, if impaired, the investment is measured and recorded at fair value in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For non-controlling equity investments in privately held companies in which we held an investment as of March 31, 2026, cumulative impairments and downward fair value adjustments were $5.3&#160;million and cumulative upward fair value adjustments were $14.8&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-285">Available-for-sale debt securities consisted of the following (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,723.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;403.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Reported under the following captions in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Non-current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,433.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;603.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;606.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,036.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.855%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Reported under the following captions in our consolidated balance sheets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Non-current marketable investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,776.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-37" decimals="-5" id="f-286" unitRef="usd">1723300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-37" decimals="-5" id="f-287" unitRef="usd">2700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-37" decimals="-5" id="f-288" unitRef="usd">3300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-37" decimals="-5" id="f-289" unitRef="usd">1722700000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-38" decimals="-5" id="f-290" unitRef="usd">403500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-38" decimals="-5" id="f-291" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-38" decimals="-5" id="f-292" unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-38" decimals="-5" id="f-293" unitRef="usd">403400000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-5" id="f-294" unitRef="usd">2126800000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-5" id="f-295" unitRef="usd">3400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-5" id="f-296" unitRef="usd">4100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-5" id="f-297" unitRef="usd">2126100000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-39" decimals="-5" id="f-298" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-40" decimals="-5" id="f-299" unitRef="usd">808700000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-41" decimals="-5" id="f-300" unitRef="usd">1317400000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-5" id="f-301" unitRef="usd">2126100000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-42" decimals="-5" id="f-302" unitRef="usd">2433000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-42" decimals="-5" id="f-303" unitRef="usd">10500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-42" decimals="-5" id="f-304" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-42" decimals="-5" id="f-305" unitRef="usd">2443200000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-43" decimals="-5" id="f-306" unitRef="usd">603100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-43" decimals="-5" id="f-307" unitRef="usd">3700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-43" decimals="-5" id="f-308" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-43" decimals="-5" id="f-309" unitRef="usd">606800000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-5" id="f-310" unitRef="usd">3036100000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-5" id="f-311" unitRef="usd">14200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-5" id="f-312" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-5" id="f-313" unitRef="usd">3050000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-44" decimals="-5" id="f-314" unitRef="usd">37000000.0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-45" decimals="-5" id="f-315" unitRef="usd">1236300000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent contextRef="c-46" decimals="-5" id="f-316" unitRef="usd">1776700000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-5" id="f-317" unitRef="usd">3050000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-318">&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following tables present gross unrealized losses and fair value for those available-for-sale debt securities that were in an unrealized loss position as of March&#160;31, 2026 and December&#160;31, 2025, aggregated by investment category and length of time that the individual securities have been in a continuous loss position (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12 months or longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;822.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;822.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;942.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.004%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;12 months or longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;234.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-37" decimals="-5" id="f-319" unitRef="usd">822600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-37" decimals="-5" id="f-320" unitRef="usd">3300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-37" decimals="-5" id="f-321" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-37" decimals="-5" id="f-322" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-37" decimals="-5" id="f-323" unitRef="usd">822600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-37" decimals="-5" id="f-324" unitRef="usd">3300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-38" decimals="-5" id="f-325" unitRef="usd">119600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-38" decimals="-5" id="f-326" unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-38" decimals="-5" id="f-327" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-38" decimals="-5" id="f-328" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-38" decimals="-5" id="f-329" unitRef="usd">119600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-38" decimals="-5" id="f-330" unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-3" decimals="-5" id="f-331" unitRef="usd">942200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-3" decimals="-5" id="f-332" unitRef="usd">4100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-3" decimals="-5" id="f-333" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-3" decimals="-5" id="f-334" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-3" decimals="-5" id="f-335" unitRef="usd">942200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-3" decimals="-5" id="f-336" unitRef="usd">4100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-42" decimals="-5" id="f-337" unitRef="usd">215000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-42" decimals="-5" id="f-338" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-42" decimals="-5" id="f-339" unitRef="usd">3500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-42" decimals="-5" id="f-340" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-42" decimals="-5" id="f-341" unitRef="usd">218500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-42" decimals="-5" id="f-342" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-43" decimals="-5" id="f-343" unitRef="usd">19600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-43" decimals="-5" id="f-344" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-43" decimals="-5" id="f-345" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-43" decimals="-5" id="f-346" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-43" decimals="-5" id="f-347" unitRef="usd">19600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-43" decimals="-5" id="f-348" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-5" id="f-349" unitRef="usd">234600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-5" id="f-350" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-5" id="f-351" unitRef="usd">3500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-5" id="f-352" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-5" id="f-353" unitRef="usd">238100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-5" id="f-354" unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-355"
      unitRef="investment">98</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-4"
      decimals="INF"
      id="f-356"
      unitRef="investment">87</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <uthr:DebtSecuritiesAvailableForSaleImpairmentLoss contextRef="c-1" decimals="INF" id="f-357" unitRef="usd">0</uthr:DebtSecuritiesAvailableForSaleImpairmentLoss>
    <uthr:DebtSecuritiesAvailableForSaleImpairmentLoss contextRef="c-5" decimals="INF" id="f-358" unitRef="usd">0</uthr:DebtSecuritiesAvailableForSaleImpairmentLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-359">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of available-for-sale debt securities (in millions). Actual maturities may differ from contractual maturities because the issuers of certain of these debt securities have the right to call the securities or prepay their obligations under the securities with or without penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;807.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;808.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Due in one to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,317.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis contextRef="c-3" decimals="-5" id="f-360" unitRef="usd">807700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue contextRef="c-3" decimals="-5" id="f-361" unitRef="usd">808700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis contextRef="c-3" decimals="-5" id="f-362" unitRef="usd">1319100000</uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughThreeAmortizedCostBasis>
    <uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue contextRef="c-3" decimals="-5" id="f-363" unitRef="usd">1317400000</uthr:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingYearOneThroughYearThreeFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="c-3" decimals="-5" id="f-364" unitRef="usd">2126800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-3" decimals="-5" id="f-365" unitRef="usd">2126100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-3" decimals="-5" id="f-366" unitRef="usd">65300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-4" decimals="-5" id="f-367" unitRef="usd">126900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-47" decimals="-5" id="f-368" unitRef="usd">91600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-48" decimals="-5" id="f-369" unitRef="usd">53800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-49" decimals="-5" id="f-370" unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-50" decimals="INF" id="f-371" unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount contextRef="c-49" decimals="-5" id="f-372" unitRef="usd">12800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount contextRef="c-47" decimals="-5" id="f-373" unitRef="usd">5300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount contextRef="c-47" decimals="-5" id="f-374" unitRef="usd">14800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-375">Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We account for certain assets and liabilities at fair value and classify these assets and liabilities within the fair value hierarchy (Level 1, Level 2, or Level 3). Our other current assets and other current liabilities have fair values that approximate their carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets and liabilities subject to fair value measurements are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;397.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;397.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;205.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;205.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;403.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;403.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;668.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,794.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;753.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;753.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;606.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;606.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;880.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,930.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;non-current marketable investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. See Note 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Marketable Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; for further information. The fair value of these securities is principally measured or corroborated by trade data for identical securities for which related trading activity is not sufficiently frequent to be considered a Level 1 input or comparable securities that are more actively traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;current marketable investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. The fair value of these securities is based on quoted market prices for identical instruments in active markets. During the three months ended March&#160;31, 2026 and March&#160;31, 2025, we recognized $61.6&#160;million and $5.3 million of net unrealized losses, respectively, on these securities. These net unrealized losses are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;other expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our consolidated statements of operations. See Note 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments&#x2014;Marketable Investments&#x2014;Investments in Equity Securities with Readily Determinable Fair Values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. The fair value of our contingent consideration obligations is estimated using probability-weighted discounted cash flow models (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;DCFs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;). The DCFs incorporate Level 3 inputs, including estimated discount rates, that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. The fair value of our contingent consideration liabilities increased by $1.7&#160;million during the period from December 31, 2025 to March&#160;31, 2026. The loss was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;The carrying amounts of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;accounts receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;accounts payable and accrued expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt; approximate fair value because of their short maturities. The fair values of our marketable investments and contingent consideration are reported above within the fair value hierarchy. See Note 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets and liabilities subject to fair value measurements are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;397.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;397.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;205.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;205.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,722.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;403.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;403.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;668.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,126.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,794.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;753.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;753.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,443.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;606.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;606.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;880.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,050.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,930.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;non-current marketable investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. See Note 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Marketable Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; for further information. The fair value of these securities is principally measured or corroborated by trade data for identical securities for which related trading activity is not sufficiently frequent to be considered a Level 1 input or comparable securities that are more actively traded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;current marketable investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. The fair value of these securities is based on quoted market prices for identical instruments in active markets. During the three months ended March&#160;31, 2026 and March&#160;31, 2025, we recognized $61.6&#160;million and $5.3 million of net unrealized losses, respectively, on these securities. These net unrealized losses are recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;other expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our consolidated statements of operations. See Note 3&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investments&#x2014;Marketable Investments&#x2014;Investments in Equity Securities with Readily Determinable Fair Values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:4.97pt"&gt;Included in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; in our consolidated balance sheets. The fair value of our contingent consideration obligations is estimated using probability-weighted discounted cash flow models (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;DCFs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;). The DCFs incorporate Level 3 inputs, including estimated discount rates, that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. The fair value of our contingent consideration liabilities increased by $1.7&#160;million during the period from December 31, 2025 to March&#160;31, 2026. The loss was recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-51" decimals="-5" id="f-377" unitRef="usd">397500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-52" decimals="-5" id="f-378" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-53" decimals="-5" id="f-379" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="-5" id="f-380" unitRef="usd">397500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-5" id="f-381" unitRef="usd">205500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-5" id="f-382" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-5" id="f-383" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-5" id="f-384" unitRef="usd">205500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-59" decimals="-5" id="f-385" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-60" decimals="-5" id="f-386" unitRef="usd">1722700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="-5" id="f-387" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-5" id="f-388" unitRef="usd">1722700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="-5" id="f-389" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="-5" id="f-390" unitRef="usd">403400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="-5" id="f-391" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="-5" id="f-392" unitRef="usd">403400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-67" decimals="-5" id="f-393" unitRef="usd">65300000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-68" decimals="-5" id="f-394" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-69" decimals="-5" id="f-395" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-70" decimals="-5" id="f-396" unitRef="usd">65300000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-67" decimals="-5" id="f-397" unitRef="usd">668300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-68" decimals="-5" id="f-398" unitRef="usd">2126100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-5" id="f-399" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-5" id="f-400" unitRef="usd">2794400000</us-gaap:AssetsFairValueDisclosure>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-67" decimals="-5" id="f-401" unitRef="usd">0</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-68" decimals="-5" id="f-402" unitRef="usd">0</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-69" decimals="-5" id="f-403" unitRef="usd">34200000</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-70" decimals="-5" id="f-404" unitRef="usd">34200000</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-67" decimals="-5" id="f-405" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-68" decimals="-5" id="f-406" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-69" decimals="-5" id="f-407" unitRef="usd">34200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-70" decimals="-5" id="f-408" unitRef="usd">34200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-5" id="f-409" unitRef="usd">753100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-5" id="f-410" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-5" id="f-411" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="-5" id="f-412" unitRef="usd">753100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="-5" id="f-413" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-5" id="f-414" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-77" decimals="-5" id="f-415" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-78" decimals="-5" id="f-416" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-5" id="f-417" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="-5" id="f-418" unitRef="usd">2443200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-5" id="f-419" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-5" id="f-420" unitRef="usd">2443200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-5" id="f-421" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-5" id="f-422" unitRef="usd">606800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="-5" id="f-423" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="-5" id="f-424" unitRef="usd">606800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-87" decimals="-5" id="f-425" unitRef="usd">126900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-88" decimals="-5" id="f-426" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-89" decimals="-5" id="f-427" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-90" decimals="-5" id="f-428" unitRef="usd">126900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-87" decimals="-5" id="f-429" unitRef="usd">880000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-88" decimals="-5" id="f-430" unitRef="usd">3050000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-89" decimals="-5" id="f-431" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-90" decimals="-5" id="f-432" unitRef="usd">3930000000</us-gaap:AssetsFairValueDisclosure>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-87" decimals="-5" id="f-433" unitRef="usd">0</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-88" decimals="-5" id="f-434" unitRef="usd">0</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-89" decimals="-5" id="f-435" unitRef="usd">32500000</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability contextRef="c-90" decimals="-5" id="f-436" unitRef="usd">32500000</uthr:BusinessAcquisitionContingentConsiderationFairValueDisclosureLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-87" decimals="-5" id="f-437" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-88" decimals="-5" id="f-438" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-89" decimals="-5" id="f-439" unitRef="usd">32500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-90" decimals="-5" id="f-440" unitRef="usd">32500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-91" decimals="-5" id="f-441" unitRef="usd">-61600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-92" decimals="-5" id="f-442" unitRef="usd">-5300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-443" unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-444">Inventories&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following, net of reserves (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;30.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Work-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;35.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;35.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;108.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;117.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;178.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;183.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following, net of reserves (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;34.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;30.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Work-in-progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;35.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;35.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;108.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;117.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;178.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;183.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-5" id="f-446" unitRef="usd">34600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-5" id="f-447" unitRef="usd">30600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-5" id="f-448" unitRef="usd">35100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-5" id="f-449" unitRef="usd">35300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-5" id="f-450" unitRef="usd">108600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-5" id="f-451" unitRef="usd">117200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-5" id="f-452" unitRef="usd">178300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-5" id="f-453" unitRef="usd">183100000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-454">Property, Plant, and Equipment&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;266.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;266.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements, and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;949.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;944.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Buildings under construction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;704.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;592.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Furniture, equipment, and vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;493.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,297.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(589.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(567.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,840.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,729.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025 was $21.6 million and $19.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant, and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;266.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;266.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements, and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;949.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;944.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Buildings under construction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;704.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;592.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Furniture, equipment, and vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;493.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2,297.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(589.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6e71;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6e71;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(567.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6e71;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,840.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1,729.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-93" decimals="-5" id="f-456" unitRef="usd">266500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-94" decimals="-5" id="f-457" unitRef="usd">266500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-5" id="f-458" unitRef="usd">949700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-5" id="f-459" unitRef="usd">944700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-97" decimals="-5" id="f-460" unitRef="usd">704200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-5" id="f-461" unitRef="usd">592700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-99" decimals="-5" id="f-462" unitRef="usd">509600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-100" decimals="-5" id="f-463" unitRef="usd">493600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-5" id="f-464" unitRef="usd">2430000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-5" id="f-465" unitRef="usd">2297500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-5" id="f-466" unitRef="usd">589300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-5" id="f-467" unitRef="usd">567800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-5" id="f-468" unitRef="usd">1840700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-5" id="f-469" unitRef="usd">1729700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-470" unitRef="usd">21600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-5" id="f-471" unitRef="usd">19600000</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-472">Debt&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;2025 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In April 2025, we entered into a credit agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2025 Credit Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) with Wells Fargo Bank, National Association (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Wells Fargo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) as administrative agent and a swingline lender, and various other lender parties, which provides for an unsecured revolving credit facility of up to $2.5&#160;billion (which facility may, at our request, be increased by up to $750&#160;million in the aggregate subject to obtaining commitments from existing or new lenders for such increase and other conditions). In accordance with the terms of the 2025 Credit Agreement, in May 2026, we extended the maturity date of the 2025 Credit Agreement by one year, to April 2031. The 2025 Credit Agreement provides the lenders with the ability to extend the maturity date by &lt;span style="-sec-ix-hidden:f-476"&gt;one&lt;/span&gt; additional year, to April 2032, if we request such an extension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;At our option, amounts borrowed under the 2025 Credit Agreement bear interest at either an adjusted Term Secured Overnight Finance Rate (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Term SOFR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) or a fluctuating base rate, in each case, plus an applicable margin determined on a quarterly basis based on our consolidated ratio of total indebtedness to EBITDA (as calculated in accordance with the 2025 Credit Agreement). To date, we have elected to calculate interest on the outstanding balance at an adjusted Term SOFR plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 25, 2025, we borrowed $200.0&#160;million under the 2025 Credit Agreement, and used the funds to repay outstanding indebtedness under the 2022 Credit Agreement, as discussed below under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025, we paid down the entire $200.0 million balance under the 2025 Credit Agreement, which brought our aggregate outstanding balance to zero as of June 30, 2025. Our aggregate outstanding balance under the 2025 Credit Agreement remained zero as of March&#160;31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The 2025 Credit Agreement contains customary events of default and customary affirmative and negative covenants. As of March 31, 2026, we were in compliance with these covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The interest expense reported in our consolidated statements of operations for the three months ended March&#160;31, 2026 and 2025 relates to the 2025 Credit Agreement and 2022 Credit Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In March 2022, we entered into a credit agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) with Wells Fargo, as administrative agent and a swingline lender, and various other lender parties, which provided for: (1) an unsecured revolving credit facility of up to $1.2&#160;billion; and (2) a second unsecured revolving credit facility of up to $800.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, our outstanding aggregate principal balance under the 2022 Credit Agreement was $300.0&#160;million. During the first quarter of 2025, we paid down $100.0&#160;million of our balance under the 2022 Credit Agreement, which brought our aggregate outstanding balance down to $200.0&#160;million as of March 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 25, 2025, we terminated the 2022 Credit Agreement and entered into the 2025 Credit Agreement. We repaid in full all our obligations under the 2022 Credit Agreement in connection with the termination of the 2022 Credit Agreement and our entry into the 2025 Credit Agreement. There were no penalties associated with the early termination of the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-101" decimals="-8" id="f-473" unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <uthr:LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity contextRef="c-101" decimals="-6" id="f-474" unitRef="usd">750000000</uthr:LineOfCreditFacilityContingentIncreaseAdditionalBorrowingCapacity>
    <uthr:DebtInstrumentExtensionTerm contextRef="c-102" id="f-475">P1Y</uthr:DebtInstrumentExtensionTerm>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-103" decimals="-5" id="f-477" unitRef="usd">200000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-104" decimals="-5" id="f-478" unitRef="usd">200000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-105" decimals="INF" id="f-479" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-106" decimals="INF" id="f-480" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-107" decimals="INF" id="f-481" unitRef="usd">1200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-108" decimals="INF" id="f-482" unitRef="usd">800000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LinesOfCreditCurrent contextRef="c-109" decimals="-5" id="f-483" unitRef="usd">300000000.0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-110" decimals="-5" id="f-484" unitRef="usd">100000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LinesOfCreditCurrent contextRef="c-111" decimals="-5" id="f-485" unitRef="usd">200000000.0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-486">Share-Based Compensation&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, we have one shareholder-approved equity incentive plan: the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2015 Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;). The 2015 Plan provides for the issuance of up to 14,770,000 shares of our common stock pursuant to awards granted under the 2015 Plan, which includes 950,000 shares that were added pursuant to an amendment and restatement of the 2015 Plan approved by our shareholders in June 2025. We also have one equity incentive plan, the United Therapeutics Corporation 2019 Inducement Stock Incentive Plan (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2019 Inducement Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), that has not been approved by our shareholders, as permitted by the Nasdaq Stock Market rules. The 2019 Inducement Plan was approved by our Board of Directors in February 2019 and provides for the issuance of up to 99,000 shares of our common stock under awards granted to newly hired employees. Currently, we grant equity-based awards to employees and members of our Board of Directors in the form of stock options and restricted stock units (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) under the 2015 Plan, and we may grant RSUs to newly hired employees under the 2019 Inducement Plan. See the sections entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; RSUs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;below for additional information regarding these equity-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026 and 2025, we issued stock options and RSUs to certain executives with vesting conditions tied to the achievement of specified performance criteria through the end of 2028 and 2027, respectively. Additionally, during the three months ended March&#160;31, 2026 and 2025, we issued RSUs to certain other employees with vesting conditions tied to the achievement of specified performance criteria during specified performance periods, with the latest performance period ending in 2028. Throughout each performance period, we reassess the estimated performance and update the number of performance-based awards that we believe will ultimately vest. Estimating future performance requires the use of judgment. Upon the conclusion of the performance period, the performance level achieved and the ultimate number of stock options and RSUs that may vest are determined. Share-based compensation expense for these awards is recorded ratably over their vesting period, depending on the specific terms of the award and anticipated achievement of the specified performance criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We previously issued awards under the United Therapeutics Corporation 2011 Share Tracking Awards Plan (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;STAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;). We discontinued the issuance of STAP awards in June 2015 and all remaining outstanding STAP awards were exercised during the first quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2012, our shareholders approved the United Therapeutics Corporation Employee Stock Purchase Plan (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), which is structured to comply with Section&#160;423 of the Internal Revenue Code. See the section entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;ESPP &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;below for additional information regarding the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of share-based compensation expense recognized in our consolidated statements of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;STAP awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;31.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options using the Black-Scholes-Merton valuation model, which requires us to make certain assumptions that can materially impact the estimation of fair value and related compensation expense. The assumptions used to estimate fair value include the price of our common stock, the expected volatility of our common stock, the risk-free interest rate, the expected term of stock option awards, and the expected dividend yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026 and 2025, in addition to time-based stock options, we granted 0.3&#160;million performance-based stock options in each period with grant date fair values of $53.9&#160;million and $38.0&#160;million, respectively, calculated based on the assumed achievement of the relevant financial performance condition. During the three months ended March&#160;31, 2026 and 2025, we recorded $10.5 million and $7.7 million of share-based compensation expense, respectively, related to performance-based stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used in estimating the fair value of stock options granted to employees during the three months ended March&#160;31, 2026 and 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected term of awards (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of the activity and status of stock options under the 2015 Plan during the three-month period ended March&#160;31, 2026 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Term (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Value (in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4,636,330&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;166.11&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;289,956&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;536.12&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(495,147)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.00&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(365)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.26&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4,430,774&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;193.46&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,770.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Exercisable as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,243,872&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;142.88&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,460.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,186,902&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;331.72&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;7.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;310.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of a stock option granted during each of the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $190.42 and $110.11, respectively. These stock options have an aggregate grant date fair value of $55.2&#160;million and $39.0 million, respectively. The total grant date fair value of stock options that vested during the three-month periods ended March&#160;31, 2026 and March&#160;31, 2025 was $36.7&#160;million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to stock options was recorded as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Related income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, unrecognized compensation cost related to stock options was $97.0&#160;million. Unvested outstanding stock options as of March&#160;31, 2026 had a weighted average remaining vesting period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Stock option exercise data is summarized below (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;495,147&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;131,474&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cash received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;68.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;182.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;29.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Each RSU entitles the recipient to one share of our common stock upon vesting. We measure the fair value of RSUs using the stock price on the date of grant. Share-based compensation expense for RSUs is recorded ratably over their vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026 and 2025, in addition to time-based RSUs, we granted 0.2&#160;million performance-based RSUs in each period, with total grant date fair values of $88.7&#160;million and $67.3 million, respectively, calculated based on the assumed achievement of the relevant financial and non-financial performance conditions. During the three months ended March&#160;31, 2026 and 2025, we recorded $5.2 million and $8.3 million of share-based compensation expense, respectively, related to performance-based RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of the activity with respect to, and status of, RSUs during the three-month period ended March&#160;31, 2026 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,416,871&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;252.86&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;295,640&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;520.38&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(274,965)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;234.77&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(16,515)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;248.71&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,421,031&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;312.06&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to RSUs was recorded as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Related income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;19.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, unrecognized compensation cost related to the grant of RSUs was $273.4 million. Unvested outstanding RSUs as of March&#160;31, 2026 had a weighted average remaining vesting period of 2.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The ESPP provides eligible employees with the right to purchase shares of our common stock at a discount through elective accumulated payroll deductions at the end of each offering period. Eligible employees may contribute up to 15 percent of their base salary, subject to certain annual limitations as defined in the ESPP. The purchase price of the shares is equal to the lower of 85 percent of the closing price of our common stock on either the first or last trading day of a given offering period. In addition, the ESPP provides that no eligible employee may purchase more than 4,000 shares during any offering period. The ESPP expires in June 2032 and limits the aggregate number of shares that can be issued under the ESPP to 3.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <uthr:NumberOfEquityIncentivePlans contextRef="c-3" decimals="INF" id="f-487" unitRef="plan">1</uthr:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-112"
      decimals="INF"
      id="f-488"
      unitRef="shares">14770000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-113"
      decimals="INF"
      id="f-489"
      unitRef="shares">950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <uthr:NumberOfEquityIncentivePlans contextRef="c-114" decimals="INF" id="f-490" unitRef="plan">1</uthr:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-115"
      decimals="INF"
      id="f-491"
      unitRef="shares">99000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of share-based compensation expense recognized in our consolidated statements of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;STAP awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;31.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-5" id="f-493" unitRef="usd">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-5" id="f-494" unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-5" id="f-495" unitRef="usd">21500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-5" id="f-496" unitRef="usd">23400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-5" id="f-497" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-5" id="f-498" unitRef="usd">-800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-5" id="f-499" unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-5" id="f-500" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-501" unitRef="usd">33900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-5" id="f-502" unitRef="usd">31800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-124"
      decimals="-5"
      id="f-503"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-125"
      decimals="-5"
      id="f-504"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue contextRef="c-124" decimals="-5" id="f-505" unitRef="usd">53900000</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue contextRef="c-125" decimals="-5" id="f-506" unitRef="usd">38000000.0</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-5" id="f-507" unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-5" id="f-508" unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following weighted average assumptions were used in estimating the fair value of stock options granted to employees during the three months ended March&#160;31, 2026 and 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.795%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected term of awards (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;32.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-116" id="f-510">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-117" id="f-511">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-116" decimals="3" id="f-512" unitRef="number">0.325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-117" decimals="3" id="f-513" unitRef="number">0.322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-116" decimals="3" id="f-514" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-117" decimals="3" id="f-515" unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-116" decimals="3" id="f-516" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-117" decimals="3" id="f-517" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of the activity and status of stock options under the 2015 Plan during the three-month period ended March&#160;31, 2026 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Term (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Value (in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4,636,330&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;166.11&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;289,956&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;536.12&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(495,147)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.00&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(365)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.26&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4,430,774&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;193.46&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,770.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Exercisable as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,243,872&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;142.88&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,460.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,186,902&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;331.72&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;7.2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;310.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-126"
      decimals="INF"
      id="f-519"
      unitRef="shares">4636330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-126"
      decimals="2"
      id="f-520"
      unitRef="usdPerShare">166.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c-116"
      decimals="INF"
      id="f-521"
      unitRef="shares">289956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-116"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">536.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-116"
      decimals="INF"
      id="f-523"
      unitRef="shares">495147</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-116"
      decimals="2"
      id="f-524"
      unitRef="usdPerShare">138.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-116"
      decimals="INF"
      id="f-525"
      unitRef="shares">365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-116"
      decimals="2"
      id="f-526"
      unitRef="usdPerShare">120.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-127"
      decimals="INF"
      id="f-527"
      unitRef="shares">4430774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-528"
      unitRef="usdPerShare">193.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-116" id="f-529">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-127" decimals="-5" id="f-530" unitRef="usd">1770200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-127"
      decimals="INF"
      id="f-531"
      unitRef="shares">3243872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-532"
      unitRef="usdPerShare">142.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-116" id="f-533">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-127" decimals="-5" id="f-534" unitRef="usd">1460100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-127"
      decimals="INF"
      id="f-535"
      unitRef="shares">1186902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">331.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-116" id="f-537">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-127" decimals="-5" id="f-538" unitRef="usd">310100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">190.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-540"
      unitRef="usdPerShare">110.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue contextRef="c-116" decimals="-5" id="f-541" unitRef="usd">55200000</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue contextRef="c-117" decimals="-5" id="f-542" unitRef="usd">39000000.0</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-116" decimals="-5" id="f-543" unitRef="usd">36700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-117" decimals="-5" id="f-544" unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to stock options was recorded as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Related income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to RSUs was recorded as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;21.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;23.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Related income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;19.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-5" id="f-546" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-129" decimals="-5" id="f-547" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-5" id="f-548" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-5" id="f-549" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-5" id="f-550" unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-5" id="f-551" unitRef="usd">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-5" id="f-552" unitRef="usd">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-5" id="f-553" unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-116" decimals="-5" id="f-554" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-117" decimals="-5" id="f-555" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-116" decimals="-5" id="f-556" unitRef="usd">11300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-117" decimals="-5" id="f-557" unitRef="usd">8300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-558" unitRef="usd">97000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-116" id="f-559">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <uthr:ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock contextRef="c-1" id="f-560">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Stock option exercise data is summarized below (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;495,147&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;131,474&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cash received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;68.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;182.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;29.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</uthr:ScheduleOfServiceShareBasedCompensationEmployeeAndNonemployeeStockOptionExerciseDataTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-116"
      decimals="INF"
      id="f-561"
      unitRef="shares">495147</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-117"
      decimals="INF"
      id="f-562"
      unitRef="shares">131474</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-116" decimals="-5" id="f-563" unitRef="usd">68300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-117" decimals="-5" id="f-564" unitRef="usd">16600000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-116" decimals="-5" id="f-565" unitRef="usd">182900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-117" decimals="-5" id="f-566" unitRef="usd">29100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting
      contextRef="c-134"
      decimals="INF"
      id="f-567"
      unitRef="shares">1</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEntitledToReceiveForEachUnitUponVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-135"
      decimals="-5"
      id="f-568"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-136"
      decimals="-5"
      id="f-569"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue contextRef="c-135" decimals="-5" id="f-570" unitRef="usd">88700000</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue contextRef="c-136" decimals="-5" id="f-571" unitRef="usd">67300000</uthr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-5" id="f-572" unitRef="usd">5200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-5" id="f-573" unitRef="usd">8300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-574">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of the activity with respect to, and status of, RSUs during the three-month period ended March&#160;31, 2026 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.482%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,416,871&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;252.86&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;295,640&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;520.38&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(274,965)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;234.77&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(16,515)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;248.71&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unvested as of March 31, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1,421,031&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;312.06&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-139"
      decimals="INF"
      id="f-575"
      unitRef="shares">1416871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-139"
      decimals="2"
      id="f-576"
      unitRef="usdPerShare">252.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-118"
      decimals="INF"
      id="f-577"
      unitRef="shares">295640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">520.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-118"
      decimals="INF"
      id="f-579"
      unitRef="shares">274965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">234.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-118"
      decimals="INF"
      id="f-581"
      unitRef="shares">16515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-582"
      unitRef="usdPerShare">248.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-134"
      decimals="INF"
      id="f-583"
      unitRef="shares">1421031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-134"
      decimals="2"
      id="f-584"
      unitRef="usdPerShare">312.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-140" decimals="-5" id="f-585" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-141" decimals="-5" id="f-586" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-142" decimals="-5" id="f-587" unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-143" decimals="-5" id="f-588" unitRef="usd">6700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-5" id="f-589" unitRef="usd">15600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="-5" id="f-590" unitRef="usd">15700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-5" id="f-591" unitRef="usd">21500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-5" id="f-592" unitRef="usd">23400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-118" decimals="-5" id="f-593" unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-119" decimals="-5" id="f-594" unitRef="usd">3800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-118" decimals="-5" id="f-595" unitRef="usd">18000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-119" decimals="-5" id="f-596" unitRef="usd">19600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-134" decimals="-5" id="f-597" unitRef="usd">273400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-118" id="f-598">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-146"
      decimals="INF"
      id="f-599"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-122"
      decimals="INF"
      id="f-600"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-122"
      decimals="INF"
      id="f-601"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-146"
      decimals="INF"
      id="f-602"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-603">Stockholders&#x2019; Equity&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Earnings Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Basic earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of our outstanding stock options, outstanding RSUs, and shares issuable under the ESPP, as if the RSUs were vested, the stock options were exercised, and the shares expected to be issued under the ESPP at the end of the current offering period were issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted earnings per common share comprised the following (in millions, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;274.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;322.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Weighted average outstanding shares &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs, and ESPP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Weighted average shares &#x2014; diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;7.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;Calculated using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;The common shares underlying certain stock options and RSUs have been excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;2026 Share Repurchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In March 2026, our Board of Directors approved a share repurchase program authorizing up to $2.0&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;which program expires on March 9, 2027&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Pursuant to this authorization, we entered into two accelerated share repurchase agreements (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2026 ASR agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) with Citibank, N.A. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Citi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) on March 9, 2026 to repurchase approximately $1.5&#160;billion of our common stock in the aggregate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2026 ASR agreements, comprised of a $750&#160;million uncollared share repurchase agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Uncollared ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and a $750&#160;million collared share repurchase agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Collared ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), we made an aggregate upfront payment of $1.5&#160;billion to Citi on March 11, 2026. Under the 2026 Uncollared ASR, we received an initial delivery of 992,120 shares of our common stock, representing approximately 70 percent of the total shares expected to be repurchased under the 2026 Uncollared ASR, measured based on the closing price of our common stock on March 9, 2026. Under the 2026 Collared ASR, we received an initial delivery of 708,657 shares of our common stock, representing approximately 50 percent of the total shares expected to be repurchased under the 2026 Collared ASR, measured based on the closing price of our common stock on March 9, 2026. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2026 Collared ASR, we received an additional 463,682 shares of our common stock on March 30, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final number of shares that we will ultimately repurchase pursuant to the 2026 ASR agreements will be determined based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2026 ASR agreements. As discussed above, under the 2026 Collared ASR, the final number of shares we will ultimately repurchase will also be subject to a collar provision establishing the minimum and maximum numbers of shares to be repurchased, as well as other adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;At the final settlement of the 2026 ASR agreements, we may be entitled to receive additional shares of our common stock, or, under certain limited circumstances, be required to make an additional cash payment to Citi or, if we so elect, deliver shares of our common stock to Citi. The scheduled termination date of the 2026 Uncollared ASR is in the second quarter of 2026. The scheduled termination date of the 2026 Collared ASR is in the third quarter of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The initial repurchase of our common stock under the 2026 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2026 ASR agreements was accounted for as a reduction to stockholders&#x2019; equity in our consolidated balance sheets. The hedging period under the 2026 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on March 30, 2026. The final settlement of the transactions under the 2026 ASR agreements is accounted for as an unsettled forward contract indexed to our common stock until the final settlement occurs. The forward contract related to the 2026 ASR agreements was equity classified, in accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, upon inception and we expect equity classification to remain appropriate through final settlement under the 2026 Uncollared ASR and the 2026 Collared ASR. During the three months ended March 31, 2026, we recorded a liability of $8.4&#160;million for an excise tax imposed under the Inflation Reduction Act of 2022 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;IRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) as a result of our repurchase of shares under the 2026 ASR agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;2025 Share Repurchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July 2025, our Board of Directors approved a share repurchase program authorizing up to $1.0&#160;billion in aggregate repurchases of our common stock (plus the amount of any customary contingent settlement obligations that may arise upon the expiration or early termination of an accelerated share repurchase contract). Pursuant to this authorization, we entered into two accelerated share repurchase agreements (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2025 ASR agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) with Citi on August 1, 2025 to repurchase approximately $1.0&#160;billion of our common stock in the aggregate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2025 ASR agreements, comprised of a $500&#160;million uncollared share repurchase agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Uncollared ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and a $500&#160;million collared share repurchase agreement (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Collared ASR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), we made an aggregate upfront payment of $1.0&#160;billion to Citi on August 4, 2025. Under the 2025 Uncollared ASR, we received an initial delivery of 1,274,296 shares of our common stock, representing approximately 75 percent of the total shares expected to be repurchased under the 2025 Uncollared ASR, measured based on the closing price of our common stock on August 1, 2025. Under the 2025 Collared ASR, we received an initial delivery of 849,531 shares of our common stock, representing approximately 50 percent of the total shares expected to be repurchased under the 2025 Collared ASR, measured based on the closing price of our common stock on August 1, 2025. Upon completion of an agreed-upon hedging period and the subsequent determination of the minimum and maximum share amounts to be repurchased under the 2025 Collared ASR, we received an additional 514,789 shares of our common stock on August 25, 2025. The final settlement of the 2025 Uncollared ASR occurred in November 2025, and we received an additional 3,882 shares of our common stock upon settlement. The final settlement of the 2025 Collared ASR occurred in January 2026, and we received no additional shares of our common stock upon settlement as a result of a collar provision that established the minimum and maximum number of shares to be repurchased, as well as other adjustments. In total, we repurchased 2,642,498 shares of our common stock under the 2025 ASR agreements that we currently hold as treasury stock in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final number of shares that we ultimately repurchased pursuant to the 2025 Uncollared ASR was based on the average of the daily volume-weighted average price per share of our common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms and conditions of the 2025 Uncollared ASR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The initial repurchase of our common stock and final settlements under the 2025 ASR agreements, including the subsequent receipt of our common stock upon completion of the hedging period, were treated as a reduction of the outstanding shares used to calculate the weighted average common stock outstanding for basic and diluted earnings per common share. The initial repurchase of our common stock under the 2025 ASR agreements was accounted for as a reduction to stockholders&#x2019; equity in our consolidated balance sheets. The hedging period under the 2025 Collared ASR was classified as part of the unsettled forward contract at inception and was equity classified upon settlement on August 25, 2025. The final settlements of the 2025 ASR agreements were accounted for as unsettled forward contracts indexed to our common stock until the final settlement occurred. The forward contracts related to the 2025 ASR agreements were equity classified, in accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, through final settlement. Excise taxes imposed under the IRA as a result of our 2025 ASR agreements were $1.8&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted earnings per common share comprised the following (in millions, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.832%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;274.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;322.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Weighted average outstanding shares &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;44.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs, and ESPP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Weighted average shares &#x2014; diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;7.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;Calculated using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;The common shares underlying certain stock options and RSUs have been excluded from the computation of diluted earnings per share because their impact would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-605" unitRef="usd">274900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-606" unitRef="usd">322200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-607" unitRef="shares">43500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-5" id="f-608" unitRef="shares">44900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-5" id="f-609" unitRef="shares">3700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-5" id="f-610" unitRef="shares">3700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-611" unitRef="shares">47200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-5" id="f-612" unitRef="shares">48600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">6.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-614"
      unitRef="usdPerShare">7.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">5.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-616"
      unitRef="usdPerShare">6.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-617" unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-618" unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-147" decimals="INF" id="f-619" unitRef="usd">2000000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements
      contextRef="c-148"
      decimals="INF"
      id="f-620"
      unitRef="agreement">2</uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-148" decimals="-8" id="f-621" unitRef="usd">1500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-149" decimals="-6" id="f-622" unitRef="usd">750000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-150" decimals="-6" id="f-623" unitRef="usd">750000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-151" decimals="-8" id="f-624" unitRef="usd">1500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-152" decimals="0" id="f-625" unitRef="shares">992120</us-gaap:TreasuryStockSharesAcquired>
    <uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased contextRef="c-153" decimals="2" id="f-626" unitRef="number">0.70</uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-154" decimals="0" id="f-627" unitRef="shares">708657</us-gaap:TreasuryStockSharesAcquired>
    <uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased contextRef="c-155" decimals="2" id="f-628" unitRef="number">0.50</uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-156" decimals="0" id="f-629" unitRef="shares">463682</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ShareRepurchaseProgramExciseTaxPayable contextRef="c-157" decimals="-5" id="f-630" unitRef="usd">8400000</us-gaap:ShareRepurchaseProgramExciseTaxPayable>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-158" decimals="INF" id="f-631" unitRef="usd">1000000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements
      contextRef="c-159"
      decimals="INF"
      id="f-632"
      unitRef="agreement">2</uthr:ShareRepurchaseProgramNumberOfAcceleratedRepurchaseAgreements>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-159" decimals="-8" id="f-633" unitRef="usd">1000000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-160" decimals="-6" id="f-634" unitRef="usd">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-161" decimals="-6" id="f-635" unitRef="usd">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-162" decimals="-8" id="f-636" unitRef="usd">1000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-163" decimals="0" id="f-637" unitRef="shares">1274296</us-gaap:TreasuryStockSharesAcquired>
    <uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased contextRef="c-164" decimals="2" id="f-638" unitRef="number">0.75</uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-165" decimals="0" id="f-639" unitRef="shares">849531</us-gaap:TreasuryStockSharesAcquired>
    <uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased contextRef="c-166" decimals="2" id="f-640" unitRef="number">0.50</uthr:StockRepurchaseProgramPercentageOfSharesToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-167" decimals="0" id="f-641" unitRef="shares">514789</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-168" decimals="0" id="f-642" unitRef="shares">3882</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-169" decimals="0" id="f-643" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-170"
      decimals="INF"
      id="f-644"
      unitRef="shares">2642498</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ShareRepurchaseProgramExciseTax contextRef="c-170" decimals="-5" id="f-645" unitRef="usd">1800000</us-gaap:ShareRepurchaseProgramExciseTax>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-646">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"&gt;Our effective income tax rate (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%"&gt;ETR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"&gt;) for the three months ended March&#160;31, 2026 and 2025 was 14 percent and 24 percent, respectively. Our ETR for the three months ended March&#160;31, 2026 decreased compared to our ETR for the three months ended March&#160;31, 2025 primarily due to increased excess tax benefits from share-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;OBBBA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) was enacted in the United States. The OBBBA includes provisions that allow both the immediate deduction of domestic research and experimental expenditures and the full expensing of the cost of certain qualifying assets in the year placed in service. The impacts of the OBBBA were reflected in our consolidated financial statements beginning in the period of enactment and continue to be reflected in the period ended March 31, 2026, resulting in decreases to both our deferred tax assets and cash tax liabilities. The OBBBA provisions did not have a material impact on our ETR for the period ended March 31, 2026.&lt;/span&gt;&lt;/div&gt;We record interest and penalties related to uncertain tax positions as a component of income tax expense. As of March&#160;31, 2026 and December 31, 2025, our unrecognized tax benefits, including related interest, were approximately $30.6&#160;million and $28.7&#160;million, respectively.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-647" unitRef="number">0.14</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="2" id="f-648" unitRef="number">0.24</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <uthr:UnrecognizedTaxBenefitsIncludingInterest contextRef="c-3" decimals="-5" id="f-649" unitRef="usd">30600000</uthr:UnrecognizedTaxBenefitsIncludingInterest>
    <uthr:UnrecognizedTaxBenefitsIncludingInterest contextRef="c-4" decimals="-5" id="f-650" unitRef="usd">28700000</uthr:UnrecognizedTaxBenefitsIncludingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-651">Segment Information&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, as our Chief Operating Decision Maker (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;CODM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), manages our company as a single operating and reporting segment at the consolidated level. Our operating segment focuses on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. The accounting policies of our one operating segment are the same as those described in Note 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;Summary of Significant Accounting Policies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February&#160;25, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Our CODM is regularly provided with revenue and expense forecasts, including product development plans, to manage the operations of our operating segment. Our CODM monitors forecasted to actual results for net income when assessing performance and allocating resources across the operating segment. Significant segment expenses are presented as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The measure of the operating segment assets is reported in our consolidated balance sheets as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;total assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other sources of revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tyvaso DPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Nebulized Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Orenitram&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unituxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Adcirca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;781.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gross profit (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;648.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;302.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;794.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gross profit (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;701.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;During the three months ended March 31, 2026 and 2025, we recorded $44.9&#160;million and $9.0&#160;million of inventory reserve expense, respectively. Tyvaso DPI inventory reserve expense accounts for $39.2&#160;million and $5.8&#160;million of the total inventory reserve expense recorded during the three months ended March 31, 2026 and 2025, respectively. The Tyvaso DPI inventory reserve expense increased in 2026 mainly because we recorded an estimated $26.8&#160;million loss related to a commercial supply agreement. This agreement is intended to provide us with sufficient inventory to meet the needs of our patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;Total revenues and cost of sales include sales of infusion devices, including the Remunity&lt;/span&gt;&lt;span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and RemunityPRO&lt;/span&gt;&lt;span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Pumps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Geographic revenues are determined based on the country to which our products are shipped. Total revenues from external customers in the United States and rest-of-world (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) for each of our commercial products were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net product sales:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Tyvaso DPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;330.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;330.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;302.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;302.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Nebulized Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;127.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;442.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;457.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;441.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;466.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;108.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;17.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Orenitram&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;135.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;135.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unituxin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;53.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;56.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;58.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Adcirca&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;744.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;37.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;781.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;749.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;794.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We recorded revenue from two distributors in the United States that exceeded ten percent of total revenues. Revenue from these two distributors as a percentage of total revenues is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Distributor 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Distributor 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-652"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <uthr:ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock contextRef="c-1" id="f-653">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total revenues, cost of sales, and gross profit (loss) for each of our commercial products and other sources of revenues were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Tyvaso DPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Nebulized Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Orenitram&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Unituxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Adcirca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;127.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;781.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gross profit (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;247.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;648.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;302.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;794.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gross profit (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;701.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e7e8;border-bottom:1.5pt solid #000;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;During the three months ended March 31, 2026 and 2025, we recorded $44.9&#160;million and $9.0&#160;million of inventory reserve expense, respectively. Tyvaso DPI inventory reserve expense accounts for $39.2&#160;million and $5.8&#160;million of the total inventory reserve expense recorded during the three months ended March 31, 2026 and 2025, respectively. The Tyvaso DPI inventory reserve expense increased in 2026 mainly because we recorded an estimated $26.8&#160;million loss related to a commercial supply agreement. This agreement is intended to provide us with sufficient inventory to meet the needs of our patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:14.4pt;text-indent:-14.4pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.97pt"&gt;Total revenues and cost of sales include sales of infusion devices, including the Remunity&lt;/span&gt;&lt;span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and RemunityPRO&lt;/span&gt;&lt;span style="color:#000000;font-family:'null',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Pumps.&lt;/span&gt;&lt;/div&gt;</uthr:ScheduleOfNetRevenueCostOfProductSalesAndGrossProfitByProductTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-5" id="f-654" unitRef="usd">330300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-5" id="f-655" unitRef="usd">127200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-173" decimals="-5" id="f-656" unitRef="usd">126600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-5" id="f-657" unitRef="usd">135600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-5" id="f-658" unitRef="usd">53600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-176" decimals="-5" id="f-659" unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-177" decimals="-5" id="f-660" unitRef="usd">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-661" unitRef="usd">781500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-171" decimals="-5" id="f-662" unitRef="usd">83200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-172" decimals="-5" id="f-663" unitRef="usd">8600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-173" decimals="-5" id="f-664" unitRef="usd">16100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-174" decimals="-5" id="f-665" unitRef="usd">7400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-175" decimals="-5" id="f-666" unitRef="usd">5000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-176" decimals="-5" id="f-667" unitRef="usd">1000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-177" decimals="-5" id="f-668" unitRef="usd">12100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-669" unitRef="usd">133400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-171" decimals="-5" id="f-670" unitRef="usd">247100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-172" decimals="-5" id="f-671" unitRef="usd">118600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-173" decimals="-5" id="f-672" unitRef="usd">110500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-174" decimals="-5" id="f-673" unitRef="usd">128200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-175" decimals="-5" id="f-674" unitRef="usd">48600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-176" decimals="-5" id="f-675" unitRef="usd">1900000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-177" decimals="-5" id="f-676" unitRef="usd">-6800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-5" id="f-677" unitRef="usd">648100000</us-gaap:GrossProfit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-178" decimals="-5" id="f-678" unitRef="usd">302500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-179" decimals="-5" id="f-679" unitRef="usd">163800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-5" id="f-680" unitRef="usd">138200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-5" id="f-681" unitRef="usd">120700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-182" decimals="-5" id="f-682" unitRef="usd">58200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-183" decimals="-5" id="f-683" unitRef="usd">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-184" decimals="-5" id="f-684" unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-5" id="f-685" unitRef="usd">794400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-178" decimals="-5" id="f-686" unitRef="usd">48100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-179" decimals="-5" id="f-687" unitRef="usd">8500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-180" decimals="-5" id="f-688" unitRef="usd">13800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-181" decimals="-5" id="f-689" unitRef="usd">8300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-182" decimals="-5" id="f-690" unitRef="usd">5200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-183" decimals="-5" id="f-691" unitRef="usd">2600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-184" decimals="-5" id="f-692" unitRef="usd">6000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-5" id="f-693" unitRef="usd">92500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-178" decimals="-5" id="f-694" unitRef="usd">254400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-179" decimals="-5" id="f-695" unitRef="usd">155300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-180" decimals="-5" id="f-696" unitRef="usd">124400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-181" decimals="-5" id="f-697" unitRef="usd">112400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-182" decimals="-5" id="f-698" unitRef="usd">53000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-183" decimals="-5" id="f-699" unitRef="usd">3400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-184" decimals="-5" id="f-700" unitRef="usd">-1000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-5" decimals="-5" id="f-701" unitRef="usd">701900000</us-gaap:GrossProfit>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-702" unitRef="usd">44900000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-5" decimals="-5" id="f-703" unitRef="usd">9000000.0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-171" decimals="-5" id="f-704" unitRef="usd">39200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-178" decimals="-5" id="f-705" unitRef="usd">5800000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-171" decimals="-5" id="f-706" unitRef="usd">26800000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-707">Total revenues from external customers in the United States and rest-of-world (&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) for each of our commercial products were as follows (in millions):&lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;ROW&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net product sales:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Tyvaso DPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;330.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;330.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;302.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;302.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Nebulized Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;127.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total Tyvaso&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;442.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;457.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;441.1&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;25.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;466.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Remodulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;108.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;17.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;126.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #6d6d6d;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #6d6d6d;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;138.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #6d6d6d;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Orenitram&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;135.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;135.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;120.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Unituxin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;49.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;53.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;56.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;58.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:3.6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Adcirca&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #939598;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #939598;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #939598;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;padding-left:10.8pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;744.2&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;37.3&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;781.5&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;749.6&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro Medium',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;794.4&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:right"&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  Net product sales include sales of infusion devices, including the Remunity and RemunityPRO Pumps.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-185" decimals="-5" id="f-708" unitRef="usd">330300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-186" decimals="-5" id="f-709" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-5" id="f-710" unitRef="usd">330300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-187" decimals="-5" id="f-711" unitRef="usd">302500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-188" decimals="-5" id="f-712" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-178" decimals="-5" id="f-713" unitRef="usd">302500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-189" decimals="-5" id="f-714" unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-190" decimals="-5" id="f-715" unitRef="usd">14600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-5" id="f-716" unitRef="usd">127200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-191" decimals="-5" id="f-717" unitRef="usd">138600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-192" decimals="-5" id="f-718" unitRef="usd">25200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-179" decimals="-5" id="f-719" unitRef="usd">163800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-193" decimals="-5" id="f-720" unitRef="usd">442900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-194" decimals="-5" id="f-721" unitRef="usd">14600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-5" id="f-722" unitRef="usd">457500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-5" id="f-723" unitRef="usd">441100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-5" id="f-724" unitRef="usd">25200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-198" decimals="-5" id="f-725" unitRef="usd">466300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-199" decimals="-5" id="f-726" unitRef="usd">108800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-200" decimals="-5" id="f-727" unitRef="usd">17800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-173" decimals="-5" id="f-728" unitRef="usd">126600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-201" decimals="-5" id="f-729" unitRef="usd">120200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-202" decimals="-5" id="f-730" unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-5" id="f-731" unitRef="usd">138200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-203" decimals="-5" id="f-732" unitRef="usd">135600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-204" decimals="-5" id="f-733" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-5" id="f-734" unitRef="usd">135600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-205" decimals="-5" id="f-735" unitRef="usd">120700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-206" decimals="-5" id="f-736" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-5" id="f-737" unitRef="usd">120700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-207" decimals="-5" id="f-738" unitRef="usd">49000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-5" id="f-739" unitRef="usd">4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-5" id="f-740" unitRef="usd">53600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-209" decimals="-5" id="f-741" unitRef="usd">56900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-210" decimals="-5" id="f-742" unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-182" decimals="-5" id="f-743" unitRef="usd">58200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-211" decimals="-5" id="f-744" unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-212" decimals="-5" id="f-745" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-176" decimals="-5" id="f-746" unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-213" decimals="-5" id="f-747" unitRef="usd">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-214" decimals="-5" id="f-748" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-183" decimals="-5" id="f-749" unitRef="usd">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-215" decimals="-5" id="f-750" unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-216" decimals="-5" id="f-751" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-177" decimals="-5" id="f-752" unitRef="usd">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-217" decimals="-5" id="f-753" unitRef="usd">4700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-218" decimals="-5" id="f-754" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-184" decimals="-5" id="f-755" unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-219" decimals="-5" id="f-756" unitRef="usd">744200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-220" decimals="-5" id="f-757" unitRef="usd">37300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-758" unitRef="usd">781500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-221" decimals="-5" id="f-759" unitRef="usd">749600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-222" decimals="-5" id="f-760" unitRef="usd">44800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-5" id="f-761" unitRef="usd">794400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-762">Revenue from these two distributors as a percentage of total revenues is as follows:&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Distributor 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;Distributor 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-223" decimals="2" id="f-763" unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-224" decimals="2" id="f-764" unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-225" decimals="2" id="f-765" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-226" decimals="2" id="f-766" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-767">Litigation &lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Sandoz Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In April 2019, Sandoz Inc. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Sandoz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and its marketing partner RareGen, LLC (now known as Liquidia PAH, LLC, a subsidiary of Liquidia Corporation) (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;RareGen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), filed a complaint in the U.S. District Court for the District of New Jersey against us and Smiths Medical ASD, Inc. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Smiths Medical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), alleging that we and Smiths Medical engaged in anticompetitive conduct in connection with the plaintiffs&#x2019; efforts to launch their generic version of Remodulin. In particular, the complaint alleged that we and Smiths Medical unlawfully impeded competition by entering into an agreement for Smiths Medical to produce cartridges used with the CADD-MS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;MS-3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) infusion system specifically for the delivery of subcutaneous Remodulin for our patients, without making these cartridges available for the delivery of Sandoz&#x2019;s generic treprostinil injection. In March 2020, the plaintiffs filed an amended complaint to add a count alleging that we breached our earlier patent settlement agreement with Sandoz by refusing to grant Sandoz access to cartridges purchased for our patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Smiths Medical was dismissed from the case in November 2020, based on a settlement resolving the disputes between the plaintiffs and Smiths Medical. As part of this settlement, Smiths Medical paid the plaintiffs $4.25&#160;million, disclosed and made available to the plaintiffs certain specifications and other information related to the MS-3 cartridges, and granted to the plaintiffs a non-exclusive, royalty-free license in the United States to Smiths Medical&#x2019;s patents and copyrights associated with the MS-3 cartridges and certain other information related to the MS-3 pumps and cartridges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In March 2022, the court granted our motion for summary judgment with respect to all claims brought by the plaintiffs except the breach of contract claim. As a result, all antitrust claims, all claims under state competition laws, and the common law tortious interference claim were resolved in our favor. These were the only claims in the case that gave rise to any potential for trebling of damages, punitive damages, disgorgement, and/or the award of attorneys&#x2019; fees. The court also denied the plaintiffs&#x2019; request for injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The court granted Sandoz&#x2019;s motion for summary judgment with respect to Sandoz&#x2019;s breach of contract claim. The issue of what, if any, damages Sandoz is entitled to based on the court&#x2019;s decision on the contract claim went to trial. On November 1, 2024, the court entered a final judgment in favor of Sandoz, ordering us to pay to Sandoz (a) approximately $61.6 million in damages; (b) prejudgment interest in the amount of approximately $9.0 million; and (c) post-judgment interest. All parties appealed the final judgment, including the court&#x2019;s March 30, 2022 summary judgment decision. The appeal is pending before the U.S. Court of Appeals for the Third Circuit, and oral argument was held in November 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We accrued a liability of $71.1&#160;million during 2024, an additional $3.0&#160;million during 2025, and an additional $0.8&#160;million through the first quarter of 2026, reflecting, in the aggregate, the damages and pre-judgment interest amounts awarded in the final judgment, as well as post-judgment interest accrued through March 31, 2026. We currently do not expect that the amount of any loss in excess of these accruals would be material to our financial results; however, the amount ultimately payable, if any, could be higher or lower than this amount depending on the amount of post-judgment interest, and the outcome of appeals. We recorded this liability within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;other non-current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We intend to continue to vigorously defend ourselves against the claims made in this litigation. Among other things, we believe our settlement agreement with Sandoz did not provide Sandoz any rights with respect to delivery systems such as the MS-3. We also believe that the plaintiffs, who were on notice that Smiths Medical would discontinue the MS-3 system, failed to fulfill their duty to properly mitigate their exposure as a result of such discontinuation, and any damages they incurred are the result of market conditions and their own failure to properly plan their own product launch. However, due to the uncertainty inherent in any litigation, we cannot guarantee that appeals will not result in an outcome adverse to us. This litigation has involved, and will likely continue to involve, substantial costs to defend, and an adverse appellate outcome could result in substantial monetary damages in excess of the liability we have accrued to-date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Litigation with Liquidia Technologies, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since March 2020, we have been engaged in litigation with Liquidia Technologies, Inc. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Liquidia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) regarding its efforts to obtain FDA approval for Yutrepia&lt;/span&gt;&lt;span style="color:#000000;font-family:'null',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, a dry powder inhalation formulation of treprostinil. That litigation has included two petitions for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; review (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;IPR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) filed by Liquidia with the Patent Trial and Appeal Board (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;PTAB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) of the U.S. Patent and Trademark Office (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;USPTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), as well as multiple lawsuits we have brought alleging infringement by Liquidia of several of our patents. Most of these cases have now been finally resolved, and Liquidia received final approval from the FDA to market Yutrepia to treat pulmonary arterial hypertension (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;PAH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and pulmonary hypertension associated with interstitial lung disease (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;PH-ILD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) in May 2025 and launched commercial sales in June 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We have an ongoing patent infringement lawsuit against Liquidia, which was originally filed on September 5, 2023 in the U.S. District Court for the District of Delaware, alleging infringement of U.S. Patent No. 10,716,793 (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2019;793 patent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), a patent related to Tyvaso with an expiration date in May 2027 that was later invalidated as a result of an IPR proceeding, and therefore is no longer at issue in this litigation. On November 30, 2023, we filed an amended complaint to assert a new patent: U.S. Patent No. 11,826,327 (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2019;327 patent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;), which expires February 3, 2042, and is the only patent remaining at issue in the case. The claims of the &#x2019;327 patent generally cover improving exercise capacity in patients suffering from PH-ILD by inhaling treprostinil at specific dosages. Trial took place in June 2025, and the parties are awaiting the court&#x2019;s decision. If we prevail in this lawsuit, we believe that we will be entitled to a court order requiring Liquidia to remove the PH-ILD indication from Yutrepia&#x2019;s product labeling, and that we may also be entitled to damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June 2021, we filed a motion in one of our earlier patent cases against Liquidia in the U.S. District Court for the District of Delaware to file an amended complaint adding trade secret misappropriation claims against Liquidia and a former Liquidia executive, Dr. Robert Roscigno. The court denied the motion based on a finding that adding the additional claims would impact the case schedule. Thus, we filed those claims as a separate case against Liquidia and Dr. Roscigno in North Carolina state court. Discovery is complete. On January 5, 2024, Dr. Roscigno filed a motion for summary judgment, which was denied on July 31, 2024. On July 3, 2024, Liquidia filed a motion for summary judgment, which was denied on July 23, 2025. The court has scheduled trial to commence in January 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We filed a new complaint on May 29, 2024, to commence a separate, related case against Liquidia and Dr. Roscigno in North Carolina state court. That case is in its early stages, and the parties are currently engaged in discovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 21, 2025, Liquidia filed a lawsuit against us in the U.S. District Court for the Middle District of North Carolina, alleging that Tyvaso DPI infringes U.S. Patent No. 10,898,494 (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2018;494 patent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;). This patent&#x2019;s claims are directed to the treatment of pulmonary hypertension by administering specified amounts of treprostinil via a dry powder inhaler in a specified number of breaths. The patent expires May 5, 2037. Liquidia seeks damages and attorneys&#x2019; fees. We filed a motion to dismiss or, alternatively, a motion to stay the case based on the argument that we co-own the asserted patent based on Liquidia&#x2019;s and Dr. Roscigno&#x2019;s alleged trade secret misappropriation subject to the pending North Carolina state court litigation. The court granted our motion to stay and denied the motion to dismiss. On May 9, 2025, we filed a lawsuit against Liquidia in the U.S. District Court for the Middle District of North Carolina, alleging that Yutrepia infringes U.S. Patent No. 11,357,782. This patent claims a method of treating pulmonary hypertension using inhaled treprostinil delivered using a specified dosage regimen. The patent expires May 14, 2027. We moved for a preliminary injunction, but the court denied that motion. Liquidia moved to dismiss or, alternatively, transfer the case to the U.S. District Court for the District of Delaware. The court denied Liquidia&#x2019;s motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We plan to continue to vigorously enforce our intellectual property rights related to Tyvaso DPI and Nebulized Tyvaso. In addition, we believe we have meritorious defenses and intend to vigorously defend ourselves against the claims made by Liquidia in its patent infringement lawsuit against us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;MSP Recovery Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July 2020, MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; and Series PMPI, a designated series of MAO-MSO Recovery II, LLC, filed a class action complaint against Caring Voices Coalition, Inc. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;CVC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and us in the U.S. District Court for the District of Massachusetts. The complaint alleged that we violated the federal Racketeer Influenced and Corrupt Organizations (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;RICO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) Act and various state laws by coordinating with CVC when making donations to a PAH fund so that those donations would go toward copayment obligations for Medicare patients taking drugs manufactured and marketed by us. The plaintiffs claim to have received assignments from various Medicare Advantage health plans and other insurance entities that allow them to bring this lawsuit on behalf of those entities to recover allegedly inflated amounts they paid for our drugs. In April 2021, the court granted our motion to transfer the case to the U.S. District Court for the Southern District of Florida.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In October 2021, the plaintiffs filed an amended complaint that includes state antitrust claims based on alleged facts similar to those raised by Sandoz and RareGen in the matter described above. The amended complaint added MSP Recovery Claims Series 44, LLC as a plaintiff and Smiths Medical and CVC as defendants. In December 2021, we filed a motion to dismiss all of the plaintiffs&#x2019; claims in the amended complaint, including the new antitrust claims. Smiths Medical also filed a motion to dismiss the plaintiffs&#x2019; claims against Smiths Medical. In September 2022, the court dismissed all of the plaintiffs&#x2019; claims against us and Smiths Medical without prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"&gt;In October 2022, the plaintiffs filed a second amended complaint, which added federal antitrust claims and consumer protection claims under other states&#x2019; laws to the claims previously asserted. The second amended complaint also named Accredo Health Group, CVS Health Corporation, Express Scripts, Inc., and Express Scripts Holding Company (collectively, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:112%"&gt;Specialty Pharmacies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"&gt;), and the Adira Foundation as additional defendants. In March 2023, we filed our motion to dismiss the second amended complaint. The Specialty Pharmacies filed their own motion to dismiss, as did Smiths Medical. On March 22, 2024, the magistrate judge recommended dismissal of the plaintiffs&#x2019; complaint against all defendants in its entirety with prejudice, and for administrative purposes, issued an order dismissing the complaint. On April 12, 2024, the plaintiffs filed an objection to the magistrate judge&#x2019;s recommendation. On May 10, 2024, we filed a response to the plaintiffs&#x2019; objection, as did the other defendants. If the district court judge adopts the magistrate judge&#x2019;s recommendation and dismisses the case, the plaintiffs will have the right to appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We intend to continue to vigorously defend ourselves against the claims made in this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;span style="color:#c12034;font-family:'Avenir Next LT Pro',sans-serif;font-size:14pt;font-weight:400;line-height:120%"&gt;Litigation with Humana and United Healthcare&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Humana Inc. (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Humana&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and United Healthcare Services, Inc. (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;United&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) filed separate lawsuits against us in the U.S. District Court for the District of Maryland in December 2022 and November 2022, respectively. Each of these lawsuits includes allegations similar to those in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; matter discussed above concer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ning our charitable &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;contributions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; to CVC. In particular, these lawsuits allege that our donations to CVC violated RICO and various state laws. We filed motions to dismiss both of these lawsuits in March 2023. On March 25, 2024, the court dismissed both the Humana and United complaints in their entirety. In both cases, the RICO claims were dismissed with prejudice. In the Humana case, the state law claims were dismissed without prejudice, and in the United case, some of the state law claims were dismissed with prejudice, while others were dismissed without prejudice. Neither Humana nor United filed an appeal to date, and their deadlines for filing appeals have passed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, Humana and United each filed lawsuits against us in the Circuit Court for Montgomery County, Maryland. These lawsuits include allegations similar to those in their lawsuits discussed above concerning charitable contributions. Humana and United allege that our donations to CVC give rise to common law causes of action, violations of state consumer protection statutes, and violations of insurance fraud statutes under the laws of various states. On July 22, 2024, we filed motions to dismiss both of these lawsuits. Oral argument on these motions to dismiss took place on October 24, 2024. On September 23, 2025, the court dismissed both lawsuits with prejudice. On October 20, 2025, Humana and United each appealed the court&#x2019;s decision to the Appellate Court of Maryland, and those appeals are currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Avenir Next LT Pro',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;We intend to continue to vigorously defend ourselves against the claims made in these lawsuits.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-227" decimals="-4" id="f-768" unitRef="usd">4250000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-228" decimals="-5" id="f-769" unitRef="usd">61600000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementInterest contextRef="c-228" decimals="-5" id="f-770" unitRef="usd">9000000.0</us-gaap:LitigationSettlementInterest>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-229" decimals="-5" id="f-771" unitRef="usd">71100000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-230" decimals="-5" id="f-772" unitRef="usd">3000000.0</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="c-231" decimals="-5" id="f-773" unitRef="usd">800000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
    <uthr:NumberOfPetitions
      contextRef="c-232"
      decimals="INF"
      id="f-774"
      unitRef="petition">2</uthr:NumberOfPetitions>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-775">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-776">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-777">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-778">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
